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ABSTRACT 
Introduction 
Neurodegenerative disease’s such as Alzheimer’s and Parkinson’s disease are becoming more 
prevalent as the aging population increases. Multiple factors are implicated including impaired 
protein degradation, mitochondrial dysfunction and oxidative stress; whose mechanisms may be 
interconnected in the so-called ‘Neurodegenerative Bermuda triangle’. Understanding these 
hallmarks is essential for developing new therapies to help ameliorate symptoms of 
neurodegenerative diseases. 
Methods and Aims 
Human neuronal (SH-SY5Y) and glial (U-87MG) cell lines were used to investigate oxidative stress 
mediated neurodegeneration. Reactive species (RS), specifically peroxy radicals and superoxide 
radicals were produced using 2,2′-Azobis(2-methylpropionamidine) dihydrochloride (AAPH; a ROS 
generating lipid peroxidation agent) and rotenone (a mitochondrial disruptor that inhibits complex 
I), respectively. Using fluorescence probes, cellular function assays, PCR analysis, protein expression 
and proteomics the effects of RS in neural cells both in mono and co-cultures were investigated.  
Results 
AAPH and rotenone were shown to have divergent effects on neural cells exposing the differences 
between these cells. Furthermore, AAPH was found to induce greater lipid peroxidation than 
rotenone, suggesting different toxins induce specific RS. In particular, the NRF2-antioxidant 
response element was highlighted as a key pathway activated by oxidative stress. Experiments with 
primary embryonic cortical neuronal cultures show the limitations of in vitro differentiation models. 
Thus, steps to create a co-culture were investigated, demonstrating the difficulties associated with 
co-cultures but showing how neuronal susceptibility to RS was altered by glial cells.  
Conclusion 
This body of work highlights AAPH for future investigations into lipid peroxidation. Furthermore, 
the results herein suggest differentiation methods should be considered when evaluating RS 
susceptibility. Finally, initial investigations have determined how transwell inserts can be used to 
create co-cultures between neural cells with materials needing to be considered for future studies. 
Conditioned media provides an alternative way to investigate secreted factors where potential 
pathways have been determined for future studies.   
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1.0 General Introduction  
1.1 Parkinson’s Disease  
With people living to greater ages in developed and developing countries, neurodegenerative 
diseases such as Alzheimer’s and Parkinson’s disease (AD and PD, respectively) are becoming more 
prevalent. PD is the second most common neurodegenerative disease (Gitler et al., 2017; Maniati 
et al., 2019), first described as “the shaking palsy” in 1817 (Parkinson, 2002). The core clinical 
features recognised in PD include: bradykinesia, tremor and rigidity (Carta and Hirsch, 2018) though 
more recently, studies have identified non-motor features preceding these motor symptoms such 
as hyposmia, sleeping disorders, depression and constipation (Schapira et al., 2017). Underlying 
these clinical features are neuropathological hallmarks including loss of dopaminergic (DA) neurons 
in the substantia nigra (SN) and intraneuronal inclusions referred to as Lewy bodies (LBs;(Walker et 
al., 2019). LBs are immunoreactive for α-synuclein, 3-nitrotyrosine, neurofilament, synphilin-1, 
ubiquitin and ubiquitin-pathway related proteins (Collier et al., 2017; Voronkov et al., 2018; Walden 
and Muqit, 2017). Yet despite multiple decades of studying PD, the cause and underlying 
mechanisms for PD’s pathology are still unknown.  
1.1.1 Familial Parkinson’s disease  
PD can be separated into two types: familial and sporadic. Familial PD patients have shown 
increased levels of oxidized lipids and proteins (Sanders and Timothy Greenamyre, 2013), as well 
as decreased levels of reduced glutathione (GSH;(H. Wei et al., 2019), theorized to contribute to 
protein accumulation and aggregation. In familial patients, mutations in α-synuclein (Ingelsson, 
2016), parkin (Kitada et al., 1998), ubiquitin carboxy-terminal hydrolase-L1 (UCH-L1; Nishikawa et 
al., 2003), PTEN-induced kinase-1 (PINK1; Valente et al., 2004) and DJ-1 (Vincenzo Bonifati et al., 
2003) have been documented.  
Mutations (Polymeropoulos et al., 1997) and overexpression (Singleton et al., 2003) of wild-
type α-synuclein, a 140 amino acid protein substrate for the ubiquitin proteasome system (UPS) (M 
C Bennett et al., 1999; Shimura et al., 2001; Tofaris et al., 2001) show increased protein misfolding 
and aggregation (Feany and Bender, 2000; Goedert, 2001; Ludtmann and Abramov, 2016). 
Furthermore α-synuclein mutants are more resistant to proteolysis (Sakai et al., 2019) and 
demonstrated a longer rate of proteasomal degradation relative to wildtype α-synuclein (Bennett 
et al., 1999). In addition, a study using transgenic mice overexpressing α-synuclein showed 
mitochondrial function was impaired while oxidative stress (OS) increased (Ludtmann et al., 2018; 
Song et al., 2004). In vitro studies using SH-SY5Y cells overexpressing α-synuclein demonstrated 
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increased caspase 3 activity alongside decreased cell viability (Perfeito et al., 2017). In addition, 
lower levels of superoxide dismutase and glutathione, responsible for scavenging superoxide, 
hydrogen peroxide and hydroxyl radicals (Marí et al., 2013; Nakamura et al., 1997; Ruszkiewicz and 
Albrecht, 2015) were observed. SH-SY5Y cells transfected with mutant α-synuclein also exhibited 
decreased cell viability, condensed nuclear apoptotic bodies and increased intracellular reactive 
oxygen species (ROS; Ju et al., 2017). Together, these studies suggest mutant α-synuclein 
accumulates suggesting protein degradation clearance is impaired contributing to OS. 
Parkin, an E3 ubiquitin ligase, is responsible for protein ubiquitination, targeting substrates 
to the 26S proteasome for degradation (Imai et al., 2000). Parkin can localise to mitochondria, 
playing a role in inhibiting mitochondrial-dependent cell death by preventing swelling and caspase 
release (Darios et al., 2003). In addition, leukocytes from patients with parkin mutations showed 
selective impairment of complex I in the electron transport chain (ETC) of mitochondria. In both 
familial and sporadic PD patients parkin deficiencies and mutations are associated with 
mitochondrial dysfunction and OS (Müftüoglu et al., 2004). Studies of parkin-null flies support this 
as they displayed altered mitochondrial morphology and tissue degeneration in wing flight muscles 
and spermatocytes (Greene et al., 2003). In another study, overexpression of mutant parkin 
increased cellular markers of OS while wildtype parkin expression reduced these markers (Hyun et 
al., 2002). Parkin-null mice exhibited lower levels of oxidative phosphorylation, weight gain and 
antioxidant capacity. These mice also showed increased RS mediated tissue damage suggesting 
parkin regulates mitochondrial function and protects cells from OS (Palacino et al., 2004). Other 
parkin-null mouse models support decreased antioxidant capacity as lower levels of reduced 
glutathione were measured (Itier, 2003). Therefore due to parkin-null mice having decreased 
antioxidant capacity they are more susceptible to RS damage, which is evident in parkin-null mice 
brains which display elevated oxidised protein and lipid levels (Palacino et al., 2004). In another 
study, RS are suggested to inactivate parkin (Winklhofer et al., 2003). Therefore, low levels of parkin 
suggest decreased antioxidant capacity resulting in RS induced damage, leading to mitochondrial 
dysfunction propagating more RS and further parkin inactivation, creating a vicious cycle of damage 
possibly leading to cell death. Together, studies suggest parkin mutations result in protein 
accumulation, mitochondrial dysfunction and RS generation.   
In rare familial forms of PD, mutations in ubiquitin C-terminal hydrolase L1 (UCH-L1), a 
deubiquitinating protein have been observed (Leroy et al., 1998; Shimura et al., 2001). Proteins in 
the UCH family are involved in the hydrolysis of small C-terminal ubiquitin adducts (Pickart and 
Rose, 1985). Due to their substrate specificity it is proposed UCH proteins are involved in ubiquitin 
recycling rather than deubiquitination (Bishop et al., 2016; Larsen et al., 1998). Four isoforms are 
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reported: UCH-L1-L4 (Mayer and Wilkinson, 1989; Shinohara et al., 1993; Wilkinson, 1995) where 
UCH-L1 is neuron-specific (Wilkinson et al., 1989). In a German family with familial PD, a missense 
mutation was observed in the gene coding UCH-L1 resulting in partial loss of hydrolase activity 
(Leroy et al., 1998). In mice with intragenic deletion of UCH-L1, neuron-specific phenotypes and 
severe neurodegeneration was observed (Lee and Hsu, 2017; Saigoh et al., 1999). Due to UCH-L1’s 
specific ubiquitin hydrolase activity it is suggested to regulate cellular levels of free ubiquitin in 
neurons (Kang et al., 2018; Larsen et al., 1998). Furthermore, recent studies suggest that UCH-L1 
undergoes S-nitrosylation both in vitro and in rotenone induced PD mouse models, resulting in 
structural instability. This provides a nucleation point allowing α-synuclein to aggregate faster 
(Kumar et al., 2017). Furthermore, lipid metabolites can react with UCH-L1; mutagenesis studies 
demonstrate that Cys90 and Cys152 are the main sites for this (Kabuta et al., 2008), ameliorating 
OS by scavenging the reactive metabolite, 4-hydroxynonenal. Therefore, UCH-L1 mutations show 
reduced hydrolase activity causing lower levels of free ubiquitin or structural changes but also 
impact levels of OS, and adversely affect protein degradation via the UPS suggesting proteasomal 
dysfunction contributes to PD pathology. 
Mitochondrial dysfunction has also been suggested in familial PD pathology where patients 
have shown PINK1 mutations. Both wildtype and mutant PINK1 localise to mitochondria (Valente 
et al., 2004). Wildtype PINK1 appears to have a protective effect against apoptosis by suppressing 
cytochrome c release, repressing mitochondrial-dependent cell apoptosis via caspase activation 
(Beilina et al., 2005; Chen and Chan, 2009; H. L. Wang et al., 2007). Furthermore, PINK1 is imported 
into healthy mitochondria where it can undergo cleavage by proteases, once N-terminally cleaved, 
PINK1 is then degraded via the proteasome. However, upon mitochondrial dysfunction PINK1 is no 
longer imported and accumulates on the outer mitochondiral membrane activating parkin, where 
together PINK1/parkin aid mitochondrial quality control by moderating proteins and mediating 
their clearance (Chan et al., 2011; Sarraf et al., 2013). For example, mitofusin-1 and -2 are targeted 
for degradation to prevent fusion of damaged mitochondria, maintaining a healthy mitochondrial 
network (Tanaka et al., 2010; Xu et al., 2011). In Drosophila, PINK1 inactivation resulted in 
progressive loss of DA neurons. However, treating inactivated PINK1 Drosophila with antioxidants 
such as vitamin E or superoxide dismutase (SOD) suppressed ommatidial degeneration. This 
suggests PINK1 maintains neuronal survival by preventing OS (Wang et al., 2006) . Similar results 
were found in human DA neuroblastoma SH-SY5Y cell lines, where PINK1 deficiency lead to 
mitochondrial dysfunction and increased OS (Wood-Kaczmar et al., 2008). SH-SY5Y cells that had 
PINK1 knockdown mediated by siRNA showed decreased cell viability, mitochondrial membrane 
potential, mitochondrial respiration and ATP levels alongside increased apoptosis (van der Merwe 
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et al., 2017). Other studies support these findings as PINK1-knockdown primates also demonstrate 
neuronal degeneration (Yang et al., 2019). These studies suggest mitochondrial dysfunction and OS 
may underlie DA neuronal loss.   
DJ-1, is another genes reported to be involved in the OS response with mutations in DJ-1 
associated with functionally inactive protein leading to early-onset PD (Bonifati et al., 2003). 
Initially, DJ-1 was identified as an oncogene able to transform cells weakly on its own but more 
strongly when combined with ras (Nagakubo et al., 1997). DJ-1 is also reported as a circulating 
tumour antigen in breast cancer (Le Naour et al., 2001), a regulatory component of the RNA-binding 
complex (Hod et al., 1999) and a hydroperoxide-responsive protein that responds to oxidative 
stimuli such as hydrogen peroxide (H2O2) or paraquat, suggesting antioxidant properties 
(Mitsumoto and Nakagawa, 2001). In neuronal cell models, DJ-1 can form large molecular 
complexes, where these associations depend on the proteins oxidative state (Piston et al., 2017). 
DJ-1 can be oxidised on Cys106, which resides in a hydrophobic pocket, resulting in conformational 
destabilisation and loss of function (Filosto et al., 2011; Kiss et al., 2017). However, this oxidation is 
not a simple ‘on-off’ switch but acts in a biphasic manner, regulated by OS levels, resulting in 
changes to cell physiology (Filosto et al., 2011). The importance of the oxidative state of DJ-1 has 
been highlighted by Saito et al. who have observed oxidised DJ-1 in both neurons and glia of PD 
brains, and levels appear to decrease with disease progression (Saito et al., 2014). Furthermore, DJ-
1 is also associated with dopamine metabolism, where oxidised intermediates of dopamine found 
in neuromelanin have been implicated in non-motor symptoms of PD (Schapira et al., 2017). In vitro 
knockdown of DJ-1 in SH-SY5Y studies have shown α-synuclein accumulation and aggregation (Xu 
et al., 2017a). Furthermore, the Met26I DJ-1 mutation affects its interaction with SUMO-1, 
enhancing mitochondrial removal resulting in greater susceptibility to dopamine toxicity (Strobbe 
et al., 2018). Therefore, DJ-1 is a multifunctional protein involved in regulating transcriptional 
processes, mitochondrial and antioxidant capacity, playing a key role in neurodegeneration. 
While only a small percentage of PD sufferers carry hereditary familial mutations, the 
mutations provide valuable information about the possible mechanims underlying 
neurodegeneration (summarised in table 1.1). Indeed, both familial and sporadic PD display a 
similar phenotype and thereby potentially share common underlying pathways. Consequently, 
familial PD patient studies can provide an insight into possible pathways underlying the 
pathogenesis of sporadic PD (Gandhi and Wood, 2005). Understanding this pathology will help us 
generate novel therapies for many who suffer from this incurable but common neurodegenerative 
disorder.  
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Table 1.1 Summary of genes associated with familial Parkinson’s disease and what neuropathological hallmarks they infer. Adapted from Ferreira and Massano, 
2017; Nuytemans et al., 2010. 
Gene Function Neuropathology References Infers  
α-synuclein  Role not fully understood but believed to be involved 
in neurotransmission.  
Substrate for ubiquitin proteasome system.  
Misfolding associated with mitochondrial dysfunction.  
Neuronal degeneration 
in the SN alongside LB’s.  
Bennett et al., 1999 
Song et al., 2004 
Ju et al., 2017 
Perfeito, Ribeiro and Rego, 
2017 
Protein homeostasis 
impairment  
Mitochondrial 
dysfunction  
 
Parkin  E3 ubiquitin ligase involved in proteasome-dependent 
protein degradation.  
Mainly localised to mitochondria and involved in 
mitochondrial function.  
Mutants show elevated oxidised protein and lipid 
levels.  
Neuronal degeneration 
in SN. 
Greene et al., 2003 
Itier et al., 2003 
Winklhofer et al., 2003 
Palacino et al., 2004 
Protein homeostasis 
impairment  
Mitochondrial 
dysfunction  
Oxidative stress  
Ubiquitin 
C-terminal 
hydrolase 
1 (UCH-L1) 
Deubiquitinating protein and regulates free ubiquitin 
levels. 
Nucleation point allowing α-synuclein aggregation.   
Neurodegeneration. Kumar et al., 2017 
Larsen et al., 1998 
Leroy et al., 1998 
Saigoh et al., 1999 
Shimura et al., 2001 
Protein homeostasis 
impairment  
 
PTEN-
induced 
putative 
kinase 1 
(PINK1) 
Localised to mitochondria suppressing mitochondrial-
dependent cell apoptosis.  
Knockout showed mitochondrial dysfunction and 
oxidative stress.  
Neuronal degeneration 
in SN accompanied by 
LB’s.  
Clark et al., 2006 
Park et al., 2006 
van der Merwe et al., 2017 
Wang et al., 2006 
Mitochondrial 
dysfunction  
Oxidative stress  
DJ-1  Multiple functions including redox reactive signalling 
intermediate.  
Dopamine metabolism.  
Not reported. Filosto et al., 2011 
Kiss et al., 2017 
Mitsumoto and Nakagawa, 
2001 
Piston et al., 2017 
Saito et al., 2014 
Strobbe et al., 2018 
Xu et al., 2017 
Oxidative stress  
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1.2 The Neurodegenerative Bermuda Triangle   
As human samples are difficult to obtain and post-mortem samples are limited as well as ethically 
demanding, in vitro and in vivo models have been generated to replicate the neuropathological 
hallmarks of PD and understand the disease process.  Early research used mitochondrial complex I 
inhibitors such as 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), rotenone or paraquat to 
reproduce selective degeneration of DA neurons both in vitro and in vivo mice (Manning-Bog et 
al., 2002; Seniuk et al., 1990) and primate (Park et al., 2019) models. However, these models did 
not completely reproduce PD as they missed the other hallmark: LB’s. Later models with chronic 
infusion of rotenone in rodents (Betarbet et al., 2000; Visanji et al., 2016) and in particular MPTP 
in mice (Fornai et al., 2005) have proven more successful as α-synuclein positive aggregates were 
detected, though these are difficult to replicate consistently.  
Our knowledge has increased substantially using familial PD findings in combination with 
both in vitro and in vivo models; from these, multiple factors have been implicated in LB 
formation and DA neuronal degradation. These include: impaired protein degradation (McNaught 
and Jenner, 2001), mitochondrial dysfunction (Naoi et al., 2009) and oxidative stress 
(Ischiropoulos and Beckman, 2003); whose mechanisms may be interconnected in the so-called 
‘Neurodegenerative Bermuda triangle’ (figure 1.1). 
 
 
Figure 1.1. Schematic representation of the ‘Neurodegenerative Bermuda Triangle’ leading to neuronal 
loss in Parkinson’s disease. Known risk factors for the pathology of PD include impaired protein 
degradation, mitochondrial dysfunction and reactive oxygen species (ROS) which seem to be interrelated 
events that underlie neurodegeneration.  
CHAPTER 1   GENERAL INTRODUCTION 
8 
 
1.2.1 Mitochondrial Dysfunction  
1.2.1.1 Role of mitochondria  
More so than other organs, the brain has a higher energy demand and thus utilises mitochondria 
to provide ATP via oxidative phosphorylation (Franco-Iborra et al., 2016), as other sources such as 
fatty acid oxidation are too slow or produce high levels of ROS (Schönfeld and Reiser, 2013). As such 
neurons almost exclusively rely on mitochondria for ATP.  
 Mitochondria generate ATP via the transfer of electrons along a series of complexes which 
together make up the electron transport chain (ETC), where the electrons reduce molecular oxygen 
to two molecules of water (Franco-Iborra et al., 2015; Grimm and Eckert, 2017; Vos et al., 2015; see 
figure 1.2). Briefly, this involves complex I transferring electrons from nicotinamide adenine 
dinucleotide (NADH) to the ubiquinone pool, while a proton is concurrently pumped through the 
inner mitochondrial membrane (Benit, 2004). Complex I is the main source of leaking electrons 
leading to ROS (Andreazza et al., 2010) and associated with mitochondrial dysfunction in 
neurodegenerative diseases (Jha et al., 2017; Ruan et al., 2017). Whereas complex II is involved in 
the Krebs cycle as well as the ETC and encoded completely by nuclear DNA, which transfers 
electrons from succinate to the ubiquinone pool (Zeviani, 2004). Complex III is also linked with 
electrons leaking leading to ROS (Borisov, 2002). Electrons are subsequently transferred from the 
ubiquinone pool to cytochrome c, while a proton is simultaneously pumped from the mitochondrial 
Figure 1.2 Reactive oxygen species generation via the electron transport chain. Electrons are passed 
through complex I to ubiquinone (UB) and then to complex III. Cytochrome c (Cyt c) then transfers the 
electrons to complex IV where they react with molecular oxygen to produce water. Meanwhile ATP synthase 
synthesises ATP using the proton electrochemical gradient. Superoxide is mainly formed at complex I and III 
where electrons can leak from. Adapted from Grimm and Eckert, 2017; Vos et al., 2015. 
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matrix space to the intermembrane space (Haut et al., 2003). Complex IV, also referred to as 
cytochrome c oxidase is the final complex involved in electron transfer, catalysing the transfer from 
cytochrome c to reduce molecular oxygen producing two molecules of water, while coupling proton 
pumping across the inner mitochondrial membrane (Diaz et al., 2006). The final complex in the ETC, 
complex V, ATP synthase is located in the inner mitochondrial membrane and synthesises ATP from 
ADP using the proton electrochemical gradient to provide energy for this reaction (Jonckheere et 
al., 2012).  
In addition to providing energy, mitochondria provide essential metabolic intermediates, 
are involved in calcium buffering and regulating apoptotic processes ensuring cellular homeostasis 
(Friedman and Nunnari, 2014; Onyango et al., 2010; Su et al., 2010). As such, mitochondrial 
dysfunction plays a key role in contributing to physiological processes in health. This is especially 
true in the brain as neurons are post-mitotic and irreplaceable in particular regions, and therefore 
sensitive to accumulation of oxidative damage and defective mitochondria during aging (Kowald 
and Kirkwood, 2000; Terman et al., 2010). Furthermore, neurons contain different compartments 
including the cell body, axon, dendrites and synapses and as such, mitochondrial distribution is 
paramount to sustaining specific energy requirements (Lin and Sheng, 2015; Obashi and Okabe, 
2013; Pernas and Scorrano, 2016). The importance of functional mitochondrial distribution in 
synapses has been demonstrated in studies where peroxide production is greater in rat synapses 
relative to other compartments (Borrás et al., 2010, 2003; Ohashi et al., 2016), and synaptic 
mitochondria are more susceptible to calcium induced depolarization in older animals (Lores-Arnaiz 
et al., 2016), suggesting greater sensitivity to mitochondrial dysfunction with age. Whereas, 
astrocytes, a sub-type of glial cells responsible for supporting neurons and regulating OS (Allaman 
et al., 2011; Gan et al., 2012; Vargas and Johnson, 2009), possess filopodial and lamellipodial 
extensions that are too narrow to accommodate mitochondria. As a result, astrocytes rely on 
glycolysis and glycogenolysis, in addition to oxidative phosphorylation to satisfy their energy 
demands (Hertz et al., 2007), suggesting they are less susceptible to mitochondrial-induced 
oxidative stress. 
1.2.1.2 Mitochondrial dysfunction during aging and neurodegeneration  
As mitochondria play a central role in energy metabolism and redox homeostasis, mechanisms of 
age related mitochondrial dysfunction are the subject of many studies to understand both normal 
aging and neurodegenerative disorders (Grimm et al., 2016). Multiple forms of familial PD are linked 
with gene mutations such as; PINK1, parkin and DJ-1, which are associated with the surveillance 
and protection of mitochondria (Chu, 2010; Fukui and Moraes, 2007). Furthermore, mitochondrial 
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dysfunction, reduced ATP levels, enhanced ROS levels (Sharma et al., 2014), toxic protein 
accumulation (Goedert et al., 2017) and failure of mitochondrial quality mechanisms (Green and 
Van Houten, 2011; Tatsuta and Langer, 2008; Ved et al., 2005), such as mitophagy (Ni et al., 2015; 
Wai and Langer, 2016; Youle and Narendra, 2011) contributes to mitochondrial DNA (mtDNA) 
mutations and damage. Together, these aberrations are associated with a greater risk of PD (Reeve 
et al., 2013; Schapira and Gegg, 2011).   
 Mitochondrial proteins are encoded by both their own mitochondrial DNA (mtDNA) within 
mitochondria and nuclear DNA, within the nucleus, where the quality control of mtDNA is not as 
efficient as nuclear thus, mtDNA mutations are more likely (DeBalsi et al., 2017). This may account 
for why complex I is more susceptible to dysfunction as mtDNA encodes 7 of the 13 subunits 
(Paradies et al., 2010). Accumulation of mtDNA mutations has been associated with age related 
diseases (Aon et al., 2016; DeBalsi et al., 2017; Kauppila et al., 2017; Kujoth, 2005) including both 
familial and sporadic PD. Further supporting this, a mouse model of PD showed mtDNA damage in 
DA neurons contributing to dysfunction (Pickrell et al., 2011). Where upon stress mitochondrial 
mutations can change mitochondrial biogenesis as described below, attributing to the cells lack of 
ability to dilute out these mutations (Guerra et al., 2019).  
More recently, genes associated with mitochondrial biogenesis have become important in 
understanding mitochondrial dysfunction. Familial PD associated gene mutations including DJ-1, α-
synuclein and parkin, have also been observed to affect fission and fusion (Van Laar and Berman, 
2013). Furthermore, peroxisome proliferator-activated receptor coactivator gamma 1α (PGC-1α), 
is considered the master controller of mitochondrial biogenesis, which has been found to be 
impaired or have decreased levels in PD patients (Cronin-Furman et al., 2013; Pacelli et al., 2011). 
Further supporting this, increased levels of PGC-1α lead to higher expression of mitochondrial 
subunits attenuating rotenone induced neuronal loss (Zheng et al., 2010).  
To decrease mtDNA mutations mitochondria can divide (fission) and fuse (fusion) to 
maintain a homogenous mitochondrial population and mix mitochondrial content (Chan, 2012; 
Grimm and Eckert, 2017; see figure 1.3). Fission and fusion is also used to maintain growth, shape 
and mitochondrial distribution (Calkins and Reddy, 2011; van der Bliek et al., 2013) with repetitive 
cycles regulating morphology and dynamics (Sharma et al., 2014). 
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Mitochondrial fission enables proliferation of mitochondria for renewal and redistribution 
(Pernas and Scorrano, 2016). Fission is regulated by dynamin related GTPases such as dynamin 
related protein 1 (DRP1), which can be regulated by post-translational modifications such as 
phosphorylation or dephosphorylation (Campello and Scorrano, 2010). Inactive DRP1 is 
cytosolically located and dephosphorylation results in activation and relocation to the 
mitochondrial membrane (Bradshaw et al., 2016; Han et al., 2008; Uo et al., 2009). DRP1 mutations 
result in aberrant mitochondrial morphology, a heterogenous population and non-uniform 
distribution of mtDNA, resulting in increased RS leading to increased apoptosis (Knott et al., 2008; 
Oettinghaus et al., 2016). Further supporting the importance of DRP1, DRP1 knockout Purkinje cells 
exhibit mitochondrial swelling, impaired ETC, increased oxidative stress and autophagy marker 
accumulation leading to neurodegeneration in the cerebellum (Kageyama et al., 2012). In addition, 
mouse synaptosomes showed increased DRP1 levels during aging (Stauch et al., 2014), suggesting 
DRP1 as a potential player in neurodegeneration.  
Fusion counteracts fission, allowing mitochondria to interact and communicate with each 
other (Chan, 2006), while regulating mutated mtDNA (Benard and Karbowski, 2009; Hung et al., 
Figure 1.3 Schematic representation of mitochondrial fission and fusion.  Phosphorylated-dynamic 
related protein (Drp1) is mainly localised to the cytoplasm, once dephosphorylated Drp1 is recruited to the 
mitochondria via fission protein 1 (Fis1). Drp1 subsequently forms spirals around mitochondria promoting 
constriction followed by fission. Pro-fusion proteins mitofusin 1 and 2 (Mfn1 and Mfn2) are localised to the 
outer mitochondrial membrane while optic atrophy 1 (Opa1) is localised to the inner mitochondrial 
membrane. Mfn1 and Mfn2 oligomerization tethers adjacent mitochondria promoting outer 
mitochondrial membrane fusion while Opa1 promotes inner membrane fusion. Adapted from Grimm and 
Eckert, 2017. 
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2018). Like fission, dynamic related GTPases are utilised in this process where mitofusin 1 and 2 
(MFN1/2) are responsible for outer membrane fusion, whereas optic atrophy 1 (OPA1) promotes 
inner membrane fusion (Friedman and Nunnari, 2014; Silva Ramos et al., 2019). Mutations in MFN2 
or OPA1 results in autosomal dominant peripheral neuropathy resulting in mitochondrial 
fragmentation (Carelli et al., 2015; Knott et al., 2008). Low stress is believed to trigger mitochondrial 
fusion, in contrast prolonged stress favours fission (Fischer et al., 2012; Rahim et al., 2016), where 
free radicals increase activation of mitochondrial fission proteins. The ratio of fission to fusion 
determines mitochondrial length and closed network formation (van der Bliek et al., 2013).  
Fission/fusion is integrated with other mitochondrial quality control mechanisms, including 
the removal of aged/damaged mitochondria via mitophagy (Haroon and Vermulst, 2016; Lou et al., 
2020; Youle and Narendra, 2011). Impaired mitophagy has been suggested to contribute to 
mitochondrial dysfunction during aging (Diot et al., 2016) and found in post-mortem PD brains 
(Beal, 2003; Ryan et al., 2015; Yakhine-Diop et al., 2019), as well as dopaminergic neurons from 
patients with sporadic or familial PD (Burbulla et al., 2017; C. Wang et al., 2018). Furthermore, a 
study showed autophagy related genes Atg4B, Atg5, Atg16L1, and histone deacetylase are 
downregulated in the peripheral blood cells of PD patients (Miki et al., 2018).  
Autophagy involves the lysosomal removal of the intracellular contents of a cell, including 
proteins and organelles that maintain cellular homeostasis (Santambrogio and Cuervo, 2011; Wang 
et al., 2016). Autophagy can be divided into 3 main categories: microautophagy, macroautophagy 
and chaperone-mediated autophagy. Microautophagy involves the lysosomal membrane engulfing 
a small cytoplasmic portion (Mizushima et al., 2008; Oshima et al., 2019). Whereas 
macroautophagy entails content engulfing via an autophagosome or phagophore. The mature 
autophagosome subsequently fuses with the lysosome, degrading its membrane and contents via 
lysosomal proteases (Cuervo and Wong, 2014; Lieberman et al., 2020). Finally, chaperone mediated 
autophagy consists of specific protein degradation via chaperones such as HSP70, which then 
interacts with lysosomal membrane receptor LAMP-2A (Cuervo and Wong, 2014; Loos et al., 2017; 
Martinez-Vicente and Cuervo, 2007).  
Deficiencies in macroautophagy leads to protein aggregation contributing to 
neurodegeneration (Anglade, 1997; Scrivo et al., 2018). As neurons rely on mitochondria to 
maintain their energy levels (Kann and Kovács, 2007) they need to replace damaged mitochondria. 
Macroautophagy (mitophagy) regulates this process, whereby mitochondria are selectively 
sequestered and delivered to the lysosome for degradation (Lemasters, 2014; Manzoni, 2017). This 
involves proteins such as p62/SQSTM1, OPTN or NDP52 on the outer mitochondrial membrane 
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acting as a mitophagy receptor (containing a LIR motif), which facilitates the interaction with LC3 
family members to recruit autophagosomal machinery (Harris et al., 2018; Zhang and Ney, 2009; 
see figure 1.4). Alternatively, PINK1 accumulates on dysfunctional mitochondria to mark them for 
lysosomal degradation (Ivankovic et al., 2016; Narendra et al., 2008). PINK1 subsequently 
phosphorylates and recruits parkin to the surface of mitochondria (Shiba-Fukushima et al., 2012) 
activating parkin’s E3 ligase activity (Kane et al., 2014; Kazlauskaite et al., 2014). This leads to the 
ubiquitination of mitochondrial surface proteins tagging them for proteasomal or autophagy 
degradation (Chan et al., 2011; Harris et al., 2018; Yoshii et al., 2011; see figure 1.4). Therefore, 
unsurprisingly mutations in PINK1 and parkin can lead to accumulation of dysfunctional 
mitochondria and increased oxidative stress (Lubbe and Morris, 2014; Obeso et al., 2017; Redmann 
et al., 2016, 2014).  
 
Figure 1.4. Schematic representation of mitophagy mechanisms. When mitochondria become 
dysfunctional, they can be degraded via ubiquitin- and receptor-mediated mitophagy. Mitochondrial 
dysfunction can lead to PINK1 localising to the outer mitochondrial membrane where it recruits and 
phosphorylates Parkin. Phosphorylation activates Parkin’s E3 ligase activity leading to ubiquitination of 
outer mitochondrial membrane (OMM) proteins facilitating phagophore formation. Alternatively, 
mitochondrial dysfunction can lead to several receptors being expressed on the OMM resulting in LC3 on 
the phagophore binding. The resultant phagophore expands enclosing the damaged mitochondria forming 
an autophagosome which can fuse with lysosomes allowing degradation via lysosomal enzymes. Adapted 
from Harris et al., 2018.   
CHAPTER 1   GENERAL INTRODUCTION 
14 
 
Most importantly in neurodegenerative diseases dysfunctional mitochondria are 
associated with increased RS levels (Islam, 2017; Liu et al., 2017). As mentioned previously electrons 
are passed down the ETC to produce ATP but dysfunctional mitochondria lead to electrons ‘leaking’, 
which react with molecular oxygen generating superoxide, which is described in greater detail 
below. Therefore, inducing oxidative stress using mitochondrial inhibitors is a common strategy to 
investigate the role of ROS in neurodegeneration.  
1.2.2 Oxidative stress 
Redox reactions consist of the transfer of electrons resulting in oxidation (loss of electrons) or 
reduction (gain of electrons). These redox reactions are central to biological functions including 
metabolism and respiration (Franco and Vargas, 2018). In aerobic organisms, oxygen is the main 
oxidising agent, the main source of ROS and subsequent reactive nitrogen species (RNS). Redox 
biology has been implicated in health and disease, which is mostly attributed to altered reactive 
species (RS) homeostasis. Redox reactions in cells consist of electrons transferring between 
molecules, which cycle between an oxidised and reduced state to regulate metabolism and cell 
signalling (Paul D. Ray et al., 2012; Trachootham et al., 2008). This redox homeostasis is an 
integrated process between neurons and glia (Baxter and Hardingham, 2016).  
Oxygen is of great importance for neural cells as they have a high metabolic rate and 
reduced regenerative capacity relative to other organs. As a result, the brain is more susceptible to 
damage via oxidative and nitrosative stress; as such these stresses are implicated in a variety of 
neurodegenerative diseases (Halliwell, 2019; Koskenkorva-Frank et al., 2013). However, despite 
being recognised as an underlying mechanism in neurodegeneration, understanding how these 
stresses contribute to the development and progression of neurodegenerative diseases is not fully 
understood. As such, a greater understanding as to how these processes are involved in 
neurodegenerative disease will lead to the identification of novel therapies.  
1.2.2.1 Generating reactive oxygen and reactive nitrogen species  
The brain utilises mitochondria to provide ATP via oxidative phosphorylation (Franco-Iborra et al., 
2016). Mitochondria also regulate cell survival and contain redox enzymes (Danial and Korsmeyer, 
2004; Karbowski, 2010) such as superoxide dismutase (SOD). Increased RS levels are mainly 
attributed to mitochondrial dysfunction (Schapira, 2008) though dopamine oxidation, xanthine 
oxidase and NADPH oxidase (NOX) also contribute (Gandhi and Abramov, 2012a; Winterbourn and 
Hampton, 2008; see figure 1.5). 
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 Incomplete reduction typically occurs as electrons can ‘leak’ from the ETC during oxidative 
phosphorylation. Such leaks initially result in superoxide (O2·-) formation (Fariss et al., 2005). The 
O2·- levels generated are relatively low and therefore neutralised by matrix localized antioxidants. 
However, if the ETC complexes become impaired or dysfunctional O2·- levels can significantly rise, 
and redox homeostasis can become unbalanced. If not scavenged, O2·- is dismutated to hydrogen 
peroxide (H2O2) by superoxide dismutase (SOD). Multiple enzymes remove H2O2 including: 
peroxiredoxins (PRDXs), glutathione peroxidases (GPXs) and catalase (Birben et al., 2012; Schafer 
and Buettner, 2001). H2O2 oxidises PRDXs at cysteine within the active, which is subsequently 
reduced by thioredoxin, thioredoxin reductase and NADPH or glutathione (Park et al., 2016). GPXs 
are also oxidised by H2O2 and then reduced by glutathione (GSH). In contrast, catalase is localised 
to peroxisomes (Winterbourn and Hampton, 2008) and decomposes H2O2 to water and oxygen. If 
H2O2 is not dismutated, iron catalyses the Fenton reaction producing hydroxyl radicals. Hydroxyl 
radicals are the most reactive ROS, which can damage protein, lipids, carbohydrates, DNA and 
initiate lipid peroxidation by removing an electron from polyunsaturated fatty acids (Birben et al., 
2012). 
Ultimately, the generation of O2·- results in a cascade of other RS that each have unique 
properties and biological targets (see figure 1.5). For example, H2O2 lacks a charge and can therefore 
diffuse across membranes, while O2·- is charged and has limited permeability (De Grey, 2002). 
Furthermore, H2O2 reacts with cysteine and methionine residues within proteins while O2·- reacts 
preferentially with iron sulphur centres and nitric oxide (D’Autréaux and Toledano, 2007). 
Therefore RS characteristics will determine their ability as damaging or signalling molecules 
(Winterbourn, 2008).  
In addition, ROS can generate reactive nitrogen species (RNS) such as nitric oxide (·NO) and 
peroxynitrite (ONOO-) (Sultana et al. 2013; see figure 1.5), which are involved in signalling and 
neuronal damage (Cobb and Cole, 2015). ·NO like O2·- is a short-lived diffusible molecule involved 
in inflammation and synaptic transmission (Moncada and Bolanos, 2006). L-Arginine, NADPH and 
oxygen act as substrates for nitric oxide synthase (NOS) producing ·NO, citrulline and water (Smith 
and Lassmann, 2002) while using cofactors flavin mononucleotide, flavin adenine dinucleotide, 
tetrahydrobiopterin, haem and NADPH. However, if tetrahydrobiopterin levels are depleted NOS 
can produce O2·- (Moncada and Bolanos, 2006). If O2·- reacts with ·NO peroxynitrite is produced. 
This reaction primarily occurs where superoxide is produced due to its short lifetime. Peroxynitrite 
can subsequently undergo protonation and homolytic cleavage producing nitrogen dioxide (·NO2) 
and hydroxyl radicals (Hogg and Kalyanaraman, 1999). Therefore, a variety of RS can be generated 
which can react with various targets (summarised in table 1.2).  
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RS are chemically reactive due to the possession of an unpaired electron making these 
molecules unstable. Under natural conditions these are involved in cellular activities such as 
inflammation, cell survival, stressor response and multiple diseases including; cardiovascular 
disorders, allergies, cancers and neurodegenerative diseases (He and Zuo, 2015; Zuo et al., 2015, 
2014). High levels of these RS can lead to disruption of the redox balance between prooxidant and 
antioxidant levels leading to alterations in cellular function and possibly cell death (Zuo et al., 2015). 
This redox balance can be disrupted by inflammation or mitochondrial dysfunction (Rego and 
Oliveira, 2003; Sharma and Nehru, 2015). Furthermore, protein aggregates can result in 
inflammation leading to RS upregulation and subsequent OS (Wyss-Coray and Mucke, 2002; Zuo et 
al., 2015). It should also be noted that OS can result in post-translational modifications to proteins 
leading to aberrant proteins, which can then aggregate causing inflammation (Bantle et al., 2019; 
Burns and Wang, 2017). Therefore, disruption of redox homeostasis can result in a feed forward 
loop leading to cell damage and ultimately death.  
Thus, to aid in attenuating OS, antioxidants such as glutathione or vitamin C and E are 
suggested as possible treatments. Unfortunately, antioxidant treatments have yielded mixed 
results. In some in vitro studies antioxidants have been successful in reducing OS and neuronal 
Figure 1.5. Superoxide generations leads to a cascade of other reactive species. Superoxide can be 
dismutated to hydrogen peroxide (H2O2) via superoxide dismutase. H2O2 can also be generated by 
monoamine oxidase. Subsequently, the toxic H2O2 can be reduced to water and oxygen via detoxifying 
enzymes catalase, peroxiredoxin and glutathione peroxidase. However, if the levels of H2O2 are too great 
to be detoxified then the high levels of iron in neurons can result in the Fenton reaction resulting in peroxy 
and hydroxyl ROS. Alternatively, superoxide can react with nitric oxide from diet or nitric oxide synthase to 
generate peroxynitrite, which can degrade into nitrogen dioxide radicals. Adapted from Winterbourn, 
2008.   
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degeneration (Ambrogini et al., 2019; Then et al., 2010). Further in vivo treatment with vitamin E 
for 2 years attenuated functional decline in AD patients (Ittner et al., 2010) and early life 
supplementation with vitamin E appears to reduce the risk of PD (Miyake et al., 2011). However, 
others report that 5 months treatment with orally administered vitamin E had no effect in PD 
patients (Pappert et al., 1996). Although another more recent double blind test showed vitamin E 
supplementation yielded more promising results (Taghizadeh et al., 2017). These controversies are 
possibly due to the limited amount of vitamins passing into the blood from the intestine as 
tocopherol can pass through the blood brain barrier (Peltzer et al., 2018). As such, understanding 
possible downstream effectors of OS may be critical to develop novel therapies for 
neurodegenerative diseases such as PD.   
Table 1.2 Summary of reactive species generated, and potential targets identified.  
Oxidant  Formula  Reaction Equation Target Outcome Ref. 
Superoxide O2•- NADPH + 202 ↔ 
NADP+ + 2O2•- 
Mitochondrial 
uncoupling  
Activates nucleotide-
sensitive mitochondrial  
proton transport 
(Echtay et 
al., 2002) 
Hydrogen 
peroxide 
H2O2 2O2•- + H+ → O2 + 
H2O2 
Hypoxanthine + H2O 
+ O2 ⇌ Xanthine + 
H2O2 
Xanthine + H2O + O2 
⇌ uric acid + H2O2   
   
STAT6 Cyclooxygenase-2 
expression and 
prostaglandin release  
(Park et 
al., 2012) 
Hydroxyl 
radical 
HO• Fe2+ + H2O2 → Fe3+ + 
OH- + HO• 
Unsaturated 
fatty acids in 
membranes 
Lipid peroxidation, 
production of 4-
hydroxynonenal 
(Sultana 
et al., 
2013a) 
Nitric oxide  •NO L-Arginine +3NADPH 
+ H+ + 4O2 ⇌ 
2Citrulline + 2•NO + 
4H2O + 3NADP+ 
Neuronal 
plasticity via 
cGMP and ERK 
Improves neuronal 
plasticity  
(Gallo and 
Iadecola, 
2011) 
Peroxynitrite  ONOO-  O2•- + •NO → ONOO- Tyrosine 
hydroxylase  
Inhibit tyrosine 
hydrogenase, decreased 
dopamine levels  
(Ara et al., 
1998; Park 
et al., 
2003) 
 
1.2.2.2 Antioxidant defences 
 As cellular RS levels increase for signalling during metabolic processes and inflammation it is 
important for the brain to have suitable defence mechanisms to scavenge and dispose of excess RS 
to return redox balance. As such, the brain has multiple enzymes that catalyse the breakdown or 
removal of RS including superoxide dismutase (SOD), catalase, peroxiredoxins (PRDX), glutathione 
peroxidases (GPX), glutathione (GSH) and a few other molecules.  
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 Within the central nervous system there are 3 isoforms of SOD; cytosolic CuZnSOD1, 
mitochondrial MnSOD2 and extracellular SOD3. These enzymes are responsible for removing 
superoxide by catalysing its dismutation to hydrogen peroxide and oxygen (Dasuri et al., 2013; Y. 
Wang et al., 2018).  
 Catalase is one enzyme responsible for the removal of hydrogen peroxide, present in the 
cytosol, mitochondria and peroxisomes but has a minor role with low levels of hydrogen peroxide 
but is more important when levels are higher (Gandhi and Abramov, 2012). Peroxiredoxins (PRDXs) 
have more recently be identified to be important for the removal of hydrogen peroxide (Stöcker et 
al., 2018). There are 3 classes of PRDXs in animals; typical 2-cysteine, atypical 2-cysteine and 1-
cysteine with 6 isoforms across these classes (PRDX1-6;(Rhee, 2016). For all PRDXs the thiol group 
of the active site cysteine is oxidised to sulfenic acid resulting in a disulphide bond (see figure 1.6; 
Espinosa-Diez et al., 2015). This disulphide bond is reduced by thioredoxin (PRDX1-5) or glutathione 
(PRDX6; Poole et al., 2011; Turner-Ivey et al., 2013) and is responsible for the removal of hydrogen 
peroxide in the cytoplasm and mitochondria (Hall et al., 2011). PRDXs are catalytically slower than 
glutathione peroxidases, but are present in large amounts within the cytosol and organelles to 
compensate for this (Rhee et al., 2005). Furthermore, it is important to note that hydrogen peroxide 
partially inactivates PRDXs possibly to allow cell signalling (Halliwell and Gutteridge, 1991; Rhee et 
al., 2005) but more PRDX is synthesised to remove excess hydrogen peroxide (Georgiou, 2003).  
Figure 1.6. Schematic representation of glutathione and thioredoxin coupling antioxidant systems. Thiol 
groups on various proteins can be oxidised to produce disulphide bridges (SS). Glutathione (GSH) or 
thioredoxin (TRX) can reduce disulphide bridges back to thiol groups while being oxidised producing 
oxidised glutathione disulphide (GSSG) and oxidised thioredoxin (TRX-SS). GSSG and TRX-SS can be reduced 
by glutathione reductase (GSH-r) and thioredoxin reductase (TRX-r), respectively, in the presence of 
NADPH allowing constant recycling of these proteins so they can act as antioxidants. Adapted from 
Espinosa-Diez et al., 2015. 
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Glutathione peroxidase (GPX) is another enzyme responsible for reducing hydrogen 
peroxide but also lipid peroxides using GSH as the electron donor (Dasuri et al., 2013; Gandhi and 
Abramov, 2012). GPX is present in both the mitochondria and cytosol (Conrad and Friedmann 
Angeli, 2018). Glutathione (GSH) is a tripeptide of glutamate, cysteine and glycine serving to protect 
against OS (Dasuri et al., 2013; Gandhi and Abramov, 2012) in both a direct and indirect manner. 
Directly via oxidation of cysteine residues and indirectly, GSH reduces peroxides (Miller et al., 2018) 
by becoming oxidised to a disulphide bridge (GSSG), which can be reduced back to GSH by 
glutathione reductase in the presence of NADPH, which donates an electron for the reduction 
(Dringen et al., 2000; Dringen and Hirrlinger, 2003; see figure 1.6). Interestingly, GSH levels are 
lower in neurons than glia; the latter assisting neuronal GSH levels by supplying cysteinyl-glycine, 
the precursor of GSH (Dringen et al., 2005; Dringen and Hamprecht, 1997). Furthermore, glia appear 
to be more resistant to RS possibly due to the higher GSH levels and accelerated GSH synthesis 
under stress relative to neurons (McBean, 2017).  
In addition to enzymes, there are also some low molecular weight antioxidants within the 
central nervous system (CNS), such as ascorbate (vitamin C) and tocopherol (vitamin E; Rice, 2000). 
Typically, intracellular mammalian levels of vitamin C range from 0-5 mM (Du et al., 2012) with 
neurons exhibiting 10 mM (Harrison and May, 2009), suggesting it plays an important role in 
survival. Further supporting this, knockout of sodium vitamin C transporter 2 in mice resulted in 
decreased ascorbate levels in the blood, brain and tissue and these mice died within a few minutes 
of birth (Sotiriou et al., 2002). Vitamin C is water soluble and at physiological pH exists as ascorbate 
which acts as an electron donor (Nishikimi, 1975; Rice, 2000). Neurons readily uptake ascorbate 
whereas astrocytes uptake dehydroascorbate and convert this to ascorbate (McBean, 2017).  
Voltammetry reveals that vitamin C can lose two electrons for reducing other molecules, 
but commonly functions as a one electron reducing agent as oxidation of ascorbate produces 
monodehydroascorbate radical, which exhibits resonance stabilisation (Deakin et al., 1986; 
Smirnoff, 2018). As a result of stabilisation monodehydroascorbate radicals do not react readily 
with oxygen or other molecules to generate more radicals but act as effective radical scavengers, 
in particular superoxide (Cabelli and Bielski, 1983; Smirnoff, 2018; Wenzel, 2003). This is supported 
by studies that show that superoxide levels and markers of oxidation, such as lipid peroxidation and 
carbonyl levels are reduced by vitamin C (Das et al., 2019; Kondo et al., 2008; Patra et al., 2001; 
Wenzel, 2003).   
Vitamin E, like vitamin C, can scavenge superoxide but with a lower affinity as 
demonstrated by the higher rate constant (Gotoh and Niki, 1992). Vitamin E, also known as 
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tocopherol, is important for the oxidative status of the brain where greater levels are observed in 
astrocytes relative to neurons (Lee and Ulatowski, 2019; Makar et al., 2008).  Vitamin E is taken up 
from the intestine (Traber et al., 1990) via eight different isoforms; α-, β-, γ-, and δ- tocopherol 
(saturated) and tocotrienols (unsaturated) which exhibit antioxidant activity. In vitro, α-tocopherol 
is the most reactive (Burton and Ingold, 1986) due to the α-tocopherol transfer protein (α-TTP) (B. 
Li et al., 2013) and redistributes to other tissues. Both oxidative status and vitamin E levels affect 
expression of α-TTP in the brain (Ulatowski et al., 2012) where levels also vary depending on specific 
areas. Interestingly, expression of α-TPP is highest in cerebellar astrocytes (Hosomi et al., 1998), 
suggesting greater levels of vitamin E in astrocytes (Lee and Ulatowski, 2019; Makar et al., 2008).  
Vitamin E has established a role in neurological health via mitigation of OS, as severe and 
prolonged deprivation leads to neurological damage (Takahashi et al., 2017). Furthermore, AD and 
PD patients exhibit lower levels of vitamin E in the blood and cerebral spinal fluid, although other 
studies contradict this (reviewed in Chang et al., 2018). However, it is believed that vitamin E 
localises mainly to cell membranes where it reduces lipoprotein oxidation by scavenging peroxyl 
radicals (Mocchegiani et al., 2014; Niki, 2014). Furthermore, more recently vitamin E has been 
demonstrated to suppress ferrotopsis in vitro preventing phospholipid oxidation, which leads to 
cell death (Wortmann et al., 2013). Therefore, vitamin E appears to play a key role in neurological 
health by modulating OS.  
DJ-1 is also reported to be involved in the OS response and mutations in DJ-1 are associated 
with the protein becoming functionally inactive resulting in early-onset PD (Bonifati et al., 2003; see 
section 1.1.1). DJ-1 is thought to act as an antioxidant via oxidation of its Cys106 residue (Taira et 
al., 2004). In support of this, the auto-oxidation of DJ-1 eliminates RS in vivo and in vitro (Taira et 
al., 2004; Yokota et al., 2003). Interestingly, OS has been shown to induce DJ-1 expression 
(Mitsumoto et al., 2001). DJ-1 is required for nuclear factor erythroid 2-related factor (NRF2) 
activity (Clements et al., 2006), as it affects NRF2’s association with the inhibitor protein Kelch-like 
ECH associated protein 1 (KEAP1), which ubiquitinates NRF2 (Dhakshinamoorthy and Jaiswal, 2001; 
Itoh et al., 1999). NRF2 is a leucine zipper transcription factor involved in the regulation of 
antioxidant pathway gene activation (Cho et al., 2006). Once dissociated from KEAP1 NRF2 becomes 
stable and translocates to the nucleus (Chen and Kong, 2004; Nguyen et al., 2005). There it forms 
heterodimers with other regulators inducing and driving the expression of antioxidant genes (Lee 
et al., 2003a) and detoxification enzymes (Alam et al., 1999; Tonelli et al., 2018) mentioned 
previously (Chen et al., 2014; see figure 1.7). 
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1.2.2.3 Oxidative and Nitrative stress during neurodegeneration  
As mentioned previously RS can be generated from a variety of sources (see figure 1.5), which are 
balanced by a variety of antioxidant defences that can be activated by RS sensitive transcription 
factors. In addition to activating transcription factors, oxidative and nitrative stress can cause a 
variety of post-translational modifications (PTMs) to different amino acid residues in various 
proteins. Despite understanding the encoding genome, the proteome is approximately 2-3 orders 
greater in size, suggesting PTMs play an important role in homeostasis.  PTMs can result from 
enzymatic and non-enzymatic attachment of chemical groups to amino acid sides chains (Walsh et 
al., 2005), which influence their structure and cellular functions. Furthermore, dysregulation of 
PTMs is associated with aging and is known to affect disease conditions (Cloos and Christgau, 2004; 
Gorisse et al., 2016; Liddy et al., 2013). PTMs can be divided into enzymatically and non-
enzymatically driven reactions, involving covalent cleavage of peptide backbones or covalent 
additions to amino acid side chains. Redox PTMs are non-enzymatic PTMs that depend on reactive 
species which involve covalent additions to side chains (summarised in table 1.3).  
 These covalent additions by redox PTMs can be reversible or irreversible. For example 
carbonylation is a common oxidative PTM where a carbonyl moiety such as aldehyde, ketone or 
lactam is added to proteins (Møller et al., 2011). Carbonylation can occur on several residues 
including arginine, histidine, lysine, proline, threonine and cysteine where cytoskeletal proteins 
such as neurofilaments and tubulin are particularly susceptible to carbonylation (Bizzozero, 2009).  
Nitration was initially believed to be an irreversible redox PTM, produced by RNS that react 
with tyrosine residues generating 3-nitrotyrosine (Sadowska-Bartosz et al., 2014) but dinitrase 
enzymes have been frond that reverse this PTM (Deeb et al., 2013). Furthermore, nitration appears 
to be highly selective with only specific tyrosine residues being nitrated, with only a fraction of the 
proteome being affected (Radi, 2013). This suggests nitration is highly regulated and it is when 
PTMs are no longer regulated this PTM contributes to neurodegeneration. This is supported by 
studies which demonstrate that 3-nitrotyrosine is associated with nitrative stress during aging 
(Bandookwala and Sengupta, 2020). More specifically, α-synuclein nitration appears to promote LB 
formation due to the PTM decreasing its solubility (He et al., 2019). Furthermore, tyrosine nitration 
of complex I in SH-SY5Y cells has been shown to irreversibly inhibit complex I in the ETC, (Murray et 
al., 2003; Yamamoto et al., 2002) and hence associated with decreased ATP synthesis alongside 
enhanced apoptotic and necrotic cell death (Davis et al., 2010). Therefore, tyrosine nitration PTMs 
may contribute to neurodegeneration via promoting protein aggregation or mitochondrial 
dysfunction.  
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 RNS can also cause another reversible PTM referred to as S-nitrosylation, which occurs in 
the presence of a transition metal that accepts an electron (Smith and Marletta, 2012), targeting 
the thiol groups of cysteine and methionine residues (Nakamura and Lipton, 2016; Stamler et al., 
1997). Like other redox PTMs, S-nitrosylation is associated with neurodegenerative diseases 
(reviewed in Nakamura et al., 2013). Similar to nitration, S-nitrosylation can inhibit components of 
the ETC (Di Giacomo et al., 2012; Montagna et al., 2020) including complex I (Chouchani et al., 
2013). S-nitrosylation can further affect mitochondria as nitrosylation of cys644 in DRP1 enhances 
its oligomerization and GTPase activity, resulting in excessive mitochondrial fragmentation leading 
to synaptic loss and neuronal damage (Cho et al., 2009; Z. Zhang et al., 2016). Furthermore, parkin 
S-nitrosylation is linked to autosomal recessive juvenile onset Parkinson’s, contributing to abnormal 
mitochondrial dynamics by effecting E3 ligase activity in a biphasic manner (Yao et al., 2004).  
 RS can also lead to lipid peroxidation. This alters lipid-lipid interactions, ion gradients, 
membrane fluidity and membrane permeability (Borst et al., 2000a; Saleh et al., 2010). In addition, 
lipid peroxides are labile and can degrade causing additional toxicity. For example, ferrous irons can 
react with lipid peroxides generating corresponding alkoxyl radicals that can propagate 
Figure 1.7. Schematic representation of NRF2-ARE pathway activated by reactive species. Under normal 
conditions NRF2 associates with KEAP1 in the cytoplasm where it becomes ubiquitinated as a signal for 
proteasomal degradation. Under oxidative stress reactive oxygen species (ROS) levels increase resulting in 
dissociation of NRF2 from KEAP1. This allows NRF2 to translocate to the nucleus where it binds to the 
antioxidant response element (ARE) upregulating transcription of antioxidants such as glutathione, 
glutathione peroxidase, peroxiredoxins, catalase and superoxide dismutase (SOD). Recently, DJ-1 is also 
believed to be important for aiding NRF2’s dissociation from KEAP1. Adapted from Chen et al., 2014.  
Cytoplas
m 
Nucleus 
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peroxidation reactions or aldehyde degradation products such as 4-hydroxynonenal (4-HNE) and 
malondialdehyde (MDA), which are highly reactive (Gaschler and Stockwell, 2017).  
 4-HNE can form stable adducts with proteins changing their function by modifying histidine, 
arginine, lysine and cysteine residues (Higdon et al., 2012), which can only be removed via 
controlled degradation of the protein. However, if not degraded these proteins can accumulate 
causing toxicity, where HNE forms adducts with mitochondrial respiratory chain subunits RS levels 
can increase (Harris et al., 2015; Lee et al., 2012; Reed et al., 2008). Mitochondrial HNE 
modifications can overwhelm autophagy as HNE concentration increases in neurons, contributing 
to mitochondrial dysfunction (Dodson et al., 2017; S. Zhang et al., 2017). In addition to 
mitochondrial dysfunction, lipid peroxidation products such as 4-HNE can induce oligomerisation 
of α-synuclein resulting in toxicity in SH-SY5Y cells and Parkinson’s disease (Näsström et al., 2011; 
Shamoto-Nagai et al., 2018).  
MDA like 4-HNE is another by product of lipid peroxidation where levels have been found 
to be 10-fold higher in the SN of post-mortem PD brains compared with other regions as well as 
age matched control (Całyniuk et al., 2016; Gökçe Çokal et al., 2017). Farias et al. also demonstrated 
increased levels of MDA and lipid hydroperoxides, both indicators of lipid peroxidation were 
elevated in the blood of PD patients (de Farias et al., 2016). Additionally, Farias et al. also showed 
that while MDA was present in both early and late phases of PD lipid hydroperoxides were only 
significantly higher in late stage PD, suggesting lipid peroxidation is associated with disease 
progression. As such MDA is another marker of oxidative stress, which is supported by prior vitamin 
E administration lowering MDA and protein carbonyl levels (Jhoo et al., 2004). MDA can also form 
protein adducts via modification of the lysyl residues of a protein (Barrera et al., 2018). Once formed 
MDA and 4-HNE can be reduced to alcohol by aldo-keto reductases or alcohol dehydrogenases or 
oxidised to acid by aldehyde dehydrogenases (Barrera et al., 2015).  
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Table 1.3 Summary of post-translational modifications associated with oxidative stress. Adapted from Santos and Lindner, 2017; Didonna and Benetti, 2015.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Post-translational 
modification  
Reversible/ 
irreversible 
Target amino acid 
residue 
Example  References  Infers 
Carboxylation  Irreversible Lysine, proline, 
arginine, threonine, 
histidine, cysteine  
Cytoskeletal proteins 
neurofilament and 
tubulin 
Bizzozero, 2009 Protein 
aggregation  
 
Nitration Reversible  Tyrosine α-synuclein promoting LB 
formation 
Complex I inhibition 
Takahashi et al., 2002 
Murray et al., 2003 
Yamamoto et al., 2002 
Davis et al., 2010 
Protein 
aggregation  
Mitochondrial 
dysfunction  
S-nitrosylation  Reversible  Cysteine, methionine Complex I inhibition  
DRP1 activation 
Parkin inactivation 
UCH-L1 inactivation 
Di Giacomo et al., 2012 
Sun et al., 2007 
Chouchani et al., 2013 
Cho et al., 2009 
Zhang et al., 2016 
Yao et al., 2004 
Kumar et al., 2017 
Mitochondrial 
dysfunction 
Protein 
aggregation 
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 In conclusion, RS can alter cell signalling but also cause changes via modification of protein 
structures (table 1.3). These protein modifications can be reversible or irreversible leading to either 
loss or gain of function. These modifications may lead to aberrant proteins that can accumulate 
forming toxic aggregates. Alternatively, cell toxicity can be caused by modifications of important 
machineries such as the complexes in mitochondria or proteasome, suggesting links between 
oxidative stress and the other hallmarks of neurodegeneration. Alternatively, lipid peroxidation can 
produce other molecules such as 4-HNE and MDA which are markers of oxidative stress but can 
also form protein adducts leading to proteotoxic stress.  
1.2.2.4 Generating oxidative stress to model neurodegeneration 
Excessive RS levels are associated with numerous pathologies (Poprac et al., 2017). The importance 
of redox balance is highlighted by the numerous biological mechanisms for combatting their toxic 
nature, including a variety of antioxidant enzymes. These RS appear to contribute to the pathology 
of various neurodegenerative disorders. Therefore multiple models have been used to investigate 
the role of RS in both signalling and neurodegenerative disorders (Reczek and Chandel, 2015).  
 Currently, most methods rely on the application of RS directly or indirect by increasing RS 
levels by inhibiting antioxidant pathways via drug treatment and/or genetic approaches to mimic 
neurodegenerative process. 6-hydroxydopamine (6-OHDA); a commonly used catecholaminergic 
neurotoxin, enters neurons via dopamine transporters resulting in catecholamine quinone 
formation leading to OS. In addition, 6-OHDA may inhibit complexes I and IV in the ETC (Glinka and 
Youdim, 1995) although this is not confirmed (Storch et al., 2000). Intracerebral injection of 6-OHDA 
resulted in increased levels of ROS including hydrogen peroxide, superoxide and hydroxyl radicals 
(Heikkila and Cohen, 1973).  
The most common way to induce RS is by using ETC inhibitors, particularly complex I 
inhibitors as complex I activity is reported to be reduced in the SN of PD patients (Blesa et al., 2015; 
Franco-Iborra et al., 2016; Schapira, 2008). Some of these reagents include rotenone, a ETC complex 
I inhibitor or antimycin A, a ETC complex III inhibitor, resulting in increased mitochondrial 
superoxide production resulting in OS (L. Wang et al., 2015). MPTP is another drug that causes 
Parkinsonian symptoms and dopaminergic neurodegeneration when humans and sub-human 
primates have been systemically injected (Choudhury and Daadi, 2018). MPTP is catabolised by 
MAOB in glia producing MPP+ which accumulates within dopaminergic neurons via dopamine 
transporters. Once within the neurons, MPP+ can then inhibit complex I generating ROS (Coyle and 
Puttfarcken, 1993). 
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Alternative genetic approaches for inducing RS include mutations in -synuclein, parkin and 
PINK which results in mitochondrial dysfunction leading to increased levels of RS (Blesa et al., 2015). 
Furthermore, evidence of point mutations in mtDNA may also be associated with complex I 
deficiency or mitochondrial dysfunction in PD (Hauser and Hastings, 2013), resulting in RS 
generation. Similar results were found in human neuroblastoma SH-SY5Y cell lines where PINK1 
deficiency lead to mitochondrial dysfunction and increased OS (Wood-Kaczmar et al., 2008). 
Genetic DJ-1 mutations promote its proteasomal degradation, promoting OS (Bonifati et 
al., 2003; Miller et al., 2003). DJ-1 null mice did not show widespread neuronal loss, however, they 
were more susceptible to toxins (Goldberg et al., 2005; Kim et al., 2005). This was supported in 
human neuronal cell lines where DJ-1 knock down resulted in cells being more susceptible to toxins 
(Taira et al., 2004; Yokota et al., 2003). Mutant forms of DJ-1 are reported to be unstable relative 
to wildtype DJ-1 (Di Nottia et al., 2017; Macedo et al., 2003). In models of Neuro2a cells where DJ-
1 was down-regulated neurons were more susceptible to H2O2 induced death. However, these cells 
were rescued with overexpression of wildtype DJ-1 but not mutant DJ-1 (Yokota et al., 2003). This 
suggests DJ-1 protects neurons from OS while mutant DJ-1 loses this function.  
 In conclusion there are multiple ways to generate RS such as directly exposing cells to RS, 
using reagents that inhibit pathways that reduce RS levels, or modulating scavenger enzymes either 
chemically or genetically. Establishing what species are generated from each toxin in precise 
locations will aid in establishing a better understanding of their role in signalling and damage in 
neurodegenerative disorders such as PD.     
1.2.3 Impaired protein degradation  
Although gene defects are not always present in sporadic cases, impaired protein handling 
is suggested to play a role in the pathogenesis of PD as part of the NBT. Protein degradation is 
important for removing aberrant toxic proteins that can accumulate and compromise cellular 
function and viability. Cytoplasmic inclusions known as Lewy bodies are a pathological feature of 
PD present in DA neurons of the SN and cerebral cortex (Braak et al., 1995). Formation of these LB’s 
is poorly understood, however, aberrant protein aggregation appears to occur when the cells ability 
to remove abnormal, mutated or oxidatively modified proteins is exceeded, or mechanisms of 
removal are impaired or inhibited (Lefaki et al., 2017). Studies have shown increased levels of 
oxidatively damaged proteins, protein aggregation and accumulation of poorly degraded proteins 
within LB’s (Thibaudeau et al., 2018). Oxidatively damaged protein levels are greater in the SN of 
PD brains, evidenced by elevated protein carbonyls and 4-hydroxynonenal (HNE) protein adducts 
(Shahmoradian et al., 2019; Zhao et al., 2017).  Evidence also suggests a general increase in protein 
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aggregation in the SN (Grünblatt et al., 2018). Together, multiple studies implicate impaired protein 
degradation or uncontrolled production of abnormal proteins plays a role in PD (Mcnaught et al., 
2001; Walden and Muqit, 2017). 
1.2.3.1 The ubiquitin proteasome system  
1.2.3.1.1 Structure and Function 
To prevent protein accumulation and aggregate formation under normal conditions intracellular 
proteins can be degraded in an ATP-dependent manner involving the ubiquitin proteasome system 
(UPS; Hough et al., 1986). This system is tightly regulated and plays a major role in cellular processes 
including: cell proliferation, differentiation, protein transport, antigen processing, DNA repair and 
apoptosis (Komander and Rape, 2012; Livneh et al., 2016). More recently studies have shown that 
the proteasome is also involved in proteolytic cleavage affecting protein function altering 
downstream processes (Olshina et al., 2018). The proteasome is one mechanism of aberrant 
protein removal  which has been reported as impaired or with reduced subunit expression in nigral 
Figure 1.8. Schematic representation of ubiquitin conjugation to target substrates to the ubiquitin 
proteasome system (UPS). Free ubiquitin (Ub) is initially activated by E1 in an ATP-dependent step to form 
a thiol-ester bond between E1 and the carboxy-terminus of Ub. Ub is transferred to E2 via a trans-
thiolation reaction. E2 associates with E3 which has a substrate already bound. Ubiquitin is then 
transferred to the substrate forming an isopeptide bond with a lysine residue in the substrate. Successive 
addition of Ub to initial Ub creates a polyubiquitin chain. If conjugated to K48 this is recognised as a signal 
for degradation by the 26S proteasome. Adapted from Glickman and Ciechanover, 2002. 
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post-mortem tissue (McNaught et al., 2003). Proteasome degradation involves ubiquitin; a 76-
amino acid globular protein, covalently added post-translationally.  
Ubiquitin conjugation proceeds via a three-step cascade mechanism involving E1, E2 and 
E3 enzymes (Figure 1.8; Glickman and Ciechanover, 2002). E1, the ubiquitin activating enzyme, 
activates ubiquitin in an ATP-dependent manner producing a high-energy thiol-ester intermediate 
with the carboxy-terminal glycine of ubiquitin. Subsequently, E2, a ubiquitin conjugating enzyme, 
accepts activated ubiquitin from E1 via a trans-thiolation reaction and transfers ubiquitin to the 
substrate that in some cases is specifically bound to E3, a ubiquitin protein ligase. Generally, 
ubiquitin is conjugated to the substrate through an isopeptide bond with the ε-NH2 of a lysine 
residue in the substrate (Ciechanover and Brundin, 2003). Successive addition of ubiquitin 
molecules to the initial ubiquitin conjugated to the substrate creates a polyubiquitin chain (Kwon 
and Ciechanover, 2017). Different linkages in these polyubiquitin chains can exhibit distinct 
functions. Polyubiquitin chains linked through lysine 48 (K48) residues target proteins for 
degradation via the 26S proteasome (Chen and Sun, 2009). 
The 26S proteasome is composed of complexes centred on the 20S proteasome core 
particle (CP) which is capped at both ends by the 19S regulatory particles (RPs), regulated by 
multiple chaperones (Bedford et al., 2010). The 20S CP structure displays a cylindrical structure 
made up of four heptameric rings composed of seven α and β subunits stacked as a α7-β7-β7-α7 
arrangement giving a pseudo-sevenfold symmetry. The -subunits form the outer ring while the β 
subunits form the inner (Groll et al., 1997). The 20S CP is responsible for degrading proteins in 
mammals via three enzymatic β-subunits (Deshmukh et al., 2019; Unno et al., 2002) which have 
chymotryptic, tryptic and post acidic-like hydrolysing activity. The CP acts as a channel with an open 
and closed conformation, where by itself it is closed due to the highly conserved N-terminals of the 
seven alpha subunits (Groll et al., 2000). The narrow channel in combination with the enzymatic 
specificity minimises non-specific proteolysis.  
The 19S RP is responsible for controlling entry to the CP channel and consists of 2 major 
assemblies defined as the lid and the base, each of which consist of nine subunits (Finley, 2009; 
Kwon and Ciechanover, 2017). Rpn11 is the key component of the lid which is a metalloprotease 
deubiquitinating enzyme situated above the Rpt entry port ring (Pathare et al., 2014; Verma, 2002; 
Worden et al., 2014). The base consists of a hexamer of non-redundant ATPases containing Rpt1-
6. These ATPases convert the energy from ATP hydrolysis into mechanical force. Within eukaryotes 
it is believed that these different Rpt subunits evolved for recognising ubiquitin signals for 
degradation. However, currently it is unknown if the 6 subunits hydrolyse ATP in a random, 
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sequential or concerted manner (Beckwith et al., 2013; Peth et al., 2013; Rubin, 1998). Within the 
Rpt subunits is a coiled coil helix domain which promotes assembly of the ring via contacts with 
other regions of the base and lid. These subunits also contain an OB domain which restricts access 
through the entry port (Lander et al., 2012; Lasker et al., 2012). The ring also has Rpn1, Rpn2 and 
Rpn13 subunits, which can dock ubiquitin both directly and indirectly (Hamazaki et al., 2015; 
Husnjak et al., 2008).  
In addition to ubiquitin, molecular chaperones are essential for folding proteins, refolding 
damaged proteins and targeting irreversibly damaged proteins to the UPS for degradation 
(reviewed in Balchin, Hayer-Hartl and Hartl, 2016). Many of these chaperones are heat shock 
proteins (HSPs). Transcription of these HSPs is controlled by heat shock transcription factor 1 
(HSF1), which is constitutively expressed in most tissue and cell types where post translational 
modifications modulate its activity (Xu et al., 2012). Under normal conditions HSF1 is a monomer 
localised to the cytosol but under stressful conditions HSF1 homotrimerises, becoming active and 
translocating to the nucleus (Rabindran et al., 1993; Utani, 2010). Once in the nucleus, HSF1 binds 
to the cis-regulatory element of DNA (the heat shock element) leading to an increase in HSP 
expression (Jacob et al., 2017).   
One member of the HSP family particularly important in response to ROS is HSP70, which 
participates in protein trafficking, early stage protein folding and refolding or degradation of 
aggregate peptides, especially those modified by RS (Bukau et al., 2006; Lazarev et al., 2016). HSP70 
recognises early stage protein folding via short hydrophobic regions that are rich in leucine residues 
(Rudiger, 1997). If folding is not possible HSP70 associates with co-chaperones to promote 
degradation (Fernández-Fernández et al., 2017).  
1.2.3.2 Proteasome dysfunction during aging and neurodegeneration 
Rare forms of familial PD have shown mutations in UCH-L1, a deubiquitinating enzyme suggesting 
protein degradation and the UPS may play a role in neuronal loss. Furthermore aggregates have 
been detected in neurons within the SN of PD patients (Braak et al., 2003), suggesting protein 
homeostasis disruption. In addition, proteasome activity declines in the brain and spinal cord with 
aging (Finley, 2018). 
Proteasome catalytic activity and subunit levels are reported to decline in SN post-mortem 
tissue but not the cortex or striatum of PD patients (Mcnaught et al., 2001; McNaught et al., 2003). 
This suggests DA neurons may be more vulnerable to dysfunctional UPS in sporadic PD. 
Furthermore rats treated with rotenone for 5-7 days to model PD exhibit significantly decreased 
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proteasomal activity in the ventral midbrain but not in striatal or cortical regions (Betarbet et al., 
2006). Additionally, greater levels of ubiquitinated proteins in DA neurons were detected in 
rotenone treated rats relative to controls, while 20S proteasome levels did not change suggesting 
loss of proteasomal activity and not subunit levels (Betarbet et al., 2006). In vitro SK-N-MC 
neuroblastoma cells treated with rotenone for 3 weeks showed an increase in proteasomal activity 
suggesting an initial compensation followed by a significant reduction in activity after 4 weeks 
(Betarbet et al., 2006). This suggests continuous rotenone exposure eventually overwhelms the 
proteasome, possibly via generation of RS and subsequent accumulation of oxidised proteins.    
Oxidatively modified proteins are present in LB’s within the SN of PD patients (Giasson, 
2000; Luk, 2019).  One method of degrading oxidatively damaged proteins involves the 20S 
proteasome (Lefaki et al., 2017) via ubiquitination or in an ATP-dependent manner (McNaught and 
Jenner, 2001; Shringarpure et al., 2003). In vitro studies with SH-SY5Y cells treated with rotenone 
showed reduced proteasomal activity with concurrently increased levels of oxidatively modified 
proteins, suggesting impaired proteasomal function leads to increased levels of damaged proteins 
(Shamoto-Nagai et al., 2003). In addition, Shamoto-Nagai et al. also report proteasomal subunit 
oxidation. Additionally, a study suggests the 26S proteasome is more vulnerable to OS than the 20S 
proteasome alone (Raynes et al., 2016; Reinheckel et al., 2000). RNS such as nitric oxide and 
peroxynitrite directly added to cell lysates also resulted in decreased 20S activity (Chou et al., 2010). 
Together, this suggests that both ROS/RNS can affect proteasome activity directly by modifying 
subunits leading to high levels of aberrant proteins, or indirectly through overwhelming the UPS 
with oxidatively damaged proteins resulting in protein aggregates and degeneration.  
Accumulation of misfolded proteins leads to upregulation of HSPs to assist in refolding 
damaged proteins or sending irreversibly damaged proteins to the UPS for degradation 
(Ciechanover and Brundin, 2003; Esser et al., 2004). For example, astrocytes are reported to have 
high levels of HSP25 under basal conditions but accumulate following proteasomal stress 
(Goldbaum et al., 2009). Furthermore, mutations in molecular chaperones have been associated 
with neurodegeneration (Gorenberg and Chandra, 2017). In AD patients, HSP90 levels have been 
reported to be elevated in cytosolic and membranous fractions (Dou et al., 2003; Gracia et al., 
2019). Another study has shown that S-nitrosylation of the critical thiol group of HSP90 abolishes 
its ATPase activity required for its function as a molecular chaperone (Martinez-Ruiz et al., 2005; 
Nakamura and Lipton, 2017). Additionally, upregulation of HSP70 prevented neurodegeneration in 
in vivo PD models (C.-W. Zhang et al., 2016). It is also important to note that aggregates have been 
found to contain chaperones such as HSP70 and HSP27 (Ito et al., 2002; Rideout and Stefanis, 
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2002).Together, these studies suggest changes in molecular chaperones, possibly via higher RS 
levels, contribute to misfolded protein accumulation, aggregation and cell death.  
1.2.4. Links between mitochondrial dysfunction, oxidative stress and impaired protein 
degradation 
The pathogenesis of neurodegenerative diseases is still unclear yet is vitally important due to the 
ever-growing aging population. While there are a variety of neurodegenerative diseases each 
affecting different brain regions, they share two key characteristics: insoluble protein aggregates 
and neuronal degeneration (Merlini and Bellotti, 2003). Post-mortem PD patient brains have shown 
reduced proteasome activity in the nigral striatum (McNaught and Jenner, 2001; McNaught et al., 
2003) alongside mitochondrial dysfunction (Goedert et al., 2017; Loeb et al., 2010; Luth et al., 2014) 
and increased levels of oxidatively modified proteins, lipids and DNA (Goedert et al., 2017; 
Ischiropoulos and Beckman, 2003; Jenner and Olanow, 1996). Therefore, there is evidence for 
multiple systems being affected in neurodegeneration and it is reasonable to investigate if these 
factors are interrelated.  
 A possible unifying mechanism that can induce protein aggregation and neuronal 
degeneration involves the pathways that reactive oxygen and nitrogen species can drive. This is 
supported by increased levels of oxidatively modified proteins, DNA and lipids observed in post-
mortem PD tissues (Goedert et al., 2017; Ischiropoulos and Beckman, 2003) as well as in familial 
cases, as mentioned previously. While this does not confirm that OS is the sole reason for the 
pathogenesis of neurodegeneration, it establishes a role for OS that links with the other hallmarks 
of neurodegeneration.   
 If antioxidant systems are overwhelmed alongside decreased mitochondrial function, OS 
has been shown to increase susceptibility to proteotoxic stress (Breitzig et al., 2016; Harris et al., 
2015; Xun et al., 2012). RS can affect proteostasis directly via post-translational modifications or 
affecting degradation via the proteasome. Modifications of proteins can result in gain or loss of 
function due to secondary and tertiary structure alteration (Nedić et al., 2013; Perez et al., 2009; 
Trougakos et al., 2013). As a result of these PTMs, proteins can misfold exposing hydrophobic 
regions which aggregate together (Weids et al., 2016). Aggregates can accumulate and overwhelm 
the UPS by forming stable insoluble complexes which can lead to cell death (Espay et al., 2019; 
Lindersson et al., 2004). As a result of reduced proteasome activity, oxidatively modified proteins 
can accumulate resulting in more aggregates and inclusion body formation. Consequently, cellular 
dysfunction and apoptosis ensues (Demasi and Davies, 2003; Ding et al., 2004; Rideout et al., 2001). 
More recently, aggregates have been demonstrated to be delivered to mitochondria resulting in 
CHAPTER 1   GENERAL INTRODUCTION 
32 
 
mitochondrial dysfunction (Ruan et al., 2017) linking OS, dysfunctional protein degradation and the 
apoptotic process.  
Rotenone, which inhibits complex I, shows a dose dependent decrease in UPS activity in 
HEK, SK-N-MC cells, and SH-SY5Y cells (McLennan and Degli Esposti, 2000; Shamoto-Nagai et al., 
2003) whereas other inhibitors of ETC complexes (e.g. antimycin or potassium cyanide) did not 
result in proteasome inhibition. Furthermore qRT-PCR revealed α- and β-subunit expression was 
the same regardless of rotenone treatment suggesting possible PTMs are affecting proteasomal 
activity (Chou et al., 2010). In addition, a previous study demonstrated α-tocopherol attenuated 
rotenone induced proteasome inhibition (Betarbet et al., 2006), though an alternate study 
contradicted this (Chou et al., 2010). Others showed pesticides effect mitochondrial morphology 
and function but also inhibited 20S and 26S proteasome activity (Chen et al., 2017). It is also 
important to note that cells treated with proteasome inhibitors exhibited increase RS levels (Dröge, 
2002). Livnat-Levanon et al have also demonstrated defective mitochondria induce RS and 
proteasome disassembly (Livnat-Levanon et al., 2014), which is supported by Rinaldi et al that show 
Rpn11-m1 mutated proteasome also exhibited increased levels of intracellular RS (Rinaldi et al., 
2002).  Whilst controversy remains on how proteasome activity is decreased under stress, RS and 
mitochondrial dysfunction appear to contribute to altered proteostasis and subsequent cell death.  
The link between dysfunctional proteostasis and RS is further highlighted by both pathways 
possessing common factors such as molecular chaperones including HSP27, HSP70, HSF1 and 
antioxidant response proteins such as NRF1 and 2. Small heat shock proteins such as HSP27 provide 
high affinity platforms for unfolded protein preventing aggregation under stress (Kayser et al., 2013; 
Somara and Bitar, 2006). These small HSPs are highly regulated by PTMs such as those that result 
from RS (Clements et al., 2007; Song et al., 2014). Furthermore, HSP27 targets damaged or mutated 
proteins to the UPS for degradation (Li et al., 2013; Outeiro et al., 2006). Additionally, HSP27 levels 
have been seen to be increased in astrocytes of PD patients (Shimura et al., 2017).  
HSP70, unlike HSP27 is a highly abundant HSP with various roles but is mainly involved in 
the correct folding of newly synthesised proteins, and refolding proteins that are misfolded or 
aggregated (Garrido et al., 2012). HSP70 is composed of 2 domains: an amino terminal ATPase 
domain and a  carboxy terminal substrate binding domain made up of a helical segment and β-
sandwich domain where the latter recognises hydrophobic amino acids (Hartl et al., 2011; Rüdiger 
et al., 1997). Furthermore HSP70 is reported to mediate dissociation and re-association of the 26S 
proteasome during adaption to OS (Grune et al., 2011).  
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These chaperones are regulated by heat shock factors (HSFs) where HSF1 is the dominant 
highly conserved transcription factor (Åkerfelt et al., 2007). Under normal homeostasis, HSF1 
remains inert as inactive monomers bound to chaperones such as HSP70 and HSP40. Stress results 
in chaperones binding aberrant proteins releasing HSF1 whereupon it undergoes phosphorylation, 
trimerization and nuclear localisation (Anckar and Sistonen, 2007). HSF1 can also sense OS via 2 
cysteine residues (Ahn and Thiele, 2003) and upon activation, HSF1 binds to the consensus heat 
shock element within the promoter regions of HSP genes, resulting in their activation and gene 
expression to aid in controlling responses to oxidative and proteotoxic stress (Anckar and Sistonen, 
2011).  
Transcription factors such as nuclear erythroid factor 1 and 2 (NRF1 and NRF2) are also 
influenced by oxidative stress. NRF2 has a short half-life of approximately 10-20 minutes (Bryan et 
al., 2013) and is regulated by the UPS as KEAP1 acts as a redox switch, via its cysteine 151,273 and 
288 residues, where under normal homeostasis KEAP1 binds NRF2 facilitating its ubiquitination and 
degradation via the proteasome (figure 1.8). Whereas upon OS NRF2 is released allowing its 
phosphorylation by a variety of kinases (Huang et al., 2015) and subsequent translocation into the 
nucleus via importins (Silva-Islas and Maldonado, 2018). Once in the nucleus NRF2 can bind to the 
ARE in the promoters of multiple genes including antioxidants such as catalase, SOD, glutathione 
synthesis proteins etc., but also increases proteasome subunits levels and ubiquitination related 
genes during OS (reviewed more thoroughly in Korovila et al., 2017; Kwak et al., 2003). Human 
embryonic stem cell studies also showed NRF2 controlled proteasome maturation and proteasome-
related chaperones (Jang et al., 2014).  
NRF1 is homologous to NRF2, and also undergoes nuclear translocation upon 
deglycosylation competing with NRF2 for the ARE (Lee and Ryu, 2017), but is also is regulated by 
proteasomal degradation despite differing in regulatory mechanisms and cellular localisation 
(Ohtsuji et al., 2008). NRF1 appears to be important in proteasome subunit regulation as NRF1 has 
been identified as a key transcriptional regulator of proteasome genes in neurons. This is 
demonstrated by NRF1 knockout mice, which showed reduced expression of genes encoding for 
the 20S and 19S subunits along with impaired proteasomal function (Lee et al., 2011).  Further 
supporting this, low concentrations of proteasome inhibitors induce NRF1, whereas higher 
concentrations lead to NRF1s inactivation (Radhakrishnan et al., 2014; Vangala et al., 2016). 
Therefore, both NRF1 and NRF2 are regulated by the proteasome via OS and help to return cells to 
homeostasis by upregulating antioxidant genes but also proteasomal subunits to degrade already 
modified proteins or aggregates (see figure 1.9).  
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In conclusion, while it is unclear what initiates neurodegeneration to produce these 
hallmarks, they appear to link in various feedback loops to try and return cells to homeostasis. Due 
to how difficult it is to determine the start of neurodegenerative pathogenesis it would be more 
beneficial to determine if there is a linking cofactor which can provide therapeutic potential.       
 
1.3 Co-Culture  
1.3.1 Glia in neurodegeneration  
Although neurons were once the focus of neurodegenerative research, many are realising the 
immune system may be involved in PD aetiology suggesting neuroinflammation may not just be a 
consequence of neuronal dysfunction or degeneration. Glia are the most abundant cell in the brain 
and can be separated into 3 types: oligodendrocytes, microglia and astrocytes which are the most 
populous (Herculano-Houzel, 2009; Verkhratsky et al., 2012). Neuronal degeneration in PD is 
associated with neuroinflammation which is mediated primarily by microglia (Kempuraj et al., 2016) 
and less so by astrocytes and oligodendrocytes (Perry, 2012). A greater density of activated 
microglia have been observed in the SN of PD patients and associated with DA neuron loss in PD 
(Ghadery et al., 2017). Activated microglia have also recently been reported in the SN and striatum 
Figure 1.9. Overwhelming the cells antioxidant systems results in defence mechanisms being induced. 
During oxidative stress NRF2 dissociates from KEAP1 leading to nuclear translocation and upregulation of 
a variety of antioxidants and ubiquitin proteasome system (UPS) subunits to come to the cells defence 
against oxidative stress. Adapted from Korovila et al., 2017 and Chen et al., 2014. 
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of animal models (Pisanu et al., 2014; Stott and Barker, 2014). In addition to microglia, astrocytes 
are also key in neurological disorders as reactive astrocytes are a key aspect of PD (Boillée et al., 
2006; Koprich et al., 2008; Miklossy et al., 2006). 
 Astrocytes are large stellate cells with multibranched processes extending their branches 
from the soma which divide into secondary branchlets, tertiary leaflet and end feet that encase 
blood vessels but also ensheath neuronal synapses (Bushong et al., 2002; Khakh and Sofroniew, 
2015).   
 In PD patients studies have shown increased GFAP expression, a marker of astrocytes 
(Manocha et al., 2017), where vimentin and nestin have also been shown to be upregulated in 
reactive astrocytes (de Pablo et al., 2018). The role of astrocytes in neurodegeneration is further 
highlighted by studies showing α-synuclein positive astrocytes correlating with nigral neuronal 
death (Cavaliere et al., 2017). Furthermore, PD models show astrogliosis following dopaminergic 
neuronal death (El Massri et al., 2016; Hirsch and Hunot, 2009), whilst administration of 6-OHDA 
also resulted in increased GFAP expression (Ganapathy et al., 2019). These studies suggest that OS 
plays a role in astrogliosis.  
 Interestingly, it is believed that astrocytes are more resistant to stress than neurons as 
aggregates are more commonly found in neurons (Jansen et al., 2014). Further supporting this, the 
UPS in glia has been shown to be more active than in neurons both in vitro and in vivo (Sung and 
Jimenez-Sanchez, 2020). The increased resistance of astrocytes to OS may help to  reduce 
proteotoxic stress, since astrocytes contain one of the highest cytosolic concentrations of 
glutathione, (approximately 8-10mM in primary astrocytes) in mammalian cells (Makar et al., 2008; 
Raps et al., 1989; Yudkoff et al., 1990). Additionally, higher levels of DJ-1 in astrocytes have been 
observed in post-mortem PD samples relative to neurons suggesting astrocytes attempt to combat 
OS during neurodegeneration (Frøyset et al., 2018; Neumann et al., 2004). In addition, the 
importance of astrocytes in combating neural OS is supported by the high level expression of 
detoxifying enzymes and transporters such as ascorbic acid, glutathione and its precursors (Allaman 
et al., 2011; Asanuma et al., 2019). Astrocytes also display greater levels of NRF2 than neurons 
(Jimenez-Blasco et al., 2015), which regulates the expression of catalase, peroxiredoxin 6 and 
glutamate-cysteine ligase; the latter being an enzyme involved in the first step of glutathione 
synthesis (Dowell and Johnson, 2013; Lee et al., 2003).  
 Overall, these studies suggest neurons are not the only cells that need to be considered 
when studying neurodegeneration as other cells display different capabilities and functions. In 
particular, astrocytes seem to have different mechanisms for coping with OS and need 
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consideration when examining neurodegeneration as they appear to be key for understanding 
underlying pathways and may support neurons in some way.   
1.3.2 Neuron-glial crosstalk  
Currently, most studies involve the study of monocultures to understand intracellular mechanisms 
involved in the pathogenesis of neurodegeneration. However, in the brain there is a not a single 
cell type, but a complex network of different cells composed of different ratios depending on the 
brain region. The importance of these networks is highlighted by the SN having the lowest glia to 
neuron ratio in the brain (von Bartheld et al., 2016), which may explain the selective vulnerability 
of dopaminergic neurons in Parkinson’s disease. Therefore, understanding not only intracellular 
mechanisms but also intercellular and feedback mechanisms are important for understanding 
neurodegeneration.  
 Glia dynamically interact with neurons by responding to neurotransmitters and in response 
regulate neuronal and synaptic function by releasing gliotransmitters (Araque et al., 2014; Eroglu 
and Barres, 2010; Perea et al., 2014). For example, astrocytes can secrete neurotrophic factors such 
as glial derived neurotrophic factor (GDNF) and brain derived neurotrophic factor (BDNF), which 
are essential for dopaminergic neuron survival and development (Pöyhönen et al., 2019). 
Furthermore, astrocytes use a malate-aspartate shuttle to transport various nutrients and 
metabolic precursor to neurons. One of the most important shuttles that astrocytes possess is the 
glutamate-glutamine shuttle allowing collection and conversion of glutamate from the extracellular 
space secreted by neurons into glutamine, which is shuttled back to the presynaptic terminal of 
synthesis and is critical for glutamate synthesis, acting as an essential neurotransmitter (Murphy-
Royal et al., 2017). In addition to helping neurotransmission astrocyte-neuron crosstalk is important 
for dendritic growth, synapse formation and removal of dysfunctional synapses through both 
soluble factors and direct contact (Haim and Rowitch, 2017; Stevens et al., 2007).  
Astrocytes release glutathione, which is subsequently broken down into γ-glutamyl group 
and cysteinyl glycine via γ-glutamyl transferase.  Ectopeptidases then break down cysteinyl glycine 
into cysteine and glycine which are taken up by neurons. Therefore, astrocytes help provide 
neurons with components to generate glutathione to aid with OS (Bolaños, 2016; McGann and 
Mandel, 2018). Additionally, astrocytes protect neurons from OS via DJ-1 as astrocytes with DJ-1 
knocked out exhibited impaired glutamate uptake (Kim et al., 2016). This leads to higher levels of 
extracellular glutamate leading to neuronal excitotoxicity, which is a known cause of 
neurodegeneration (Jakaria et al., 2018). The importance of DJ-1 from astrocytes in 
neuroprotection is highlighted by knockout DJ-1 astrocytes displaying reduced ability to protect 
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neurons against PD models using rotenone (Larsen et al., 2011). Further supporting astrocytes 
protecting neurons from OS is a study where NRF2 overexpression in astrocytes delayed disease 
onset in mouse models with mutant α-synuclein expression in neurons (Gan et al., 2012).  
 Therefore, studies suggest that crosstalk between astrocytes and neurons is important for 
controlling neuronal and synaptic function but also aids with OS. As such, there is a greater need 
for co-culture systems to investigate the crosstalk between different cell types in the CNS to 
establish an in vitro model that replicates more in vivo like conditions for the development of novel 
therapies for neurodegenerative diseases.  
 
1.4 Aims of the study   
The overall objective of this study is to investigate the role of OS during neurodegeneration and 
start development of a neural co-culture model. This will be achieved through establishing the 
consequences of different RS on individual neural cell types. These investigations will allow greater 
understanding of these cells prior to developing a neural co-culture. As a result, the pathways 
underlying neurodegeneration can be investigated and future novel therapies for 
neurodegenerative diseases proposed. Hence the main aims of this study are: 
• To generate OS using different oxidising agents, rotenone (a complex I) and AAPH (an 
oxidising agent), in neuronal and glial monocultures whilst also investigating other factors 
such as mitochondrial and proteasome dysfunction to investigate pathways involved in the 
pathology of neurodegeneration. This has the potential to determine if specific RS influence 
the hallmarks of neurodegeneration in various ways in different neural cells.   
 
• To investigate these RS inducing agents in a differentiated model to greater mimic more in 
vivo like conditions to determine a more representative model of the human brain, allowing 
downstream effects of RS to be determined.  
 
• Finally, crosstalk between neurons and glia will be investigated in a co-culture. When 
investigating, these secreted factors will be probed from conditioned media and non-
contact co-cultures. This has the potential to identify possible protective secreted factors 
which may provide future novel therapies for neurodegenerative diseases.  
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2.0 Materials and Methods 
2.1 Materials  
2.1.1 Cell Culture  
2.1.1.1 Cell Lines  
SH-SY5Y cell line acquired from the European Collection of Authenticated Cell Cultures (ECACC;  
Salisbury, UK)  
U-87MG cell line acquired from the European Collection of Authenticated Cell Cultures (ECACC;  
Salisbury, UK)  
2.1.1.2 Reagents 
B-27TM Supplement (50X), serum free (17504044) – ThermoFisher Scientific, Loughborough, UK 
Dulbecco’s phosphate buffered saline without Ca2+ and Mg2+ (17-512F) – Lonza, Slough, UK  
Foetal bovine serum (10270-160) – ThermoFisher Scientific, Loughborough, UK   
Gibco Dulbecco’s Modified Eagle Medium/ F12 Ham (DMEM: F12) 1:1 with 15 mM Hepes L-
Glutamine without phenol red (21041025) – ThermoFisher Scientific, Loughborough, UK   
GlutaMAXTM supplement (35050061) – ThermoFisher Scientific, Loughborough, UK  
Hybri-max sterile, filtered dimethylsulfoxide (DMSO; D2650-5X10ML) – Sigma Aldrich, Dorset, UK 
Lonza Dulbecco’s Modified Eagle Medium/ F12 Ham (DMEM: F12) 1:1 with 15 mM Hepes L-
Glutamine (LZBE12-719F) – Scientific Laboratory Suppliers, Nottingham, UK  
MEM Eagle non-essential amino acid solution (100X) (13-114E) – Lonza, Slough, UK 
NeurobasalTM Medium (21203049) – ThermoFisher Scientific, Loughborough, UK 
Opti-MEMTM reduced serum media (31985062) – ThermoFisher Scientific, Loughborough, UK  
Penicillin-Streptomycin (17-603E) – Lonza, Slough, UK  
Trypsin-10X (BE02-007) – Lonza, Slough, UK  
2.1.1.3 Plasticware 
15 ml and 50 ml red capped tubes – Sarstedt, Leicester, UK  
6 well, 12 well, 24 well and 96 well sterile tissue culture plates – Sarstedt, Leicester, UK  
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Cell culture flasks (T25, T75, T175) – Sarstedt, Leicester, UK  
Cryovials – Sarstedt, Leicester, UK  
E-plate L8 (300600840) – ACEA Biosciences, US  
E-Plate Insert 16 (6465382001) – ACEA Biosciences, US 
Pipette filter tips (10 µl, 200 µl and 1000 µl) – Dutscher Scientific, France  
Polypropylene sterilin tubes – Sarstedt, Leicester, UK  
TC insert for 24 well plate, PET membrane bottom, transparent, pore size 0.4µm sterile, 
non-pyrogenic/endotoxin-free, non-cytotoxic (83.3932.041) – Sarstedt, Leicester, UK 
Seahorse XF24 cell culture microplate (100777-004) – Agilent, Santa Claret, US  
Sterile serological pipettes (1 ml, 5 ml, 10 ml, 25 ml) – Sarstedt, Leicester, UK 
Thermo ScientificTM NuncTM Lab-TekTM Chmaber Slide system 8 wells – Fisher Scientific, Leicester, 
UK 
2.1.2 Laboratory reagents  
2,2’-Azobis[2-methylpropionamidine] dihydrochloride (AAPH; 440914) – Sigma Aldrich, Dorset, UK  
2′,7′-Dichlorofluorescin diacetate (DCFDA; 4091-99-0) – Sigma Aldrich, Dorset, UK  
3-(4,5-dimethylthiaol-2-yl)-2,5-diphenyltetrazoulium bromide (MTT; M2128) – Sigma Aldrich, 
Dorset, UK  
2-mercaptoethanol (M6350) – Sigma Aldrich, Dorset, UK  
Ascorbic acid (A5960-25G) – Sigma Aldrich, Dorset, UK 
α-tocopherol (T3251) – Sigma Aldrich, Dorset, UK 
Accugel 29:1 (40% solution) acrylamide (A2-0068) – Geneflow Ltd., UK   
Adenosine 5’-triphosphate (ATP; A3377) – Sigma Aldrich, Dorset, UK  
Agarose (A9539) – Sigma Aldrich, Dorset, UK  
All-trans retinoic acid (R2625) – Sigma Aldrich, Dorset, UK 
Ammonium persulphate (A3678) – Sigma Aldrich, Dorset, UK  
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Bicinchoninic acid (B9643) – Sigma Aldrich, Dorset, UK 
Bio-Rad protein assay dye reagent concentrate (5000006) – BioRad Laboratories Ltd, 
Hertfordshire, UK 
Bovine serum albumin (BSA; A2153) – Sigma Aldrich, Dorset, UK 
Click-iT™ Lipid Peroxidation Imaging Kit - Alexa Fluor™ 488 (C10446) – ThermoFisher Scientific, 
Loughbourough, UK 
Copper phthalocyanine 3,4‘,4‘‘,4‘‘‘ terasulphonic acid tetrasodium salt (245356) – Sigma Aldrich, 
Dorset, UK 
Copper (II) sulphate (451657) – Sigma Aldrich, Dorset, UK  
Copper (II) sulphate solution (C2284) – Sigma Aldrich, Dorset, UK 
Dimethyl Sulfoxide (DMSO) (472301) – Sigma Aldrich, Dorset, UK  
Dual-colour prestained precision plus proteinTM standards, 10-250 kDa (161-0374) – BioRad 
Laboratories Ltd, Hertfordshire, UK  
EZ-PCR Mycoplasma Test Kit (20-700-20) – Biological Industries, Staffordshire, UK 
Fluorescein Diacetate – Sigma Aldrich, Dorset, UK 
Folin-ciocalteu phenol reagent (F9252) – Sigma Aldrich, Dorset, UK  
GAPDH positive control siRNA (4390849) – ThermoFisher scientific, Loughborough, UK  
Glycine (G8898) – Sigma Aldrich, Dorset, UK  
Glutathione fluoremetric assay (CS1020) – Sigma Aldrich, Dorset, UK 
Hanks balanced salt solution (HBSS CAMGPR) – Brainbits, Springfield, US 
Hellmanex III (Z805939-1EA) – Sigma Aldrich, Dorset, UK  
InstantBlueTM stain (SKU: ISB1L) – Expedeon, Cambridge, UK  
iScriptTM cDNA Synthesis kit (1708890) – BioRad Laboratories Ltd, Hertfordshire, UK 
iTaqTM universal SYBR® green supermix (172-5120) – BioRad Laboratories Ltd, Hertfordshire, UK 
JC-1 (CAY15003-5 mg) – Cambridge bioscience, Cambridge, UK  
Laemli buffer (S3401-10VL) – Sigma Aldrich, Dorset, UK 
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Laminin (L2020-1MG) – Sigma Aldrich, Dorset, UK 
Lipofectamine 3000 – ThermoFisher Scientific, Loughborough, UK  
Methanol (67-56-1) – Fisher Scientific, UK 
MitotrackerTM Red CMXRos (M22425) – ThermoFisher Scientific, Loughborough, UK  
N-Succinyl-Leu-Leu-Val-Tyr-AMC (7-amino-4-methylcoumarin; BML-P802-0005)– Enzo Life 
Sciences, Exeter, UK 
N,N,N’,N’-Tetramethylethylenediamine (TEMED; T9281) – Sigma Aldrich, Dorset, UK 
NRF2 siRNA (4392420) – ThermoFisher Scientific, Lougborough, UK  
Paraformaladehyde (158127) – Sigma Aldrich, Dorset, UK  
Pierce ECL Western blotting substrate (32106) – ThermoFisher Scientific, Loughborough, UK  
Pierce LDH cytotoxicity assay kit (88953) – ThermoFisher Scientific, Loughborough, UK   
Poly-L-lysine (P4707-50ML) – Sigma Aldrich, Dorset, UK  
Potassium sodium tartrate tetrahydrate (217255) – Sigma Aldrich, Dorset, UK  
Precision plus proteinTM Kaleidoscope standards (161-0375) - BioRad Laboratories Ltd, 
Hertfordshire, UK 
Protease inhibitor cocktail (P8340) – Sigma Aldrich, Dorset, UK 
Protein carbonyl colorimetric assay kit (10005020) – Cambridge bioscience, Cambridge, UK  
RIPA buffer (R0278) – Sigma Aldrich, Dorset, UK 
RNeasy mini kit (74134) – Qiagen Ltd, UK 
Rotenone (R8875-1G) – Sigma Aldrich, Dorset, UK  
RT2 First strand kit (330404) – Qiagen Ltd, UK  
RT² Profiler™ PCR Array Human Oxidative Stress Plus (PAHS-065YC-6) – Qiagen Ltd, UK  
RT² SYBR Green ROX qPCR Mastermix (330524) – Qiagen Ltd, UK 
Scramble control siRNA (sc-37007) – Santa Cruz biotechnology, USA  
S-nitrosylation protein detection kit (10006518) – Cambridge bioscience, Cambridge, UK  
CHAPTER 2  MATERIALS AND METHODS 
43 
 
Sodium azide (S2002) – Sigma Aldrich, Dorset, UK 
Sodium carbonate (451614) – Sigma Aldrich, Dorset, UK  
Sodium dodecyl (lauryl) sulphate (SDS; L22040-1000.0) – Melford biolaboratories Ltd., Suffolk, UK   
Sodium hydroxide (795429) – Sigma Aldrich, Dorset, UK  
SYBR safe DNA gel stain (S33102) – ThermoFisher Scientific, Loughborough, UK 
TBARS assay kit (CAY100090 55-96 wells) – Cambridge bioscience, Cambridge, UK 
Tris(hydroxymethyl)aminomethane (Tris; B2005) – Melford biolaboratories Ltd., Suffolk, UK   
TritonTM X-100 (T8787) – Sigma Aldrich, Dorset, UK 
Trypan blue (T8154) – Sigma Aldrich, Dorset, UK  
Tween ® 20 (274348) – Sigma Aldrich, Dorset, UK  
XF real-time ATP assay (103592-100) – Agilent, Santa Claret, US 
2.1.3 Equipment  
ACEA Biosciences – RTCA iCELLigence, San Fracisso, US 
Bio-rad cell counter – BioRad Laboratories Ltd, Hertfordshire, UK 
Bio-Rad Mini-Protean III system – Biorad laboratories Ltd, Hertfordshire, Dorset, UK 
Bio-Rad T100 thermocycler – Biorad laboratories Ltd, Hertfordshire, Dorset, UK 
BMGLabtech CLARIOSTAR plate reader – BMG labtech, Aylesbury, UK  
Corbett Rotor-gene 6000 real-time PCR machine – ThermoFisher Scientific, Loughborough, UK  
ErgoOne ® Multi-channel pipette – StarLab Ltd, Milton Keynes, UK   
ErgoOne ® Single-channel pipettes (0.5-10 μl, 2-20 μl, 20-200 μl, 200-1000 μl) – StarLab Ltd, 
Milton Keynes, UK   
EVOS FLOID cell imaging station – ThermoFisher Scientific, Loughborough, UK  
Incucyte S3 live-cell analysis system – Sartorius, Goettingen, Germany  
ImageQuantTM Las 4000 – GE  healthcare life sciences, Buckinghamshire, UK 
Leica DMI8 inverted microscope – Leica Microsystems, GmbH, Manheim, Germany 
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Leica TSC SPS II confocal microscope – Leica Microsystems, GmbH, Manheim, Germany 
Nanodrop 8000 spectrophotometer – ThermoFisher, Scientific, Loughborough, UK   
Nikon Eclipse TS100 inverted microscope – Nikon, Japan  
Nikon digital sight DS-Fi2 – Nikon Instruments Inc., Japan  
Nikon digital sight DS-U3 – Nikon Instruments Inc., Japan 
Seahorse XFe24 analyzer – Agilent, Santa Claret, US 
StepOnePlusTM real-time PCR system – Applied biosystems, Foster City, CA, USA 
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2.1.4 Antibodies  
Table 2.1 Primary antibody list detailing their molecular weight, characteristics, applications, dilution factor and the company they were purchased from.  
Name Specificity Host Species Concentration for each application Supplier (Cat No) 
WB IF 
Anti-β III tubulin  50 kDa Mouse, polyclonal 1:1000 1:500 Abcam (ab41489) 
Anti-nuclear 
erythroid-derived 
2 like factor (NRF2) 
68/110 kDa Rabbit, polyclonal  1:1000 1:200 Genetex (GTX103322) 
Anti-S100 21 kDa Mouse, 
monoclonal  
1:500 N/A Abcam (ab14849) 
Anti-
Synaptophysin 
38 kDa Rabbit, 
monoclonal 
1:1000 1:100 Abcam (32127) 
B512 α-tubulin, 50 kDa Mouse, 
monoclonal 
1:2000 N/A Sigma (T6074) 
DJ-1  20 kDa Rabbit, polyclonal 1:10000 N/A Genetex (GTX132552) 
GFAP 50 kDa Rabbit, polyclonal  1:1000 1:250 Genetex (GTX108711) 
HSF1  82 kDa Rabbit, Polyclonal 1:1000 N/A Cell signalling technology 
(4356T) 
HSP27 23 kDa Rabbit, polyclonal 1:1000 N/A Genetex (GTX112964) 
HSP70 72/73 kDa Rabbit, polyclonal 1:1000 N/A Cell signalling technology 
(4872T) 
Lamin A/C 74/ 63 kDa Mouse, 
monoclonal  
1:2000 N/A Cell Signalling Technology 
(4777S) 
MFN1 84 kDa Mouse, 
monoclonal 
1:1000 N/A Santa Cruz 
(SC-166644) 
OPA1 92 kDa 
Mouse, 
monoclonal 
1:1000 N/A 
BD Bioscience 
(612606) 
pDRP1 82 kDa 
Rabbit, 
Polyclonal 
1:1000 N/A 
Cell Signalling Technology 
(3455S) 
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Table 2.2 Secondary antibody list detailing their dilution factor and the company they were purchased from.  
Name  Concentration Supplier (Cat no.) 
Polyclonal horse anti-mouse IgG HRP conjugated 
antibody 
1:1000 Cell signalling technology (#7076) 
Polyclonal goat anti-rabbit IgG HRP conjugated antibody 1:1000 Cell signalling technology (#7074) 
Alexa Fluor 488 donkey anti-mouse IgG 1:500 Invitrogen Ltd (A21202) 
Alexa Fluor 488 donkey anti-rabbit IgG 1:500 Invitrogen Ltd. (A21206) 
Alexa Fluor 350 goat anti-mouse IgG 1:500 Invitrogen Ltd. (A11045) 
 
 
 
 
 
 
Peroxiredoxin 6 25 kDa Mouse, 
monoclonal  
1:1000 N/A Abcam (ab16947) 
SOD1 18 kDa Mouse, 
monoclonal 
1:1000 N/A Cell Signalling technology 
(4266T) 
Ubiquitin (P4D1) Ladder Mouse, 
monoclonal  
1:1000 N/A Cell Signalling technology 
(3936T) 
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2.2 Cell culture   
2.2.1 Maintenance of human cell lines  
SH-SY5Y and U-87MG cells were cultured in sterile growth media composed of DMEM: F12 with a 
1:1 ratio of 15 mM Hepes L-Glutamine (Scientific Laboratory Suppliers, Nottingham, UK)  
supplemented with 10% (v/v) heat inactivated foetal bovine serum (FBS; ThermoFisher Scientific, 
Loughborough, UK), 100 units/ml penicillin (Lonza, Slough, UK), 10 µl/ml streptomycin (Lonza, 
Slough, UK) and 1% (v/v) non-essential amino acid solution (100X; NEAA; Lonza, Slough, UK) in 
tissue culture flasks. These flasks were maintained at 37°C in a humidified atmosphere of 95% (v/v) 
air and 5% (v/v) CO2. Once the cells reached 70-80% confluence they were passaged using 
trypsinisation. To achieve this, cells were briefly washed twice with Dulbecco’s phosphate buffered 
saline without Ca2+ and Mg2+ (DPBS; Lonza, Slough, UK), where washes were retained to remove all 
traces of serum. Cells were then incubated with 250 µg/ml trypsin (300 µl for T25 flasks and 900 µl 
for T75 flasks; Lonza, Slough, UK) for approximately 3 minutes at 37°C. Trypsin was quenched with 
serum containing growth media and added to the previous washes prior to harvesting cells by 
centrifugation at 300g for 5 minutes. The supernatant was discarded, and the resultant pellet was 
re-suspended in fresh growth media and the required cell number (17000 cells/cm2) was 
transferred into sterile tissue culture flasks containing pre-warmed growth media.     
2.2.2 Co-cultures 
2.2.2.1 Contact co-cultures  
Cells were split as detailed in section 2.2.1. Cells were subsequently pelleted and counted as 
detailed in section 2.2.5. Cells were again seeded at total density of 17000 cells/cm2 where half of 
the cell population were SH-SY5Y and half were U-87MG cells. This resulted in a 1:1 seeding ratio.  
2.2.2.2 Non-contact co-cultures 
Cells were split as detailed in section 2.2.1. Cells were subsequently pelleted and counted as 
mentioned in section 2.2.5. Inserts were incubated with growth media for 5 minutes prior to 
seeding to improve adhesion to the cell insert material. Cells were seeded at 6900 cells/cm2 in both 
cell inserts and the 24 well plate to maintain a 1:1 ratio and allowing for differentiation. 
2.2.2.3 Conditioned media  
Cells were seeded at 6900 cells/cm2 to allow for differentiation over 5 days. Media was collected 
from U-87MG cells at 5 days to aid SH-SY5Y differentiation. In addition, following 5-day 
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differentiation cells were treated with 1 mM AAPH or 0.5 μM rotenone for 48 hours and media was 
collected. The collected conditioned media was frozen immediately at -20°C until needed. When 
cells were ready for treatment cells were treated with a 1:1 ratio of conditioned media and fresh 
media to account for the loss of nutrients in the conditioned media.  
2.2.3 Cell count and seeding   
To estimate cell numbers cells were counted using a haemocytometer where the cell density was 
estimated using the following calculation:  
𝐶𝑒𝑙𝑙𝑠
𝑚𝑙
= 𝐴𝑣𝑒𝑟𝑎𝑔𝑒 𝑐𝑒𝑙𝑙 𝑐𝑜𝑢𝑛𝑡 (1 𝑚𝑚2) × 104 × 𝑑𝑖𝑙𝑢𝑡𝑖𝑜𝑛 𝑓𝑎𝑐𝑡𝑜𝑟  
To achieve the required cell density within a known volume of growth media, the cell number was 
subsequently used in the following calculation: 
𝑉𝑜𝑙𝑢𝑚𝑒 𝑟𝑒𝑞𝑢𝑖𝑟𝑒𝑑 𝑓𝑜𝑟 𝑑𝑒𝑠𝑖𝑟𝑒𝑑 𝑐𝑒𝑙𝑙 𝑛𝑢𝑚𝑏𝑒𝑟 (𝑚𝑙) =  
𝐷𝑒𝑠𝑖𝑟𝑒𝑑 𝑐𝑒𝑙𝑙 𝑛𝑢𝑚𝑏𝑒𝑟
𝐶𝑒𝑙𝑙𝑠
𝑚𝑙
 
The appropriate cell density was then seeded into the required tissue culture flask and incubated 
at 37°C in a humidified atmosphere of 95% (v/v) air and 5% (v/v) CO2.  
2.2.4 Cryopreservation of cells  
For long term cell preservation, cells were frozen in liquid nitrogen. Cells were seeded in T25 flasks 
and harvested whilst in the log phase of growth. Cells were briefly washed twice with DPBS to 
remove serum and washes were kept before incubating cells with 250 µg/ml trypsin for 
approximately 3 minutes at 37°C. Trypsin was quenched with growth media and added to the DPBS 
washes prior to centrifugation at 300g for 5 minutes. The supernatant was then discarded and the 
pellet was re-suspended in 1 ml of ice-cold freezing media (10% (v/v) dimethyl sulfoxide (DMSO) in 
sterile DMEM: F12 with a 1:1 ratio with 15 mM Hepes L-Glutamine growth media supplemented 
with 10% (v/v) heat inactivated FBS, 100 units/ml penicillin, 10 µl/ml streptomycin and 1% (v/v) 
NEAA solution (100X)) and transferred into a cryovial. These vials were kept at -80°C in cryopods 
for approximately 48 hours before transferring to a liquid nitrogen storage facility for long term 
storage.  
2.2.5 Revival of cryopreserved cells 
Cryovials containing preserved cells were removed from liquid nitrogen storage and thawed in a 
37°C water bath before being transferred dropwise to a sterile tube containing growth media to 
dilute the DMSO. The cells were subsequently centrifuged at 300g for 5 minutes. The supernatant 
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was then discarded, and the pellet was re-suspended in 1 ml of growth media before being 
transferred to a 6-well plate containing appropriate levels of pre-warmed growth media. Cells were 
then maintained appropriately as described in section 2.2.1. 
2.2.6 Mycoplasma testing  
Once revived and cells reached 70-80% confluence, 1 ml of cell supernatant was briefly centrifuged 
at 250g to pellet cellular debris prior to testing for mycoplasma using an EZ-PCR mycoplasma test 
kit (Biological Industries, Staffordshire, UK). The supernatant was subsequently transferred to a 
fresh sterile tube and centrifuged at 15000g for 10 minutes to sediment mycoplasma. The 
supernatant was carefully decanted, and the pellet was re-suspended thoroughly with 50 µl buffer 
solution supplied with the kit. The mixture was then heated to 95°C for 3 minutes before storing at 
-20°C. A reaction mixture was then prepared as follows for polymerase chain reaction (PCR) 
amplification:  
Table 2.3 Volume of reagents needed for polymerase chain reaction amplification.  
Reagents Volume (μl) 
H2O 35 
Reaction mix 10 
Test Sample 5 
   
All samples including a positive and negative mycoplasma DNA sample were then transferred to a 
thermal cycler with the following parameters:  
Table 2.4 PCR cycle temperatures and time.     
Temperature (°C) Time (secs) 
94 30 
94 30 
60 120 
72 60 
94 30 
60 120 
72 300 
   
During PCR amplification 50 ml of a 2% agarose (w/v) gel was cast in Tris-acetate-EDTA (TAE) buffer 
(40 mM Tris, 20 mM acetic acid, 1 mM ethylenediamineetetraacetic acid, EDTA) with 10% (v/v) 
35 Cycles  
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SYBR safe (ThermoFisher Scientific, Loughborough, UK) into a mould whereupon a comb was 
immediately positioned within the gel to form wells to load the PCR samples. The gel was allowed 
to polymerise for approximately 30 minutes prior to comb removal and placement in an agarose 
gel tank containing TAE buffer. Subsequent to PCR amplification, 5 µl of blue/orange loading dye 
was added to the PCR samples prior to loading onto the gel. The gel was then subjected to a 
constant 90V for 30 minutes before the gel was visualised using U:Genius3 (Syngene, Cambridge, 
UK).      
2.2.7 Differentiation   
Cells were seeded at 6900 cells/cm2 and incubated overnight at 37°C in a humidified atmosphere 
at 5% CO2 in 10% full growth medium. Following overnight growth, media was removed and 
replaced with differentiation media containing 0.5% (v/v) heat inactivated foetal bovine serum, 1% 
(v/v) MEM non-essential amino acids, 200 units/ml penicillin and 200 μg/ml streptomycin and 10 
μM all trans-retinoic acid (Sigma Aldrich, Dorset, UK) in DMEM/F12 media. Differentiation media 
was replaced with fresh media every 2 days. Cells were grown for a period of 5 days in retinoic acid 
containing differentiation media or grown with retinoic acid for 5 days followed by 50 ng/ml BDNF 
for 3 days. Following differentiation, cells were ready to be used in experiments.  
2.2.8 Coating plates  
Plates were coated with poly-L-lysine (Sigma Aldrich, Dorset, UK) overnight at 4°C with gentle 
agitation. Poly-L-lysine was subsequently removed, and plates were washed three times with 
double distilled water. Plates were then incubated with laminin (5 μg/ml) for 2 hours at room 
temperature. The plates were again washed 3 times with double distilled water prior to cell seeding.   
2.2.9 Embryonic rat neuronal cultures 
Timed pregnant CD Sprague Dawley rats (Charles River, Margate, UK) were killed in accordance with 
the UK Animals (Scientific Procedures) Act 1986 by overdose with inhaled isoflurane (Merial Animal 
Health, Harlow, UK) and confirmed with cervical dislocation at embryonic day 18. Embryos were 
then rapidly removed and decerebrated on ice. Cortical tissue was micro-dissected under sterile 
conditions and subjected to papain (2 mg/ml) digestion for 10 minutes at 37°C with inversion after 
5 minutes. Papain was subsequently removed, and media was added to the tissue. Using a salinized 
glass pipette, tissue was mechanically triturated, and any debris allowed to settle for 1 minute. 
Supernatant was then centrifuged at 300g for 2 minutes. Supernatant was discarded, and pellet 
was resuspended in fresh growth media. Cells were counted using a 1:1 ratio of Trypan blue to 
determine cell viability using the Bio-Rad cell counter. Cells were plated at density of 25000 
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cells/cm2 on poly-L-lysine and laminin (5 μg/ml) coated plates in NeurobasalTM medium 
supplemented with B-27TM supplement (1X; Thermofisher Scientific, Loughborough, UK), 100 
units/ml penicillin and 10 µl/ml streptomycin, at 37°C in a humidified atmosphere of 5% CO2. Cells 
were cultured for 5 days prior to treatment. Cells were seeded at 25000 cells/cm2 on poly-L-lysine 
and laminin (5 μg/ml) coated plates.  
2.2.10 Quantification of axon, process and branching growth  
Neurite outgrowth was studied using the IncuCyte S3 live-cell analysis system from Essen Biosceince 
(Ann Arbor, MI, USA). During the differnetiation process neurite outgrowth was tracked using the 
neurotracker software, which quantified neurite length and branch points.  
Following masking, using the neurotracker software, the number of neuronal branches was 
quantified. Since branching varies with distance from the cell body, we used a Sholl analysis plugin 
in Fiji (Ferreira et al., 2014). Sholl analysis created a series of concentric circles from the centre of 
the cell body. The network of circles radii increased at regular steps of 0.05 m for 150 m. The 
number of intersections of branches was calculated and plotted against distance from the centre. 
This approach allowed multiple image quantification.  
We also used the Skeleton analysis plugin (Lee and Kashyap, 1994) in Fiji to determine the length 
of branches in the same area used for the Sholl analysis. A total of 5 random neurons were analysed 
from 3 fields of view. 
2.2.11 2,2’-Azobis(2-methylpropionamidine) dihydrochloride treatment  
Cells were seeded in appropriate tissue culture vessels and then incubated at 37°C in a humidified 
atmosphere of 95% (v/v) air and 5% (v/v) CO2 for approximately 48 hours. Cells were subsequently 
treated with growth media containing different concentrations of 2,2’-azobis(2-
methylpropionamidine) dihydrochloride (AAPH; Sigma Aldrich, Dorset, UK; 0.1, 0.25, 0.5, 0.75, 1, 
2.5, and 5 mM) for 24 or 48 hours.  
2.2.12 Rotenone treatment  
Cells were seeded in appropriate tissue culture vessels and then incubated at 37°C in a humidified 
atmosphere of 95% (v/v) air and 5% (v/v) CO2 for approximately 48 hours. Cells were subsequently 
treated with growth media containing different concentrations of rotenone (Sigma-Aldrich, Dorset, 
UK; 0, 0.01, 0.05, 0.1, 0.5, 1 and 2.5 µM) for 24 or 48 hours.  
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2.2.13 Antioxidant treatment  
Cells were seeded in appropriate tissue culture vessels and then incubated at 37°C in a humidified 
atmosphere of 95% (v/v) air and 5% (v/v) CO2 for approximately 48 hours. Cells were subsequently 
treated with growth media containing different concentrations of rotenone (0, 0.1, 0.5 and 2.5 μM), 
AAPH (0, 0.25, 1, 5 mM) concurrently with 200 μM α-tocopherol (Sigma-Aldrich, Dorset, UK) or 1 
mM ascorbic acid (Sigma-Aldrich, Dorset, UK).  
2.3 Cell viability measurements    
2.3.1 MTT reduction assay   
The reduction of MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide to formazan 
via mitochondrial dehydrogenase provides a colorimetric assay to assess cell viability, particularly 
mitochondrial status, which is an early indicator of redox changes. Cells were seeded at the cell 
density mentioned previously and treated with their respective compounds (rotenone or AAPH) for 
up to 24 or 48 hours where they were treated with MTT to a final concentration of 0.5 mg/ml for 1 
hour. The supernatant was removed, and the resultant formazan product was solubilised using 100 
µl of DMSO. Absorbance was measured at 570 nm in a plate reader (BMG Labtech CLARIOSTAR). 
Cells not treated with MTT were used as blanks. Experiments were performed in triplicate where 
data was expressed as the mean ± SEM.    
2.3.2 Luminometric ATP reduction assay   
Total ATP reduction was estimated using the Vialight ® Plus Cell proliferation and cytotoxicity 
bioassay kit (Lonza, Slough, UK) luminescence assay according to the manufacturer’s instructions. 
Briefly, cells were seeded as described previously and treated with their respective compounds for 
24 or 48 hours. Cells were then washed with 100 µl serum free media prior to the addition of 50 µl 
of serum free media and 25 µl of lysing reagent (1:2 dilution) for 10 minutes. Aliquots of 50 µl of 
each cell lysate were transferred to a fresh white walled luminescence plate where 50 µl of ATP 
monitoring reagent PLUS was added to generate luminescence. Luminescence was read after a 2-
minute incubation using a plate reader (BMG Labtech CLARIOSTAR). Results were expressed as a 
percentage change in ATP reduction against the control which was set to 100% and compared to 
known ATP standards.  Each sample and standard were performed in triplicate where data is 
expressed as the mean ± SEM. 
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2.3.3 Lactate dehydrogenase assay   
Lactate dehydrogenase is a soluble cytosolic enzyme found in most eukaryotic cells that is released 
into culture medium when cells lyse due to cellular membrane damage. Therefore, the increase in 
LDH activity is approximately proportional to the amount cell death and can be used to indirectly 
measure cytotoxicity. LDH release was estimated using Pierce LDH cytotoxicity assay kit 
(ThermoFisher, Scientific, Loughborough, UK). Extracellular LDH can be quantified by a coupled 
enzymatic reaction where LDH catalyses the dehydrogenation of lactate to pyruvate while NAD+ is 
reduced to NADH. Next diaphorase also known as NADH dehydrogenase then reduces tetrazolium 
salt to a red formazan product which can be measured at 490 nm.  
Cells were seeded in 96-well plates and treated with different concentrations of various treatments 
as described previously. Cells were incubated with treatments for 24 or 48 hours, prior to 
transferring a 50 µl aliquot of the cell supernatant to a fresh 96-well plate containing 50 µl of 
reconstituted reaction mix. After 45 minutes, the reaction was terminated with 50 µl of stop 
solution and the absorbance was measured at 490 nm using a plate reader (BMG Labtech 
CLARIOSTAR). Results are expressed as a percentage of control LDH release which was set to 100%. 
Experiments were performed in triplicate where data is expressed as the mean ± SEM.   
2.3.4 Cellular impedance assay using the iCELLigence system  
The real-time cell analysis system (RTCA) iCELLigenceTM (ACEA Biosceinces, San Diego, CA, USA) was 
used to monitor cellular impedance to measure neural cytotoxicity according to the manufacturer’s 
instructions. Briefly, 150 μl of growth media was added to each of the E-plate L8 and a calibration 
measurement was taken. Subsequently, each well was seeded with 17000 cells/cm2 in 300 μl. Plates 
were left at room temperature for 20 minutes allowing cell adherence prior to plate insertion into 
the iCELLigence station. The system was set to take measurements every 15 minutes for 8 hours 
and then every hour for 40 hours. After 48 hours, plates were removed from the station and media 
was replaced with 350 μl of fresh media containing different concentrations of treatments 
(rotenone: 0, 0.1, 0.5, 2.5 μM and AAPH: 0, 0.25, 1, 5 mM with or without antioxidant). The plate 
was returned to the station and the system was set to take measurements every hour for 48 hours. 
Data analysis was initially performed using iCELLigence software where cell index was automatically 
calculated from the change in electrical impedance. The Cell Index was normalised at 48 hours when 
treatment was added to determine the cytotoxicity of the compounds. Experiments were 
performed in triplicate where data was expressed as the mean ± SEM.   
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2.3.5 Cytotoxicity analyses with the incucyte system  
Differentiated neural cytotoxicity was assessed using the incucyte S3 live-cell analysis system. 
Neuronal SH-SY5Y and glial U-87MG were cultured in 96-well plates and differentiated as 
mentioned in section 2.2.9. Cells were subsequently treated with AAPH (0, 0.25, 1 and 5 mM) or 
rotenone (0, 0.1, 0.5 and 2.5 μM) with or without antioxidants (200 μM tocopherol or 1 mM 
ascorbic acid). Phase contrast images were automatically taken every hour for 48 hours using the 
incucyte S3 live-cell analysis system (Sartorius, Goettingen, Germany). The images were analysed 
by the incucyte software package (Sartorius).   
2.4 Measuring reactive species   
2.4.1 Real-time RS levels  
The non-fluorescent probe 2′,7′-dichlorofluorescin diacetate (DCFDA; Sigma Aldrich, Dorset, UK) is 
a cell permeable chemical which is de-esterified intracellularly. Subsequent oxidation via RS forms 
fluorescent 2’,7’-dichlorofluorescein (DCF). This method was used to estimate the levels of 
endogenous ROS in control and experimental cells in a time-dependent manner. Cells were seeded 
as mentioned above and grown to 60-70% confluence. Media was subsequently replaced with 100 
µl of phenol red free DMEM-F12 growth media containing 10 µM DCFDA. Cells were incubated with 
the dye at 37°C for 30 minutes. The dye was carefully removed and replaced with phenol red free 
growth media containing the treatments mentioned previously. Fluorescence intensity 
(representative of RS levels) was measured in a plate reader using an excitation wavelength 485 nm 
and emission wavelength of 535 nm which was read every hour for 12 hours at 37°C with 5% CO2. 
RS levels were expressed as fluorescence intensity (arbitrary units) at each corresponding time 
point. 
2.4.2 Endpoint RS levels  
The non-fluorescent probe 2’,7’-dichlorofluorescin diacetate (DCDFA) was also used to measure 
endpoint RS levels due to difficulty in sensitivity with rotenone. Cells were seeded as mentioned 
above and grown to 60-70% confluence. Cells were treated with rotenone treatment (0, 0.1, 0.5 
and 2.5 μM) with or without antioxidant for the desired time. Following treatment media was 
removed and replaced with phenol red free DMEM-F12 growth media containing 10 µM DCFDA. 
Cells were incubated with the dye at 37°C for 30 minutes. The dye was carefully removed and 
replaced with phenol red free growth media and fluorescence was measured in a plate reader using 
an excitation wavelength 485 nm and emission wavelength of 535 nm or the S3 incucyte live-cell 
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analysis system to normalise fluorescence against cell phase contrast confluence. Experiments were 
performed in triplicate where data is expressed as the mean ± SEM.   
2.4.3 Live imaging 
The fluorescent dye DCDFA was also used to obtain live images of cellular RS levels. Cells were 
seeded in 8-well chamber slides at 7000 cells/cm2 and incubated until 60-70% confluent. Media was 
subsequently replaced with rotenone (0, 0.1, 0.5 and 2.5 μM) or AAPH (0, 0.25, 1 and 5 mM) 
treatments and incubated for 24 hours. Following treatment, cells were washed with Dulbecco’s 
phosphate buffered cells (DPBS) and incubated with growth media containing 100 μM DCDFA for 
30 minutes. Slides were then washed with DPBS and incubated with fresh DPBS for visualisation. 
Images of cells were taken using a 20X objective. Following RS imaging, slides were washed with 
DPBS and fixed with ice-cold 90% (v/v) methanol/tris buffer saline (TBS) for 30 minutes at -20°C. 
Chambers were then removed and coverslips were mounted with anti-fade mountant vectorshield® 
containing DAPI nuclear stain. The coverslip was sealed with clear nail vanish and viewed using a 
Leica CLSM laser confocal microscope. Images were captured using a 20X objective.  
2.5 Fluorogenic total glutathione assay  
Total cellular glutathione levels were estimated using a commercially available glutathione 
fluorometric kit (Sigma, Dorset, UK). Both SH-SY5Y and U-87MG cells were seeded into two T25 
flask at 17000 cells/cm2. Cells were allowed to proliferate for the appropriate amount of time prior 
to treatment with AAPH and rotenone. Following treatment cells were mechanically detached, 
centrifuged at 300g for 5 minutes and then washed with PBS. The resulting pellet was subsequently 
incubated with lysis buffer for 15 minutes on ice. The resultant lysate was then centrifuged at 
16000g for 5 minutes and the supernatant was collected. A range of standards (1.3-10 nM) and 
samples were then pipetted into a 96-well plate with 82.5 μl of assay buffer followed by the addition 
of 5 μl of glutathione S-transferase and 2.5 μl substrate solution to initiate the reaction. The plate 
was then incubated at 37°C for 1 hour prior to recording fluorescence levels on a BMGLabtech 
CLARIOSTAR using an excitation wavelength of 390 nm and emission wavelength 480 nm. The 
bicinchoninic acid (BCA) assay was then used to quantify the protein content of samples as 
described in section 2.7.5.2. Experiments were performed in quadruplicate and the results were 
expressed as mean % glutathione levels after calculating change in fluorescence/μg of protein ± 
SEM for control samples.  
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2.6 Preparation of cell lysates  
2.6.1 Total protein extraction 
Whole cell lysates were prepared by mechanically detaching cells into the growth medium which 
were then harvested by centrifugation at 300g for 5 minutes. The supernatant was discarded, and 
the pellet was re-suspended in ice-cold DPBS. Pellet was harvested by centrifugation at 300g at 4°C 
for 5 minutes. The supernatant was decanted carefully, and the pellet was washed two more times 
by re-suspending the pellet in ice-cold DPBS and harvesting at 300g at 4°C for 5 minutes. The pellet 
was extracted by re-suspension in 120 µl of boiling total extraction buffer (50 mM Tris, pH 6.8; 5 
mM EDTA; 1% w/v SDS; 1% (v/v) protease cocktail inhibitor) and further boiled at 100°C for 5 
minutes. Lysates were then cooled on ice. Samples were quantified using the Lowry assay described 
in section 2.7.5.1 and then stored at -20°C until needed.  
2.6.2 RIPA extraction  
Whole cell lysates were prepared by mechanically detaching cells into the growth medium which 
were then harvested by centrifugation at 300g for 5 minutes. The supernatant was discarded, and 
the pellet was re-suspended in ice-cold DPBS prior to harvesting by centrifugation at 300g at 4°C 
for 5 minutes. Pellet was then resuspended in 120 μl RIPA buffer with 0.1% protease inhibitor 
cocktail. Lysates were incubated on ice for 15 minutes and then centrifuged at 13000g for 5 minutes 
at 4°C. Supernatant was then collected and the pellet was discarded. Protein concentration was 
determined by the BCA protein estimation described in section 2.7.5.2. Lysates were stored at -
20°C until needed.  
2.6.3 Subcellular fractionation  
Whole cell lysates were prepared by mechanically detaching cells into growth media which was 
then harvested by centrifugation at 300g for 5 minutes at 4°C. The supernatant was discarded, and 
the pellet was re-suspended in ice-cold DPBS. Pellet was harvested by centrifugation at 300g at 4°C 
for 5 minutes. The pellet was then resuspended in in 100 μl extraction buffer (10 mM HEPES, pH 
7.5, 200 mM mannitol, 70 mM sucrose, 1 mM EGTA and 0.1% protease inhibitor cocktail) and 
transferred to a handheld homogeniser. Using the loose pestle 10 movements followed by 10 
movements with the tight pestle to homogenise at room temperature. The sample was then 
removed from the handheld homogeniser and centrifuged at 1000g for 10 minutes at 4°C. The 
cytosolic supernatant fraction was collected, and the pellet nuclear fraction was resuspended in 50 
μl of extraction buffer. The protein concentration of both cytosolic and nuclear fractions was 
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determined using the BCA protein estimation described in section 2.7.5.2. Lysates were stored at -
20°C until needed.    
2.6.4 Proteasome extraction  
Lysates were prepared by mechanically detaching cells into growth media and harvested by 
centrifugation at 300g for 5 minutes. The supernatant was discarded, and pellets were frozen until 
all lysates were obtained. Pellet was re-suspended in ice-cold DPBS at 300g at 4°C for 5 minutes 
prior to resuspension in 100 μl ice-cold homogenisation buffer (20 mM Tris/HCl, pH 7.2, 0.1 mM 
EDTA, 1 mM 2-mercaptoethanol, 5 mM ATP, 20% (v/v) glycerol, 0.4% (v/v) Igepal CA-630). Samples 
were vortexed thoroughly for 2 minutes followed by centrifugation at 13000g for 2 minutes at 4°C. 
The resultant supernatant was transferred to a fresh Eppendorf tube and kept on ice ready for the 
fluorogenic assay described in section 2.8. Samples were quantified using the Bio-Rad estimation 
as described in section 2.7.5.3.      
2.6.5 Protein quantification  
2.6.5.1 Lowry protein estimation  
The Lowry estimation is a colorimetric assay used to quantify the total protein content of lysates. A 
standard curve was generated by diluting 5-40 µg of 1 mg/ml bovine serum albumin (BSA) to a final 
volume of 100 µl with distilled water and total extraction buffer while samples were diluted with 
water, all of which were done in triplicate. 1 ml of working Lowry solution (containing 2% Na2CO3 
and 0.1 M NaOH in distilled water with 1% (w/v) CuSO4 and 2.7% NaK-tartrate) was added to both 
standards and samples, which were mixed by inversion. Samples were then incubated at room 
temperature for 15 minutes before adding 100 μl of Folin-Ciocalteu phenol reagent (1:1 with 
distilled water) to both standards and samples. Subsequently, all were vortex mixed and incubated 
at room temperature for 30 minutes. Finally, 100 μl of each standard and sample was transferred 
to a 96-well plate that was read at 750 nm using a plate reader. BSA standards were used to 
construct a standard curve to then calculate the protein content of lysates (figure 2.1).   
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2.6.5.2 Bicinchoninic acid protein estimation 
Protein content was assessed using a commercially available bicinchoninic acid (BCA) kit (Sigma 
Aldrich, Dorset, UK) where dilutions of BSA was used to create a linear standard curve with 
concentrations ranging from 0-1 mg/ml to which extraction or RIPA buffer was also added. 20 μl of 
samples and standards was added to a 96-well plate in triplicate. A 200 μl aliquot of working BCA 
reagent (BCA: copper II sulphate at 50:1) was added to each well and the plate was incubated at 
37°C for 30 minutes. Absorbance was read at 540 nm using a Labtech BMG CLARIOSTAR plate 
reader.   
2.6.5.3 Bio-Rad protein estimation 
The Bio-Rad microassay was performed as per the manufacturer’s instructions to assay the protein 
content of cell lysates prepared for the fluorogenic proteasome activity assay. A standard curve was 
generated by diluting 0-25 µg/ml of 1 mg/ml bovine serum albumin (BSA) in a volume of 800 μl. A 
10 μl aliquot of each sample was prepared in a volume of 800 μl. Both samples and standards were 
assayed in triplicate. A 200 μl aliquot of Bio-Rad dye reagent concentrate (Coomassie Brilliant Blue 
G-250, phosphoric acid, methanol) was added to both standards and samples prior to vortex mixing. 
A 100 μl aliquot of both standards and samples was then transferred to a 96-well plate and the 
absorbance was measured at 595 nm. Standards were used to construct a graph to then calculate 
the protein content.  
 
Figure 2.1 Standard calibration curve for Lowry protein estimation measured at 750 nm. The protein 
content of the samples (unknowns) was calculated using the equation for the line of best fit.   
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2.7 Proteasome activity assay using a fluorogenic peptide assay  
10 μl aliquots of lysates were incubated at 37°C with 5 μl of 1 mM fluorogenic substrate for 
chymotrypsin-like activity (CLA), for the 20S proteasome (N-Succinyl-Leu-Leu-Val-Tyr-AMC) in assay 
buffer (50 mM HEPES, pH 8.0, 5 mM EGTA) in a total reaction volume of 100 μl to give a final 50 μM 
CLA working concentration. Using the CLARIOSTAR plate reader, readings were taken every 5 
minutes for 1 hour at excitation and emission wavelengths of 360 nm and 465 nm, respectively 
(figure 2.2). Protein estimation was determined by the Bio-Rad protein assay described in section 
2.7.5.3. The LINEST function was used to determine the line of best fit to calculate the change in 
fluorescence. Experiment was performed in triplicate and results were expressed as change in 
fluorescence units/min/μg protein mean ± SEM.  
2.8 Sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE)  
Once the protein concentration was estimated and the volume needed was calculated this was 
dissolved in a 1:1 ratio with 2X reducing Laemmli buffer (Sigma Aldrich, Dorset, UK) and boiled at 
100°C for 5 minutes, allowing denaturation. Prior to the preparation of the separating gel the Bio-
Rad mini-PROTEAN® tetra vertical electrophoresis cell was assembled as per the manufacturer’s 
guidelines. For each gel, 10 ml of resolving gel was prepared described in table 2.5. To initiate the 
polymerisation 50 µl of 10% (w/v) ammonium persulfate (APS; Sigma Aldrich, Dorset, UK) and 10 µl 
Figure 2.2 Example plot of fluorescence (arbitrary units) versus time (minutes) used to determine the 
proteasome activity. The activity of the proteasome was determined using the LINEST function to 
determine the line of best fit for the data using the least squares method for the linear part of the curve 
where readings were taken every 5 minutes for 60 minutes. The rate in change of reaction was expressed 
as rate in change of fluorescence per μg protein calculated using the bio-rad protein estimation.   
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of N,N,N’,N’- tetramethylethylenediamine (TEMED; Sigma Aldrich, Dorset, UK) was added before 
casting 7 ml between two glass plates leaving the appropriate amount of space for the stacking gel. 
Distilled water was then added to the surface to create a smooth gel interface and allow 
polymerisation. The gel was left to polymerise at room temperature for approximately 30 minutes 
to an hour. Once the gel had polymerised the water was removed by blotting. Subsequently, 5 ml 
of 4% (w/v) acrylamide stacking gel was prepared for each gel. A 50 ml stock of stacking gel was 
prepared as described in table 2.6. When needed 10 μl of TEMED and 25 μl of APS was added to 5 
ml of the stacking gel to initiate polymerisation. 3-4ml of stacking gel was cast onto the resolving 
gel and a plastic comb was immediately inserted to form wells. The stacking gel was left to 
polymerise for approximately 20-30 minutes at room temperature. Once polymerised the comb 
was removed and the gel was placed in the electrophoretic tank and submerged in SDS-running 
buffer (25 mM Tris, 192 mM Glycine and 0.1% (w/v) SDS, pH 8.5). The protein samples (20-50 
μg/well) were loaded alongside 1 μl of the protein ladder (Bio-Rad Laboratories Ltd, Hertfordshire). 
Initially, the gel was run at 90V for approximately 20-30 minutes to allow the samples to enter the 
resolving gel. Subsequently, voltage was increased to 140V for approximately 40 minutes to 
separate the proteins.   
Different percentages resulted is different protein separations where table 2.5 lists the various 
resolving gel compositions.  
Table 2.5 Preparation of different percentage acrylamide resolving gels for SDS-PAGE.   
Reagent  7.5% (w/v) gel 10% (w/v) gel 12.5% (w/v) gel 15% (w/v) gel 
40% acrylamide 
solution (29:1) 
1.9 ml 2.5 ml 3.0 ml 3.75 ml 
1.5 M Tris buffer 
pH 8.8 
2.5 ml 2.5 ml 2.5 ml 2.5 ml 
10% (w/v) SDS 100 μl 100 μl 100 μl 100 μl 
Distilled water  5.5 ml 4.9 ml 4.4 ml 3.65 ml 
 
2.9 Western Blotting  
Western blotting involves the transfer of proteins from a gel to a nitrocellulose membrane which is 
subsequently immunoprobed for the protein or protein modification of interest.  
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2.9.1 Wet blotting  
Following electrophoresis, separated proteins were transferred to a nitrocellulose membrane (0.22 
μM pore) by wet blotting. Briefly, the blotting sandwich was prepared as follows: sponge, filter 
paper, nitrocellulose membrane, gel, filter paper and sponge, all of which were initially soaked in 
ice-cold transfer buffer (25 mM Tris, 192 mM glycine, pH 8.3 and 20% (v/v) methanol). Bubbles 
were removed by submerging the sandwich in transfer buffer and use of a roller. The sandwich was 
clamped together in a western blotting cassette and transferred to the electrophoretic tank with 
the nitrocellulose facing the anode. The cassette was then submerged in transfer buffer and 
transferred at a constant 40V for 16 hours. Transfer success was evaluated by staining with 0.05% 
(w/v) copper phthalocyanine 3,4’,4’’,4’’’ tetrasuphonic acid terasodium salt in 12 mM HCl (Sigma 
Aldrich, Dorset, UK). The stain was then captured using an ImageQuantTM Las 4000 (GE healthcare, 
Buckinghamshire, UK) camera and the membrane was de-stained with 12 mM NaOH with gentle 
agitation.  
2.9.2 Protein immunoprobing  
Following destaining the nitrocellulose membrane was blocked in 3% (w/v) BSA in TBS-Tween for 1 
hour at room temperature with gentle agitation. The blot was then immersed in primary antibody 
diluted in 3% (w/v) BSA in TBS-Tween at the relevant concentrations specified in table 2.1 on a roller 
at 4°C, overnight. Blots were then washed 3X with TBS-Tween for 15 minutes each on a roller at 
room temperature. Following this, blots were immersed in the appropriate HRP-conjugated 
secondary antibody diluted in 3% (w/v) marvel milk in TBS-tween at the dilutions mentioned in 
table 2.2 on a roller at room temperature for 2 hours. After this, blots were again washed 3X with 
TBS-tween for 15 minutes each on a roller at room temperature. Finally, blots were developed by 
adding Pierce ECL Western blotting substrate (ThermoFisher Scientific, Loughborough, UK) as 
described by the manufacturer for the appropriate time and chemiluminescence images captured 
by an ImageQuantTM Las 4000 (GE healthcare, Buckinghamshire, UK). Image development was 
terminated by extensive washing in distilled water.  
2.9.3 Stripping and reprobing  
Following termination of blot development, previous immunoprobed blots were incubated with 0.5 
M NaOH for 8 minutes with gentle agitation. Blots were then washed 3X with distilled water for 5 
minutes each and then 3X with TBS-tween for 5 minutes each. Finally, blots were blocked for 1 hour 
in 3% (w/v) BSA in TBS-Tween at room temperature with gentle agitation followed by the method 
described in section 2.11.2.  
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2.9.4 Western blot quantification  
Western blot and copper stained images were quantified using the Aida Image Analyser v4.03, 
following the manufacturer’s guidelines. Pixel intensity for equal sized areas around each band was 
obtained and quantified based on the number and intensity of the pixels in the area. Changes in 
protein loading were corrected against the control (using copper stains or B512 Tubulin respective 
lane pixel intensity). Corrected protein bands were expressed as % against control.  
2.10 Mitochondrial staining  
For morphological analyses mitochondria were stained with MitotrackerTM Red CMXRos as per the 
manufacturer’s instructions prior to fixation. Briefly, cells were seeded as described previously and 
treated with rotenone (0, 0.1, 0.5 and 2.5 μM) or AAPH (0, 0.25, 1, 5 mM) with or without an 
antioxidant for 24-48 hours. Cells were subsequently washed with serum-free media and incubated 
with 300 nM MitotrackerTM Red CMXRos in serum-free media for 1 hour at 37°C. Cells were then 
washed with serum-free media and PBS and subsequently fixed with 3.7% (w/v) paraformaldehyde 
in PBS at room temperature for 30 minutes. Images were captured at 20X magnification on an EVOS 
FLOID cell imaging station (ThermoFisher Scientific, Loughborough, UK) and edited using Fiji 
software.  
2.11 JC-1 staining  
JC-1 (5′,6,6′-tetrachloro-1,1′,3,3′-tetraethylbenzimidazolylcarbocyanine iodide; Cambridge 
bioscience, Cambridge, UK) was used to visualise and quantify changes in mitochondrial membrane 
potential. SH-SY5Y and U-87MG cells were treated with AAPH or rotenone for 24 hours and then 
incubated with 30 μM JC-1 in phenol red free media for 30 minutes. Cells were then washed twice 
with PBS and imaged in both red and green using the incucyte S3 live cell analysis system.  
2.12 Seahorse ATP live assay 
To measure the rate of ATP production from mitochondria and glycolysis in live cells, a Seahorse 
XFe24 extracellular flux analyser was used. Cells were seeded at 17000 cells/cm2 for 
undifferentiated experiments and 10000 cells/cm2 for differentiation experiments in the XF24 cell 
culture microplate (Agilent, Santa Claret, US). Once cells were sufficiently confluent, they were 
treated with 1 mM AAPH or 0.5 μM rotenone for 24 hours. The Seahorse XFe24 extracellular flux 
analyser was then used to assess ATP production from mitochondrial respiration and glycolysis by 
sequentially injecting oligomycin (1.5 μM) and then rotenone/antimycin A (0.5 μM). The Seahorse 
XF analyser simultaneously measures the flux of protons resulting in extracellular acidification 
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(ECAR) and O2 consumption (OCR) under basal conditions and after serial addition of mitochondrial 
inhibitors allowing mitochondrial and glycolytic rates of ATP production to be calculated. OCR and 
ECAR was calculated using the Wave software (Agilent, Santa Claret, US) and the Seahorse XF-real 
time ATP rate assay report generator.   
2.13 Immunofluorescence microscopy  
2.13.1 Methanol fixation  
SH-SY5Y neuroblastoma and U-87MG glioblastoma cells were seeded in 8 well chamber slides at a 
density of 17000 cells/cm2. Following treatment, cells were washed with PBS once and then fixed 
with ice-cold 90% (v/v) methanol/TBS for 20 minutes at -20°C.  
2.13.2 Paraformaldehyde fixation  
SH-SY5Y neuroblastoma and U-87MG glioblastoma cells were seeded in 8 well chamber slides at a 
density of 17000 cells/cm2. Following treatment, cells were washed with PBS once and then fixed 
with 3.7% paraformaldehyde solution in PBS for 20 minutes at room temperature.  
2.13.3 Immunofluorescence antibody staining  
Previously fixed cells were permeabilised with 0.5% triton-X100 (v/v) in TBS for 15 minutes at room 
temperature.  Cells were then washed with PBS 3X for 15 minutes each prior to block with 3% (w/v) 
BSA in PBS for 1 hour at room temperature. Cells were then incubated overnight at 4°C with primary 
antibody in blocking buffer at the dilutions stated in table 2.1. Following incubation cells were 
washed 3X with PBS for 5 minutes each. Cells were subsequently incubated with secondary 
antibodies in blocking buffer as described in table 2.2 for 2 hours at room temperature. After 
incubation with secondary antibody cells were washed 3X with PBS for 5 minutes each and nuclei 
was counter stained using DAPI in Vectorshield ® mounting medium. Slides were then sealed with 
glass coverslips and secured using transparent nail vanish. Slides were stored at 4°C until required. 
Images were acquired using Leica TCS SP5 II confocal microscope (Leica Microsystems, GmbH, 
Manheim, Germany).  
2.14 Quantitative reverse transcription real time PCR 
2.14.1 RNA extraction using Qiagen RNeasy columns  
Following treatment, cells were washed with DPBS. RNA was extracted as per the manufacturer’s 
instructions (Qiagen Ltd, UK). Briefly, cells were resuspended in RLT buffer (500 μl RLT buffer + 10 
μl 2-mercaptoethanol) and 1 volume of 70% ethanol. A 700 μl aliquot of the sample was transferred 
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to a RNeasy Mini spin column and placed in a 2 ml collection tube. Samples were subsequently 
centrifuged at 10000g for 15 seconds. The sample flow-through was discarded and 700 μl of RW1 
buffer was added to the RNeasy spin column and centrifuged at 10000g for 15 seconds. The sample 
flow-through was discarded and 500 μl of RPE buffer (1 volume RPE buffer + 4 volumes of 100% 
ethanol) was added to the column prior to centrifugation at 10000g for 15 seconds. The flow-
through was discarded and 500 μl RPE buffer was added to column and centrifuged at 10000g for 
2 minutes. The column was then transferred to fresh 1.5 ml collection tube. Finally, 20 μl of 60°C 
RNase-free water was added to the column and centrifuged at 10000g for 1 minute to elute the 
RNA. RNA samples were quantified using Nanodrop 8000 spectrophotometer (ThermoFisher, 
Scientific, Loughborough, UK), using the modified Beer-lambert law: 
𝑐 = 𝐴𝜀/𝑙 
Where c: concentration, A: absorbance, ε: wavelength-dependent extinction coefficient and l: 
pathway length. Samples were used immediately to synthesise cDNA or stored at -80°C until 
required. 
2.14.2 DNA extraction using PureLink™ Genomic DNA Mini Kit 
Cells were washed with DPBS and DNA was extracted as per the manufacturer’s instructions 
(ThermoFisher Scientific, Loughborough, UK). Cells were resuspended in 200 μl of DPBS and added 
to 20 μl Proteinase K. 20 μl of RNase A was added to the sample prior to vortexing and incubating 
at room temperature for 2 minutes. 200 μl of PureLink® Genomic lysis/binding buffer was added, 
and samples were made homogenous by vortexing. Samples were then incubated for 10 minutes 
at 55°C promoting protein digestion. A 200 μl aliquot of 100% ethanol was added to each sample 
and mixed by vortexing prior to adding the sample to a PureLink® spin column. Columns were 
centrifuged at 10000g for 1 minute at room temperature. The flow-through was discarded and DNA 
was washed with 500 μl of wash buffer 1 and the column was centrifuged at 10000g for 1 minute 
at room temperature. Flow-through was discarded and 500 μl of wash buffer 2 was added to the 
column before centrifuging at 20000g for 3 minutes at room temperature. DNA was eluted by 
adding 26 μl of PureLink® genomic elution buffer and incubating the columns at room temperature 
for 1 minute and transferred to a fresh 1.5 ml collection tube and then centrifuged at 20000g for 1 
minute. DNA samples were quantified using Nanodrop 8000 spectrophotometer (ThermoFisher, 
Scientific, Loughborough, UK). Samples were stored at -20°C.   
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2.14.3 cDNA synthesis using iScriptTM cDNA synthesis kit  
Prior to quantitative real-time PCR RNA was reverse transcribed to cDNA using the mixture 
described in table 2.6 below.  
Table 2.6 Component compositions for cDNA synthesis from RNA templates using iScriptTM cDNA synthesis 
kit. 
Reagents  Volume (µl) 
5X iScript Reaction mix  4 
iScript Reverse Transcriptase 1 
Nuclease-free water  Variable 
RNA template (100 ng) Variable 
Total volume 20 
 
The complete reaction was then put in a Bio-Rad T100 thermal cycler (Bio-Rad, Hertfordshire, UK) 
using the following protocol (table 2.7). 
Table 2.7 Reaction protocol for reverse transcribing cDNA using a thermal cycler.  
Step Time (min) Temperature (°C) 
Priming  5 25 
Reverse transcription  20 46 
Reverse transcriptase inactivation  1 95 
 
Newly synthesised cDNA was stored at -20°C until needed.  
2.14.4 Quantitative real-time PCR   
The iTaqTM universal SYBR® green supermix reaction mix was prepared as per the manufacturer’s 
instructions (Bio-Rad, Hertfordshire, UK) mentioned in table 2.8 in Rotogene® PCR tubes.   
Table 2.8 Component compositions for quantitative real-time PCR using a thermal cycler.  
Reagents  Volume (µl) 
iTaqTM universal SYBR® green supermix (2x)  5 
Forward and reverse primers 0.5 (10 μM) 
DNA template (100 ng) Variable 
H2O  Variable  
Total volume 10 
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Tubes were transferred to Rotor-gene 6000 real-time PCR machine (ThermoFisher, Loughborough, 
UK). The thermocycler was set for the following protocol in table 2.9.  
Table 2.9 Reaction protocol for quantitative real-time PCR using a real-time PCR machine. 
Step Time (sec) Temperature (°C) 
Initial denaturation  600 95 
Denaturation  30 95 
Annealing  30 Described in table 2.11 
Extension  30 72 
 
A melt curve was generated by ramping the temperature from the annealing temperature to 95°C. 
the results were analysed using the 2-ΔΔCt method. Results were performed in triplicate and 
expressed as percentage change in gene expression compared to the control ± SEM.   
Table 2.10 Primer sequences and related information for quantitative real-time PCR.  
Primer name NCBI accession 
number 
Sequence (5’-3’) Annealing 
temperature (°C) 
NRF2 forward 
NM_006164 
AACCAGTGGATCTGCCAACTACTC 
61 
NRF2 reverse CTGCGCCAAAAGCTGCAT 
KEAP1 forward  
NM_012289 
CCTVCTGGCCGGGTAATAGG 
61 
KEAP1 reverse CCCCTCCCAGGTATCCAAGA 
GCLM forward 
NM_002061 
ACAGGTAAAACCAAATAGTAACAAAGTTAA 
61 
GCLM reverse TGTTTAGCAAATGCAGTCAAATCTG 
HPRT forward 
NM_000194  
TGACACTGGCAAAACAATGCA  
61 
HPRT reverse GGTCCTTTTCACCAGCAAGCT  
TBP forward 
NM_001172085 
TGCACAGGAGCCAAGAGTGAA 
61 
TBP reverse CACATCACAGCTCCCCACCA 
SDH 1 forward SY140405458-
092-3 
TGGGAACAAGAGGGCATCTG 
60 
SDH 1 reverse CCACCACTGCATCAAATTCATG 
SDH 2 forward SY140305473-
087--088 
CCAGCAAAATGGAATTATCTTGT 
60 
SDH 2 reverse TCTCCTTCAATAGCTGGCTT 
MIT A forward SY140305458—
089-090 
CACCATTAGCACCCAAAGCT 
60 
MIT A reverse TACTTGACCACCTGTACTAC 
MIT B forward SY140305458-
091-094 
GAGGATGGTGGTCAAGGGAC 
60 
MIT B reverse  TTTGATGTGGATTGGGTTT 
 
40 Cycles  
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2.14.5 Agarose gel electrophoresis 
A 1.5% (w/v) agarose gel was cast in Tris-acetate-EDTA (TAE) buffer (40 mM Tris, 20 mM acetic acid, 
1 mM EDTA) supplemented with SYBR safe DNA gel stain (1:10000). Subsequent to PCR 
amplification, 5 µl of blue/orange loading dye was added to the PCR samples prior to loading onto 
the gel. A 2 μl aliquot of 100 bp DNA ladder (Promega®, Southampton, UK) was loaded alongside 
20 μl of sample. The gel was then subjected to a constant 90V for 30 minutes before visualisation 
using U:Genius3 (Syngene, Cambridge, UK).     
2.14.6 PCR array 
Following RNA extraction using the Qiagen RNeasy columns and nanodrop 8000 spectrometer 
quantification (Thermo Scientific, Waltham, MA USA) gene expression changes induced by 
treatments following differentiation were analysed utilising 1 μg of total RNA using the RT2 first 
strand kit and the human oxidative stress plus RT2 profiler PCR array (Qiagen, Hilden, Germany) on 
the StepOnePlusTM real-time PCR system (Applied biosystems, Foster City, CA, USA). Data was 
normalised to B2M and HPRT. Relative gene expression was obtained using the ΔCt calculation 
(Livak and Schmittgen, 2001).  
2.15 Small interference RNA (siRNA) analysis  
SH-SY5Y and U-87MG cells were transfected with scramble, GAPDH or NRF2 siRNA. Briefly, cells 
were seeded with DMEM: F12 in plates at 7500 cells/cm2. Non-selective or selective (NRF2 or 
GAPDH) knock-down was achieved using 15 pmol of scrambled (Santa Cruz biotechnology, USA), 
GAPDH (ThermoFisher Scientific, Loughborough, UK) or NRF2 (ThermoFisher Scientific, 
Loughborough, UK) siRNA, respectively utilising Lipofectamine 3000 transfection reagent 
(ThermoFisher Scientific, Loughborough, UK), according to the manufacturer’s instructions. The 
transfection procedure was carried out 24 hours after seeding.  
2.16 Lipid peroxidation 
2.16.1 Click-iT lipid peroxidation imaging kit  
To evaluate lipid peroxidation of differentiated neural cells in response to AAPH and rotenone the 
click-iT lipid peroxidation kit was used as per the manufacturer’s instructions (ThermoFisher 
Scientific, Loughborough, UK). Briefly, SH-SY5Y and U-87MG cells were seeded and differentiated 
over 5 days with 10 μM retinoic acid as mentioned before in section 2.2.9. Cells were subsequently 
treated with 1 mM AAPH or 0.5 μM rotenone with and without tocopherol (200 μM) or ascorbic 
acid (1 mM) in the presence of 5 μM linoleamide alkyne (LAA) for 48 hours. 2 hours prior to the end 
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of treatment for a positive control cells were treated with 100 μM cumene hydroperoxide. Cells 
were then washed twice with PBS and incubated with 3.7% (w/v) paraformaldehyde in PBS for 20 
minutes. Fixed cells were subsequently washed with PBS twice and incubated at room temperature 
with 0.5% (v/v) triton X-100 in PBS for 20 minutes. Cells were then blocked by adding 1% (w/v) BSA 
in PBS for 30 minutes at room temperature. The Click-iT reaction cocktail was then prepared as 
mentioned in table 2.11 in the order listed in the table.  
Table 2.11 Click-iT reaction cocktail  
Reaction components 96-well plate 
1X Click-iT reaction buffer 5.15 ml 
CuSO4 240 μl 
Alexa Fluor 488 azide 15 μl 
1X Click-iT buffer additive 600 μl 
Total volume 6005 μl 
  
The blocking solution was removed, and cells were washed twice with PBS and 50 μl of Click-iT 
reaction cocktail was added to each sample and incubated at room temperature in the dark with 
agitation. Cells were then washed once with 1% (w/v) BSA/PBS and then twice with PBS alone. Fresh 
PBS was added to each well prior to imaging and quantification using the incucyte S3 live-cell 
analysis system.    
2.16.2 TBARs assay  
Screening for thiobarbituric acid reactive substances (TBARS) is a commonly used method to 
monitor lipid peroxidation (Armstrong and Browne, 1994). Therefore, the TBARS assay kit 
(Cambridge bioscience, Cambridge, UK) was used as per the manufacturer’s instructions to assess 
lipid peroxidation in differentiated neural cells treated with AAPH or rotenone. Briefly, SH-SY5Y and 
U-87MG cells were seeded and differentiated over 5 days with 10 μM retinoic acid as mentioned 
before in section 2.2.9. Cells were subsequently treated with 1 mM AAPH or 0.5 μM rotenone with 
and without tocopherol (200 μM) or ascorbic acid (1 mM) for 48 hours. Cells were then 
mechanically detached and centrifuged at 300g for 5 minutes. Pellets were washed twice with PBS 
and harvested at 600g for 5 minutes at 4°C. Lysates were then extracted using RIPA buffer as 
mentioned in section 2.7.2. Standards were made up using the provided MDA standard (500 μM) 
as described in table 2.12. 
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Table 2.12 MDA standards preparation for TBARS fluorometric assay. 
MDA (μl) Water (μl) MDA concentration (μM) 
0 1000 0 
5 995 0.625 
10 990 1.25 
20 980 2.5 
40 960 5 
80 920 10 
200 800 25 
400 600 50 
 
50 μl of sample and standards was added to 50 μl SDS solution and mixed with inversion. 2 ml of 
colour reagent was then added to all samples and standards and vortex mixed. Vials were 
subsequently incubated in a 100°C water bath for 1 hour before incubating on ice for 10 minutes. 
Vials were then centrifuged at 1600g at 4°C for 10 minutes. 100 μl of each sample and standard 
was added in duplicate to a plate and fluorescence was read at 530 nm excitation and 550 nm 
emission. Finally, protein content was estimated using the BCA protein estimation described in 
section 2.7.5.2. Data was presented as MDA concentration per protein concentration (μM MDA/μg 
protein) where experiments were performed in triplicate and data is expressed as mean ± SEM.   
2.17 Oxidative stress induced post-translational modifications  
2.17.1 S-nitrosylation protein detection assay  
Reactive nitrogen species can undergo reactions with thiol groups known as S-nitrosylation, which 
is a reversible post-translational modification. To monitor nitrosylation in differentiated neural cells 
the S-nitrosylation protein detection kit was used with some modifications to the manufacturer’s 
instructions. Briefly, SH-SY5Y and U-87MG cells were seeded and differentiated over 5 days with 10 
μM retinoic acid as mentioned before in section 2.2.9. Cells were subsequently treated with 1 mM 
AAPH or 0.5 μM rotenone with and without tocopherol (200 μM) or ascorbic acid (1 mM) for 48 
hours. Cells were then washed twice with PBS and incubated with 3.7% paraformaldehyde in PBS 
for 20 minutes. Fixed cells were subsequently washed with PBS twice and incubated at room 
temperature with 0.5% triton X-100 in PBS for 20 minutes. Cells were then blocked with the blocking 
reagent in the kit in 0.1% triton X-100 in PBS for 30 minutes at 4°C. Cells were then washed with 
0.1% triton X-100 in PBS twice. Subsequently cell were incubated with S-nitrosylation reducing 
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reagent in 1 ml of 0.1% triton X-100 mixed with S-nitrosylation labelling reagent which was 
dissolved in 100 μl DMF and 900 μl 0.1% triton X-100 in PBS  made up to 10 ml with 0.1% triton X-
100 in PBS for 1 hour at room temperature. Cells were then washed twice again with 0.1% triton X-
100 in PBS prior to incubating with detection reagent II (Fluorescein) at a 1:20 dilution in 0.1% triton 
X-100 in PBS for 1 hour in a humidified chamber protected from light. Finally, cells were washed 
twice with PBS and fresh PBS was added to wells prior to imaging and quantification using the 
incucyte S3 live-cell analysis system.  
2.17.2 Protein Carbonylation colorimetric assay  
Reactive oxygen species are a common occurrence in neurodegenerative diseases and involved in 
oxidation of lipids, proteins and DNA. The most common post-translational modification of reactive 
oxygen species is carbonylation of proteins. Therefore, the carbonyl colorimetric kit (Cambridge 
bioscience, Cambridge, UK) was used to detect carbonyl content using 2,4-dinitrophenylhydrazine 
(DNPH) which reacts with protein carbonyls producing a Schiff base then the corresponding 
hydrazine which can be analysed spectrophotometrically as per the manufacturer’s instructions. 
Briefly, SH-SY5Y and U-87MG cells were seeded and differentiated over 5 days with 10 μM retinoic 
acid as mentioned before in section 2.2.9. Cells were subsequently treated with 1 mM AAPH or 0.5 
μM rotenone with and without tocopherol (200 μM) or ascorbic acid (1 mM) for 48 hours. Cells 
were then mechanically detached and centrifuged at 300g for 5 minutes. Pellets were then washed 
twice with PBS and harvested at 600g for 5 minutes at 4°C. Lysates were then extracted using RIPA 
buffer as mentioned in section 2.7.2. A 25 μl aliquot of each sample was transferred into two 
Eppendorf’s where one tube was the sample and one the control. 200 μl of DNPH was added to the 
samples, whereas 200 μl of 2.5 M HCl was added to the control tubes. All samples were then 
incubated at room temperature for 1 hour with a vortex mix every 15 minutes. 250 μl of 20% 
trichloroacetic acid (TCA) was added to all tubes and the incubated-on ice for 5 minutes prior to 
centrifugation at 10000g at 4°C for 10 minutes. The supernatant was discarded, and the pellet was 
resuspended in 250 μl of 10% TCA and again incubated on ice for 5 minutes. Tubes were then 
centrifuged at 10000g for 10 minutes at 4°C. Again, the supernatant was discarded, and the pellet 
was resuspended in 1:1 ethanol/ethyl acetate, vortexed thoroughly and centrifuged at 4°C for 10 
minutes. This step was repeated once more, and the pellet was then resuspended in 250 μl of 
guanidine hydrochloride by vortexing. Tubes were then centrifuged at 10000g at 4°C for 10 
minutes. Finally, 100 μl of both sample and control were transferred to a 96-well plate in duplicate 
and absorbance was measured at 385 nm. Protein content of the pellets was then estimated using 
the BCA protein estimation described in section 2.7.5.2. Carbonyl content (nmol) was calculated by 
subtracting the corresponding average control from the average sample to obtain the corrected 
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absorbance (CA) Protein carbonyl content was then determined via the following equations where 
protein (mg/ml) was calculated using the BCA protein estimation:  
𝑃𝑟𝑜𝑡𝑒𝑖𝑛 𝑐𝑎𝑟𝑏𝑜𝑛𝑦𝑙 (
𝑛𝑚𝑜𝑙
𝑚𝑙
) = [(
𝐶𝐴
0.011 𝜇𝑀−1
) (
250
100
)] 
𝐶𝑎𝑟𝑏𝑜𝑛𝑦𝑙 𝑐𝑜𝑛𝑡𝑒𝑛𝑡 (
𝑛𝑚𝑜𝑙
𝑚𝑔
) = (𝑃𝑟𝑜𝑡𝑒𝑖𝑛 𝑐𝑎𝑟𝑏𝑜𝑛𝑦𝑙 (
𝑛𝑚𝑜𝑙
𝑚𝑙
))(𝑝𝑟𝑜𝑡𝑒𝑖𝑛 (
𝑚𝑔
𝑚𝑙
)) 
Data is presented as carbonyl content (nmol/mg) where experiments were performed in triplicate 
and data is expressed as the mean ± SEM.   
2.18 Mass spectrometry and pathway enrichment  
2.18.1 Protein extraction and trypsinisation 
Proteins were extracted by RIPA as described in section 2.6.2. The concentration of each 
supernatant was determined using the BCA assay described in section 2.6.5.2 before storage of the 
protein at -20°C.  
Cell lysate/secretome (50 µg) were diluted in 50 mM tri-ethyl ammonium bicarbonate (TEAB, Sigma 
Aldrich UK) before reduction (5 mM DTT, 56°C, 20 min), alkylation (15 mM iodoacetamide , room 
temperature, 15 min in the dark) and digestion for 16 hours using Trypsin (Promega, UK)  at 37°C 
at a 25:1 protein:protease ratio (w/w) in a thermomixer (650rpm). Samples were concentrated and 
de-salted using HyperSep C18 spin tips (10-200 µL size; ThermoFisher Scientific, Loughborough, UK) 
using the manufacturers protocol. The samples were concentrated using a vacuum concentrator 
before resuspension in 5% acetonitrile + 0.1% formic acid.  
2.18.2 Mass Spectrometry  
Each sample was analysed on a Sciex TripleTOF 6600 mass spectrometer coupled in line with a 
eksigent ekspert nano LC 425 system running in micro flow. Samples (4 L) were injected and 
trapped onto a YMC Triart-C18 pre-column (0.3 x 5 mm, 300 µm ID) (mobile phase A; 0.1% formic 
acid, B; acetonitrile with 0.1% formic acid)  at a flow rate of 10 µL/min mobile phase A for 2 min 
before gradient elution onto the YMC Triart-C18 analytical column (15 cm, 3 µm, 300 µm ID) in line 
to a Sciex TripleTOF 6600 Duospray Source using a 50 m electrode, positive mode +5500V. Samples 
were analysed in both IDA (Information Dependent Acquisition, for the generation of a spectral 
library) and SWATH (Data Independent Acquisition, to generate quantitative data) modes. The 
following linear gradients were used: for IDA, mobile phase B increasing from 3-30% over 68 min; 
40% B at 73 min followed by column wash at 80% B and re-equilibration (87 min total run time).  
CHAPTER 2  MATERIALS AND METHODS 
72 
 
For SWATH, 3-30% B over 38 min; 40% B at 43 min followed by wash and re-equilibration as before 
(57 min total run time). IDA acquisition mode was used with a top 30 ion fragmentation (TOFMS 
m/z 400-1250; product ion 100-1500) followed by 15 sec exclusion using rolling collision energy, 50 
ms accumulation time; 1.8 s cycle. SWATH acquisition was performed using 100 variable windows, 
25 ms accumulation time, 2.6 s cycle (m/z 400-1250) (Mele et al., 2018). IDA data was searched 
together using ProteinPilot 5.0.2, iodoacetamide alkylation, thorough search with emphasis on 
biological modifications (Swissprot human database October 2018). SWATH data was analysed 
using Sciex OneOmics software (Lambert et al., 2013) extracted against the locally generated library 
(false discovery rate filtering of 1% and excluding shared peptides) with the parameters 12 peptides 
per protein, 6 transitions per peptide, XIC width 30 ppm, 6 min retention time window. The IDA 
data was also searched using PEAKS X software (Bioinformatics Solutions Inc. Canada) to identify 
any sites of post translational modifications (Swissprot human database March 2018, search with 
313 built-in modifications) with the parameters precursor mass tolerance 25ppm, peptides -10lgP 
≥ 15, proteins -10lgP ≥ 20, A-score ≥ 20.  
2.18.3 Enriched pathway analysis  
To identify enriched pathways between AAPH and rotenone treated U-87MG lysates and 
secretomes was loaded into Metacore, version 6.34 (https://portal.genego.com/), which enriched 
network, molecular functions, gene ontology processes, gene ontology functions, gene ontology 
localisations, pathways and diseases associated with the list of differentially expressed genes. 
Enrichment was calculated with mass spectrometry differentially identified proteins greater than 
50% confidence. Pathways were considered significant if more than one of the given pathway were 
present in the data than would be expected by chance, based on the total number of genes 
associated with the pathway.     
2.18.4 Validation of mass spectrometry identified proteins 
Samples used for mass spectrometry were also used for western blots to validate differentially 
identified proteins as described in section 2.8 and 2.9 using antibodies against proteins 
differentially identified including HSP70 (1:1000) and HSP27 (1:1000).  
2.18.5 String analysis for protein clusters among identified protein  
Understanding what groups of proteins are impacted from treatments in both lysates and 
secretomes is important for understanding what biological processes and functions are altered. To 
understand what identified proteins interactions and how they link to cellular processes, a 
bioinformatics approach was used. STRING analysis utilises a biological database to predict protein-
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protein interactions including physical and functional interactions. Using STRING 11.0 software to 
predict and associate the interactions between protein identified through mass spectrometry 
protein clusters were generated, where proteins related to specific functions were identified for U-
87MG lysates and secretomes treated with AAPH or rotenone. These diagrams (chapter 5) help 
demonstrate the different responses to AAPH and rotenone.    
2.19 iCelligence washes  
Wells/inserts were submerged with 70% ethanol for 20 minutes on a shaker. Ethanol was aspirated, 
and wells/inserts were washed with a thorough flow of water. Wells/inserts were then submerged 
with 5% (v/v) Hellmanex III (Sigma Aldrich, Dorset, UK) for 1 hour on a shaker prior to aspiration 
and washing with a thorough flow of 70% (v/v) ethanol followed by water. Wells/inserts were left 
to dry overnight and exposed to UV light for approximately 20 minutes prior to cell seeding.  
2.20 Statistical analysis  
All results are represented as mean ± S.E.M and converted to % against control where appropriate, 
where the number of replicates (n) for each experiment is noted in the figure legend. Multiple 
statistical analyses were conducted using GraphPad Prism 8 software (GraphPad, Inc, USA). One-
way ANOVA test were used for statistical analysis using the when with Dunnett’s post-hoc test to 
compare treatment means to control mean. Two-way ANOVA multiple comparison test followed 
by Tukey or Sidak post hoc tests as appropriate were used to compare means of individual groups 
(i.e with or without tocopherol for the same concentrations).  Results where p values <0.05 were 
considered statistically significant.   
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3.1 INTRODUCTION  
Multiple studies with animal models have and are still providing information into the possible 
mechanisms underlying neuronal degeneration. Some of these factors include mitochondrial 
dysfunction, impaired protein degradation and oxidative stress, which may be interconnected in 
the so-called ‘Neurodegenerative Bermuda triangle’ (NBT; figure 3.1). However, animal models 
make it difficult to understand the feedback mechanisms between neurons and glia, increasing the 
complexity in understanding this disease pathology. The use of in vitro studies allows the 
investigation of specific pathways within monocultures to be understood, while controlling 
environmental factors. This allows primary investigations to be conducted to understand individual 
cell mechanisms before probing a more complex co-culture. 
3.1.1 Use of the neuronal SH-SY5Y and glial U-87MG cell line to model 
neurodegeneration  
3.1.1.1 SH-SY5Y neuroblastoma cell line  
SH-SY5Y cells are derived from the SK-N-SH cell line which was obtained from a human metastatic 
bone tumour biopsy from a 4-year old patient in 1970. SK-N-SH cells can be divided into 2 cell types 
with distinct morphologies: neuroblastic cell type (N-type) that exhibit small areas of cytoplasm and 
cell processes with various lengths. The other cell type is a larger epithelial cell referred to as the 
substrate adherent type (S-type) (Kovalevich and Langford, 2013; Ross et al., 1983).  
SH-SY5Y are suitable for in vitro investigations into neurodegeneration as characterisation 
reveals neuronal properties such as moderate dopamine-β-hydroxylase activity with minimal levels 
of choline acetyl transferase (Kovalevich and Langford, 2013), in addition to noradrenaline release 
and tyrosine hydroxylase activity (Cheung et al., 2009; Presgraves et al., 2003; Xicoy et al., 2017). 
SH-SY5Y cells can also display a catecholaminergic phenotype with enzymes that synthesise both 
dopamine and noradrenaline. Therefore, SH-SY5Y cells may not be purely dopaminergic but are still 
widely used for modelling neurodegeneration. This is further highlighted as the SH-SY5Y cell line 
has been used to study AD, neurotoxicity and ischemia through different differentiation methods 
to obtain a neuronal phenotype (Kovalevich and Langford, 2013; Krishna et al., 2014).  
 Alternative options are available but also have their own disadvantages including limited 
sample size, cost and ethical problems. For high throughput screening, phenotypically homogenous 
cells with identical genetic backgrounds, such as SH-SY5Y cells are required. Furthermore, SH-SY5Y 
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cells have high differentiation efficiency providing an advantage over other neuronal models such 
as primary neurons and induced pluripotent stem cells (J I Forster et al., 2016).  
3.1.1.2 U-87MG glioblastoma cell line  
The CNS is composed of two major cell types: neurons and glia where glia are the most abundant 
cell within the brain. Initially, glia were believed to serve as the connective tissue between neurons. 
Studies have revealed glia to be  essential for neuronal development and cell-cell communication 
(Oswald et al., 2018; Seifert et al., 2006; Wilton et al., 2019). There are three types of glial cells: 
astrocytes, oligodendrocytes and microglia where astrocytes are the most numerous (Sauvageot, 
2002; Sun et al., 2003). It is important to note that nigrostriatal dopaminergic neurons have the 
lowest glia/neuron ratio in the brain (von Bartheld et al., 2016), which may explain why glial 
dysfunction has a more critical effect in the substantia nigra relative to other areas of the brain 
(Mena and García de Yébenes, 2008). Indeed, the importance of astrocytes is highlighted with their 
high expression levels of detoxifying compounds such as ascorbic acid (AA), glutathione (GSH) and 
glutathione precursors, in addition to high levels of the NRF2 transcription factor responsible for 
regulating antioxidant defence mechanisms (Allaman et al., 2011; Oswald et al., 2018).  
 U-87MG, is a long established cell line from a grade IV glioblastoma, the most common 
aggressive brain tumour in adults (Ohgaki and Kleihues, 2005; Pontén, 1975). U-87MG cells have 
been chosen for these experiments to create a suitable model system as they display astrocyte-like 
morphology, functional similarity to normal astrocytes (Nishiguchi et al., 2003; Saeed et al., 2015; 
Yoshida et al., 2011) and can produce and release neurotrophic growth and brain derived 
neurotrophic factor, supporting these studies (Laganiere et al., 2010; Zabłocka et al., 2015). 
Furthermore, like SH-SY5Y cells, U-87MG cells can be differentiated with similar concentrations of 
all-trans retinoic acid that downregulates telomerase activity and increases glial fibrillary associated 
protein (GFAP), inducing morphological changes associated with a differentiated astrocyte 
phenotype (Das et al., 2008; Haque et al., 2007). As both SH-SY5Y and U-87MG cell lines can be 
differentiated with all-trans retinoic acid this will allow future co-culture experiments to have the 
same conditions.  
However, it is important to note that like the SH-SY5Y cell line using U-87MG cells also has 
its limitations. For example, studies show that the U-87MG line differs from the originally supplied 
line possibly due to contamination or because of the cancerous nature of the cell line (Allen et al., 
2016). Additionally, cancer cells produce higher levels of reactive species (RS) due to the increased 
metabolic stress and proliferative capacity (Schumacker, 2006; Trachootham et al., 2006; Waris and 
Ahsan, 2006). Furthermore, Jelluma et al. show the U-87MG glioblastoma line is susceptible to 
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apoptosis upon glucose withdrawal, leading to OS but not ATP depletion that is not observed in 
normal astrocytes (Jelluma, 2006). Further supporting this, glioblastoma’s exhibit a 3-fold increase 
in glycolysis relative to their normal astrocytic counterparts (Fu et al., 2019). However, despite 
these limitations more studies are using SH-SY5Y and U-87MG cell lines in co-culture to investigate 
diseases (Olson et al., 2012; Saeed et al., 2015; Wang et al., 2015, Wang et al., 2014). They provide 
an adequate model of neurons and astrocytes that can be differentiated under similar conditions 
and allow high-throughput experiments, which are more difficult to perform with limited stem cells 
or ethically demanding primary cells.   
3.1.2 Neurodegenerative Bermuda triangle  
The brain has a high energy demand utilising mitochondria to provide ATP via oxidative 
phosphorylation (Franco-Iborra et al., 2016). Multiple studies suggest mitochondrial dysfunction is 
involved in dopaminergic neuronal degeneration in the pathogenesis of PD (Islam, 2017). In both 
familial and sporadic PD patients several gene mutations and defects in proteins linked to 
mitochondrial activity, protein degradation and antioxidant capacity have been implicated and are 
associated with OS (Müftüoglu et al., 2004).  
In SH-SY5Y cells, down regulation of PINK1 leads to mitochondrial dysfunction and 
increased OS (van der Merwe et al., 2017). Similarly, dopaminergic neurons from post mortem 
brains from patients with idiopathic PD exhibit PINK1 deficiency and mitochondrial complex I 
dysfunction (Azkona et al., 2018; Hattingen et al., 2009). In addition, mitochondrial inhibitors are 
commonly used to model PD.  
Astrocytes are important contributors to the pathology of PD (Maragakis and Rothstein, 
2006), with astrocyte dysfunction preceding neuronal death (Abramov, 2004; Booth et al., 2017). 
For example, astrocytes bearing a SOD1 mutation displayed impaired mitochondrial function 
resulting in increased OS, which affected neuronal viability (Cassina et al., 2008). Furthermore, a 
study has identified astrocytes to be able to improve synaptogenesis of neurons treated with 
mitochondrial inhibitors (Du et al., 2018), further highlighting the importance of astrocytes in 
regulating the neurodegenerative process.  
Increased RS levels are mainly attributed to mitochondrial dysfunction (Islam, 2017), 
though dopamine oxidation, xanthine oxidase and NADPH oxidase (NOX) also contribute (Gandhi 
and Abramov, 2012). Under normal homeostasis the redox balance is regulated by detoxifying 
proteins and peptides such as superoxide dismutase (SOD), DJ-1 and glutathione whose temporal 
production are regulated by RS involving a transcriptional level mechanism (Ighodaro and Akinloye, 
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2018). Genes encoding for proteins involved in detoxification of RS share a common promoter 
element referred to as the antioxidant response element (ARE).  
Activation of ARE via RS involves NRF2 (a transcription factor), which is negatively regulated 
by KEAP1 in the cytoplasm. However NRF2 is also negatively regulated in the nucleus by a complex 
of Cul3/Rbx1 that degrades NRF2 under basal conditions (Schmidlin et al., 2019). In addition, in the 
nucleus there is Src subfamily A member including Fyn, Src, Yes and Fgr which phosphorylates 
Tyr568 in NRF2 resulting in nuclear export and degradation (Niture et al., 2011). Furthermore, 
within the nucleus Bach1 also competes with NRF2 for binding to the ARE suppressing antioxidant 
gene transcription (Dhakshinamoorthy et al., 2005). Upon exposure to RS, NRF2 translocates to the 
nucleus, where it binds to the ARE upregulating antioxidant enzymes such as Mn-SOD and 
glutathione peroxidase (Holley et al., 2010; Itoh et al., 2003; Kobayashi and Yamamoto, 2006; 
Motohashi and Yamamoto, 2004; R. Zhang et al., 2017). NRF2 has also been associated with 
mitochondrial function and different cell dynamics (Dinkova-Kostova et al., 2015; Dinkova-Kostova 
and Abramov, 2015). Furthermore, NRF2 has been reported to be unstable without the well-known 
redox regulating protein, DJ-1 (Taira et al., 2004; van Horssen et al., 2010). More recently dietary 
vitamins with antioxidant properties have also been implicated in the NRF2-ARE pathway (Hegazy 
et al., 2019), stressing the importance in regulating RS levels.  
 These RS can cause post-translational modifications impairing protein degradation and 
altering protein homeostasis. Impaired protein handling has been suggested in sporadic cases of 
PD, from increased oxidatively damaged proteins, protein aggregation and accumulation of poorly 
degraded proteins within inclusions (Lopiano et al., 2000). Studies show increased levels of 
carbonyls and 4-hydroxynonenal (HNE) protein adducts in the SN of PD brains (Shahmoradian et 
al., 2019; Zhao et al., 2017), alongside accumulation of both ubiquitinated and non-ubiquitinated 
proteins (Walden and Muqit, 2017). Furthermore, in sporadic PD a decrease in chymotrypsin, 
trypsin and postacidic-like activities have been observed.  Proteasomal activity has also been shown 
to be reduced in rotenone treated SH-SY5Y cells with oxidative modification to the proteasome 
(Caneda-Ferrón et al., 2008; Shamoto-Nagai et al., 2003). Furthermore, in a recent study 
proteasome inhibition of LUHMES cells in monoculture led to proteotoxic and OS, which was 
alleviated by astrocyte-derived glutathione and NRF2 upregulation (Gutbier et al., 2018). Together, 
this evidence suggests impaired protein degradation or uncontrolled production of abnormal 
proteins plays a role in PD.  
 Therefore, mitochondrial dysfunction, RS and impaired protein degradation each 
contribute to neurodegeneration. Though these factors also appear to be interconnected, possibly 
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resulting in feed forward loops, where one could lead or contribute to another factor in what is 
known as the ‘Neurodegenerative Bermuda triangle’.   
3.1.3 Chemical induction of oxidative stress  
Modelling neurodegenerative diseases in vitro and in vivo is challenging as it is difficult to reproduce 
all features of the disease. As such chemical toxins have been used to induce the pathological 
hallmarks of neurodegenerative diseases such PD. PD has been linked with both genetic and 
environmental contributions (Cannon and Greenamyre, 2013; Marchetti et al., 2011; Twelves et al., 
2003). Epidemiological studies suggest exposure to environmental agents such as pesticides 
increase PD risk (Delamarre and Meissner, 2017). Rotenone is a naturally occurring organic 
pesticide used in lakes and reservoirs to kill unwanted fish and associated with an increased risk of 
PD (Betarbet et al., 2006).  
 Rotenone was initially used in 1985 to model PD where direct injection into the brain 
resulted in dopaminergic neuronal death (Heikkila et al., 1985). Rotenone was experimented with 
further as PD became associated with mitochondiral defects, whereby rotenone toxicity depends 
on its interaction with complex I in the ETC with an affinity of 10-20 nM (Higgins and Greenamyre, 
1996). Rotenone binds downstream of an electron leak site in complex I (Dunham-Snary et al., 2019; 
Feng, 2006), resulting in more free electrons being released to react with intracellular oxygen 
producing superoxide, which can further damage complex I and other complexes within the ETC 
leading to more free electrons and RS (García-García et al., 2005).  
Rotenone models demonstrate the importance of RS as they exhibit increased lipid 
peroxidation (Hasan et al., 2020), as well as increased protein carbonyl levels in neuroblastoma cell 
lines (Chiaradia et al., 2019). In addition to protein modifications, rotenone leads to DNA damage 
including oxidation of DNA bases and DNA strand breaks (Shokolenko et al., 2009; Swarnkar et al., 
2012). Furthermore, in vitro studies show chronic rotenone treatment results in accumulation and 
aggregation of both α-synuclein and ubiquitin (Hao et al., 2017). Rotenone has also been linked 
with decreased proteasomal activity and associated with PD (Chen et al., 2017; Shamoto-Nagai et 
al., 2003). In addition, rotenone can also disrupt microtubules leading to tubulin polymerisation 
that may account for neuron toxicity (Passmore et al., 2017). As rotenone affects the ETC this leads 
to decreased ATP synthesis (Caneda-Ferrón et al., 2008; Sherer et al., 2003) however, it seems 
toxicity is primarily induced via OS. Indeed, the importance of rotenone’s interaction with complex 
I leading to RS is highlighted, by replacement of complex I with the single subunit NADH 
dehydrogenase from Saccharomyces cerevisiae blocking mitochondrial impairment, oxidative 
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damage and cell death suggesting rotenone’s specific interaction with complex I causes 
neurodegeneration primarily via OS (Chernivec et al., 2018).   
Whilst rotenone is commonly used to replicate the pathological hallmarks of PD, it is 
difficult to use to examine the effect of specific types of RS. Using different oxidants with different 
structures allows specific RS to be generated (Piga et al., 2007). Therefore 2,2′-azobis(2-
amidinopropane) dihydrochloride (AAPH), a hydrophilic azo compound may be used as this 
thermally degrades at a defined rate. AAPH degrades to carbon radicals via the loss of nitrogen 
whereupon these radicals can react with intracellular oxygen generating predominantly peroxyl 
radicals (Bassett et al., 1999; Ben Othman et al., 2016; Werber et al., 2011). Peroxyl radicals can 
react with membrane lipids, forming highly reactive lipid peroxyl radicals. These radicals can 
repeatedly attack other lipids generating lipid hydroperoxides; a known hallmark of 
neurodegeneration and Parkinson’s disease (Angelova et al., 2015; Reed, 2011; Sultana et al., 
2013b).  
AAPH induced OS is also demonstrated by increased protein carbonyl, protein-bound HNE, 
3-NT and HSP70 levels (Joshi et al., 2006; Razack et al., 2015). These results support AAPH’s use as 
a toxin to model neurodegeneration as increased lipid peroxidation, HNE and acrolein levels are 
observed in neurodegenerative disorders (Simpson et al., 2004; Taso et al., 2019). However, unlike 
rotenone AAPH generates more specific types of RS rather than a cascade, allowing more 
investigations into how specific types of RS initiate different pathways which has yet to be 
investigated in neurodegenerative models.   
3.1.4 Countering reactive species with antioxidants  
Aerobic organisms have elaborate defences to cope with and protect against OS (Lemire et al., 
2017). Initially antioxidants will attempt to prevent RS production by sequestering metal ions or 
reducing RS such as H2O2 to water. The second line of defence involves antioxidants scavenging and 
removing RS before damage can occur. Vitamin E and C as well as carotenoids are the major radical 
scavengers in vivo, where vitamin E (tocopherol) and C (ascorbic acid) are essential for lipophilic 
and hydrophilic radical removal, respectively (Niki, 2014; Traber and Atkinson, 2007; Zakharova et 
al., 2017).  
Tocopherol is predominantly reported as an effective peroxyl and related alkyl peroxyl 
radical scavenger (Angeli et al., 2017; Fukuzawa et al., 1997). As a result, tocopherol reduces lipid 
peroxidation, which is aided by the localisation of tocopherol to membranes (Niki, 2014). Whereas 
ascorbic acid unlike tocopherol is reported to be an effective scavenger of superoxide radicals, 
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hydrogen peroxide and singlet oxygen (Buettner, 1993; Cabelli and Bielski, 1983; Tu et al., 2017). 
Patra et al. and others highlight the ability of tocopherol to reduce lipid peroxidation levels more 
than ascorbic acid when rat brains are exposed to lead, suggesting this is due to tocopherol being 
able to react with peroxyl radicals faster (Gotoh and Niki, 1992; Patra et al., 2001). 
Antioxidants such as tocopherol and ascorbic acid are known to reduce OS and, in some 
part, this is done by NRF2. Antioxidants are strong activators of NRF2, as upon antioxidant 
metabolism a small amount of OS is produced stimulating NRF2 activation. There are multiple 
stages to antioxidant NRF2 activation: preinduction, induction and postinduction (Niture et al., 
2014). During the preinduction phase, antioxidants initially lead to negative regulators being 
exported from the nucleus via tyrosine kinase phosphorylation of Cul3/Rbx1 complex, Fyn and 
Bach1, ultimately leading to their removal via ubiquitination and degradation (Kaspar and Jaiswal, 
2011, 2010a, 2010b). This allows NRF2 to move into the nucleus unhindered, where it 
heterodimerises with small Maf or c-Jun protein resulting in subsequent binding to the ARE and 
activation of cytoprotective genes (Kaspar et al., 2009; Shelton and Jaiswal, 2013). As a result, these 
cytoprotective genes aid in decreasing RS, supporting the observed lowered fluorescence. 
Following this induction NRF2 is switched off, where GSK3β activation phosphorylates Fyn leading 
to nuclear localisation (Jain and Jaiswal, 2007) leading to NRF2 phosphorylation, followed by 
nuclear export and degradation (Jain and Jaiswal, 2006). In addition, during this induction de novo 
synthesis of Cul3/Rbx1, Fyn and Bach1 occurs and these are imported into the nucleus switching 
off NRF2, leading to cytoprotective gene levels returning to basal levels (Dhakshinamoorthy et al., 
2005).  
3.1.5 Aims of the chapter  
While it is theorised that mitochondrial dysfunction, OS and impaired protein degradation are 
interconnected and influence neuronal death, few have shown this experimentally in both neurons 
and glia. Rotenone, known to inhibit complex I provoking mitochondrial dysfunction increases 
superoxide radicals, which subsequently generates a cascade of other RS. Thus, rotenone has been 
used extensively to investigate OS and model neurodegeneration. More recent studies have 
additionally investigated how rotenone also effects proteasome activity, though few have 
investigated the link between these factors. Furthermore, the effect of different RS has yet to be 
fully understood, which may be important in understanding how OS effects neurodegeneration and 
therefore using different chemicals may aid this.  
To assess how OS effects different neural cells neuronal SH-SY5Y and glial U-87MG cells 
were exposed to mitochondrial complex I inhibitor, rotenone and RS generating agent, AAPH. 
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Rotenone was used as a complex I inhibitor resulting in mitochondrial dysfunction increasing RS 
levels linked with the occurrence of PD, whereas AAPH generates primarily peroxy radicals by 
thermal degradation. The ability of these agents to influence RS levels and cell death was 
investigated alongside the ability of known antioxidants, α-tocopherol (vitamin E) and ascorbic acid 
(vitamin C), to potentially attenuate these effects. This approach will characterise the differing 
responses of neural cell types to different RS and help to establish suitable pathological co-culture 
conditions. The ability of sub-lethal RS levels to alter mitochondrial and proteasomal function will 
evaluate how RS impact the NBT and alter levels of antioxidant response proteins, providing insight 
into how different RS influence both mitochondrial function and protein degradation. 
Understanding the pathways underlying the ‘Neurodegenerative Bermuda Triangle’ and how 
different RS effect this will improve our understanding of their role in neurodegeneration so novel 
therapies can be produced. 
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3.2 RESULTS  
3.2.1 Differences in reactive species levels between neurons and glia 
RS are a pathological hallmark of PD and can be generated in a few ways. AAPH can increase RS via 
thermal degradation into carboxyl radicals, which can react with intracellular oxygen mainly 
generating peroxy radicals that target cell membranes. Both neuronal SH-SY5Y and glial U-87MG 
cells were exposed to the same concentration range of AAPH, to compare how different neural cell 
types react to this paradigm. RS accumulation in neural cells following AAPH exposure was 
measured using the fluorescent probe 2’,7’-dichlorofluorescin diacetate (DCFDA).  
Live fluorescence microscopy showed a dose-dependent increase in RS-mediated 
fluorescence within neural cells exposed to increasing AAPH concentrations (figure 3.1A, B and 
3.3A, B). Similarly, AAPH treatment showed a dose- and time-dependent increase in RS-mediated 
fluorescence when quantified temporally (figure 3.2A, B). The rate of RS generated was calculated 
(figure 3.2 and 3.4, table 1 and 2), which showed glial cells had a lower rate of fluorescence change 
relative to neuronal cells, although not significant.  
 Both antioxidants, α-tocopherol (figure 3.2) and ascorbic acid (figure 3.4), lowered AAPH-
induced neural RS levels demonstrated by reduced fluorescence (figure 3.1A, B and figure 3.3A, B, 
respectively). This was supported with temporal measurements that showed a significant decrease 
in the rate of RS-mediated fluorescence generation for 1 mM AAPH, for both neural cell types and 
antioxidants (figure 3.2C, D and figure 3.4C, D). This supports the change in fluorescence is due to 
RS generated by AAPH, which can be attenuated with antioxidants α-tocopherol and ascorbic acid.  
Rotenone was used to generate RS through mitochondrial dysfunction. Unfortunately, due 
to the fast nature of the RS generated by rotenone, experiments were restricted and thus, we relied 
on endpoint measurements to understand how rotenone affected RS levels in neural cells. For 
comparison, endpoints assays were also run with AAPH.  
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Figure 3.1 AAPH-induced RS levels are attenuated by α-tocopherol in neural cells using the fluorescent dye DCFDA. 
Neuronal (A) and glial (B) RS levels measured using DCFDA (green) and nuclei stained with DAPI (blue) with and without 
200 μM α-tocopherol. Scale bar = 100 μm.  
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Figure 3.2 AAPH-induced RS levels are attenuated by a-tocopherol in neural cells. Temporal measurement of 
RS using DCDFA (Fluorescence ± SEM) in cells treated with AAPH alone (A, B) or AAPH + a-tocopherol (C, D). 
Neuronal (Table 1) and glial (Table 2) rates of change of fluorescence for AAPH only or AAPH + 200 μM α-
tocopherol. Statistical analysis was performed using two-way ANOVA with Sidak’s post-hoc test where n=3 
for all experiments. Statistical significance was recorded as *p<0.05, **p<0.01 and ***p<0.001. 
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Figure 3.3 AAPH-induced RS levels are attenuated by ascorbic acid in neural cells using the fluorescent dye DCFDA. 
Neuronal (A) and glial (B) RS levels measured using DCFDA (green) and nuclei stained with DAPI (blue) with and without 
1 mM ascorbic acid. Scale bar = 100 μm.  
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Figure 3.4 AAPH-induced RS levels are attenuated by ascorbic acid in neural cells. Temporal measurement 
of RS using DCDFA (Fluorescence ± SEM) in cells treated with AAPH alone (A, B) or AAPH + ascorbic acid (C, D). 
Neuronal (Table 1) and glial (Table 2) rates of change of fluorescence for AAPH only or AAPH + 1 mM ascorbic 
acid. Statistical analysis was performed using two-way ANOVA with Sidak’s post-hoc test where n=3 for all 
experiments. Statistical significance was recorded as *p<0.05, **p<0.01, ***p<0.001 and ****p<0.0001. 
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Figure 3.5 AAPH-induced RS levels are affected by a-tocopherol and ascorbic acid in neural cells.  AAPH induced neuronal (A) and glial (C) reactive species 
levels measured using DCFDA (green) with and without 200 μM α-tocopherol or 1 mM ascorbic acid. Images taken using incucyte S3 live-cell analysis system. 
Scale bar = 200 μm. Endpoint measurement of fluorescence was quantified using the incucyte S3 live-cell analysis system (Fluorescent intensity/cell area ± SEM) 
in neurons (B) and glia (D) where results are presented as % against control. Statistical analysis was performed using two-way ANOVA with Dunnett’s post-hoc 
test relative to the control of each condition when n=4 for all experiments. Statistical significance was recorded as *p<0.05, **p<0.01 and *p<0.001. 
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Figure 3.6 Rotenone-induced RS levels are affected by a-tocopherol and ascorbic acid in neural cells.  Rotenone induced neuronal (A) and glial (C) reactive 
species levels measured using DCFDA (green) with and without 200 μM α-tocopherol or 1 mM ascorbic acid. Images taken using incucyte S3 live-cell analysis 
system. Scale bar = 200 μm. Endpoint measurement of fluorescence was quantified using the incucyte S3 live-cell analysis system (Fluorescent intensity/cell area 
± SEM) in neurons (B) and glia (D) presented as % against control. Statistical analysis was performed using two-way ANOVA with Dunnett’s post-hoc test relative 
to the control of each condition when n=4 for all experiments. Statistical significance was recorded as *p<0.05, **p<0.01, ***p<0.001 and ****p<0.0001. 
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Neural cells were treated with AAPH (figure 3.5) or rotenone (figure 3.6) for 48 hours with 
and without antioxidants, prior to the addition of DCFDA, then subsequently imaged and quantified 
using the incucyte S3-live cell analysis system. Again, AAPH showed a dose-dependent increase in 
fluorescence in both neuronal (figure 3.5A, B) and glial (figure 3.5C, D) cells, suggesting AAPH 
mediated RS generation. Furthermore, α-tocopherol was successfully able to attenuate 
fluorescence for 0.25 mM AAPH, suggesting the antioxidant was able to scavenge and reduce RS 
levels. Interestingly, ascorbic acid that previously at 12 hours showed reduced fluorescent levels 
did not show lower fluorescent levels for 1 mM AAPH in neurons and for all AAPH concentrations 
in glia. This suggests that α-tocopherol can continuously scavenge RS and thus, lower the 
fluorescent levels whereas ascorbic acid loses capacity to do so over time becoming less effective.  
Rotenone, like AAPH, showed a dose-dependent increase in fluorescence for both neuronal 
(figure 3.6A, B) and glial (figure 3.6C, D) cells, suggesting rotenone could generate quantifiable 
levels of RS. The addition of α-tocopherol attenuated fluorescent levels for both neurons and glia 
suggesting α-tocopherol could scavenge the RS generated by rotenone. Ascorbic acid successfully 
lowered rotenone-induced RS in neuronal cells but was less successful than α-tocopherol within 
glial cells, suggesting ascorbic acid displays different effects in neurons and glia. In addition, in 
neuronal cells ascorbic acid was successfully able to reduce fluorescence induced by rotenone but 
not for higher concentrations of AAPH, highlighting differences between the RS generators and 
distinct scavenging capabilities of different antioxidants.  
As temporal measurements with AAPH suggested a lower rate of change of fluorescence 
for glia relative to neurons, the antioxidant capacity of the different neural cells was investigated. 
One common antioxidant peptide that literature suggests is greater in glia than neurons is 
glutathione. Using a commercially available fluorometric kit, glutathione levels were measured 
(figure 3.7). Interestingly, U-87MG glial cells showed higher glutathione levels per μg protein 
relative to SH-SY5Y neuronal cells at 24 and 48 hours (figure 3.7A), suggesting glia have greater 
levels of glutathione. Additionally, when neurons and glia were treated with AAPH for 48 hours only 
neurons showed significantly higher levels of glutathione for 5 mM AAPH (figure 3.7B). This may be 
due to glia possessing greater basal levels of glutathione and as such can scavenge the RS generated 
by AAPH more effectively. Following 48-hour treatment with rotenone, both neurons and glia 
exhibited higher levels of glutathione (figure 3.7C). Together, this supports differences between the 
RS generators and activation of antioxidant mechanisms in the two neural cell types.      
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3.2.2 Oxidative stress mediated changes in the cellular antioxidant response  
To confirm sub-lethal levels of RS and possible pathways involved, antioxidant response element 
binding proteins and downstream antioxidant protein levels were investigated.  
Western blot results show AAPH and rotenone treatment in both neural cells showed no 
significant change in levels of the antioxidant response binding protein, NRF2 (figure 3.8A and B). 
DJ-1 levels showed a dose-dependent decrease in SH-SY5Y cells treated with both AAPH and 
rotenone (figure 3.8C and D), whereas no significant change was observed in U-87MG cells. Both 
neural cells showed a significant decrease in peroxiredoxin 6 (PRDX6) levels when treated with 
AAPH (figure 3.8E). Whereas rotenone caused opposing effects on PRDX6 levels in both neural cells 
(figure 3.8F), where there was a significant decrease in SH-SY5Y cells but a significant increase in 
glial U-87MG cells.  
Figure 3.7 AAPH and rotenone alter glutathione levels in neural cells. (A) Total glutathione levels were 
measured after 24 and 48 hours of growth for both SH-SY5Y and U-87MG cells. Both SH-SY5Y and U-87MG 
cells were treated with AAPH (B) or rotenone (C) for 48 hours and total glutathione levels were measured. 
Results are presented as % glutathione levels (GSH nmoles/μg protein) ± SEM against untreated control. 
Statistical analysis was performed using one-way ANOVA with Dunnett’s post-hoc test where n=4 in all 
experiments. Statistical analysis was performed using one-way ANOVA with Dunnett’s post-hoc test where 
n=4 for all experiments. Statistical significance was recorded as *p<0.05 and **p<0.01.  
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Figure 3.8 AAPH and rotenone-induced oxidative stress effects antioxidant response element proteins in 
neural cells. Representative Western blots of neuronal SH-SY5Y and glial U-87MG total cell extracts were 
probed with (A, B) NRF2 (1:1000), (C, D) DJ-1 (1:10000) and (E, F) peroxiredoxin 6 (PRDX6; 1:1000). Each 
Western blot is accompanied by a plot summarising densitometric analyses of Western blots using AIDA 
software. Results are presents as % against control ± SEM. Statistical analysis was performed using one-
way ANOVA with Dunnett’s post-hoc test where n=4 for all experiments. Statistical significance was 
recorded as *p<0.05, **p<0.01 and ***p<0.001. 
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Together, these results suggest RS in neural cells resulted in no significant change in NRF2 
levels. However, neurons showed decreased levels of subsequent downstream antioxidant 
response proteins, while glial cells exhibited either no significant change or an increase in 
downstream antioxidant protein PRDX6 following rotenone treatment. Furthermore, these results 
suggest specific RS generated by rotenone or AAPH treatment results in different neural cell 
responses, where proteins downstream of the antioxidant response element protein are affected. 
Therefore, even though there is no significant change in total NRF2 levels the transcription factor 
may change cellular localisation affecting downstream protein levels.  
As such, NRF2 subcellular localisation following AAPH and rotenone treatment was 
investigated. AAPH and rotenone treatment of SH-SY5Y cells (figure 3.9A and C) resulted in a dose-
dependent increase in NRF2 co-localisation within the nucleus. Successful subcellular fractionation 
of total cell lysates also revealed that both rotenone and AAPH increased NRF2 nuclear expression 
relative to the control (figure 3.9D), supporting immunofluorescence images. Additionally, the 
antioxidant α-tocopherol successfully attenuated NRF2 nuclear colocalisation for both treatments, 
suggesting OS resulted in this translocalisation. However, while ascorbic acid was able to prevent 
nuclear localisation in rotenone treated cells the antioxidant was not able to do this in AAPH treated 
cells, which subcellular fractionation also exhibited (figure 3.9D). These results supported previous 
DCFDA fluorescence studies that ascorbic acid is not able to successfully scavenge the RS generated 
by AAPH.  
The RS generated by AAPH and rotenone resulted in a similar effect in U-87MG glial cells 
where there was dose-dependent increase in nuclear localisation (figure 3.10A, C). Furthermore, 
subcellular fractionation revealed a significant increase in nuclear expression of NRF2 in both AAPH 
and rotenone treated U-87MG cells (figure 3.10D). Similarly, α-tocopherol was able to prevent 
nuclear localisation for both treatments. In contrast, ascorbic acid did not prevent NRF2 nuclear 
localisation. Subcellular fractionation Western blot results contravene this (figure 3.10D). However, 
immunofluorescence images suggest nuclear localisation in control ascorbic acid U-87MG cells 
suggesting ascorbic acid itself stresses U-87MG cells.  
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Figure 3.9 AAPH and rotenone induces NRF2 nuclear localisation in neuronal SH-SY5Y cells which is affected by antioxidants. Immunofluorescence showed AAPH (A) and 
rotenone (C) induced nuclear localisation of NRF2 (green) where 200 μM α-tocopherol prevented this localisation but 1 mM ascorbic acid only prevented nuclear localisation in 
rotenone treated SH-SY5Y cells. Scale bar = 25 μm. (B) Localisation of NRF2 was confirmed in subcellular fractions (Total; Cyto-cytoplasmic; Nuc-nuclear) using SDS-PAGE and 
Western blots using subcellular markers vinculin (cytoplasmic), lamin a/c (nuclear) and GAPDH (cytoplasmic). (D) Representative Western blot of nuclear subcellular fraction of 
NRF2 expression where SH-SY5Y cells were treated with (R) 0.5 μM rotenone or (A) 1 mM AAPH with and without 200 μM α-tocopherol and 1 mM ascorbic acid. Western blot is 
accompanied by a plot summarising densitometric analyses of Western blots using AIDA software. Results are presents as % against control ± SEM. Statistical analysis was 
performed using two-way ANOVA with Dunnett’s post-hoc test relative to the control of each condition when n=4 for all experiments. Statistical significance was recorded as 
*p<0.05 and **p<0.01. 
CHAPTER 3                                             MODELLING THE NEURODEGENERATIVE BERMUDA TRIANGLE 
 
95 
 
 
 
 
 
Figure 3.10 AAPH and rotenone induces NRF2 nuclear localisation in glial U-87MG cells which is affected by antioxidants.  Immunofluorescence showed AAPH (A) and 
rotenone (C) induced nuclear localisation of NRF2 (green) where 200 μM α-tocopherol prevented this localisation but 1 mM ascorbic acid doesn’t. Scale bar = 25 μm. (B) 
Localisation of NRF2 was confirmed in subcellular fractions (Total; Cyto-cytoplasmic; Nuc-nuclear) using SDS-PAGE and Western blots using subcellular markers vinculin 
(cytoplasmic), lamin a/c (nuclear) and GAPDH (cytoplasmic). (D) Representative Western blot of nuclear subcellular fraction of NRF2 expression where U-87MG cells were 
treated with (R) 0.5 μM rotenone or (A) 1 mM AAPH with and without 200 μM α-tocopherol and 1 mM ascorbic acid. Western blot is accompanied by a plot summarising 
densitometric analyses of Western blots using AIDA software. Results are presents as % against control ± SEM. Statistical analysis was performed using two-way ANOVA with 
Dunnett’s post-hoc test relative to the control of each condition when n=4 for all experiments. Statistical significance was recorded as *p<0.05 and **p<0.01. 
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Together, these results suggest AAPH and rotenone result in a dose-dependent nuclear 
localisation of NRF2, possibly leading to binding to the antioxidant response element (ARE) and 
subsequent transcription of OS response genes. This colocalisation was attenuated by α-tocopherol 
for both neural cells types and treatments, whereas ascorbic acid was only successful in preventing 
NRF2 nuclear localisation in SH-SY5Y cells treated with rotenone. This localisation mimicked changes 
in RS species seen in DCFDA fluorescence studies (figure 3.1-6), suggesting the RS generated by AAPH 
and rotenone influenced NRF2 nuclear localisation, indicating the ARE is activated in response to RS.  
 
 
 
Figure 3.11 Antioxidants α-tocopherol and ascorbic acid effects NRF2 levels in neural cells. (A) 
Representative Western blots of neuronal SH-SY5Y and glial U-87MG treated with 200 μM α-tocopherol and 
1 mM ascorbic acid total cell extracts were probed with NRF2 (1:1000). (B)Western blot is accompanied by 
a plot summarising densitometric analyses of Western blots using AIDA software. (C) Western blots were 
also used to determine NRF2 levels in U-87MG cells relative to SH-SY5Y cells using AIDA software. NRF2 
levels per unit protein for SH-SY5Y and U-87MG cells were 0.26 and 0.72, respectively. Results are presented 
as mean % against control ± SEM. Statistical analysis was performed using one-way ANOVA with Dunnett’s 
post-hoc test where n=4 for all experiments. Statistical significance was recorded as *p<0.05, **p<0.01 and 
***p<0.001. 
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Furthermore, NRF2 immunofluorescent images appeared brighter with the addition of α-
tocopherol and ascorbic acid relative to their control counterparts for both neural cells, as such NRF2 
levels were investigated in both neurons and glia treated with antioxidants (figure 3.11). Western blot 
results show increased NRF2 levels in neurons treated with both antioxidants but did not significantly 
affect levels in glial cells (figure 3.11B), suggesting antioxidants may attenuate RS levels by increasing 
NRF2 levels in neurons but not in glia. This is possibly because glia rely on other antioxidant 
mechanisms or because glia have greater basal levels of NRF2 than neurons (figure 3.11C).  
3.2.3 Oxidative stress influences neural viability  
Following confirmation of RS generation neural cell viability was assessed via morphological changes, 
viability and functional activity assays. Neural cells were exposed to a range of AAPH concentrations 
(0.1- 5 mM) for up to 48 hours.  
Phase contrast microscopy showed neuronal SH-SY5Y cells exhibited decreased processes and 
morphological rounding, alongside increased intercellular distance in a dose-dependent manner at 24 
hours (figure 3.12A), which was exacerbated at 48 hours (figure 3.14A) relative to the control, 
consistent with loss of cell viability. However, glial U-87MG cells showed no significant change in 
morphology and intercellular distance as the concentration of AAPH increased at 24 hours (figure 
3.12B), but higher concentrations resulted in decreased intercellular distances and extended 
processes at 48 hours (figure 3.14B). Furthermore, mitochondria of treated cells labelled with 
Mitotracker Red® (figure 3.12A, B and 3.14A, B) showed more diffuse staining indicating loss of 
mitochondrial integrity in SH-SY5Y neuronal and glial U-87MG cells.  
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Figure 3.12 Neuronal SH-SY5Y and glial U-87MG morphology after 24-hour AAPH exposure. Phase 
contrast microscopy and mitotracker staining (red) of (A) SH-SY5Y and (B) U-87MG monocultures after 
24-hour AAPH exposure. Scale bar = 100 μm. Inset scale bar = 30 μm. 
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Figure 3.13 Neuronal SH-SY5Y and glial U-87MG cell viability after 24-hour AAPH exposure. MTT reduction 
assay of (A) SH-SY5Y and (B) U-87MG cells treated with AAPH.  Total ATP levels of (C) SH-SY5Y and (D) U-87MG 
monocultures treated with AAPH for 24 hours. LDH release of (E) SH-SY5Y and (F) U-87MG monocultures 
treated with AAPH for 24 hours. All viability assays are presented as mean % against control ± SEM. Statistical 
analysis was performed using one-way ANOVA with Dunnett’s post-hoc test where n=3 for all experiments. 
Statistical significance was recorded as *p<0.05, **p<0.01, ***p<0.001 and ****p<0.0001. 
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Figure 3.14 Neuronal SH-SY5Y and glial U-87MG morphology after 48-hour AAPH exposure. Phase 
contrast microscopy and mitotracker staining (red) of (A) SH-SY5Y and (B) U-87MG monocultures after 
48-hour AAPH exposure. Scale bar = 100 μm. Inset scale bar = 30 μm. 
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Figure 3.15 Neuronal SH-SY5Y and glial U-87MG cell viability after 48-hour AAPH exposure. MTT reduction 
assay of (A) SH-SY5Y and (B) U-87MG cells treated with AAPH. Total ATP levels of (C) SH-SY5Y and (D) U-87MG 
monocultures treated with AAPH for 48 hours. LDH release of (E) SH-SY5Y and (F) U-87MG monocultures 
treated with AAPH for 48 hours. All viability assays are presented as mean % against control ± SEM. Statistical 
analysis was performed using one-way ANOVA with Dunnett’s post-hoc test where n=3 for all experiments. 
Statistical significance was recorded as *p<0.05, **p<0.01, ***p<0.001 and ****p<0.0001. 
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SH-SY5Y and U-87MG cells showed no significant change in metabolic function (MTT reduction 
and ATP levels; figure 3.13A, B, C, D) following 24-hour AAPH treatment. However, concentrations 
≥2.5 mM AAPH resulted in increased LDH release (figure 3.13E and F), relating to reduced membrane 
integrity. Following 48-hour AAPH treatment, a dose-dependent effect on SH-SY5Y cell viability was 
observed with MTT reduction significantly decreased for ≥2.5 mM AAPH (figure 3.15A). In contrast, 
glial U-87MG cells showed a significant increase in MTT reduction for ≥0.75 mM AAPH following 48-
hour treatment, suggesting a potential proliferative response (figure 3.15B). Cellular energy levels for 
neuronal SH-SY5Y cells showed a similar profile to the MTT reduction assays, where higher AAPH 
concentrations resulted in significantly decreased ATP levels (figure 3.15C). However, glial U-87MG 
cells showed no significant change in ATP levels for all concentrations of AAPH (figure 3.15D). 
Furthermore, at 48 hours LDH assays were exacerbated, where higher concentrations of AAPH (≥2.5 
mM) resulted in significant LDH release (figure 3.15E, F), suggesting AAPH generated RS that may 
affect membrane integrity. In addition, glial cells showed lower LDH release with AAPH treatment than 
neurons for both 24- and 48-hours suggesting glia are less susceptible to loss of membrane integrity.    
Neural cell viability was also investigated with rotenone induced RS assessed via 
morphological changes, viability and functional activity assays. Neural cells were exposed to a range 
of rotenone concentrations (0.01- 2.5 μM) for up to 48 hours. 
Phase contrast microscopy of both neural cells (figure 3.16A, B) showed a dose-dependent 
decrease in cell density with greater intercellular distance observed, alongside a more rounded 
morphology consistent with loss of viability, further exacerbated at 48 hours (figure 3.18A, B). In 
addition, accumulation of cellular debris was observed at higher concentrations of rotenone. 
Furthermore U-87MG glia also showed aggregation and clustering with higher rotenone 
concentrations. Untreated cells labelled with MitoTracker Red® CMXRos (figure 3.16 and 3.18A, B) 
showed defined mitochondrial foci, whilst rotenone treatment of both neural cell types resulted in 
diffuse staining, indicative of loss of mitochondrial membrane integrity. Higher concentrations 
showed significantly reduced MTT (figure 3.17A, B), and ATP levels (figure 3.17C, D) with a 
corresponding increase in LDH release (figure 3.17E, F).  
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Figure 3.16 Neuronal SH-SY5Y and glial U-87MG cell morphology after 24-hour rotenone exposure. 
Phase contrast microscopy and mitotracker staining (red) of (A) SH-SY5Y and (B) U-87MG monocultures 
after 24-hours rotenone exposure. Scale bar = 100 μm. Inset scale bar = 30 μm. 
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Figure 3.17 Neuronal SH-SY5Y and glial U-87MG cell viability after 24-hour rotenone exposure. MTT 
reduction assay of (A) SH-SY5Y and (B) U-87MG cells treated with rotenone. Total ATP levels of (C) SH-SY5Y 
and (D) U-87MG monocultures treated with rotenone for 24 hours. LDH release of (E) SH-SY5Y and (F) U-87MG 
monocultures treated with rotenone for 24 hours. All viability assays are presented as mean % against control 
± SEM. Statistical analysis was performed using one-way ANOVA with Dunnett’s post-hoc test where n=3 for 
all experiments. Statistical significance was recorded as *p<0.05, **p<0.01 and ***p<0.001. 
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Figure 3.18 Neuronal SH-SY5Y and glial U-87MG cell morphology after 48-hour rotenone exposure. 
Phase contrast microscopy and mitotracker staining (red) of (A) SH-SY5Y and (B) U-87MG monocultures 
after 48-hours rotenone exposure. Scale bar = 100 μm. Inset scale bar = 30 μm. 
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Figure 3.19 Neuronal SH-SY5Y and glial U-87MG cell viability after 48-hour rotenone exposure. MTT 
reduction assay of (A) SH-SY5Y and (B) U-87MG cells treated with rotenone. Total ATP levels of (C) SH-SY5Y 
and (D) U-87MG monocultures treated with rotenone for 48 hours. LDH release of (E) SH-SY5Y and (F) U-87MG 
monocultures treated with rotenone for 48 hours. All viability assays are presented as mean % against control 
± SEM. Statistical analysis was performed using one-way ANOVA with Dunnett’s post-hoc test where n=3 for 
all experiments. Statistical significance was recorded as *p<0.05, **p<0.01, ***p<0.001 and ****p<0.0001. 
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Following 48-hour rotenone treatment, cells showed an exacerbated dose-dependent loss of 
viability. MTT reduction assays showed concentrations of ≥0.1 μM significantly decreased viable SH-
SY5Y cells (figure 3.19A), whereas all rotenone concentrations significantly decreased U-87MG cell 
viability (figure 3.19B); these results suggest glial cells are more susceptible to the cytotoxic effect of 
rotenone. Both neural cells exhibited significantly lower ATP levels at ≥0.1 μM rotenone (figure 3.19C, 
D) showing a concentration-dependent decrease in cellular energy levels for both neural cell types. 
Furthermore, LDH assays support decreased SH-SY5Y cell viability for ≥0.5 μM as a significant increase 
in LDH release was observed (Figure 3.19E). However, for glial cells only ≥1 μM rotenone showed a 
significant increase in LDH release (Figure 3.19F), further suggesting glia as less susceptible to loss of 
membrane integrity via RS induction.  
3.2.4 Antioxidants attenuate neural death caused by oxidative stress 
To confirm RS levels affected cell viability the antioxidants α-tocopherol (200 μM) and ascorbic 
acid (1 mM) were added concurrently with treatment (figure 3.20-7). Neural viability was again 
assessed by morphological changes, viability and functional activity assays. In addition, real-time 
analysis using the iCelligence system was used to track cell viability in a temporal manner.  
Following 48-hour AAPH and rotenone treatment in the presence of α-tocopherol, cell death 
was attenuated (figure 3.20-3.21 and 3.22-3.23, respectively). Morphologically, both neural cells 
showed reduced intercellular distance and less rounding (figure 3.20 and 3.22A, B) when treated with 
AAPH and α-tocopherol, indicating improved neural viability. Neural viability improvement was also 
indicated by greater % MTT reduction (figure 3.21 and 3.23A, B) and reduced % LDH release (figure 
3.21 and 3.23C, D) for both neural cell types, with both RS inducers. In addition, real-time analysis 
showed greater normalised cell index for both neural cell types treated with α-tocopherol (figure 3.21 
and 3.23E, F) supporting viability assay data. Interestingly, U-87MG cells treated with AAPH and α-
tocopherol showed greater % MTT reduction suggesting lowering the RS increases metabolic activity 
(figure 3.21B).  
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Figure 3.20 Neuronal SH-SY5Y and glial U-87MG cell morphology after 48-hour AAPH and α-
tocopherol. Viability assays were conducted on SH-SY5Y or U-87MG cells treated with AAPH for 48 hours 
with and without 200 μM α-tocopherol. Phase contrast microscopy and mitotracker staining (red) of (A) 
SH-SY5Y or (B) U-87MG monocultures. Scale bar = 100 μm. Inset scale bar = 30 μm. 
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Figure 3.21 Neuronal SH-SY5Y and glial U-87MG cell viability after 48-hour AAPH and α-tocopherol. Viability 
assays were conducted on SH-SY5Y or U-87MG cells treated with AAPH for 48 hours with and without 200 μM 
α-tocopherol. MTT reduction assay for (A) SH-SY5Y or (B) U-87MG monocultures. LDH release for (C) SH-SY5Y 
or (D) U-87MG monocultures. Real-time analysis with iCelligence for (E) SH-SY5Y or (F) U-87MG monocultures. 
Statistical analysis was performed using one-way ANOVA with Dunnett’s post-hoc test where n=3 for all 
experiments. Statistical significance was recorded as *p<0.05, **p<0.01, ***p<0.001 and ****p<0.0001, 
where *’s above individual bars are relative to the control. 
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Figure 3.22 Neuronal SH-SY5Y and glial U-87MG cell morphology after 48-hour rotenone and α-
tocopherol. Viability assays were conducted on SH-SY5Y or U-87MG cells were treated with rotenone for 
48 hours with and without 200 μM α-tocopherol. Phase contrast microscopy and mitotracker staining 
(red) of (A) SH-SY5Y or (B) U-87MG monocultures. Scale bar = 100 μm. Inset scale bar = 30 μm. 
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Figure 3.23 Neuronal SH-SY5Y and glial U-87MG cell viability after 48-hour rotenone and α-tocopherol. 
Viability assays were conducted on SH-SY5Y or U-87MG cells were treated with rotenone for 48 hours with 
and without 200 μM α-tocopherol. MTT reduction assay for (A) SH-SY5Y or (B) U-87MG monocultures. LDH 
release for (C) SH-SY5Y or (D) U-87MG monocultures. Real-time analysis with iCelligence for (E) SH-SY5Y or 
(F) U-87MG monocultures. Statistical analysis was performed using one-way ANOVA with Dunnett’s post-
hoc test where n=3 for all experiments. Statistical significance was recorded as *p<0.05, **p<0.01, 
***p<0.001 and ****p<0.0001, where *’s above individual bars are relative to the control. 
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Figure 3.24 Neuronal SH-SY5Y and glial U-87MG cell morphology after 48-hour AAPH and ascorbic 
acid. Viability assays were conducted on SH-SY5Y or U-87MG cells were treated with AAPH for 48 hours 
with and without 1 mM ascorbic acid. Phase contrast microscopy and mitotracker staining (red) of (A) 
SH-SY5Y or (B) U-87MG monocultures. Scale bar = 100 μm. Inset scale bar = 30 μm. 
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Figure 3.25 Neuronal SH-SY5Y and glial U-87MG cell viability after 48-hour AAPH and ascorbic acid. Viability 
assays were conducted on SH-SY5Y or U-87MG cells were treated with AAPH for 48 hours with and without 1 
mM ascorbic acid. MTT reduction assay for (A) SH-SY5Y or (B) U-87MG monocultures. LDH release for (C) SH-
SY5Y or (D) U-87MG monocultures. Real-time analysis with iCelligence for (E) SH-SY5Y or (F) U-87MG 
monocultures. Statistical analysis was performed using one-way ANOVA with Dunnett’s post-hoc test where 
n=3 for all experiments. Statistical significance was recorded as * or # - *p<0.05, **p<0.01, ***p<0.001 and 
****p<0.0001, where *’s above individual bars are relative to the control. 
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Figure 3.26 Neuronal SH-SY5Y and glial U-87MG cell morphology after 48-hour rotenone and ascorbic 
acid. Viability assays were conducted on SH-SY5Y or U-87MG cells were treated with rotenone for 48 
hours with and without 1 mM ascorbic acid. Phase contrast microscopy and mitotracker staining (red) of 
(A) SH-SY5Y or (B) U-87MG monocultures. Scale bar = 100 μm. Inset scale bar = 30 μm. 
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Figure 3.27 Neuronal SH-SY5Y and glial U-87MG cell viability after 48-hour rotenone and ascorbic acid. 
Viability assays were conducted on SH-SY5Y or U-87MG cells were treated with rotenone for 48 hours with 
and without 1 mM ascorbic acid. MTT reduction assay for (A) SH-SY5Y or (B) U-87MG monocultures. LDH 
release for (C) SH-SY5Y or (D) U-87MG monocultures. Real-time analysis with iCelligence for (E) SH-SY5Y or (F) 
U-87MG monocultures. Statistical analysis was performed using one-way ANOVA with Dunnett’s post-hoc test 
where n=3 for all experiments. Statistical significance was recorded as * or # - *p<0.05, **p<0.01, ***p<0.001 
and ****p<0.0001. 
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Ascorbic acid treatment showed different effects on rotenone- or AAPH-induced cell death 
(figure 3.24-3.25 and figure 3.26-3.27, respectively). For both neural cells treated with ascorbic acid, 
morphological changes induced by AAPH were unchanged (figure 3.24A, B). In addition, MTT reduction 
(figure 3.25A, B) and LDH release were unchanged (figure 3.25C, D). Real-time analysis with the 
iCelligence showed a comparable normalised cell index (figure 3.25E, F), indicating no improvement 
in cell viability from ascorbic acid treatment. In contrast, ascorbic acid improved rotenone-induced 
neuronal cell death as shown by the increased % MTT reduction (figure 3.27A), reduced LDH release 
(figure 3.27C) and a higher normalised cell index (figure 3.27E). However, glial U-87MG cells treated 
with rotenone and ascorbic acid still retained greater intercellular distances, as well as rounding and 
clustering (figure 3.26B), indicative of cell death and apoptosis. Viability assays also suggested ascorbic 
acid did not improve glial viability with no improvements seen in % MTT reduction (figure 3.27B), LDH 
release (figure 3.27D), or normalised cell index (figure 3.27F).  
Together, these results suggest that α-tocopherol, a known scavenger of peroxy radicals can 
rescue both neurons and glia exposed to AAPH and rotenone. Whereas ascorbic acid, a predominantly 
superoxide scavenger was only able to increase the viability of neurons treated with rotenone but had 
no effect on AAPH treated neural cells or rotenone treated glial cells. This supports previous 
measurements of RS with DCF, suggesting OS generated by AAPH and rotenone affect neural cell 
viability through distinct RS production, which are attenuated by specific antioxidants.  
3.2.5 Oxidative stress effects mitochondrial function  
As mitochondrial dysfunction is another pathological hallmark of neurodegeneration the effect of the 
RS-inducers on mitochondrial function was investigated. Furthermore, as viability assays suggested U-
87MG glia cells were more sensitive to rotenone induced RS (figure 3.19), it was important to examine 
the effect of RS on mitochondrial pathways in the different neural cell types.  
 Initially, mitochondrial DNA content was determined using quantitative real-time polymerase 
chain reactions (qRT-PCR) for both SH-SY5Y neuronal and U-87MG glial cells (figure 3.28). qRT-PCR 
revealed U-87MG glial cells exhibited significantly lower expression of mitochondrial genes relative to 
SH-SY5Y neuronal cells.  
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Further supporting U-87MG glial possibly having lower mitochondrial levels than SH-SY5Y 
neuronal cells, oxygen consumption rate (OCR) and extracellular acidification rate (ECAR) was 
measured using the Seahorse XFe real-time cell analyser (figure 3.29A, B). Analysis showed that overall 
U-87MG cells had a greater ATP production (figure 3.29D) and ECAR (figure 3.29B) than SH-SY5Y 
neuronal cells. Specifically, control U-87MG glial cells exhibited a higher rate of ATP production from 
glycolysis than control SH-SY5Y neuronal cells; the latter relying more on mitochondrial ATP 
production (figure 3.29C, E). Therefore, qRT-PCR and Seahorse analysis highlighted the differences in 
mitochondrial function for distinct neural cell types.  
 
 
 
 
 
 
 
 
Figure 3.28 Glial U-87MG cells express lower levels of mitochondrial DNA than neuronal SH-SY5Y cells. 
Cells were grown to 70-80% confluence before DNA was extracted using the PureLink® genomic DNA kit as 
per the manufacturer’s instructions. 50 ng of DNA was subsequently used for qRT-PCR. Statistical analysis 
was performed using an unpaired t-test where n=3 for all experiments. Statistical significance was recorded 
as *p<0.05 and **p<0.01. 
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Figure 3.29 AAPH and rotenone increases glycolytic respiration in neuronal and glial cells. (A) Oxygen 
consumption rate (OCR) and (B) extracellular acidification rate (ECAR) were concomitantly measured after 
24 hours of 1 mM AAPH or 0.5 μM rotenone treatment for both SH-SY5Y neuronal and U-87MG glial cells. 
Using the Seahorse ATP report generator (C) glycolytic and mitochondrial basal ATP production rate was 
calculated. (D) An energetic map was also generated to show if cells or treatments resulted in a more 
glycolytic or mitochondrial ATP production which is further demonstrated in the (E) XF ATP rate index.  
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To investigate the effect of RS inducers on cellular respiration both SH-SY5Y and U-87MG cells 
were incubated with 1 mM AAPH and 0.5 μM rotenone for 24 hours, prior to Seahorse analysis. 
Mammalian cells mainly generate ATP via glycolysis and oxidative phosphorylation (OXPHOS) utilising 
mitochondria. Both pathways contribute to media acidification (ECAR), either by glucose conversion 
to lactate during glycolysis accompanied by proton efflux, or OXPHOS, which consumes oxygen (OCR) 
while producing CO2. Using the Seahorse basal ECAR and OCR were simultaneously measured for each 
cell line and treatment. Oligomycin and a combination of rotenone/antimycin A were added 
sequentially, where oligomycin inhibits ATP synthase decreasing OCR allowing mitochondrial ATP rate 
to be calculated. The addition of rotenone and antimycin A completely inhibits the electron transport 
chain so only the proton efflux from glycolysis occurs allowing glycolysis ATP production to be 
calculated. Both AAPH and rotenone treated SH-SY5Y cells exhibited higher ECAR and reduced OCR, 
suggesting a more glycolytic ATP production rate relative to control SH-SY5Y cells (figure 3.29C, D, and 
E). Rotenone but not AAPH increased ECAR and decreased OCR, suggesting a greater glycolytic ATP 
production rate in U-87MG glial cells (figure 3.29C, D and E). This suggests rotenone affects 
mitochondrial function as both cell lines show an increase in ECAR and drop in OCR, suggesting these 
cells increased their use of glycolysis to compensate for their loss of OXPHOS for ATP production. 
Whereas AAPH only appears to affect SH-SY5Y neuronal cell respiration and not glial, which suggests 
specific neural cell types respond differently to RS. 
 As RS generated by AAPH and rotenone affected respiration and mitochondrial damage is 
often associated with loss of membrane potential, the dual wavelength fluorescent probe, JC-1 was 
used to assess mitochondrial membrane potential. Both 24-hour AAPH and rotenone treated SH-SY5Y 
neuronal cells exhibited reduced membrane potential as a lower ratio of red aggregates to green 
monomers was observed (figure 3.30A, C, G, and E). Interestingly, while U-87MG glial cells treated 
with rotenone showed reduced membrane potential (figure 3.31C and D), AAPH increased membrane 
potential for the highest concentration of AAPH, suggesting AAPH initially improved mitochondrial 
function in glia (figure 3.31A and B). Therefore, rotenone appears to decrease both neural cells 
mitochondrial membrane potential, whereas AAPH decreases SH-SY5Y while increasing U-87MG 
membrane potential suggesting RS effect mitochondrial function in different ways.  
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Figure 3.30 Mitochondrial membrane 
assessment in neuronal SH-SY5Y cells in 
response to 24-hour AAPH and rotenone 
treatment. JC-1 was used to assess neuronal 
membrane potential of SH-SY5Y cells treated 
with AAPH (A, B) or rotenone (C, D) after 24-hour 
treatment. Scale bar = 200 μm. Phase, green and 
red images were taken and quantified using the 
incucyte S3 live-cell analysis system. Red to 
green ratio was calculated and statistical 
analysis was performed using one-way ANOVA 
with Dunnett’s post-hoc test where n=4 for all 
experiments. Statistical significance was 
recorded as *p<0.05, **p<0.01, ***p<0.001 and 
****p<0.0001. 
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Figure 3.31 Mitochondrial membrane 
assessment in glial U-87MG cells in response to 
24-hour AAPH and rotenone treatment. JC-1 
was used to assess glial membrane potential of 
U-87MG cells treated with AAPH (A, B) or 
rotenone (C, D) after 24-hour treatment. Scale 
bar = 200 μm. Phase, green and red images were 
taken and quantified using the incucyte S3 live-
cell analysis system. Red to green ratio was 
calculated and statistical analysis was 
performed using one-way ANOVA with Dunnett’s 
post-hoc test where n=4 for all experiments. 
Statistical significance was recorded as *p<0.05, 
**p<0.01, ***p<0.001 and ****p<0.0001. 
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Figure 3.32 AAPH and rotenone-induced oxidative stress affects mitochondrial fission and fusion protein 
levels. Representative Western blots of neuronal SH-SY5Y and glial U-87MG cells were treated with AAPH 
or rotenone for 24 hours and total cell extracts were probed with (A,B) optic atrophy 1(OPA1; 1:1000), (C,D) 
mitofusin-1 (MFN1; 1:500) and (E,F) phosphorylated dynamin-1-like protein (pDRP1; 1:500). Each Western 
blot is accompanied by a plot summarising densitometric analyses of Western blots using AIDA software. 
Results are presents as % against control ± SEM. Statistical analysis was performed using one-way ANOVA 
with Dunnett’s post-hoc test where n=4 for all experiments. Statistical significance was recorded as *p<0.05, 
**p<0.01, ***p<0.001 and ****p<0.0001.  
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 To determine the molecular mechanisms responsible for the change in ATP production and 
the effect of mitochondrial dysfunction, mitochondrial fission and fusion proteins were examined 
following 24-hour treatment. Various protein responsible for the fission/fusion balance including 
optic atrophy 1 (OPA1), mitofusion-1 (MFN1) and phosphorylated-dynamin 1-like protein (pDRP1) 
were investigated. Western blot analyses showed AAPH resulted in a dose-dependent decrease in 
fusion associated protein OPA1 (figure 3.32A) and MFN1 (figure 3.32C), while the level of pDRP1 
was unchanged in SH-SY5Y neuronal cells. Whereas AAPH treated U-87MG glial cells showed no 
significant change in mitochondrial biogenesis proteins OPA1, MFN1 and pDRP1 (figure 3.32A, C, 
and E). Rotenone treated SH-SY5Y and U-87MG cells exhibited a dose-dependent decrease in OPA1 
and MFN1 levels (figure 3.32B, D). Furthermore, SH-SY5Y neurons treated with rotenone exhibited 
significantly increased pDRP1 levels, whereas U-87MG glial cells showed no significant change in 
pDRP1. Therefore, AAPH decreased mitochondrial fusion associated proteins in neurons whilst 
having no significant effect in U-87MG glial cells. In contrast, rotenone decreased mitochondrial 
fusion associated proteins in both neural cell types while increasing fusion associated protein 
pDRP1 in neurons but not glial.  
 Together, these results suggest basal mitochondrial function differs between neuronal SH-
SY5Y and glial U-87MG cells. Furthermore, AAPH and rotenone affect mitochondrial function and 
associated molecular mechanisms differently in neurons and glia. This highlights the differences in 
neuronal and glial mitochondrial function and their response to RS.  
3.2.6 Oxidative stress decreases neural proteome function 
With oxidative and mitochondrial stress generated by AAPH and rotenone the effect on the neural 
proteome was investigated. Neural cells were treated with AAPH and rotenone for 24 hours and 
the proteasome activity of the collected lysates was assessed. The chymotrypsin-like activity of the 
20S subunit of the proteasome was measured using N-Succinyl-Leu-Leu-Val-Tyr-AMC with 
exogenously added ATP (figure 3.33A, B). Both neuronal SH-SY5Y and glial U-87MG cells treated 
with AAPH for 24 hours showed a dose-dependent decrease in proteasome activity where the 
highest concentration was significant (figure 3.33A). Like AAPH, rotenone also resulted in decreased 
proteasome activity in both neural cells (figure 3.33B). Interestingly, both neural cells and 
treatments showed similar significant decreases in proteasome activity, suggesting that despite 
different RS downstream pathways were affected in similar ways. 
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Figure 3.33 AAPH and rotenone-induced oxidative stress affects proteasome activity and subsequent 
ubiquitination levels. Neuronal SH-SY5Y and glial U-87MG cells were treated with (A) AAPH or (B) rotenone 
for 24 hours and then proteasome activity was measured in the presence of ATP. Results are expressed as 
mean % against control ± SEM. (C, D) Following 48-hour treatment with AAPH and rotenone SH-SY5Y and 
U-87MG total cell extracts were probed with ubiquitin (1:1000) to examine levels of ubiquitinated proteins. 
Each Western blot is accompanied by a plot summarising densitometric analyses of Western blots using 
AIDA software. Results are presents as % against control ± SEM. Statistical analysis was performed using 
one-way ANOVA with Dunnett’s post-hoc test where n=4 for all experiments. Statistical significance was 
recorded as *p<0.05, **p<0.01 and ***p<0.001.  
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Figure 3.34 AAPH and rotenone-induced oxidative stress affects heat shock and chaperone protein levels. 
Representative Western blots of neuronal SH-SY5Y and glial U-87MG cells were treated with AAPH or 
rotenone for 48 hours and total cell extracts were probed with (A,B) heat shock factor 1 (HSF1; 1:1000), 
(C,D) heat shock protein 70 (HSP70; 1:1000) and (E,F) heat shock protein 27 (HSP27; 1:1000). Each Western 
blot is accompanied by a plot summarising densitometric analyses of Western blots using AIDA software. 
Results are presents as % against control ± SEM. Statistical analysis was performed using one-way ANOVA 
with Dunnett’s post-hoc test where n=4 for all experiments. Statistical significance was recorded as *p<0.05, 
**p<0.01 and ***p<0.001.  
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To confirm proteasome dysfunction protein ubiquitination levels were measured. Western 
blots confirmed protein degradation was impaired, as levels of ubiquitinated proteins increased in 
a dose-dependent manner for both neural cells treated with AAPH and rotenone (figure 3.33C, D). 
Furthermore, as neural cells are dependent on the proteome for maintaining cell health, 
chaperones, which also help bind and refold misfolded proteins or target them for degradation 
were investigated to determine how OS affects these mechanisms. Heat shock factor 1 (HSF1) a 
master transcription factor of proteostasis did not change levels in neurons treated with either 
AAPH or rotenone (figure 3.34A, B). However, glial U-87MG cells showed a dose-dependent 
decrease in HSF1 levels following AAPH (figure 3.34A) and rotenone (figure 3.34B) exposure, where 
the decrease was more significant in AAPH treated cells. Heat shock protein 70 (HSP70; figure 
3.34C), an OS modulated chaperone and the smaller heat shock protein 27 (HSP27; figure 3.34E) 
decreased in neurons treated with AAPH, while levels did not significantly change in U-87MG glial 
cells. However, in rotenone treated SH-SY5Y neuronal cells there was significant dose-dependent 
increase in both HSP70 (figure 3.34D) and HSP27 (figure 3.34F), while like AAPH there was no 
significant change in U-87MG glial cell levels.   
Together, these results suggest pathways downstream of RS involved in neural proteostasis are 
affected including proteasome activity, protein ubiquitination and chaperone proteins levels 
supporting the idea that these pathological hallmarks of neurodegeneration are linked.   
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3.3 DISCUSSION   
There is increasing evidence to suggest OS plays an important role in the pathology associated with 
neurodegenerative diseases such as PD (Puspita et al., 2017). In the present study we investigated 
the effect of OS on the antioxidant response, mitochondrial and proteasomal function in both 
neurons and glia in vitro, to gain a better understanding of the mechanisms underlying 
neurodegeneration in different neural cell types. Various oxidants with different structures and 
reactivity can cause different types of OS and RS (Piga et al., 2007). Two compounds were 
investigated: AAPH; a peroxyl radical generator that targets membranes and rotenone; a 
mitochondrial complex I inhibitor, which primarily generates superoxide.  
AAPH, a hydrophilic azo compound that thermally degrades at physiological temperature 
producing free radicals at a defined rate (Werber et al., 2011) was used in this study to determine 
the effect of radicals in neural cells. AAPH resulted in a dose- and time-dependent increase in RS 
levels (figure 3.1-3.8). Due to dye sensitivity primarily measuring peroxy radicals (Kalyanaraman et 
al., 2012; Winterbourn, 2008), fluorescence was measured temporally allowing the rate of change 
of fluorescence and hence the rate of RS generation to be calculated. Previous studies with renal 
tubular epithelial cells (Yokozawa et al., 2000) and synaptosomes (Joshi et al., 2006) treated with 
AAPH showed increased lipid peroxidation and protein carbonyl levels. Furthermore SH-SY5Y cells 
labelled with diphenyl-1-pyrenylphosphine subsequently treated with 10 mM AAPH resulted in 
increased fluorescence, suggesting lipid peroxidation of the cell surface (Othman et al., 2016). This 
effect is not restricted to neurons as C6 rat glial cells treated with AAPH also show increased TBARS 
levels indicative of increased lipid peroxidation suggesting AAPH increases RS in glia (Sun et al., 
2001). Similar to these results others show AAPH treated retinal ganglion cells (Yokoyama et al., 
2014) and hippocampal neurons (Kanski et al., 2002) induced higher levels of RS, indicated with 
fluorescent probes, demonstrating RS generation across multiple cell types.   
Antioxidants, α-tocopherol and ascorbic acid exhibited different effects in neural cells in 
response to oxidising agents AAPH and rotenone, where α-tocopherol efficiently attenuated RS 
levels against both RS inducers in neural cells (figure 3.1-3.6). In contrast, ascorbic acid was not as 
effective attenuating RS levels in neural cells treated with AAPH, but also glial cells treated with 
rotenone, suggesting different RS scavenging abilities.  
Supporting the observed attenuation of RS fluorescence in this study, α-tocopherol is 
reported to be effective at removing lipid peroxyl and related alkyl peroxyl radicals (Angeli et al., 
2017; Fukuzawa et al., 1997), which are believed to be the primary RS generated by AAPH (Bassett 
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et al., 1999; Ben Othman et al., 2016; Werber et al., 2011). Similar to Zhang et al., this study shows 
rotenone treatment of neural cells resulted in a dose-dependent increase in fluorescence indicating 
increased levels of RS (Zhang et al., 2017). As rotenone can generate other RS downstream due to 
the cascade of reactions following superoxide production, it is not surprising that α-tocopherol also 
lowers RS levels in neural cells treated with rotenone (figure 3.6). Supporting these findings, SH-
SY5Y cells treated with AAPH and α-tocopherol by Ben Othman et al. and others showed 
attenuation of RS levels and reduced fatty acid peroxidation (Ben Othman et al., 2016; Rehncrona 
et al., 1980; Tappel, 1972). Other studies also highlight the ability of tocopherol to reduce RS levels 
not just in neurons but also in astrocytes (Mannelli et al., 2013; Yu et al., 2015). 
The observed decrease in RS fluorescence with neurons treated with rotenone and ascorbic 
acid is supported by Wenzel et al., who demonstrate camptothecin that significantly increased 
mitochondrial superoxide levels in tumour cells was attenuated by ascorbic acid (Wenzel, 2003). 
This suggests ascorbic acid can scavenge superoxide radicals, which is the predominant RS 
generated by rotenone. Further supporting ascorbic acid as a superoxide scavenger is SMP30/GNL 
knockout mice with vitamin C depletion show increased superoxide levels in the brain (Kondo et 
al., 2008).  
However, in U-87MG cells treated with rotenone ascorbic acid was not as effective at 
attenuating rotenone induced RS fluorescence relative to α-tocopherol. The reason for this is 
unclear but may possibly be due to the U-87MG cell line’s high glycolytic rate (Kim et al., 2015; 
Oudard et al., 1996), resulting in media acidification. This is corroborated by the Seahorse findings 
herein, which show U-87MG glia mainly produce ATP via glycolysis and have a higher ECAR than 
neurons (figure 3.29). Cheng et al.’s findings also support this as they reported L-ascorbic acid 
inhibits astrocytic growth of both normal and tumour cells due to media acidification (Cheng et al., 
1988). Together, with other studies the observed change in fluorescence and hence RS for neural 
cells when treated with AAPH and rotenone suggests these two chemicals generate different RS in 
neural cells, attenuated by distinct antioxidants.  
In addition to RS, AAPH treatment resulted in a lower rate of the change in fluorescence in 
glial U-87MG cells relative to neuronal SH-SY5Y cells (figure 3.2 and 3.4), which suggests neural cells 
behave differently and possibly have different antioxidant capacity. It is generally proposed that 
astrocytes possess greater levels of glutathione than neurons (Dringen and Hamprecht, 1997), 
though this does vary depending on the brain region (Asanuma et al., 2019; Langeveld et al., 1996). 
Furthermore, glia are believed to be important in the brains antioxidant defence system as glial 
resistance to OS induced by hydrogen peroxide or peroxynitrite is greater than neuronal (Baxter 
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and Hardingham, 2016; Ben-Yoseph et al., 1996; Bolaños et al., 1995). Others also show incubation 
of glia with 6-OHDA or hydrogen peroxide for 6 and 24 hours showed no significant change in cell 
viability, but increased total glutathione levels with lower lipid peroxidation levels relative to 
neurons (Asanuma et al., 2019; Iwata-Ichikawa et al., 1999). Therefore, we investigated glutathione 
levels in neural cells using a commercially available fluorometric glutathione assay kit. Like others, 
we showed that glial U-87MG cells had greater basal levels of glutathione (figure 3.7A), potentially 
explaining why there was no change in glutathione levels in U-87MG cells treated with AAPH but 
was for neurons (figure 3.7B). Furthermore, glutathione assays further support the possibility of 
these two chemicals producing different RS, as rotenone induced higher glutathione expression in 
both neural cells (figure 3.7C); whereas AAPH only effected neuronal cells (figure 3.7B) highlighting 
the possibility of different antioxidant pathway activation in neural cells.  
Neural cells in an effort to restore redox balance respond to RS by activating signalling 
pathways such as the NRF2-ARE, known to play a part in cell protection via an antioxidant and anti-
inflammatory role (Lee et al., 2003b; Shih et al., 2005; Tufekci et al., 2011). Under basal conditions 
NRF2 is cytoplasmic due to KEAP1 binding, resulting in ubiquitination and proteasomal degradation 
of NRF2 (Zhang et al., 2017). Upon OS NRF2 dissociates from KEAP1 becoming stable, translocating 
to the nucleus (Chen and Kong, 2004), where it forms heterodimers with other regulators inducing 
and driving the expression of antioxidant genes (Itoh et al., 1997; Kovac et al., 2015; Tonelli et al., 
2018). Therefore, with different RS generated in neural cells from AAPH and rotenone treatment 
we evaluated NRF2 and downstream OS related protein levels, to see how these pathways were 
affected. Western blot analysis showed no significant change in NRF2 levels following AAPH and 
rotenone exposure. However, like others we showed OS resulted in a concentration-dependent 
NRF2 activation where NRF2 translocates to the nucleus in neural cells as shown by 
immunofluorescent and subcellular fractionation studies (figure 3.9-3.10; Liddell et al., 2016; 
Malone and Hernandez, 2007; Quesada et al., 2011; Rizzi et al., 2018; Zagoura et al., 2017).  
Antioxidants can activate NRF2 leading to pre-induction, induction and post-induction 
(Niture et al., 2014). Therefore, the lack of NRF2 localisation in α-tocopherol treated neural cells 
and ascorbic acid treated neurons is possibly due to the constitutively active ARE, scavenging RS. 
Indeed, α-tocopherol and ascorbic acid have been shown to protect against OS via NRF2 (Joshi and 
A. Johnson, 2012; Mostafavi-Pour et al., 2017; Vineetha et al., 2018). In this study, ascorbic acid did 
not prevent NRF2 nuclear localisation in AAPH treated neural cells and rotenone treated glia, 
perhaps because RS levels were not shown to be lower, as such OS is still present and as a result 
NRF2 is still active and located to the nucleus. It is also important to note that immunofluorescence 
showed NRF2 localised to the nucleus in U-87MG cells treated with ascorbic acid, likely because of 
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the increased media acidification relative to the control resulting in stress and hence, nuclear 
localisation. Furthermore, both ascorbic acid and α-tocopherol significantly upregulated NRF2 
levels in neuronal cells but not glial cells (figure 3.11). This suggests antioxidants in neurons may 
combat OS by increasing NRF2 levels leading to ARE binding, increasing cytoprotective gene 
transcription allowing the return to basal conditions more quickly. Whereas antioxidants did not 
significantly change NRF2 levels in glia, possibly because glial cells have greater basal levels of NRF2 
(figure 3.11C) relative to neurons, as some report glia protect neurons via NRF2 dependent 
mechanisms (Baxter and Hardingham, 2016; Jimenez-Blasco et al., 2015; Shih et al., 2003; Vargas 
et al., 2006). Additionally, glial cells have other mechanisms for removal of RS such as glutathione 
so they may not predominantly rely on the NRF2-ARE pathway for the activation of antioxidant 
proteins (Dringen et al., 2005; Dringen and Hamprecht, 1997).   
NRF2 translocation to the nucleus induces and drives the expression of antioxidant genes 
and detoxification enzymes (Alam et al., 1999; Chen and Kong, 2004; Venugopal and Jaiswal, 1996). 
Neurons treated with both AAPH and rotenone exhibited decreased DJ-1 levels contravening other 
studies that show enhanced levels of DJ-1 in Parkinson’s patients (Hong et al., 2010; Waragai et al., 
2006), possibly due to high levels of oxidation inactivating DJ-1 leading to its degradation (Choi et 
al., 2006). In contrast, glial cells exhibited no significant change in DJ-1 levels for both RS inducers. 
This is potentially because glia are suggested to have a high antioxidant capacity and protect 
neurons via DJ-1 against OS inducers such as 6-hydroxydopamine (Lev et al., 2013). Furthermore, 
OS is reported to cause DJ-1 to co-localise with mitochondria or nuclei to enhance neuroprotection 
(Junn et al., 2009; Kim et al., 2012; Li et al., 2005; Zhang et al., 2005) and therefore localisation 
rather than total levels are key. Finally, peroxiredoxin 6 (PRDX6) levels decreased in both neural 
cells upon AAPH treatment, which may be due to PRDX6 being able to scavenge H2O2 and 
phospholipid hydroperoxides (Fisher, 2011; Manevich et al., 2009). As a result of high levels of RS 
generated by AAPH neural cells may have insufficient levels of glutathione to reduce PRDX6 
disulphide binds resulting in its degradation (Poole et al., 2011a; Turner-Ivey et al., 2013). In 
contrast, PRDX6 levels in neurons and glia exhibited opposite reactions to rotenone where PRDX6 
decreased in neurons and increased in glia (figure 3.8). This may be because antioxidant defence 
systems are overwhelmed in neurons, whereas in glia they remain active.  
Together, these results suggest different RS from AAPH, and rotenone activate the 
antioxidant system via NRF2 nuclear translocation. This is supported by α-tocopherol attenuating 
this localisation possibly by reducing RS levels and thus, returning neural cells to redox balance. 
Whereas ascorbic acid did not prevent NRF2 localisation in AAPH treated neural cells and rotenone 
treated glia, possibly due to ascorbic acid not scavenging RS effectively in these models resulting in 
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activation of the NRF2-ARE pathway. Further downstream NRF2 levels are unchanged by treatment 
but are increased by antioxidants in neurons but not in glia. This suggests antioxidants increase 
basal NRF2 levels in neurons, enhancing RS removal via the NRF2-ARE pathway. In contrast, glial 
cells rely on other antioxidant pathways to reduce RS levels. Additionally, downstream proteins 
associated with OS such as DJ-1 and PRDX6 levels appeared to be differentially affected by specific 
RS in different neural cells. Therefore, AAPH and rotenone induce OS in neural cells but generate 
different types of RS resulting in divergent effects on protein levels and localisation.   
With OS stimulated neural toxicity was investigated. The results herein show as AAPH 
concentration increases neuronal viability decreases with cellular morphology being affected 
(figure 3.10-3.15). This is supported by previous studies where SH-SY5Y exposed to 35mM AAPH for 
6 hours showed 65% reduced viability (Othman et al., 2016). AAPH studies show decreased cellular 
viability in neuronal cells via OS (Ben Othman et al., 2016; Kanski et al., 2002; Rapin et al., 1998), 
with only higher concentrations having a significant effect on glial cells (Guo et al., 2016; Sun et al., 
2001), which can be attenuated with antioxidants (Dooley et al., 1990; Terao and Niki, 1986). In 
contrast, glial cells showed no change in viability after 24-hour (figure 3.13) AAPH exposure but 
showed increased viability and maintenance of mitochondrial function as demonstrated by 
Mitotracker staining and ATP level stability after 48 hours (figure 3.14). Like our results, studies with 
astrocytes cultured from Sprague-Dawley rats showed increased astrocyte viability when they were 
incubated for short periods of time with low concentrations of AAPH. Whereas higher 
concentrations of AAPH (>20 mM) resulted in astrocyte viability decreasing (Guo et al., 2016). 
Furthermore C6 rat glial cultures showed low concentrations of AAPH had no significant effect on 
cell viability and only slightly increased levels of lipid peroxidation (Sun et al., 2001). In addition, 
concurrent treatment of both neuronal and glial cells with AAPH in the presence of α-tocopherol 
increased cell viability (figure 3.21), suggesting RS induced cell toxicity. This is supported by previous 
studies that indicate decreased neural cell viability when treated with OS inducers (Othman et al., 
2016; Guo et al., 2016), while cells treated with α-tocopherol reduced levels of lipid peroxidation 
(Foret et al., 2019; Palozza and Krinsky, 1992). However, ascorbic acid was not successful in 
attenuating cell death induced by AAPH (figure 3.25). This could be related to the fact that ascorbic 
acid did not decrease RS levels as it predominantly scavenges superoxide (Patra et al., 2001; 
Wenzel, 2003), whereas AAPH primarily produces peroxyl radicals (Bassett et al., 1999; Werber et 
al., 2011).  
This suggests that AAPH generates peroxy radicals, which may result in lipid peroxidation 
that is observed in neurodegenerative disorders possibly resulting in cellular apoptosis or 
ferroptosis, a regulated form of non-apoptotic death via altering lipid membrane assembly, 
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composition, structure and dynamics (Gaschler and Stockwell, 2017; Simpson et al., 2004; Zarkovic, 
2003). This is supported by the LDH assays in this study that show for higher concentrations of AAPH 
both neural cells showed significant increases in LDH release, which has also been shown in renal-
tubular epithelial cells (Yokozawa et al., 2000), and α-tocopherol (figure 3.21) but not ascorbic acid 
(figure 3.25) is able to attenuate.  
With increasing rotenone concentrations and exposure time, loss of neural processes, 
morphological rounding, loss of cell viability and reduced cellular energy levels was observed (figure 
3.16-3.19). Rotenone, a lipophilic organic pesticide is a complex I inhibitor used to model PD as both 
early and advanced PD patients have displayed reduced complex I activity (Dexter et al., 1994; 
Hattingen et al., 2009). This is supported by previous studies where neuronal and glial exposure to 
rotenone resulted in decreased number and process length (Goswami et al., 2015; Voronkov et al., 
2016). This is possibly via apoptosis as suggested by previous rotenone research with SH-SY5Y cells 
(Fitzgerald et al., 2014; Newhouse et al., 2004; Ryter et al., 2007). However, it was also noted that 
there was a decrease in cellular energy for both cell types shown by the dose-dependent decrease 
in ATP levels, which may also contribute to cell death, supported by previous studies (Caneda-
Ferrón et al., 2008; Sherer et al., 2003). This reduction in cellular energy may explain why all 
rotenone concentrations significantly decreased U-87MG cell viability, as in vivo studies suggest 
mitochondria isolated from neurons have greater complex IV activity, while mitochondria isolated 
from glia have higher ATPase activity (Hamberger, 1970; Hertz and Chen, 2016). Furthermore, qRT-
PCR showed U-87MG glial cells exhibited lower mitochondrial gene expression relative to SH-SY5Y 
neuronal cells (figure 3.29), suggesting U-87MG cells possess less mitochondria than neurons. 
Indeed, this is not surprising as neurons are reported to rely exclusively on mitochondria for ATP 
(Franco-Iborra et al., 2016), while astrocytes depend on glycolysis for their high energy demands 
(Hertz et al., 2007). Therefore, the same rotenone concentration possibly results in saturation of 
glia mitochondria further affecting the ATP demand from glycolysis, whereas neurons still possess 
mitochondria that have not been inhibited by rotenone. Reduced ATP levels also suggests impaired 
mitochondrial function, which is supported by the more diffuse Mitotracker staining (figure 3.16-
3.18), decreased red: green JC-1 ratio (figure 3.31-3.32) and a higher glycolytic rate of ATP 
production (figure 3.29) that has also been shown by others (Sarafian et al., 2010; Veenman et al., 
2010). This suggests OS induces mitochondrial dysfunction as demonstrated previously (Cobb and 
Cole, 2015; Lin and Beal, 2006; Navarro and Boveris, 2004). 
 Further supporting rotenone induces cell death via RS, concurrent antioxidant α-
tocopherol treatment attenuated rotenone induced death (figure 3.23), suggesting like others that 
rotenone causes cell death via OS (Filomeni et al., 2012; Testa et al., 2005). Furthermore, in neurons 
CHAPTER 3                                             MODELLING THE NEURODEGENERATIVE BERMUDA TRIANGLE 
 
133 
 
ascorbic acid like α-tocopherol attenuated cell death (figure 3.27), possibly via reduced RS levels 
(figure 3.6) as shown previously (Gomez-Lazaro et al., 2008; Hongo et al., 2012). However, this was 
not the case for glia treated with rotenone and ascorbic acid possibly due to the acidification of the 
media (Cheng et al., 1988) and the lack of reduced RS levels (figure 3.6), as cells still showed 
rounding and clustering.  
Considering both AAPH and rotenone treatment it is also important to note glial cells 
showed less LDH release with the same concentrations relative to neurons suggesting glia are less 
susceptible to loss of membrane stability (figure 3.14-3.27). This is possibly due to the higher levels 
of antioxidants such as glutathione and glutathione peroxidase in glia relative to neurons (figure 
3.6; Dringen et al., 2005; Dringen and Hamprecht, 1997), which are responsible for the removal of 
hydrogen peroxide and lipid peroxides (Dasuri et al., 2013; Gandhi and Abramov, 2012). 
Furthermore, glia may also be more resistant to RS due to the accelerated glutathione synthesis 
under stress relative to neurons (McBean, 2017). 
With RS species generated via AAPH and rotenone another pathological hallmark of 
neurodegeneration is mitochondrial dysfunction (Hattingen et al., 2009; Lou et al., 2020; Swerdlow, 
2009). The importance of mitochondria as an important source of ATP for neurons is highlighted by 
the brain’s high consumption of oxygen, leading to the idea that oxidative phosphorylation is the 
main source of energy (Franco-Iborra et al., 2016). The importance of aerobic glycolysis for fuelling 
nerve terminal activities and providing energy for other neural cells such as astrocytes (Pellerin and 
Magistretti, 1996; Vaishnavi et al., 2010). Our investigations support these and others findings that 
astrocytes utilise glycolysis as their main source of energy, as U-87MG glial cells showed a higher 
ECAR than SH-SY5Y neuronal cells (figure 3.29; Jády et al., 2016; Juaristi et al., 2019). This suggests 
glia rely on glycolysis as their source of ATP, while neurons rely more on mitochondria. Like 
Giordano et al. rotenone as expected, lowered ECAR for both neural cells proposing rotenone had 
a significant effect on mitochondrial function consistent with complex I inhibition, and as a result 
cells reverted to glycolysis to meet the cells energy demand (Giordano et al., 2014). However, the 
effect of AAPH on respiration has yet to be investigated in neural cells and while AAPH has been 
confirmed as a radical generator (Bassett et al., 1999; Terao and Niki, 1986; Werber et al., 2011), 
downstream effects on mitochondria has not been investigated. As such, it was interesting to see 
that AAPH induced a similar effect to rotenone in SH-SY5Y neuronal cells, where ECAR increased 
and OCR decreased suggesting AAPH resulted in a greater glycolytic ATP production but had no 
effects on U-87MG glial respiration. This may be because AAPH generates peroxyl radicals leading 
to lipid peroxidation of the mitochondrial membrane and dysfunction (Fuentes-Lemus et al., 2016; 
Niki, 1990; Werber et al., 2011). This was observed in SH-SY5Y neurons, but not in U-87MG glial 
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cells, possibly due glia being able to cope with the RS generated by AAPH due to their greater 
antioxidant capacity (Dringen and Hamprecht, 1997).  
Indeed, mitochondria dysfunction is associated with loss of mitochondrial membrane 
potential associated with RS, leading to cytochrome C release into the cytosol resulting in caspase-
9 and caspase 3 activation potentiating apoptosis in neural cells (Ikeda et al., 2008; Kugler et al., 
2008; Veenman et al., 2008). Our studies using the fluorescent probe, JC-1 support this and other 
studies, as complex I inhibition by rotenone resulted in a dose-dependent decrease in aggregate to 
monomer ratio (figure 3.30-3.31; Dadakhujaev et al., 2010; De Pedro et al., 2016; Deng et al., 2013). 
Whereas AAPH only resulted in membrane depolarisation in SH-SY5Y but not U-87MG cells, 
supporting ATP studies suggesting AAPH may cause mitochondrial depolarisation in SH-SY5Y 
neurons resulting in cells resorting to glycolysis to meet the cells energy demands, while U-87MG 
glia may have a greater antioxidant system to cope with AAPH generated RS (Dringen and 
Hamprecht, 1997).  
To adapt to the cells energy demands mitochondrial biogenesis is very important where 
mitochondria can undergo fission (division) and fusion (fuse) to maintain a homogeneous 
mitochondrial population (Chan, 2012; Grimm and Eckert, 2017), with reptitive cycles regulating 
morphology and dynamics (Sharma et al., 2014) to adapt to stress (Kowald and Kirkwood, 2011). As 
RS are implicated in mitochondrial dysfunction, fission/fusion proteins that determine 
mitochondrial motility and function were measured. OPA1 and MFN1 are pro-fission proteins, 
where MFN1 facilitates outer mitochondrial membrane fusion, while OPA1 promotes inner 
membrane fusion (Campello and Scorrano, 2010; Friedman and Nunnari, 2014; Hudson et al., 2008; 
Ishihara, 2004). In addition, cellular models of sporadic PD have been found to have altered 
expression of OPA1 and DRP1 (Santos et al., 2015). Like Peng et al. we observed a decrease in OPA1 
expression while observing an increase in pDPR1 with rotenone treated neurons, which has been 
implicated in mitochondrial fragmentation (Guo et al., 2015; Peng et al., 2017). Rotenone treated 
glia showed similar changes in fission protein levels while fusion proteins were unchanged, 
potentially because they scavenge more RS in the early stages of treatment. Indeed, changes in 
mitochondrial fission/fusion induced by rotenone was not surprising due to the direct inhibition of 
complex I leading to mitochondrial dysfunction. Similarly, AAPH treatment showed a decrease in 
fusion proteins OPA1 and MFN1 without changing pDRP1 levels in neurons but had no effect on 
levels in glial cells. This suggests RS generated by rotenone and AAPH results in mitochondrial fusion 
rather than fission leading to disruption in mitochondrial biogenesis and cell death. 
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Together, this study along with others suggests different RS disrupt mitochondrial 
biogenesis, respiration and membrane permeability in neural cells linking these pathological 
hallmarks of neurodegeneration. However, as little is known about how AAPH effects mitochondrial 
dysfunction further research is needed to determine if cell apoptosis like rotenone, is linked to 
release of cytochrome C and caspase activation in neural cells.   
In addition to mitochondrial dysfunction proteome dysfunction is also associated with 
ageing. All proteins exist in a dynamic state between synthesis and degradation known as turnover, 
which contribute to cellular development, differentiation and ageing. Protein degradation is 
important for the removal of aberrant proteins such as those post-translationally modified by RS 
that can accumulate, aggregate and compromise cellular function and viability (Douglas and Dillin, 
2010; Gidalevitz, 2006; Lopiano et al., 2000). Neurons are particularly susceptible to proteotoxic 
stress due to being post-mitotic cells that are not replaced and axons regenerate poorly (Liu et al., 
2011). Protein homeostasis involves three stages: protein synthesis and folding, conformational 
stability and degradation. 
Under OS, degradation pathways such as the UPS can be directly or indirectly impaired 
resulting in toxic protein accumulation, leading to neuronal dysfunction and cellular apoptosis 
(Betarbet et al., 2005). Our results show like Shamoto-Nagai et al. that rotenone and AAPH results 
in a dose-dependent decrease in 20S proteasomal function in both neural cell types (figure 3.33; 
Shamoto-Nagai et al., 2003b). This is possibly because the 26S proteasome is susceptible to OS 
(Raynes et al., 2016; Reinheckel et al., 2000), where the 20S unit is responsible for the degradation 
of oxidised proteins via ubiquitination and ATP dependent degradation (Shringarpure et al., 2003), 
suggesting RS lead to proteasome dysfunction. Further supporting this, impaired protein 
degradation was demonstrated by increased ubiquitination levels, which has been shown in 
dopaminergic neurons of rotenone treated rats (Betarbet et al., 2006), as well as in Lewy bodies of 
PD patients (Giasson, 2000; Luk, 2019). This may be due to proteasomal posttranslational 
modifications by RS that has also been reported by others (Chou et al., 2010; Shamoto-Nagai et al., 
2003). Alternatively, RS can post translationally modify proteins leading to high levels of aberrant 
proteins overwhelming the proteasome, leading to a feed-forward cycle resulting in cell 
cytotoxicity.  
Aberrant protein accumulation can lead to aggregates and upregulation of chaperones 
aiding in refolding misfolded proteins or sending damaged protein for degradation (Ciechanover 
and Brundin, 2003; Esser et al., 2004). The possible role of chaperone heat shock proteins is 
highlighted by the presence of HSP70 and HSP27 in aggregates in neurodegenerative patients (Ito 
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et al., 2002; Rideout and Stefanis, 2002). This is further supported by studies showing upregulation 
of HSP27 and HSP70 attenuated cell death caused by MPP+ or MPTP in cellular models of PD 
(Donaire et al., 2005; Fan et al., 2005; Quigney et al., 2003). Heat shock factor 1 (HSF1) is a master 
transcription factor of heat shock proteins, where under basal conditions it resides in the cytosol in 
a non-phosphorylated state. Upon stress such as RS, for example hydrogen peroxide, HSF1 is 
phosphorylated and dissociates from inhibiting chaperones exposing the nuclear localisation signal 
resulting in nuclear translocation (Katschinski et al., 2000; Morimoto, 2002; Raychaudhuri et al., 
2014). Once in the nucleus HSF1 can bind to heat shock element promoting initiation of 
transcription of chaperones, upregulating their levels which can negatively regulate HSF1 (Pirkkala 
et al., 2001). Both AAPH and rotenone significantly lowered HSF1 levels in U-87MG cells but had no 
effect on SH-SY5Y neuronal cells (figure 3.34). The lack of change in SH-SY5Y cells may be similar to 
NRF2, in that RS results in its translocation to the nucleus leading to upregulation of heat shock 
proteins. HSP70 and HSP27 are two well-known heat shock proteins known to be cytoprotective 
against apoptosis and regulated by HSF1 (Au et al., 2008; Ekimova et al., 2018; Manzerra et al., 
1997). 
Chaperones are a major first line of defence against aberrant proteins and known to 
induced by RS, particularly in neural cells (Franklin et al., 2005; Gorman et al., 1999; Voth and Jakob, 
2017). HSP70 is an ATP-dependent chaperone, which has little or no constitutive expression in the 
brain with particularly low levels detected in neurons (Khalouei et al., 2014; Manzerra et al., 1997). 
However stress induces HSP70, increasing its levels to help cells cope with increased misfolded, 
denatured or oxidatively modified proteins (Kabiraj et al., 2015; Nollen et al., 1999; Wang et al., 
2002; Yoon et al., 2010). Therefore, HSP70 is possibly upregulated under OS to help refold 
denatured proteins or send them to the proteasome for degradation, if they are irreversibly 
damaged (Garrido et al., 2012). Whereas HSP27 is an ATP-independent chaperone responsible for 
preventing protein aggregation (Ehrnsperger, 1997) and is also protective against OS (Behdarvandy 
et al., 2020; Rogalla et al., 1999). Additionally, HSP27 is reported to increase antioxidant defences 
by increasing glutathione levels (Abaspour et al., 2019; Mehlen et al., 1996). Both HSP70 and HSP27 
are also reported to have antiapoptotic activity as they can block caspase induced apoptosis (Bruey 
et al., 2000; Buzzard et al., 1998) by interacting with cytochrome c, or preventing recruitment of 
procapase-9 to the apoptosome (Beere et al., 2000; Bruey et al., 2000; Concannon et al., 2001).  
Therefore, in response to RS these chaperones may have been upregulated in rotenone 
treated SH-SY5Y neuronal cells to counteract RS induced mitochondrial dysfunction, possibly 
leading to cytochrome C induced apoptosis. No change in HSP70 and HSP27 levels was observed in 
U-87MG glial cells treated with either AAPH or rotenone, potentially because they scavenge the RS 
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levels needed to induce activation of chaperones. While rotenone and AAPH effected proteasome 
activity and ubiquitination levels in similar ways, SH-SY5Y cells treated with AAPH showed 
decreased HSP70 and HSP27 levels, suggesting that despite both chemicals inducing RS, they 
resulted in different effects on neuronal chaperone levels. Therefore, the RS generated appear to 
have a different effect on chaperone levels within neural cells but this requires further investigation 
to determine which apoptotic pathways have been induced by these specific RS.  
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Table 3.1 Table summarising experimental findings of this study suggesting how AAPH and rotenone lead to the pathological hallmark of the ‘neurodegenerative 
Bermuda triangle’. 
RESULTS  
SH-SY5Y U-87MG 
AAPH Rotenone Infers AAPH Rotenone Infers 
RS Levels  ↑ ↑ Rotenone and AAPH increases RS 
levels where antioxidants suggest 
specific RS generated  
↑ ↑ Rotenone and AAPH increase 
RS levels but ascorbic acid not 
effective 
RS levels + tocopherol  ↓ ↓ ↓ ↓ 
RS levels + ascorbic acid  ↑ ↓ ↑ ↑ 
NRF2 colocalisation  Nuclear Nuclear RS induce activation of the NRF-
ARE pathway where localisation 
reflects RS levels suggesting 
antioxidants help scavenge RS via 
the NRF-ARE pathway   
Nuclear Nuclear RS induce activation of the 
NRF-ARE pathway where 
localisation reflects RS levels 
but ascorbic acid stresses glia 
as control with ascorbic acid 
also exhibits nuclear 
localisation possibly due to 
media acidification 
NRF2 colocalisation + 
tocopherol  
Cytoplasmic  Cytoplasmic  Cytoplasmic  Cytoplasmic  
NRF2 colocalisation + 
ascorbic acid  
Nuclear Cytoplasmic Nuclear Nuclear 
DJ-1 levels  ↓ ↓ Antioxidant protein levels decrease 
suggesting antioxidant defences 
have been overwhelmed 
- - Glia have greater antioxidant 
capacity as levels differ from 
neurons  
PRDX6 levels  
↓ ↓ ↓ ↑ 
Viability  ↓ ↓ Antioxidant viability assays reflect 
RS levels suggesting RS result in 
cytotoxicity  
↑ ↓ Glia exhibit different viability 
for AAPH and rotenone 
suggesting specific RS cause 
different effects  
Viability + tocopherol ↑ ↑ ↑ ↑ 
Viability + ascorbic acid  
↓ ↑ ↓ ↓ 
Main source of ATP Glycolytic Glycolytic RS generated by AAPH and 
rotenone effect downstream 
mitochondrial function and 
biogenesis. Suggests mitochondria 
susceptible to RS.  
Glycolytic Glycolytic  RS generated by AAPH and 
rotenone effect downstream 
mitochondrial function and 
biogenesis. Suggests 
mitochondria susceptible to 
RS. 
JC-1 mitochondrial 
membrane potential  
↓ ↓ ↑ ↓ 
Fusion protein OPA1 and 
MFN1 levels  
↓ ↓ - ↓ 
pDRP1 levels  - ↑ - - 
Proteasome activity  ↓ ↓ RS generated effect downstream 
protein degradation by UPS 
↓ ↓ RS generated effect 
downstream protein 
degradation by UPS 
Ubiquitination levels  
↑ ↑ ↑ ↑ 
HSF1 Levels  - - Chaperones activation depends of 
the RS generated  
↓ ↓ Glia have greater antioxidant 
capacity as no change in 
chaperone levels observed 
HSP70 Levels  ↓ ↑ - - 
HSP27 Levels  ↓ ↑ - - 
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In conclusion, this study shows AAPH and rotenone result in a multitude of changes to 
biochemical pathways in both SH-SY5Y neuronal and U-87MG glial cells as summarised in table 3.1 
where differences appear to be due to the specific RS generated and neural cell type. This suggests 
neural cells react to RS differently. Furthermore, viability assays suggest that both RS inducers 
resulted in cytotoxicity, but glia are less susceptible. OS also results in mitochondrial dysfunction as 
suggested by increased glycolytic respiration, changes in mitochondria membrane permeability and 
biogenesis. Finally, proteomic activity in both neural cells was reduced by both treatments while 
also increasing ubiquitination levels but interestingly effecting chaperone levels in different ways, 
suggesting types of RS may affect the neural proteome differently.   
Neurodegeneration is an incredibly complex multifaceted disease with multiple pathways 
being affected including OS, mitochondrial and proteomic function being affected where the only 
universal factor is aging (Ehrnhoefer et al., 2011). However, currently most research and treatments 
target one of these hallmarks. However, the work herein proposes these pathways are linked, 
where specific RS cause different responses depending on the type of neural cells. Future use of 
this model will help identify common factors that underlie these pathways and how different RS 
affect them in the hope of generating novel therapies.
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4.1 INTRODUCTION  
4.1.1 Differentiation of neural cells  
Neurodegenerative diseases are characterised by multiple hallmarks however, cellular models do 
not always recapture these. This is possibly due to immortalised neuronal cell lines lacking some of 
the features that define neurons such as long neurites, lack of cell division and expression of 
selected neuron specific markers (Carolindah et al., 2013). While alternatives are available, 
including human stem and primary cells, they have their own limitations. Human stem cells have 
are expensive, while primary cells from rats do not express some of the human proteins most 
closely associated with neurodegeneration (Kovalevich and Langford, 2013). Therefore, 
differentiation of immortalised cells lines into a neuronal phenotype is preferred for initially 
investigating neurodegenerative mechanisms.  
The neuroblastoma SH-SY5Y cell line is commonly used for neurodegenerative studies. SH-
SY5Y cells can produce both substrate adherent (S-type) and neuroblastic (N-type) cells that can 
undergo transdifferentiation (Ross et al., 1983; Teppola et al., 2016). There are multiple methods 
and protocols for SH-SY5Y differentiation leading to a more mature neuronal like phenotype 
(Påhlman et al., 1995; Shipley et al., 2016).  Most common protocols involve serum reduction and 
retinoic acid (RA), which improves neurite outgrowth but also neuronal marker expression (Lopes 
et al., 2010; Xicoy et al., 2017). RA is a metabolite of vitamin A, derived from retinol in a 2-step 
enzymatic process via a retinaldehyde intermediate (Pavlovic et al., 2014). RA, as a neurotrophic 
factor, binds to nuclear receptors activating transcription and regulating physiological features at a 
genomic level (Khatib et al., 2019; Mey and Mccaffery, 2004). RA can also help neuronal 
differentiation independent of the genome, where RA can activate ERK1/2 which plays a role in 
cytoskeletal rearrangement and neurite outgrowth (Bruck et al., 2009; Cañón et al., 2004; Khatib et 
al., 2019; Pan et al., 2005). Therefore, the dual potency of RA makes it a good differentiating agent 
to enhance neurite outgrowth.  
Furthermore, while RA promotes neuronal differentiation of SH-SY5Y N-type cells, S-type 
cells do not undergo any morphological changes over 5 days (Mario Encinas et al., 2002). Whereas 
longer time periods with RA can result in S-type cells overgrowing the culture due to their 
continuous proliferation, while N-type cell proliferation is attenuated leading to an imbalanced 
population (Mario Encinas et al., 2002; Påhlman et al., 1984). Though others contravene RA’s ability 
to attenuate cell proliferation (Teppola et al., 2016). Consequently, RA is not suitable for long term 
differentiation due to the generation of a non-homogenous population.  
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Alternatively, RA can be combined with 12-o-tetradecanoyl-phorbol-13-acetate (TPA) to 
improve SH-SY5Y neuronal processes and increase membrane potential (Åkerman et al., 1984; P.-
C. Wei et al., 2019). Furthermore RA/TPA differentiation increased expression of tyrosine 
hydroxylase and dopamine transporter, favouring differentiation towards a dopaminergic 
phenotype (Presgraves et al., 2003).  
Other methods exploit RA’s induction of neurotrophic tyrosine kinase receptor B (NTrkB), 
enabling cells to become responsive to brain derived neurotrophic factor (BDNF;(Arcangeli et al., 
1999; M. Encinas et al., 2002; Xicoy et al., 2017). NTrkB is part of a neurotrophin family of receptors, 
composed of multiple receptors with preferences to specific neurotrophins (Huang and Reichardt, 
2003). NTrkB specifically binds BDNF activating intracellular kinase signalling cascades, increasing 
the selective pressure against S-type cells and enhancing RA induced differentiation, giving rise to 
a homogenous neuronal population with increased neurite outgrowth and attenuated proliferation 
(Constantinescu et al., 2007; de Medeiros et al., 2019).  
These methods of differentiation in addition to improving neurite outgrowth, also increase 
neuronal protein markers such as dopaminergic cell markers (Cheung et al., 2009), while others 
report induction of cholinergic neuronal phenotypes (de Medeiros et al., 2019; Edsjö et al., 2003; 
Zimmermann et al., 2004). Some markers of neuronal differentiation include βIII tubulin, an 
exclusive neuronal marker (Katsetos et al., 2003); synaptophysin, a marker of synapse generation 
at the end of neurites and tyrosine hydroxylase, an enzyme required for dopamine synthesis 
(Cheung et al., 2009). Thus, while multiple studies use these methods for SH-SY5Y differentiation it 
remains controversial as to what neuronal phenotypes are generated. As many key features of 
neurons are generated through differentiation there is still a preference for use of these methods 
to study neurodegenerative diseases, due to their low cost and high-throughput nature.  
RA is also used for U-87MG differentiation to produce a more astrocytic phenotype, 
upregulating GFAP expression (Das et al., 2009; Karmakar et al., 2008). Indeed, RA is used in 
combination with other drugs to combat glioblastomas through attenuating growth (Burton and 
Prados, 1999; Dreyfus et al., 2018). RA suppresses U-87MG proliferation through downregulation 
of telomerase activity leading to telomere shortening (Das et al., 2008; Haque et al., 2007; Pendino 
et al., 2001). Furthermore, RA is associated with the phosphorylation and inactivation of the anti-
apoptotic bcl-2 protein (Neviackas and Kerstein, 1976; Papi et al., 2007; Xia et al., 2006). Hence, RA 
is not only used to differentiate SH-SY5Y cells but also U-87MG glial cells into an astrocytic 
phenotype.  
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Astrocytes have neuroprotective effects possibly via secreted factors (Jha et al., 2018; 
Werber et al., 2011). This is supported by in vitro studies that show differentiation of dopaminergic 
neurons from primary cultures can be manipulated by region specific glial cells (O’Malley et al., 
1992) and striatal derived factors (Tomozawa and Appel, 1986). Furthermore, Engele et al. 
demonstrated conditioned media from multiple glial cell lines enhanced survival and differentiation 
of dopaminergic neurons, although the exact underlying mechanism is not fully understood 
(Caldwell et al., 2020; Engele et al., 1991). Glial cell lines are known to release a number of 
neurotrophins such as nerve growth factor, BDNF, ciliary neurotrophic factor and neurotrophin-3 
effecting proliferation, differentiation and migration of neuronal cells (Coutinho-Budd et al., 2017; 
Maisonpierre et al., 1990; Popova et al., 2017; Rosewater and Sontheimer, 1994). Indeed, BDNF has 
been demonstrated to enhance differentiation of neurons (Wang and Kisaalita, 2011) and was 
shown to be present in higher levels in astrocyte conditioned media (Liu et al., 2012; Y. et al., 2016).  
Mature neurons are post-mitotic and as such depend on OXPHOS for their energy demands 
whereas immortalised cell lines mainly rely on glycolysis (Choi et al., 2009). This is further supported 
by the Warburg hypothesis, which suggests rapidly dividing undifferentiated cells rely on glycolysis 
for cell division (Kaczanowski et al., 2018; Warburg, 1956, 2010). Furthermore, differentiation of 
SH-SY5Y neuronal cells has resulted in some controversy over susceptibility to RS. Some report 
differentiated SH-SY5Y cells are more resistant to RS induced by 6-hydroxydopamine, dopamine 
and MPP+ (Cheung et al., 2009; Ferreira et al., 2013; Lopes et al., 2017). While others report 
differentiation results in greater vulnerability to RS induced by MPP+ and 6-hydroxydopamine (Beck 
et al., 2006; J. I. Forster et al., 2016; Lopes et al., 2010). Others demonstrate differentiation also 
effects mitochondrial function (Gerencser et al., 2009; Schneider et al., 2011). This suggests other 
changes take place under differentiation including alteration to cellular metabolism and function.  
4.1.2 Axonal degeneration 
Neurodegenerative diseases are characterised by progressive neuronal death and loss of synapses. 
Axonal degeneration is a consequence of aging (Neukomm and Freeman, 2014), but also occurs in 
the early stages of neurodegeneration, preceding cell death and clinical symptoms in PD 
(Tagliaferro and Burke, 2016) and AD (Adalbert and Coleman, 2013). This suggests delaying axonal 
degeneration could provide a therapeutic potential for neurodegenerative disease.  
 During development, neurons generate more axons then necessary but later connections 
are fine-tuned where redundant connections are lost, this is referred to as neurite pruning which 
maximises network efficiency (Neukomm and Freeman, 2014; Raff, 2002). After development, 
axons can undergo degeneration through traumatic injury, chemical insults or general aging 
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(Salvadores et al., 2017). These different conditions can alter axonal morphology via multiple 
mechanisms (summarised in figure 4.1) including: retraction, local degeneration and Wallerian 
degeneration.  
  
Retraction, unlike the other methods of degeneration, does not show morphological signs 
of fragmentation but involves axons retracting in a distal to proximal manner (Bagri et al., 2003). 
Axonal tips involute their membranes resulting in bulbous vesicle filled terminals at the end of 
axonal shafts referred to as retraction bulbs (Kao et al., 2019; Riley, 1981). The axon continues to 
involute in a retrograde manner until it is reabsorbed into the parent arbour where this 
degeneration preferentially occurs with shorter neurites to maximise energy efficiency and return 
contents to the cell body (Blanquie and Bradke, 2018; Portera-Cailliau et al., 2005).  
 Local axon degeneration primarily occurs with longer neurites and involves axon 
granulation and subsequent degradation by other cells (Portera-Cailliau et al., 2005). Initially, axons 
undergo blebbing where microtubules disassemble while axons swell. Finally, neurofilament 
Figure 4.1 Distinct morphological methods of axon degeneration. Schematic representation of neurons 
where soma and nucleus are on left with branched axons and dendrites. The axon and undergoes different 
methods of degeneration as shown in (A) – (C). (A) During axon retraction dendrites and axons retract in a 
retrograde manner without loss of integrity. (B) Local degeneration results in axons undergoing 
fragmentation in a synchronous manner where debris is subsequently removed by surrounding glia. (C) 
Wallerian degeneration is similar to local degeneration where axons undergo fragmentation due to 
axotomy but axons and dendrites fragment in an asynchronous manner fragmenting distal to the sight of 
injury. Adapted from Neukomm and Freeman et al., 2014.  
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proteins fragment and the axon shaft degenerates in a synchronous manner (Kneynsberg et al., 
2016; Saxena and Caroni, 2007).  
 Wallerian degeneration similar to local degeneration also results in axonal fragmentation 
but is as a result of axotomy (Coleman and Höke, 2020; Lee, 1963; Thomas, 1964). This involves 3 
phases; initially acute degeneration effects both the proximal and distal stumps of the axons upon 
injury (Kerschensteiner et al., 2005). There is a brief latency period where these axons remain 
morphological intact and electrically active (Tsao et al., 1994). Finally, granular degeneration occurs 
where rapid asynchronous fragmentation of the axonal cytoskeleton occurs distal to the injury site 
(Coleman and Höke, 2020; Lubińska, 1982) within 24-48 hours in vivo (George and Griffin, 1994; 
Lubińska, 1977) and 12-24 hours in vitro (Araki et al., 2004; Coleman and Höke, 2020; Glass et al., 
1993).  
4.1.3 Antioxidant defences   
There are multiple studies highlighting how RS are important for signalling including cellular growth 
and differentiation (Esposito et al., 2004; Paul D Ray et al., 2012), but when redox homeostasis 
becomes imbalanced cells become dysfunctional. As neural cells are susceptible to RS, they have 
multiple antioxidant defences to protect cells against specific RS including catalase, peroxiredoxin 
(PRDX), glutathione peroxidase (GPX), glutathione and superoxide dismutase (SOD).  
 Hydrogen peroxide is one of the few more stable RS able to cross membranes (De Grey, 
2002), but cells contain multiple enzymes responsible for its removal. Catalase, is one enzyme 
present in numerous compartments including the cytosol, mitochondria and peroxisomes, playing 
a role in the removal of high levels of hydrogen peroxide (Gandhi and Abramov, 2012). Alternatively 
PRDX’s are also important for hydrogen peroxide removal where there are a range of isoforms; 
PRDX1-6 (Fisher, 2011; Park et al., 2016). These isoforms localise to various compartments where 
PRDX1, 2, 5 and 6 are present in the cytosol where PRDX5 has also been shown in peroxisomes 
(Oberley et al., 2001). Whereas PRDX3 localises to mitochondria (Cox et al., 2010; Drechsel and 
Patel, 2010) while PRDX4 is present in the endoplasmic reticulum but is also secreted (Klichko et 
al., 2016; Rhee et al., 2005).  
 GPX’s like PRDX’s have multiple isoforms that are responsible for reducing hydrogen 
peroxide but also lipid peroxides (Dasuri et al., 2013; Gandhi and Abramov, 2012). These isoforms 
again have different cellular localisations such as the cytosol and mitochondria (Conrad and 
Friedmann Angeli, 2018). While detoxifying peroxides, GPX’s also oxidise reduced glutathione 
(Dasuri et al., 2013; Gandhi and Abramov, 2012). Therefore, glutathione can protect against RS in 
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both a direct and indirect way, indirectly by becoming oxidised during GPX’s reactions and directly 
through oxidation by RS themselves (Dringen et al., 2000; Maher, 2018). The difference in the 
glutathione defence system between different neural cell types is more understood, where glia are 
reported to have higher glutathione levels relative to neurons (Dringen et al., 2005; Dringen and 
Hamprecht, 1997), and synthesis is accelerated under stress more so in glia than neurons (Gleixner 
et al., 2016; Halliwell, 2003).  
Other RS include superoxide where various isoforms of catalase are present in neural cells 
to combat this including cytosolic SOD1, mitochondrial SOD2, and extracellular SOD3. These 
enzymes are one of first defences against superoxide, catalysing its dismutation to hydrogen 
peroxide and oxygen (Dasuri et al., 2013; Donnelly et al., 1989; Fridovich, 1995).  
 Other enzymes are responsible for reducing oxidised proteins to allow recycling of PRDXs. 
For example, thioredoxin (TXN) that is responsible for reducing the disulphide bonds in PRDX’s 1-5 
(Poole et al., 2011b; Turner-Ivey et al., 2013). However, if there is not enough PRDX to cope with 
higher levels of RS, PRDX can be hyperoxidised to sulfinic or sulfonic acid, inactivating peroxidase 
activity as this cannot be reduced by thioredoxin (Rhee et al., 2007). This hyperoxidation has been 
associated with OS induced neuronal death in vitro (Bettegazzi et al., 2019; Papadia et al., 2008), 
and previously thought to be irreversible. However it is now known that sulfiredoxin, an ATP-
dependent reductase is responsible for restoring inactive PRDX’s back to the thioredoxin cycle, 
preventing permanent inactivation (Jönsson et al., 2008; Rhee et al., 2007; Shi et al., 2017).  
 Thus, antioxidant expression is essential to return cells to a balanced redox homeostasis. 
One of the major regulators of this antioxidant response is the NRF2/ARE pathway. NRF2 is a 
member of the leucine zipper transcription factor family playing a key role in cytoprotection and 
detoxification related to OS. NRF2 is regulated at multiple levels including transcription, translation, 
degradation, translocation and post-translational modifications (Dodson et al., 2019; Kong et al., 
2001; Zhang and Hannink, 2003). Under physiological conditions NRF2 is maintained in the cytosol 
through binding with kelch-like ECH-associated protein (KEAP1), facilitating its degradation via the 
ubiquitin proteasome system (Dhakshinamoorthy and Jaiswal, 2001; Schmidlin et al., 2019; Suzuki 
and Yamamoto, 2015). Once redox becomes imbalanced RS result in NRF2 releasing from KEAP1 
allowing translocation to the nucleus, binding to the ARE leading to upregulation of genes involved 
in redox balance (Chen and Kong, 2004; Dinkova-Kostova et al., 2018; Nguyen et al., 2005). NRF2 
controls upregulation of various genes including those involved in glutathione synthesis (Lu, 2013; 
Nguyen et al., 2009), SOD (Holley et al., 2010), PRDX’s, GPX’s, TXN’s and sulfiredoxin (reviewed 
more thoroughly in Korovila et al., 2017; Kwak et al., 2003).   
CHAPTER 4                                                                     REACTIVE SPECIES IN A DIFFERENTIATED MODEL 
 
147 
 
4.1.4 Reactive species induce post-translational modifications  
The plethora of RS including both ROS and RNS can react with multiple cellular components leading 
to cellular dysfunction. These can include a variety of changes such as lipid peroxidation, 
carbonylation and nitrosylation.  
 RS can attack lipid membranes initiating the self-propagating lipid peroxidation (Darley-
usmar et al., 1992; Taso et al., 2019). Lipid peroxidation can subsequently result in a loss of 
membrane fluidity, affecting membrane permeability and slowing lateral diffusion (Borst et al., 
2000b; Saleh et al., 2010). This process can also result in lipid peroxidation by-products such as 4-
hydroxynonenal (4-HNE) and malondialdehyde (MDA), which are highly reactive toxic molecules 
due to their ability to interact with a variety of cellular components and proteins (Esterbauer et al., 
1991; Gaschler and Stockwell, 2017). By covalently binding with proteins these molecules can alter 
function and can only be removed via degradation (Higdon et al., 2012). If not removed these 
proteins accumulate resulting in toxicity as interactions with mitochondrial subunits can overwhelm 
autophagy, contributing to mitochondrial dysfunction in neurons (Dodson et al., 2017; S. Zhang et 
al., 2017).  
 Carbonylation is a post-translational modification (PTM) commonly observed as a marker 
of OS in neurons where aldehyde, ketone or lactam groups are added to proteins (Møller et al., 
2011; Reed and Butterfield, 2017). Multiple residues can by carbonylated where higher levels of 
carbonylated proteins have been reported in neurodegenerative diseases (Alam et al., 1997; Reed 
and Butterfield, 2017). Carbonylation is an irreversible PTM but other PTM’s such as nitration and 
S-nitrosylation are reversible. While carbonylation is due to ROS, nitration is due to RNS that effect 
tyrosine residues (Nakamura and Lipton, 2017; Sadowska-Bartosz et al., 2014). Dinitrase enzymes 
are responsible for reversing this PTM (Deeb et al., 2013) but if not regulated this PTM contributes 
to neurodegeneration (Ljubuncic et al., 2010; Nakamura and Lipton, 2017). This is further 
highlighted by nitration of complex I in SH-SY5Y cells leading to ETC inhibition, enhancing apoptosis 
(Davis et al., 2010; Murray et al., 2003; van Horssen et al., 2019). S-nitrosylation is another 
reversible PTM that specifically effects thiol groups on cysteine and methionine residues. Like 
nitration, S-nitrosylation can inhibit ETC components (Di Giacomo et al., 2012; Foley et al., 2017) 
but also effect mitochondria via DRP1 enhancing oligomerisation resulting in mitochondrial 
fragmentation (Cho et al., 2009; Z. Zhang et al., 2016).  
 Therefore, while RS can induce signalling pathways that alter gene expression, they also 
affect cellular components and proteins via PTM’s. Thus, understanding which PTM’s RS induce will 
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aid in deciphering what pathways are activated during OS and hopefully provide more therapeutic 
potentials for neurodegenerative diseases.  
4.1.5 Aims of the chapter  
While immortalised cell lines are good for investigating neurodegenerative diseases due to their 
low-cost and high-throughput nature, they do not fully recapitulate all neurodegenerative 
hallmarks. Furthermore, there is controversy in the literature as to how differentiation effects 
susceptibility to RS. Therefore, different methods of SH-SY5Y differentiation were investigated 
while considering conditions would also have to be applicable to U-87MG glial cells for future co-
culture work. Differentiation also allows this cellular model to better represent in vivo like 
conditions, improving investigations into the neuropathological hallmarks of neurodegeneration.  
 Once differentiation was established, neural cells were exposed to mitochondrial inhibitor 
rotenone and RS generating agent AAPH to assess how differentiation effects neural cell 
susceptibility to OS. This will provide a better model for investigating changes in gene expression 
and post-translational modifications in response to RS, allowing investigations into neural cell 
biochemical pathways underlying neurodegeneration. Furthermore, to determine if these cellular 
models are more representative of neurodegeneration, embryonic rat primary cortical neurons 
were also used to compare findings.   
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4.2 RESULTS  
4.2.1 Differentiating SH-SY5Y neuronal and U-87MG glial cells  
While mitotic cells are practical and effective for high throughput experiments, they have 
limitations. Therefore, to mimic an in vivo model we investigated differentiation methods for SH-
SY5Y neuronal and U-87MG glial cells.  
 As complete differentiation of a mitotic line is difficult, we investigated optimal density for 
differentiation to ensure cells did not overgrow prior to treatment. Both SH-SY5Y (figure 4.2) and 
U-87MG (figure 4.3) neural cells were plated at 3450, 5180, 6900 and 10360 cells/cm2 and 
differentiated over 5 days with 0.1, 0.5 and 1% (v/v) FBS in the presence of 10 μM retinoic acid (RA). 
Phase contrast microscopy images of SH-SY5Y neuronal cells (figure 4.2A) at 10360 cells/cm2 
appeared to have the greatest confluence with 1% (v/v) FBS, while 3450 cells/cm2 showed fewer 
cells. SH-SY5Y cells differentiated with 0.1% (v/v) FBS showed large intercellular distances, some 
cell shrinkage and rounding with reduced neurites indicative of poor cell health. This was supported 
by confluence quantification using the incucyte S3 live-cell analysis system (figure 4.2B) and MTT 
reduction assays which showed the lowest absorbance values for 1% (v/v) FBS when compared to 
other FBS concentrations with the same cell density (figure 4.2E). 0.5 and 1% (v/v) FBS still showed 
pyramidal morphology and process development following 5-day differentiation instead of the 
usual cuboidal epithelial-like morphology observed with mitotic SH-SY5Y cells. Furthermore, 
incucyte proliferation quantification showed 0.5% (v/v) FBS had lower phase confluence (cell 
density) than 1% (v/v) FBS as growth plateaued at approximately 80 hours except with 10360 
cells/cm2 (figure 4.2C). Whereas SH-SY5Y cells differentiated with 1% (v/v) FBS, did not appear to 
plateau until approximately 100 hours (figure 4.2D). This suggests 0.5% (v/v) FBS was more 
successful in arresting cell division.   
 
 
 
CHAPTER 4                                                                     REACTIVE SPECIES IN A DIFFERENTIATED MODEL 
 
150 
 
Figure 4.2 Minimal plating 
density for SH-SY5Y 
neuronal differentiation. 
SH-SY5Y cells were plated at 
various densities and 
differentiated with 0.1, 0.5 
and 1% (v/v) FBS with 10 μM 
retinoic acid over 5 days 
where media was changed 
every other day. (A) Day 5 
images were taken using the 
incucyte S3 live-cell analysis 
system. Scale bar = 200 m. 
Cell growth for 0.1% (B), 
0.5% (C) and 1% (D) was 
monitored and quantified 
using the incucyte S3 live-cell 
analysis system. Viability on 
day 5 was quantified using 
the MTT reduction assay (E). 
Viability assay results are 
presented as % against 
control. Statistical analysis 
was performed using one-
way ANOVA with Dunnett’s 
post-hoc test where n=8 for 
all experiments. Statistical 
significance was recorded as 
* where *p<0.05, **p<0.01, 
***p<0.001 and 
****p<0.0001. 
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Figure 4.3 Minimal plating 
density for U-87MG glial 
differentiation. U-87MG 
cells were plated at various 
densities and differentiated 
with 0.1, 0.5 and 1 % (v/v) 
FBS with 10 μM retinoic acid 
over 5 days where media was 
changed every other day. (A) 
Day 5 images were taken 
using the incucyte S3 live-cell 
analysis system. Scale bar = 
200 m. Cell growth for 0.1% 
(B), 0.5% (C) and 1% (D) was 
monitored and quantified 
using the incucyte S3 live-cell 
analysis system. Viability on 
day 5 was quantified using 
the MTT reduction assay (E). 
Viability assay results are 
presented as % against 
control. Statistical analysis 
was performed using one-
way ANOVA with Dunnett’s 
post-hoc test when n=8 for all 
experiments. Statistical 
significance was recorded as 
* where *p<0.05, **p<0.01, 
***p<0.001 and 
****p<0.0001. 
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Unlike SH-SY5Y cells, U-87MG glial cells were less affected by plating density as all but 
10360 cell/cm2 showed similar growth curves for each FBS concentration (figure 4.3B, C and D), 
despite changes in MTT reduction (figure 4.3E). At 0.1% (v/v) FBS U-87MG cells showed few cell 
processes (figure 4.3A). Additionally, 0.5 and 1% (v/v) FBS showed cell body clustering with 
processes extended between clusters creating a network (figure 4.3A). As with SH-SY5Y cells, 1% 
(v/v) FBS showed the greatest U-87MG proliferation rate compared to 0.1 and 0.5% (v/v) FBS. 
Furthermore, 0.1% (v/v) FBS resulted in U-87MG glial cells exhibiting proliferation arrest at 
approximately 80 hours (figure 4.3B).   
 As axons and cell processes are characteristic of neurons in vivo, we also investigated which 
conditions improved neurite outgrowth and the influence of glia on this. One condition involved 
glia grown and differentiated over 5 days, prior to decellularisation to leave an extracellular matrix 
(ECM) scaffold. Debris was washed away prior to SH-SY5Y seeding. SH-SY5Y cells were subsequently 
incubated overnight in complete 10% (v/v) FBS media, whereupon media was replaced with 
differentiation media (0.5 or 1% (v/v) FBS with 10 μM RA). The second glia condition involved U-
87MG glia being differentiated over 5 days where media was then collected and used to create 
conditioned media. This involved mixing the collected media 1:1 with fresh differentiation media, 
which was then added to the SH-SY5Y cells on the first day of differentiation, following overnight 
growth. Media was changed every other day where proliferation and neurite length was monitored 
using the incucyte S3 live-cell analysis system. 
0.5% (v/v) FBS resulted in less proliferation during differentiation (figure 4.4C). However, 
SH-SY5Y seeded on decellularised U-87MG ECM showed the lowest increase in phase 
confluence/cell density (figure 4.4C), as supported by greater intercellular distance and cell 
rounding (figure 4.4B). In contrast, glial conditioned media increased proliferation relative to 
FBS/RA alone, suggesting U-87MG conditioned media supported SH-SY5Y growth. However, 0.5% 
(v/v) FBS with U-87MG conditioned media while increasing phase confluence arrested cell 
proliferation earlier, as growth plateaued at approximately 80 hours contrary to 1% (v/v), which 
plateaued at approximately 130 hours (figure 4.4C). Neurite growth mimicked phase confluence, 
where decellularised glia showed the lowest neurite growth over time as opposed to U-87MG 
conditioned media that showed the greatest (figure 4.4D). However, it is important to note 0.5% 
and 1% (v/v) FBS/RA with glia conditioned media showed similar neurite growth. Therefore, 
together this suggests that decellularised glia were not successful in improving neurite growth 
relative to FBS/RA differentiation, while U-87MG conditioned media aided neurite outgrowth.  
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Figure 4.4 Optimising neurite outgrowth during differentiation. Various conditions were used to determine 
the optimum conditions for neurite outgrowth during SH-SY5Y differentiation. (A) 3 conditions were used, each 
with 0.5 and 1% (v/v) FBS: where glia were grown and differentiated over 5 days prior to decellularising and 
washing prior to seeding. Following overnight incubation in complete 10% (v/v) FBS media fresh differentiation 
media (0.5 or 1% (v/v) FBS with 10 μM retinoic acid) was added to previous U-87MG wells. SH-SY5Y cells seeded 
in untouched wells were used as controls and the other condition had a 1:1 mixture of fresh differentiation 
media and U-87MG conditioned media taken from U-87MG cells differentiated over 5 days. (B) Images were 
taken using the incucyte S3 live-cell analysis system, and neurites were masked using the neurotracker software 
(purple). Scale bar = 200 μm. Inset scale bar = 100 μm. (C) Cell growth for each condition was monitored and 
quantified using the incucyte S3 live-cell analysis system. (D) Neurite outgrowth for each condition was 
monitored and quantified using the incucyte S3 live-cell analysis system.  
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Figure 4.5 Evaluating the incucyte phase mask for monitoring cell proliferation and cytotoxicity studies. 
Viability assays were conducted on SH-SY5Y and U-87MG cells differentiated at various FBS concentrations 
and 10 μM retinoic acid. MTT reduction assay for SH-SY5Y (A) and (B) U-87MG cells following 5 days of 
differentiation. LDH reduction assay for (C) SH-SY5Y and (D) U-87MG cells following 5 days of differentiation. 
Real-time analysis with iCelligence for (E) SH-SY5Y or (F) U-87MG differentiation. Real-time analysis using 
the incucyte S3 live-cell analysis system for (G) SH-SY5Y or (H) U-87MG differentiation. Statistical analysis 
was performed using one-way ANOVA with Dunnett’s post-hoc test where n=4 for all experiments. 
Statistical significance was recorded as * where *p<0.05, **p<0.01, ***p<0.001 and ****p<0.0001. 
Media change Media change 
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To confirm proliferation results quantified by the incucyte were accurate, we also 
investigated differentiation viability with other assays. MTT reduction assays of SH-SY5Y and U-
87MG differentiation (figure 4.5A and B, respectively) showed a dose-dependent increase in MTT 
reduction with increasing FBS concentration. This was supported by LDH release assays that showed 
lower LDH release for higher FBS percentages for both SH-SY5Y and U-87MG neural cells (figure 
4.5C and D, respectively). Furthermore, real-time cell analysis with the iCelligence showed similar 
patterns for growth as incucyte quantification for SH-SY5Y cells (figure 4.5E), where a plateau was 
observed at approximately 80 hours. Whereas differences were observed between iCelligence 
(figure 4.5F) and incucyte (figure 4.5H) results for U-87MG glial cells, possibly due to the clustering 
and network like formation observed with differentiation (figure 4.3A), as clustering would result 
in less iCelligence plate surface being covered, lowering cellular impedance while not impacting 
incucyte quantification. 
 BDNF, is a commonly used neurotrophic factor used to induce SH-SY5Y differentiation and 
neurite outgrowth. As such, we investigated the effect of BDNF on SH-SY5Y proliferation and 
neurite outgrowth following RA differentiation with and without U-87MG conditioned media. SH-
SY5Y neuronal cells differentiated over 5 days with retinoic acid exhibited pyramidal morphology 
with some processes, where U-87MG conditioned media improved the length of these processes 
(figure 4.6A). Cells treated with BDNF alone and cells treated with BDNF and U-87MG conditioned 
media for a further 3 days showed less proliferation, where U-87MG conditioned media resulted in 
almost no proliferation (figure 4.6B). Additionally, following BDNF treatment cells showed a more 
flattened and elongated morphology but showed little change in neurite length (figure 4.6C), which 
is supported by the increased average cell diameter and process length summarised in table 4.1. 
Therefore, while BDNF improved neurite length for SH-SY5Y cells differentiated with FBS/RA alone 
it did not improve neurite length when compared to differentiation with FBS/RA and U-87MG 
conditioned media. However, BDNF did arrest proliferation more effectively than FBS/RA with or 
without U-87MG conditioned media alone. It is also interesting to note that there is an initial 
increase in neurite length upon addition of U-87MG conditioned media and BDNF (figure 4.6C). This 
is potentially due to the fresh U-87MG conditioned media promoting neurite outgrowth through 
secreted factors, but these are used up quickly and thus, not able to maintain this growth. Together, 
this suggests U-87MG cells secrete factors that aid neurite outgrowth and help arrest proliferation 
suggesting a more differentiated state but BDNF attenuates further cell proliferation.   
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Figure 4.6 Effect of BDNF and U-87MG conditioned media on neurite outgrowth. Following 5-day 
differentiation with 0.5% (v/v) FBS and 10 μM retinoic acid with and without U-87MG conditioned media 
50 ng/ml of BDNF was added to cells in 0.5% (v/v) FBS for 3 days to investigate the effect on neurite 
outgrowth. (A) Images were taken every hour using the incucyte S3 live-cell analysis system, where the 
neurite mask is shown in purple and the cell bodies are masked in yellow. Scale bar = 200 μm. Inset scale 
bar = 100 μm. (B) Cell growth was monitored and quantified using the incucyte S3 live-cell analysis system. 
(C) Neurite outgrowth for each condition was monitored and quantified using the incucyte S3 live-cell 
analysis system neurotracker software.  
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Table 4.1 Comparing morphological changes induced by different methods of differentiation. Cell diameter and process length was assessed where 10 random neurons 
were selected per image, averaged and repeated in triplicate to calculate standard deviation where values were determined to be significant by t-tests relative to mitotic 
cells.  
 
Average cell 
diameter (μm) 
Standard 
deviation 
P (t-test against 
mitotic) 
Average 
process 
length (μm) 
Standard 
deviation 
P (t-test against 
mitotic) 
Mitotic cells 33.1 3.06 
 
38.4 9.44 
 
5 days retinoic acid 46.6 2.21 0.00148 73.2 8.09 0.00381 
5 days retinoic acid/ U-87 
conditioned media 
64.5 1.80 0.00751 108 10.6 0.0119 
5 days retinoic acid/ 3 days BDNF 62 3.29 0.0000250 85.5 17.2 0.0862 
5 days retinoic acid/ 3 days 
BDNF/ 
 U-87 conditioned media  
63.4 8.20 0.019366 99.3 15.8 0.00462 
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 To confirm differentiation, neural marker expression was investigated using Western blotting. 
All FBS/RA differentiated SH-SY5Y cells expressed both βIII tubulin and synaptophysin (figure 4.7A, C 
and E). Similarly, FBS/RA differentiated U-87MG glial cells expressed astrocytic markers GFAP and S100 
(figure 4.7B, D and F). For both SH-SY5Y and U-87MG cells FBS concentration did not significantly affect 
the expression of these neural markers. 
Creating a co-culture with SH-SY5Y and U-87MG was a project objective. Therefore, we opted 
to differentiate both SH-SY5Y and U-87MG cells with 0.5% (v/v) FBS with a density of 5180 cells/cm2.  
Figure 4.7 SH-SY5Y and U-87MG cells express markers of differentiation following reduced serum and 
retinoic acid exposure. SH-SY5Y and U-87MG glial cells were differentiated with 0.1, 0.5 and 1% (v/v) FBS 
and 10 μM retinoic acid over 5 days were probed for neuronal and astrocyte markers, respectively.  
Representative Western blots of (A) neuronal SH-SY5Y total cell extracts were probed with (C) βIII tubulin 
(1:1000) and (E) synaptophysin (1:1000). (B) Glial U-87MG total cell extracts were probed with (D) GFAP 
(1:1000) and S100 (1:500). Each Western blot is accompanied by a plot summarising densitometric analyses 
of Western blots using AIDA software. Results are presented per μg of protein. Statistical analysis was 
performed using one-way ANOVA with Tukey’s post-hoc test where n=3 for all experiments. Statistical 
significance was set at *p<0.05.  
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   To determine whether differentiation with RA influences cellular respiration we assessed ATP 
levels in both mitotic and differentiated SH-SY5Y and U-87MG neural cells (figure 4.8). By measuring 
extracellular acidification rate (ECAR) and oxygen consumption rate (OCR) simultaneously with the 
Seahorse XFe24 analyser, ATP generation through glycolysis and OXPHOS was calculated. The basal 
OCR of differentiated SH-SY5Y and U-87MG cells was greater than their mitotic counterparts (figure 
4.8A and B, respectively), while ECAR remained similar for SH-SY5Y and U-87MG cells (figure 4.8C and 
D). Following the addition of mitochondrial inhibitors (oligomycin and a mixture of 
rotenone/antimycin A) the rate of ATP production from glycolysis and mitochondria was calculated. 
Basal rates of both mitotic and differentiated SH-SY5Y cells showed comparable total ATP levels (figure 
4.8E and F). However, the rate of ATP production by glycolysis decreased in differentiated SH-SY5Y 
neuronal cells, which was further supported by the change in energetic maps, where no glycolytic ATP 
production was observed in differentiated SH-SY5Y cells (figure 4.8G and H). In contrast, U-87MG cells 
showed greater ATP production following differentiation alongside a greater mitochondrial ATP 
production rate (figure 4.8E and F). Together, these results suggest differentiation with FBS/RA results 
in SH-SY5Y and U-87MG neural cells relying on mitochondria more for their ATP demand.  
 To confirm the greater rate of ATP production from mitochondria was not a result of increased 
mitochondrial numbers in differentiated cells, we investigated mitochondrial DNA content using 
quantitative real-time polymerase chain reactions. Cell lysates were collected after 5 days of FBS/RA 
differentiation to assess potential changes in mitochondrial number. Mitochondrial DNA copy number 
normalised to nuclear DNA copy number showed comparable values between differentiated and 
mitotic SH-SY5Y (figure 4.9B) and U-87MG (figure 4.9C) cells. In addition, as with previous mitotic 
investigations, SH-SY5Y cells showed a significantly greater number of mitochondria than U-87MG glial 
cells even when differentiated (figure 4.9A) suggesting U-87MG glial cells possibly rely more on 
glycolysis than SH-SY5Y cells.  
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Figure 4.8 Changes to respiration following differentiation in neuronal and glial cells. Following 5-day 
differentiation of SH-SY5Y and U-87MG cells with 0.5% (v/v) FBS and 10 μM retinoic acid respiration was 
measured using the Seahorse XFe24 analyser and compared to corresponding mitotic cells. To determine 
the cells main source of ATP, (A, C) oxygen consumption rate (OCR) and (B, D) extracellular acidification rate 
(ECAR) were concomitantly measured. Using the Seahorse ATP report generator glycolytic and 
mitochondrial basal ATP production rate was calculated for (E) mitotic and (F) differentiated neural cells. 
An energetic map was also generated to show how differentiation altered glycolytic or mitochondrial ATP 
production.  
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4.2.2 The effect of reactive species on differentiated neural cell viability  
Following differentiation of neural cells, we examined their susceptibility to RS generated by AAPH 
and rotenone following 48-hour treatment. Neural cell viability was assessed via morphological 
changes, viability and functional activity assays.  
 Phase contrast microscopy showed increased intercellular distance as well as cellular 
shrinkage and rounding for differentiated SH-SY5Y neuronal cells treated with AAPH suggesting 
reduced cell viability (figure 4.10A). In contrast, U-87MG cells treated with 1 mM AAPH show 
decreased intercellular distance and a more elongated morphology (figure 4.10A). However, with 5 
mM AAPH U-87MG glial cells showed greater intercellular distance and cellular rounding like SH-SY5Y 
cells. This was supported by viability assays that showed MTT reduction significantly decreased in a 
dose-dependent manner for AAPH treated SH-SY5Y cells relative to the control (figure 4.11A). 
Figure 4.9 Differentiation does not affect mitochondrial DNA copy number. DNA was extracted from mitotic 
or differentiated cells (5 days with 0.5% (v/v) FBS and 10 μM retinoic acid) using the PureLink® genomic DNA kit, 
as per the manufacturer’s instructions. 50 ng of DNA was subsequently used for qRT-PCR. (A) Mitochondrial 
DNA expression of differentiated SH-SY5Y and U-87MG neural cells where results are expressed relative to SH-
SY5Y expression. Expression between mitotic and differentiated (B) SH-SY5Y and (C) U-87MG cells where results 
are expressed relative to mitotic expression. Statistical analysis was performed using an unpaired t-test where 
n=3 for all experiments. Statistical significance was set at *p<0.05. 
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Whereas U-87MG glial cells showed a significant increase in MTT reduction with 1 mM AAPH but 
significantly decreased at 5 mM AAPH (figure 4.11A). SH-SY5Y LDH assays showed LDH release 
significantly increased for ≥1 mM AAPH supporting MTT reduction assays (figure 4.11C). In contrast, 
U-87MG glial cells only showed significant LDH release for 5 mM AAPH (figure 4.11C), suggesting like 
the MTT reduction assays, 5 mM AAPH resulted in reduced cell viability. Phase contrast images at 48 
hours reinforced these observations as there was a dose-dependent decrease in SH-SY5Y phase 
confluence, while U-87MG glia increased for 1 mM AAPH but decreased for 5 mM (figure 4.10A).  
 Following 48-hour rotenone treatment, phase contrast microscopy showed both 
differentiated SH-SY5Y and U-87MG exhibited characteristics of poor cell health (i.e. increased 
intercellular distance, loss of processes, cellular shrinkage and rounding; figure 4.10B). Interestingly, 
U-87MG glial cells also exhibited increased clustering in a dose dependent manner, alongside release 
of cellular debris. Further supporting this, viability assays show significantly decreased MTT reduction 
in a dose-dependent manner for both SH-SY5Y and U-87MG cells (figure 4.11B). LDH assays also 
showed that ≥0.5 μM rotenone treatment resulted in a significant release of LDH (figure 4.11D) and a 
decrease in phase confluence (figure 4.11F) in both cell types. 
 Interesting to note is that differentiated SH-SY5Y neuronal cells appear to have greater 
resistance to rotenone, as MTT reduction for mitotic SH-SY5Y cells shows a more significant reduction 
for ≥0.5 μM (figure 3.23A and 3.27A). This is supported by LDH assays, where mitotic SH-SY5Y cells 
show a greater significant increase in LDH release for 0.5 μM rotenone (figure 3.23C and 3.27C) than 
differentiated SH-SY5Y neuronal cells (figure 4.11D). In contrast, differentiated U-87MG glial cells 
appear to be more susceptible to rotenone than mitotic cells, as the latter only show significant LDH 
release at 2.5 μM rotenone (figure 3.23D and 3.27D). Rotenone treatment (≥0.5 μM) results in a 
significant LDH release for differentiated U-87MG cells (figure 4.11D). Additionally, differentiated SH-
SY5Y neuronal cells appear to be more susceptible to AAPH as there is a significant increase in LDH 
release for 1 mM AAPH (figure 4.11C) that was not observed with mitotic SH-SY5Y cells (figure 3.21C 
and 3.25C). Both mitotic and differentiated U-87MG cells showed increased MTT reduction for 1 mM 
AAPH. However, mitotic U-87MG glial cells still showed increased MTT reduction with 5 mM AAPH 
(figure 3.21D and 3.25D), while differentiated U-87MG cells showed reduced MTT levels (figure 4.11C). 
Together, this suggests that reduced FBS and RA differentiation of SH-SY5Y and U-87MG neural cells 
results in changes in RS susceptibility.  
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Figure 4.10 Differentiated neuronal SH-SY5Y and 
glial U-87MG cell morphology following 48-hour 
AAPH or rotenone exposure. Morphology was 
examined following 5-day differentiated SH-SY5Y 
or U-87MG cells treated with AAPH or rotenone for 
48 hours. Phase contrast microscopy of (A) SH-SY5Y 
or (B) U-87MG monocultures. Scale bar = 200 μm. 
Inset scale bar = 100 μm. 
CHAPTER 4                                                                       EACTIVE SPECIES IN A DIFFERENTIATED MODEL 
 
164 
 
 
To confirm the changes in viability were due to RS, antioxidants α-tocopherol (200 μM) and 
ascorbic acid (1 mM) were added concurrently with treatment (figure 4.12-4.15). Differentiated neural 
viability was assessed by morphological changes, viability assays and real-time analysis using to 
incucyte S3 live-cell analysis system.  
Figure 4.11 Differentiated neuronal SH-SY5Y and glial U-87MG cell viability following 48-hour AAPH or 
rotenone exposure. Viability assays were conducted on 5-day differentiated SH-SY5Y or U-87MG cells treated 
with AAPH or rotenone for 48 hours. MTT reduction assay for (A) SH-SY5Y or (B) U-87MG monocultures. LDH 
release for (C) SH-SY5Y or (D) U-87MG monocultures. Real-time analysis using the incucyte S3 live-cell analysis 
system for (E) SH-SY5Y or (F) U-87MG monocultures. Viability assay results are presented as % against control. 
Statistical analysis was performed using one-way ANOVA with Dunnett’s post-hoc test where n=3 for all 
experiments. Statistical significance was recorded as *p<0.05, **p<0.01, ***p<0.001 and ****p<0.0001, relative 
to each respective control.  
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 Following 48-hour treatment with 1 mM AAPH and α-tocopherol, differentiated SH-SY5Y cell 
death was attenuated. However, α-tocopherol was ineffective against 5 mM AAPH. In contrast, 
ascorbic acid was unable to attenuate AAPH-induced cell death (figure 4.12-4.13) at all concentrations 
tested. Phase contrast microscopy showed α-tocopherol attenuated the loss of cellular processes and 
improved cellular morphology for 1 mM AAPH. In contrast, ascorbic acid treated SH-SY5Y cells showed 
cellular rounding and shrinkage for all AAPH concentrations (figure 4.12A). Improved neuronal viability 
with α-tocopherol was also indicated by significantly increased MTT reduction for 1 mM but not for 5 
mM AAPH, while ascorbic acid did not significantly change MTT reduction levels for all AAPH 
concentrations tested (figure 4.13A). LDH assays showed both antioxidants significantly improved 
membrane integrity for 1 mM AAPH treatment. However, both α-tocopherol and ascorbic acid were 
not able to reduce LDH levels for 5 mM AAPH where ascorbic acid exacerbated LDH release (figure 
4.13C). Live-cell analysis showed concurrent treatment with α-tocopherol, but not ascorbic acid 
resulted in a higher phase confluence/cell density (figure 4.13E).  
 Differentiated U-87MG glial exhibited increased proliferation with 1 mM AAPH treatment 
which was attenuated by both antioxidants (figure 4.12-4.13). Phase contrast microscopy for both α-
tocopherol and ascorbic acid showed greater intercellular distance, and less cellular elongation than 
1 mM AAPH treated differentiated U-87MG glial cells alone (figure 4.12B). However, both antioxidants 
still showed cellular rounding and loss of processes for 5 mM AAPH (figure 4.12B). MTT reduction 
assays supported this, as both antioxidants significantly reduced MTT reduction levels relative to 1 
mM AAPH alone, while having no significant effect on 5 mM AAPH treated cells (figure 4.13B). 
However, while MTT levels showed no significant change for 5 mM AAPH, LDH assays showed both 
antioxidants significantly decreased LDH release (figure 4.13D). Live-cell analysis supported MTT 
reduction and phase microscopy results as both antioxidants reduced differentiated U-87MG glia 
phase confluence (figure 4.13F).  
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Figure 4.12 Differentiated neuronal SH-SY5Y and glial U-87MG cell morphology following 
48-hour AAPH in the presence of antioxidants. Morphology investigations were conducted 
on 5-day differentiated SH-SY5Y or U-87MG cells treated with AAPH, with or without 200 μM 
α-tocopherol or 1 mM ascorbic acid for 48 hours. Phase contrast microscopy of (A) SH-SY5Y or 
(B) U-87MG monocultures. Scale bar = 200 μm. Inset scale bar = 100 μm. 
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Figure 4.13 Differentiated neuronal SH-SY5Y and glial U-87MG cell viability following 48-hour AAPH in 
the presence of antioxidants. Viability assays were conducted on 5-day differentiated SH-SY5Y or U-87MG 
cells treated with AAPH with or without 200 μM α-tocopherol or 1 mM ascorbic acid for 48 hours. MTT 
reduction assay for (A) SH-SY5Y or (B) U-87MG monocultures. LDH release for (C) SH-SY5Y or (D) U-87MG 
monocultures. Real-time analysis using the incucyte S3 live-cell analysis system for (E) SH-SY5Y or (F) U-
87MG monocultures. Viability assay results are presented as % against control. Statistical analysis was 
performed using one-way ANOVA with Dunnett’s post-hoc test where n=3 for all experiments. Statistical 
significance was recorded as *p<0.05, **p<0.01, ***p<0.001 and ****p<0.0001, where if not indicated this 
is relative to the appropriate cell control. 
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 Antioxidant treatments were also investigated with rotenone exposure. Unlike AAPH 
exposure, both α-tocopherol and ascorbic acid were able to attenuate differentiated SH-SY5Y 
rotenone induced cell death. Phase contrast microscopy showed each antioxidant was able to reduce 
intercellular distance, while attenuating cellular shrinkage and rounding suggesting improved viability 
(figure 4.14). This was supported by MTT reduction assays, which showed MTT reduction significantly 
increased when rotenone exposed cells were treated with either α-tocopherol or ascorbic acid (figure 
4.15A). LDH assays also confirmed these findings as both antioxidants significantly reduced LDH 
release for both rotenone concentrations (figure 4.15C). Live-cell analysis also showed this as both α-
tocopherol and ascorbic resulted in greater phase confluence compared to 0.5 μM rotenone alone 
(figure 4.15E).  
 Similar results were observed for differentiated U-87MG glial cells concurrently treated with 
α-tocopherol and ascorbic acid, where rotenone induced death was attenuated (figure 4.14-4.15).  
Antioxidants attenuated loss of processes and cell shrinkage observed with rotenone alone (figure 
4.14B). Viability assays supported these findings as MTT reduction was significantly increased for 0.5 
μM rotenone when concurrently treated with both antioxidants (figure 4.15B). Additionally, LDH 
release was significantly reduced for 0.5 μM rotenone when treated with either antioxidant (figure 
4.15D). Live-cell analysis also confirmed improved viability as quantified phase confluence was greater 
for antioxidant treated differentiated U-87MG glial cells (figure 4.15F).  
 Together, these results suggest AAPH and rotenone damage differentiated SH-SY5Y and U-
87MG viability via RS, which can be attenuated with antioxidants. Whilst ascorbic acid was not 
effective in attenuating cell death in mitotic U-87MG glial cells (figure 3.24-3.27), the antioxidant was 
able to attenuate cell death in differentiated U-87MG cells. This suggests differentiation results in 
some changes to cell metabolism, susceptibility to cellular stress and antioxidant capacity.   
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Figure 4.14 Differentiated neuronal SH-SY5Y and glial U-87MG cell morphology following 
48-hour rotenone in the presence of antioxidants. Morphology investigations were 
conducted on 5-day differentiated SH-SY5Y or U-87MG cells treated with rotenone with or 
without 200 μM α-tocopherol or 1 mM ascorbic acid for 48 hours. Phase contrast microscopy 
of (A) SH-SY5Y or (B) U-87MG monocultures. Scale bar = 200 μm. Inset scale bar = 100 μm. 
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Figure 4.15 Differentiated neuronal SH-SY5Y and glial U-87MG cell viability following 48-hour rotenone 
in the presence of antioxidants. Viability assays were conducted on 5-day differentiated SH-SY5Y or U-
87MG cells treated with rotenone with or without 200 μM α-tocopherol or 1 mM ascorbic acid for 48 hours. 
MTT reduction assay for (A) SH-SY5Y or (B) U-87MG monocultures. LDH release for (C) SH-SY5Y or (D) U-
87MG monocultures. Real-time analysis using the incucyte S3 live-cell analysis system for (E) SH-SY5Y or (F) 
U-87MG monocultures. Viability assay results are presented as % against control. Statistical analysis was 
performed using one-way ANOVA with Dunnett’s post-hoc test where n=3 for all experiments. Statistical 
significance was recorded as *p<0.05, **p<0.01, ***p<0.001 and ****p<0.0001, where if not indicated this 
is relative to the appropriate cell control. 
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The effect of AAPH and rotenone on cells differentiated with conditioned media/BDNF was 
also investigated. Like FBS/RA differentiated SH-SY5Y neuronal cells, both BDNF alone and in 
combination with U-87MG conditioned media showed a dose-dependent decrease in cell viability for 
both AAPH and rotenone treatment (figure 4.16-4.17). Phase contrast morphology showed similar 
effects where higher concentrations of AAPH (figure 4.16A) and rotenone (figure 4.16B) resulted in 
greater intercellular distances, and loss of processes accompanied by cellular rounding, suggesting 
poor cell health. BDNF differentiation resulted in SH-SY5Y cells being less susceptible to AAPH induced 
death as only 5 mM AAPH resulted in a significant decrease in MTT reduction (figure 4.17A) and a 
significant increase in LDH release (figure 4.17C), while ≥1 mM AAPH had this effect on FBS/RA 
differentiated SH-SY5Y cells (figure 4.16). In contrast, BDNF differentiated SH-SY5Y cells appeared 
more susceptible to rotenone induced cell death as all concentrations of rotenone significantly 
decreased MTT reduction relative to the control (figure 4.17B).   
U-87MG conditioned media further increased resistance to AAPH as there was significantly 
greater MTT reduction at 1 mM AAPH, although LDH release was only significantly decreased for 5 
mM AAPH (figure 4.17A and B). However, phase confluence results suggested this change in 
susceptibility was minor (figure 4.17E). In contrast, U-87MG conditioned media appeared to have a 
greater effect in conferring resistance to rotenone induced death as there was significantly greater 
MTT reduction for U-87MG conditioned media with 0.1 and 0.5 μM rotenone (figure 4.17B), which is 
further highlighted by the greater phase confluence (figure 4.17F).     
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Figure 4.16 Differentiated neuronal 
SH-SY5Y cell morphology following 
retinoic acid and BDNF differentiation 
with or without U-87MG conditioned 
media and 48-hour AAPH and 
rotenone exposure. Morphology 
investigations were conducted on 5-day 
retinoic acid, 3 days BDNF 
differentiated SH-SY5Y cells with or 
without differentiated U-87MG 
conditioned media. Phase contrast 
microscopy of (A) AAPH or (B) rotenone 
treated differentiated SH-SY5Y 
monocultures. Scale bar = 200 μm. 
Inset scale bar = 100 μm. 
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Figure 4.17 Differentiated neuronal SH-SY5Y cell viability following retinoic acid and BDNF differentiation 
with or without U-87MG conditioned media and 48-hour AAPH and rotenone exposure. Viability assays 
were conducted on 5-day retinoic acid, 3 days BDNF differentiated SH-SY5Y cells with or without 
differentiated U-87MG conditioned media. MTT reduction assay for (A) AAPH or (B) rotenone treated 
differentiated cells. LDH release for (C) AAPH or (D) rotenone treated differentiated cells. Real-time analysis 
using the incucyte S3 live-cell analysis system for (E) AAPH or (F) rotenone treated monocultures. Viability 
assay results are presented as % against control. Statistical analysis was performed using one-way ANOVA 
with Dunnett’s post-hoc test where n=4 for all experiments. Statistical significance was recorded as *p<0.05, 
**p<0.01, ***p<0.001 and ****p<0.0001, where if not indicated this is relative to the appropriate cell 
control. 
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4.2.3 Reactive species effect on primary cortical neurons  
Following dissection and plating of primary cortical neurons, we monitored growth to determine an 
optimal toxicity regimen to compare with the differentiation models. Images were taken every hour 
using the incucyte S3 live-cell analysis system to monitor cell morphology and neurite growth.  
 In the initial 24-hours after seeding, primary cortical neurons already showed signs of neurite 
outgrowth from multiple cell bodies (figure 4.18A). These neurites continued to exhibit linear growth 
up to day 4 (figure 4.18B), accompanied by multiple branch points (figure 4.18C). Furthermore, it is 
interesting to note after 48 hours, neuronal cell bodies appear to cluster as they use their neurites to 
pull each other together. After 4 days both neurite length and branch points appear to plateau, 
suggesting primary cortical neurons extend neurites over the first 4 days and then possibly reach a 
stable state. This suggests day 5 would be suitable for cytotoxicity assays similar to the SH-SY5Y cell 
differentiation time frame with FBS/RA.  
 Following 5-day growth, primary cells were treated with AAPH or rotenone for 24 hours, as 
morphological changes were visible for all concentrations as early as 24 hours (figure 4.19A and B). 
Interestingly, AAPH and rotenone appeared to have different effects on primary cortical neuron 
morphology. AAPH resulted in axon/neurite fragmentation producing punctate axon/neurite 
remnants, whereas rotenone treatment resulted in a reduced number of axons with fewer branches 
compared to untreated controls. This loss of axonal processes suggests both AAPH and rotenone 
treatment resulted in degenerating cortical neuron structure and viability, which was supported by 
viability assays. MTT reduction assays were significantly lower suggesting loss of viability for all 
concentrations of AAPH and rotenone (figure 4.20A and B, respectively). These results were supported 
by LDH assays, which showed significantly greater LDH release for AAPH and rotenone treatment 
(figure 4.20C and D, respectively). Furthermore, LDH assays showed greater levels of LDH release for 
AAPH treated primary cortical neurons compared to rotenone. Live-cell analysis showed a linear 
decrease in normalised phase confluence over 24 hours, with AAPH (figure 4.20E) and rotenone 
treatment (figure 4.20F).  
Concurrent treatment with α-tocopherol was unable to improve MTT reduction of cortical 
neurons treated with AAPH (figure 4.20A) and was only able to significantly protect against 2.5 μM 
rotenone treatment (figure 4.20B). However, α-tocopherol treatment reduced LDH release for both 
AAPH and rotenone treatments (figure 4.20C and D, respectively). This may be due to the nature of 
the assays, where the MTT assay measures mitochondrial function. Mitochondria are known to be 
located to neurites and as α-tocopherol did not affect neurite loss (figure 4.14A and B), which may 
explain why MTT levels were unaffected. However, live-cell analysis showed α-tocopherol initially 
CHAPTER 4                                                                       EACTIVE SPECIES IN A DIFFERENTIATED MODEL 
 
175 
 
attenuated AAPH induced death but was not able to keep protecting primary cortical neurons over 
time (figure 4.20E). In contrast, α-tocopherol was able to alleviate the effect of rotenone over 24-
hours as measured by phase confluence (figure 4.20F). 
 
 
 
  
Figure 4.18 Primary embryonic rat cortical neuronal growth. Once dissected and seeded on poly-L-lysine and 
laminin coated plates primary cortical neuron growth was monitored using the incucyte S3 live-cell analysis 
system. (A) Phase contrast images were taken every hour for 5 days and quantified using the incucyte 
neurotracker software to mask neurites (purple) and cell bodies (yellow). Scale bar = 200 μm. Inset scale bar = 
100 μm. (B) Neurite length and (C) branch points were quantified over 5 days.   
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Figure 4.19 The effect of reactive species on primary cortical neuronal morphology with and without α-
tocopherol. Primary cortical neurons were grown for 5 days and then treated with AAPH or rotenone for 24 
hours prior to morphology investigations. Phase contrast microscopy of 24-hour (A) AAPH or (B) rotenone 
treated primary neurons. Scale bar = 200 μm. Inset scale bar = 100 μm. 
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Figure 4.20 The effect of reactive species on primary cortical neuronal viability with and without α-
tocopherol. Primary cortical neurons were grown for 5 days and then treated with AAPH or rotenone for 24 
hours prior to viability assays. MTT reduction assay of 24-hour (A) AAPH or (B) rotenone treated primary 
neurons. LDH release of 24-hour (C) AAPH or (D) rotenone treated primary neurons. Real-time analysis using 
the incucyte S3 live-cell analysis system for (E) AAPH or (F) rotenone treated primary neurons. Viability assay 
results are presented as % against control. Statistical analysis was performed using one-way ANOVA with 
Dunnett’s post-hoc test where n=4 for all experiments. Statistical significance was recorded as *p<0.05, 
**p<0.01, ***p<0.001 and ****p<0.0001. 
CHAPTER 4                                                                       EACTIVE SPECIES IN A DIFFERENTIATED MODEL 
 
178 
 
 Due to the interesting morphological differences observed with AAPH and rotenone, we 
quantified neurite length and branch points in real time using the incucyte S3 live-cell analysis system. 
Quantification was normalised to account for different starting neurite lengths. Phase contrast 
microscopy showed AAPH resulted in a dose-dependent decrease in neurite length over 24-hours 
(figure 4.21A). Furthermore, over time axons appeared to fragment in a retrograde manner towards 
the neuronal cell soma (figure 4.22A). This was supported by axon/neurite quantification, which 
showed that as the concentration of AAPH increased, the neurite length and branch points showed a 
similar time- and dose-dependent decline (figure 4.22C and E, respectively). In contrast, rotenone 
treatment resulted in a less significant decrease in neurite length and branch points (figure 4.22D and 
F, respectively). Furthermore, phase contrast microscopy showed different changes in axonal 
morphology as rotenone appeared to reduce the number of branch points over time, while not 
effecting axon length as prominently as AAPH and did not result in fragmentation (figure 4.22B).  
 α-tocopherol treatment was unable to attenuate AAPH or rotenone induced reduction of 
neurite length (figure 4.23). This is possibly due to primary cortical neurons being more sensitive to 
RS and further titration of α-tocopherol was needed. However, due to the different sensitivities of cell 
batches it was difficult to investigate this.       
 As neurite length quantification by the incucyte S3 live-cell analysis system also considers the 
branches in the overall length of neurites, the impact on branch length was unclear. Therefore, to 
investigate if AAPH and rotenone affect primary neuron branching the Sholl analysis (Ferreira et al., 
2014) and Skeleton plugin (Lee and Kashyap, 1994) in ImageJ/Fiji were used. Sholl analysis works on 
the principle of measuring the number of intersections in contact with the sampling shells, which 
expand out from the centre of a neuronal arbour (figure 4.24A). Steps for Sholl analysis are described 
in figure 4.24B, where phase contrast images were initially masked using the neurotracker software 
from the incucyte S3 live-cell analysis system, which was then converted to a binary image and 
thresholded for Sholl analysis. Sholl analysis shows a dose-dependent decrease in the number of 
interactions for AAPH (figure 4.25A and B) and rotenone (Figure 4.25D and E), demonstrated by the 
Sholl heat maps and corresponding plots. Skeleton analysis also supported a dose-dependent 
decrease in average branch length for primary neurons treated with AAPH (figure 4.25C) or rotenone 
(figure 4.25F) for 24 hours.   
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Figure 4.21 The effect of reactive species on primary cortical neurite morphology. Following 5 days of growth 
primary neurons were treated with AAPH or rotenone for 24 hours and neurite outgrowth was monitored using 
the incucyte S3 live-cell analysis system. Scale bar = 200 μm. Inset scale bar = 100 μm. Phase contrast images of 
24-hour (A) AAPH and (B) rotenone treated neurons. Phase contrast images were taken every hour for 24-hours 
and quantified using the incucyte neurotracker software to mask neurites (purple). 
CHAPTER 4                                                                       EACTIVE SPECIES IN A DIFFERENTIATED MODEL 
 
180 
 
 
Figure 4.22 The effect of reactive 
species on primary cortical neurite 
outgrowth. Following 5 days of 
growth primary neurons were 
treated with AAPH or rotenone for 
24 hours and neurite outgrowth was 
monitored using the incucyte S3 live-
cell analysis system. Scale bar = 100 
μm. Phase contrast images 
monitoring neurites over time when 
treated with (A) AAPH or (B) 
rotenone. Live cell monitoring of 
neurite length of (C) AAPH and (D) 
rotenone treated primary neurons. 
Live cell monitoring of branch points 
of (E) AAPH and (F) rotenone treated 
primary neurons.  
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Figure 4.23 The effect of reactive species on primary cortical neurite outgrowth with α-tocopherol. Following 5 days of growth primary neurons were treated with AAPH or rotenone with and 
without α-tocopherol for 24 hours and neurite outgrowth was monitored using the incucyte S3 live-cell analysis system. Scale bar = 200 μm. Inset scale bar = 100 μm. (A) Phase contrast images 
of 24-hour (A) AAPH and (B) rotenone treated neurons with and without α-tocopherol. Phase contrast images were taken every hour for 24-hours and quantified using the incucyte neurotracker 
software to mask neurites (purple). Live cell monitoring of neurite length of (C) AAPH and (D) rotenone treated primary neurons with and without α-tocopherol. Live cell monitoring of branch 
points of (E) AAPH and (F) rotenone treated primary neurons with and without α-tocopherol.  
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Figure 4.24 The steps involved in Sholl analysis. (A) Diagrammatic representation of Sholl analysis, which involves creating a series of concentric shells around the focus 
of a neuronal arbour where the number of intersections is calculated from how neurits many intersect the sampling shells. (B) Stepwise imageJ processing of primary 
cortical neurons where phase contrast images were taken using the incucyte S3 live-cell analysis system and mask was generated using the neurotracker software. Mask 
was converted to a binary thresholded image and individual neurons were selected to generate a heat map according to the Sholl profile. 
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Figure 4.25 The effect of reactive species on 
primary cortical neurite complexity. Phase 
contrast microscopy, binary and Sholl analysis 
images for 24-hour (A) AAPH and rotenone (D) 
treated neurons. Scale bar = 200 μm. Sholl plots of 
(B) AAPH and (E) rotenone treated primary 
neurons generated from images. Skeleton 
analysis in imageJ was also used to determine the 
average branch length for (C) AAPH and (F) 
rotenone treated neurons. Plots are 
representative of group means ± SEM where 
n=15. Statistical analysis was performed using 
one-way ANOVA with Dunnett’s post-hoc test. 
Statistical significance was recorded as *p<0.05, 
**p<0.01, ***p<0.001 and ****p<0.0001. 
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Together these results suggest neurite length, branch number and length are affected by 
AAPH and rotenone. Interesting to note though is lower rotenone concentrations effect branch 
number more than lower concentrations of AAPH suggesting rotenone possibly effects branching 
more than AAPH.  
 As branching appeared to be affected differently by AAPH and rotenone, we investigated the 
effect on synaptophysin (membrane glycoprotein) expression. Immunofluorescence staining showed 
a decrease in synaptophysin (green) expression with AAPH along neurites (figure 4.26A) whilst 
increasing with rotenone treatment (Figure 4.26B). Rotenone treated primary neurons showed more 
synaptophysin puncta along βIII tubulin stained processes (red) and within the cell soma as rotenone 
concentration increased. This suggests AAPH and rotenone affects synaptophysin in different ways. 
The distribution of synaptophysin expression corresponds with phase microscopy observations, where 
AAPH resulted in axonal process fragmentation while rotenone appeared to reduce branch length and 
interactions.  
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Figure 4.26 Toxicity of reactive species on primary cortical neuronal synaptophysin expression. Primary cortical neurons were treated with increasing concentrations of (A) 
AAPH or (B) rotenone for 24 hours. Cells were co-stained with synaptophysin (green), βIII-tubulin (red) and DAPI (blue). Scale bar = 100 μm. AAPH resulted in decrease 
synaptophysin expression while rotenone increased expression.  
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4.2.4 The effect of reactive species on differentiated neural processes  
To investigate if our model of differentiation could replicate observations in primary cortical neurons, 
we investigated neurite outgrowth. BDNF with and without U-87MG conditioned media 
differentiation protocols were used, as they showed the greatest neurite network (figure 4.6).  
 As differentiated SH-SY5Y neurons showed similar viability at 48 hours to 24-hour treatment 
of primary cortical neurons we ran neurite outgrowth experiments for 48 hours. Similar to primary 
neurons, differentiated SH-SY5Y cells showed a dose-dependent decrease in neurite length for BDNF 
differentiated cells treated with AAPH or rotenone (figure 4.27A and B, respectively and quantified in 
figure 4.28A and B, respectively). Differentiation with U-87MG conditioned media showed AAPH 
treatment resulted in a neurite length decreasing at an earlier time point at an exponential rate (figure 
4.28C) relative to BDNF differentiation (figure 4.28A). Rotenone treatment of differentiated cells using 
conditioned media resulted in a consistent reduction in neurite length (figure 4.29D); a phenomenon 
that was also observed with primary neurons (figure 4.22B). Indeed, the differentiation model 
mimicked some of the changes observed with primary neurons albeit with some differences in the 
extent of neurite retraction for rotenone and AAPH treatment (figure 4.28C and D, respectively).  
 To investigate if the observations were due to RS, we concurrently treated differentiated cells 
with AAPH or rotenone with and without α-tocopherol (figure 4.29-4.30). However, like primary 
neuronal cultures our differentiation models showed α-tocopherol had no significant effect on AAPH 
or rotenone induced neurite retraction (figure 4.30C).  
 Unfortunately, the differentiation models we used did not appear to show branching that was 
quantifiable and as such Sholl analysis was not conducted. As the mask was unable to quantify 
branching, we also investigated synaptophysin changes to compare with primary neurons. However, 
synaptophysin did not show punctate staining for either differentiation model (figure 4.31). 
Furthermore, while cells showed a dose-dependent decrease in viability and neurite loss in phase 
contrast microscopy, there was no obvious changes in synaptophysin staining between AAPH (figure 
4.31A, C) or rotenone (Figure 4.31B, D) as was seen with primary neurons.  
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Figure 4.27 The effect of reactive species on differentiated SH-SY5Y neurite outgrowth morphology. Following differentiation with FBS/RA and BDNF with and without U-
87MG conditioned media SH-SY5Y cells were treated with AAPH or rotenone for 48 hours, where neurite outgrowth was monitored using the incucyte S3 live-cell analysis 
system. (A) Phase contrast images of 48-hour (A) AAPH and (B) rotenone treated neurons where neurotracker software from the incucyte S3 live-cell analysis system was 
used to mask neurites (purple). Scale bar = 200 μm. Inset scale bar = 100 μm. 
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Figure 4.28 The effect of reactive species on differentiated SH-SY5Y neurite outgrowth. Following 
differentiation with FBS/RA and BDNF with and without U-87MG conditioned media SH-SY5Y cells were treated 
with AAPH or rotenone for 48 hours, where neurite outgrowth was monitored using the incucyte S3 live-cell 
analysis system. Phase contrast images were taken every hour for 48-hours and quantified using the neurotracker 
software. Live cell monitoring of neurite length of (A) AAPH and (B) rotenone treated BDNF only differentiated 
SH-SY5Y cells. Live cell monitoring of neurite length of (C) AAPH and (D) rotenone treated U-87MG conditioned 
media differentiated SH-SY5Y cells.  
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Figure 4.29 The effect of reactive species on differentiated SH-SY5Y neurite morphology with α-tocopherol. Following differentiation with FBS/RA and BDNF with and 
without U-87MG conditioned media SH-SY5Y cells were treated with AAPH or rotenone for 48 hours with or without α-tocopherol, where neurite outgrowth was monitored 
using the incucyte S3 live-cell analysis system. (A) Phase contrast images of 48-hour (A) AAPH and (B) rotenone treated neurons where neurotracker software from the 
incucyte S3 live-cell analysis system was used to mask neurites (purple). Scale bar = 200 μm. Inset scale bar = 100 μm. 
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Figure 4.30 The effect of reactive species on differentiated SH-SY5Y neurite outgrowth with α-tocopherol. 
Following differentiation with FBS/RA and BDNF with and without U-87MG conditioned media SH-SY5Y cells were 
treated with AAPH or rotenone for 48 hours with or without α-tocopherol, where neurite outgrowth was 
monitored using the incucyte S3 live-cell analysis system. Phase contrast images were taken every hour for 48-
hours and quantified using the neurotracker software. Live cell monitoring of neurite length of (C) AAPH and (D) 
rotenone treated BDNF only differentiated SH-SY5Y cells. Live cell monitoring of neurite length of (E) AAPH and 
(F) rotenone treated U-87MG conditioned media differentiated SH-SY5Y cells.  
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Figure 4.31 Toxicity of reactive species on differentiated SH-SY5Y neuronal cells. SH-SY5Y neurons were 
differentiated over 5 days with retinoic acid followed by 3 days of BDNF with or without U-87MG conditioned 
media prior to 48-hour treatment with AAPH or rotenone. SH-SY5Y cells differentiated with BDNF alone were 
treated with (A) AAPH or (B) rotenone for 48 hours. SH-SY5Y differentiated in the presence of U-87MG 
conditioned media treated with (C) AAPH or (D) rotenone for 48 hours. Cells were co-stained with 
synaptophysin (green), βIII-tubulin (red) and DAPI (blue). Scale bar = 100 μm.  
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Together, these neurite studies demonstrate the limitations of the differentiation models we 
are working with. While showing similar qualities in terms of viability, morphologically differentiated 
cells pose problems. Changes in neurite length for AAPH and rotenone were the opposite of those 
observed in primary cortical neurons with uncharacteristic synaptophysin staining or differences in 
distribution upon treatment. These problems may be due to the differentiated models lacking 
substantial neurite branching as was seen with primary cells and therefore require improved 
differentiation protocols.   
 We also used the incucyte S3 live-cell analysis neurotracker software to quantify glia 
processes. Phase contrast images showed 1 mM AAPH alongside increased cell number also resulted 
in U-87MG glial cells having longer processes (figure 4.32A and figure 4.32C). Rotenone treatment of 
U-87MG glial cells resulted in cellular rounding (figure 4.32B) and shortened processes (figure 4.32D). 
To investigate if this was as a result of RS, we treated U-87MG glial cells with α-tocopherol which 
attenuated process growth in 1 mM AAPH treated cells relative to the control (figure 4.33C). α-
tocopherol improved processes observed in phase contrast images (figure 4.33B) in response to 
rotenone treatment (figure 4.33D). This suggests RS induced by AAPH and rotenone effect glial 
processes.  
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Figure 4.32 The effect of reactive species on glial processes. Following differentiation with FBS/RA U-87MG glial cells were treated with AAPH or rotenone for 48 hours, where 
process outgrowth was monitored using the incucyte S3 live-cell analysis system. Phase contrast images of 48-hour (A) AAPH and (B) rotenone treated glia where neurotracker 
software from the incucyte S3 live-cell analysis system was used to mask processes (purple). Scale bar = 200 μm. Inset scale bar = 100 μm. Phase contrast images were taken 
every hour for 48-hours and quantified using the neurotracker software. Live cell monitoring of process length of (C) AAPH and (D) rotenone treated differentiated glial cells.  
CHAPTER 4                                                                       EACTIVE SPECIES IN A DIFFERENTIATED MODEL 
 
194 
 
 
Figure 4.33 The effect of reactive species on glial processes in the presence of tocopherol. Following differentiation with FBS/RA U-87MG glial cells were treated with 
AAPH or rotenone for 48 hours with or without α-tocopherol, where process outgrowth was monitored using the incucyte S3 live-cell analysis system. Phase contrast 
images of 48-hour (A) AAPH and (B) rotenone with and without α-tocopherol treated glia, where neurotracker software from the incucyte S3 live-cell analysis system 
was used to mask processes (purple). Scale bar = 200 μm. Inset scale bar = 100 μm. Phase contrast images were taken every hour for 48-hours and quantified using the 
neurotracker software. Live cell monitoring of process length of (C) AAPH and (D) rotenone treated differentiated glial cells with and without α-tocopherol.  
CHAPTER 4                                                                       EACTIVE SPECIES IN A DIFFERENTIATED MODEL 
 
195 
 
4.2.5 The effect of reactive species on gene expression in differentiated neural 
cells  
With viability and morphology affected by RS inducers rotenone and AAPH we investigated the OS 
profile induced in both differentiated SH-SY5Y and U-87MG neural cells following 48-hour exposure. 
A RT2 profiler PCR array focused on genes involved in OS was utilised.  
 SH-SY5Y and U-87MG profiles were compared to investigate the differences in basal gene 
expression between these different neural cell types. Genes significantly upregulated or 
downregulated in U-87MG glial cells relative to SH-SY5Y (figure 4.34A) were identified, and presented 
as a heatmap of differentially expressed OS related genes (figure 4.34B). Interestingly, U-87MG glial 
exhibited lower basal expression of most genes associated with glutathione synthesis, despite glia 
possessing greater levels of glutathione (figure 4.34C). Furthermore, peroxiredoxin (PRDX) and SOD 
levels appear to be expressed differently where some are upregulated while others are 
downregulated (figure 4.34B and 4.34D). Together, these results suggest differences in expression of 
OS associated genes in differentiated SH-SY5Y neuronal and U-87MG glial cells. 
 Next, we investigated differences in upregulated and downregulated genes from AAPH (figure 
4.35A) or rotenone (figure 4.35B) treatment of differentiated SH-SY5Y cells. Heatmaps allowed 
significant differences in gene expression to be identified (figure 4.35C), where AAPH resulted in a 
greater proportion of genes being upregulated, while rotenone lead to more being downregulated. 
This was further demonstrated by fold changes in expression with rotenone inducing a decrease in 
glutathione related genes (figure 4.35D), PRDX genes (figure 4.35E) and thioredoxin related genes 
(figure 4.35F), whereas AAPH resulted in increased expression. This may be influenced by the 
treatment timeframe reaction of rotenone and AAPH.  
 Using Venny (an interactive tool; Oliveros, 2007), we compared differences in upregulated 
(figure 4.36A) and downregulated (figure 4.36B) genes following AAPH and rotenone treatment of SH-
SY5Y cells. Only 6 genes were simultaneously upregulated, and 2 genes were downregulated in AAPH 
and rotenone treated SH-SY5Y cells, suggesting each RS stressor induced a unique gene profile. 
Pathway analyses showed AAPH treatment upregulated antioxidant genes (figure 4.36C), genes 
involved in the metabolism of RS (figure 4.36D) and OS responsive genes (figure 4.36E), while rotenone 
showed a decrease in genes linked to several of these pathways. This suggests the OS response is still 
active in AAPH treated SH-SY5Y cells while it is no longer active in rotenone treated SH-SY5Y neuronal 
cells at 48-hours.  
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Figure 4.34 Oxidative stress related gene profile in U-87MG glial cells relative to SH-SY5Y neuronal cells 
using RT2 profile array. Comparisons among groups were analysed and normalised to mRNAs of DHCR24, 
SIRT2, GPX4, TRAPPC6A and SEPP1 as recommended. (A) Scatterplots comparing U-87MG glia against SH-
SY5Y neuronal cells showing the normalised genes. Red: normalised expression of genes upregulated 
relative to SH-SY5Y neuronal cells. Green: normalised expression of genes downregulated relative to SH-
SY5Y neuronal cells. Black: Normalised expression of unchanged genes. (B) Heatmap comparing genes 
significantly up- and downregulated in U-87MG glial cells relative to SH-SY5Y neuronal cells. (C) Fold change 
of glutathione related genes in U-87MG glia relative to SH-SY5Y neurons. (D) Fold change of peroxiredoxin 
and chaperone gene expression in U-87MG glial relative to neurons.  
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Figure 4.35 Oxidative stress related gene profile in SH-SY5Y neuronal cells in response to rotenone or 
AAPH using RT2 profile array. Cells were differentiated with FBS/RA over 5 days and then treated with AAPH 
or rotenone for 48-hours. Comparisons among treatments were analysed and normalised to mRNAs of B2M 
and HRPT1. Scatterplots comparing (A) AAPH and (B) rotenone treated SH-SY5Y neuronal cells showing the 
normalised expression. Red: normalised expression of genes upregulated by AAPH or rotenone relative to 
control neuronal cells. Green: normalised expression of genes downregulated by AAPH or rotenone relative 
to control neuronal cells. Black: Normalised expression of unchanged genes. (C) Heatmap comparing genes 
significantly up- and downregulated by AAPH or rotenone. (D) Fold change of glutathione related genes in 
response to AAPH or rotenone. (D) Fold change of peroxiredoxin and chaperone gene expression in response 
to AAPH or rotenone. (E) Fold change of thioredoxin related genes in response to AAPH or rotenone.  
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Figure 4.36 Differences and similarities between AAPH and rotenone induced gene profile in SH-SY5Y 
neuronal cells. Venn diagram illustrating the proteins (A) up- and (B) downregulated by AAPH or rotenone 
treatment in neuronal cells. Numbers represent the number of significantly altered proteins and 
percentages represent how many are unique or shared between each treatment. Respective genes are 
noted in table 1 and table 2. Heatmaps comparing genes significantly up- and downregulated by AAPH or 
rotenone grouped into (C) antioxidant genes, (D) genes involved in reactive species metabolism and (E) 
genes responsive to oxidative stress in neuronal cells.    
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Differences in oxidative stress gene expression was also investigated in differentiated U-87MG 
glial cells treated with AAPH and rotenone. Both AAPH (figure 4.37A) and rotenone (figure 4.37B) 
resulted in a significant increase in several OS related genes. This is further highlighted by the 
heatmap, which shows similar clusters of genes upregulated by both AAPH and rotenone (figure 
4.37C) including: glutathione related genes (figure 4.38D), PRDX’s (figure 4.37E) and thioredoxin 
related genes (figure 4.37F). 
 The similarities in expression profiles in response to AAPH or rotenone treatment is visible in 
the Venn diagrams. A total of 61 genes are upregulated (figure 4.38A) and 10 genes downregulated 
(figure 4.38B) with both AAPH and rotenone treatment (87.1% and 55.6%, respectively). Groups of 
related genes appear to be regulated in similar ways for both AAPH and rotenone, for example 
glutathione peroxidases (GPX’s) and thioredoxins (TXN’s) are both upregulated. Of note, SOD isoform 
expression was different for AAPH or rotenone treatment as SOD1 was upregulated in both 
treatments but SOD2 was only upregulated in rotenone treated U-87MG glial cells.  
 Together, these findings suggest 48-hour AAPH or rotenone treatment of differentiated SH-
SY5Y neuronal cells resulted in different gene expression profiles, suggesting divergent RS induce 
different gene expression responses. In contrast, AAPH or rotenone treatment of U-87MG glial cells 
showed similar gene expression profiles.    
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Figure 4.37 Oxidative stress related gene profile in U-87MG glial cells in response to rotenone or AAPH using RT2 
profile array. Cells were differentiated with FBS/RA over 5 days and then treated with AAPH or rotenone for 48-
hours. Comparisons among treatments were analysed and normalised to mRNAs of B2M and HRPT1. Scatterplots 
comparing (A) AAPH and (B) rotenone treated U-87MG glial cells showing the normalised expression. Red: 
normalised expression of genes upregulated by AAPH or rotenone relative to control glial cells. Green: normalised 
expression of genes downregulated by AAPH or rotenone relative to control glial cells. Black: Normalised expression 
of unchanged genes. (C) Heatmap comparing genes significantly up- and downregulated by AAPH or rotenone. (D) 
Fold change of glutathione related genes in response to AAPH or rotenone. (D) Fold change of peroxiredoxin and 
chaperone gene expression in response to AAPH or rotenone. (E) Fold change of thioredoxin related genes in 
response to AAPH or rotenone.  
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Figure 4.38 Differences and similarities between AAPH and rotenone induced gene profile in U-87MG glial 
cells. Venn diagram illustrating the proteins (A) up- and (B) downregulated by AAPH or rotenone treatment 
in glial cells. Numbers represent the number of significantly altered proteins and percentages represent how 
many are unique or shared to each treatment. Respective genes are noted in table 1 and table 2. Heatmaps 
comparing genes significantly up- and downregulated by AAPH or rotenone grouped into (C) antioxidant 
genes, (D) genes involved in reactive species metabolism and (E) genes responsive to oxidative stress in glial 
cells.    
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To validate some of these findings at the protein level, Western blots were performed. We 
demonstrated HSP70 (referred to as HSPA1A in the array) increased with both AAPH and rotenone 
treatment in differentiated SH-SY5Y cells (figure 4.39A), while only increasing for AAPH treatment in 
differentiated U-87MG glial cells (figure 4.39B) mimicking gene profile expression. In addition, PRDX6 
protein levels of SH-SY5Y cells (figure 4.39B) remained stable in response to AAPH or rotenone 
treatment whilst being significantly reduced in U-87MG treated cells. These profiles were also 
observed with the gene expression data.  
 
  
 
 
 
Figure 4.39 Western blot validation of PCR array. Representative Western blots of differentiated neuronal 
SH-SY5Y and glial U-87MG total cell extracts were probed with (A) HSP70 (1:1000) or (B) PRDX6 (1:1000) 
following treatment with either 1 mM AAPH or 0.5 μM rotenone. Each Western blot is accompanied by a 
plot summarising densitometric analyses of Western blots using AIDA software. Results are presents as % 
against control ± SEM. Statistical analysis was performed using one-way ANOVA with Dunnett’s post-hoc 
test where n=4 for all experiments. Statistical significance was recorded as *p<0.05, **p<0.01, ***p<0.001 
and ****p<0.0001.  
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OS gene profiles of SH-SY5Y and U-87MG treated cells was then analysed by MetaCore 
(Clavirate analytics) pathway analysis. Figure 4.40A summarises the significantly up- and 
downregulated pathways linked to differentially expressed genes. Further analysis revealed various 
upstream transcription factors summarised in 4.40 table 1. Of interest was NRF2, a transcription factor 
that regulates several genes altered by AAPH and rotenone treatment (circled on figure 4.40A). As 
previous studies with mitotic cells also showed nuclear translocation of NRF2 (figures 3.9 and 3.10), 
we investigated NRF2 and KEAP1, (an inhibitor of NRF2) gene expression via qRT-PCR. Both neural cells 
showed increased NRF2 expression upon treatment with AAPH or rotenone with significant changes 
being observed for AAPH treated SH-SY5Y neuronal cells and rotenone treated U-87MG glial cells 
(figure 4.40B). In contrast, only rotenone treated U-87MG glial cells showed significantly 
downregulated levels of KEAP1 (figure 4.40C). Together, with previous localisation studies, this 
suggests NRF2 may play a role in the antioxidant stress response in AAPH and rotenone treated neural 
cells.   
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Figure 4.40 Pathways associated with oxidative stress gene profiles. MetaCore from Clarivate analytics 
was used to analyse gene array data with SH-SY5Y neuronal and U-87MG glial cells treated with rotenone 
or AAPH.  Symbols numbered 1-4 where 1: Rotenone treated SH-SY5Y neuronal cells, 2: AAPH treated SH-
SY5Y neuronal cells, 3: Rotenone treated U-87MG glial cells and 4: AAPH treated U-87MG glial cells. 
Metacore was also used to identify upstream transcription factors summarised in table 1 and NRF2, an 
identified transcription factor is circled in the pathways diagram. qRT-PCR was used to determine (B) NRF2 
and (C) KEAP1 gene expression in differentiated SH-SY5Y neuronal and U-87MG glial cells following 48-hour 
exposure to 1 mM AAPH or 0.5 μM rotenone, where results are expressed relative to control. Statistical 
analysis was performed using an unpaired t-test where n=3 for all experiments. Statistical significance was 
recorded as *p<0.05, **p<0.01 and ***p<0.001.   
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4.2.6 The effect of NRF2 knockdown of neural cells  
In order to investigate NRF2’s potential role in neural cells in response to RS we knocked down NRF2 
expression with siRNA in SH-SY5Y and U-87MG neural cells, prior to treatment with AAPH and 
rotenone.  
Initially, the optimum concentration of lipofectamine for each cell line was determined using 
green fluorescent protein expression, where transfection was monitored and quantified using the 
incucyte S3 live-cell analysis system. Phase contrast and fluorescent microscopy at 48 hours showed 
green fluorescent protein in both 1.5 and 3% (v/v) lipofectamine transfected SH-SY5Y and U-87MG 
cells (figure 4.41A and D, respectively). SH-SY5Y cells showed greater green fluorescence protein 
expression with 3% (v/v) lipofectamine (figure 4.41A), whereas U-87MG glial cells showed greater 
green fluorescence for 1.5% (v/v) lipofectamine (figure 4.41D). This was supported by live-cell analysis, 
which showed fluorescence increased over the first 48 hours for SH-SY5Y cells with 3% (v/v) 
lipofectamine (figure 4.41C), while more green fluorescence was observed with 1.5% lipofectamine 
for U-87MG cells (figure 4.41F). To ensure lipofectamine was not toxic to cells we also investigated 
viability by quantifying phase confluence images and found that 1.5 and 3% (v/v) lipofectamine 
exhibited similar growth to control SH-SY5Y and U-87MG cells (figure 4.41B and E, respectively). 
Therefore, these results suggest the optimum lipofectamine concentration is 3% (v/v) for SH-SY5Y 
neuronal cells, whereas 1.5% (v/v) was optimal for U-87MG glial cells.  
With optimum lipofectamine concentrations determined, we transfected both neural cells 
with NRF2 siRNA for up to 72 hours to determine the optimum transfection time to knockdown NRF2. 
Western blots of NRF2 levels showed the greatest knockdown of NRF2 at 72 hours for SH-SY5Y 
neuronal cells (figure 4.42E) while U-87MG glial cells showed the greatest knockdown at 24 hours 
(figure 4.42F). In addition, cell proliferation was monitored over 72 hours to determine if cell viability 
was affected by NRF2 knockdown. Live-cell analysis using the incucyte S3 live cell analysis showed no 
significant difference between control and NRF2 knockdown for both SH-SY5Y neuronal (figure 4.42C) 
and U-87MG glial cells (figure 4.42D), which was supported by phase contrast microscopy images 
(figure 4.42A and B). Together, these results suggest 72 hours was optimal for NRF2 knockdown in SH-
SY5Y neuronal cells whereas 24 hours was suitable for U-87MG glial NRF2 knockdown.  
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Figure 4.41 Optimising 
lipofectamine transfection in 
neural cells with green fluorescent 
protein.  48-hour images of 
Neuronal (A) and glial (D) cells were 
incubated with 1.5% or 3% (v/v) 
lipofectamine with or without 0.5 
μg green fluorescent protein. 
Transfection was monitored over 
time and images were taken using 
the incucyte S3 live-cell analysis 
system. Scale bar = 200 μm. 
Normalised phase confluence of 
neurons (B) and glia (E) was 
quantified over time. Transfection 
of neurons (C) and glia (F) was 
monitored by measuring green 
fluorescence intensity/cell area ± 
SEM.  
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Figure 4.42 NRF2 knockdown 
in neural cells. Neural cells 
were transfected with NRF2 
siRNA for up to 72 hours, 
viability and successful 
knockdown was investigated. 
Phase contrast microscopy of 
(A) SH-SY5Y and (B) U-87MG 
cells with and without NRF2 
siRNA. Scale Bar = 200 μm. 
Images were taken 2 hours 
using the incucyte S3 live-cell 
analysis system, which was 
then used to quantify phase 
confluence of (C) SH-SY5Y and 
(D) U-87MG with and without 
NRF2 siRNA ± SEM. Total cell 
lysates were collected at 24, 
48 and 72h, and SDS-PAGE 
and Western blot was run to 
determine the optimum time 
for NRF2 knockdown in (E) 
SH-SY5Y neuronal and (F) U-
87MG glial cells. Each 
Western blot is accompanied 
by a plot summarising 
densitometric analyses of 
Western blots using AIDA 
software. 
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To investigate the potential role of NRF2 in response to RS both SH-SY5Y and U-87MG neural 
cells were transfected with scramble, GAPDH or NRF2 siRNA prior to treatment with AAPH or 
rotenone. Following 48-hour AAPH and rotenone treatment, neural viability was assessed via 
morphological changes, viability and functional activity assays.  
Phase contrast microscopy of SH-SY5Y neuronal cells showed greater intercellular distance, 
cellular shrinkage and rounding for 1 mM AAPH treated NRF2 knockdown cells relative to scramble 
and GAPDH transfected cells (figure 4.43A). Whereas rotenone (0.5 M) treated NRF2 knockdown SH-
SY5Y cells showed little morphological differences from scramble and GAPDH transfected cells (figure 
4.43A). Viability assessment showed NRF2 knockdown of SH-SY5Y cells treated with 1 mM AAPH had 
significantly lower viability (MTT reduction), relative to scramble and GAPDH transfected cells (figure 
4.44A). In contrast, NRF2 knockdown did not significantly affect rotenone treated SH-SY5Y cells as 
viability (MTT reduction) was not significantly different from scramble, but was significantly greater 
than GAPDH transfected SH-SY5Y neuronal cells (figure 4.44A). LDH assays supported the SH-SY5Y 
AAPH findings where NRF2 knockdown showed significantly greater LDH release than scramble and 
GAPDH transfected cells (figure 4.44C). Phase confluence quantification with the incucyte S3 live-cell 
analysis system also confirmed MTT results, as NRF2 knockdown resulted in a significant decrease in 
phase confluence relative to scramble when treated with 1 mM AAPH, while rotenone treatment of 
NRF2 knockdown cells showed significantly greater phase confluence than GAPDH siRNA transfected 
cells (figure 4.44E). Together, these results suggest NRF2 knockdown increased SH-SY5Y susceptibility 
to AAPH but not rotenone induced cell death.  
Interestingly, NRF2 knockdown in U-87MG glial cells resulted in attenuation of 1 mM AAPH 
induced proliferation, as phase contrast microscopy showed greater intercellular distances for NRF2 
knockdown relative to scramble siRNA transfected cells (figure 4.43B), which was further supported 
by MTT assays showing a significant decrease in MTT reduction for NRF2 knockdown relative to 
scramble cells (figure 4.44B). LDH assays supported these findings as scramble transfected U-87MG 
cells showed significantly less LDH release than NRF2 knockdown glia, whereas GAPDH transfected 
glia showed significantly greater LDH release (figure 4.44D). Furthermore, glial NRF2 knockdown 
resulted in greater susceptibility to rotenone induced death as MTT reduction levels were significantly 
lower compared to scramble and GADPH transfected glia (figure 4.44B). Phase contrast images 
showed NRF2 knockdown glia exhibited greater cellular rounding and intercellular distance when 
treated with rotenone relative to scramble controls (figure 4.43B). LDH assays reinforced these 
findings as NRF2 knockdown in glia showed greater LDH release for 48-hour exposure to 1 mM AAPH 
or 0.5 μM rotenone relative to scramble controls (figure 4.44D). Quantification of images also 
suggested NRF2 knockdown in glia resulted in lower phase confluence relative to scramble when 
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treated for 48 hours with AAPH or rotenone (figure 4.44F). Together, these results suggest NRF2 
knockdown in U-87MG glial cells attenuated AAPH induced proliferation and increased susceptibility 
to rotenone-induced death, suggesting NRF2 is an important response factor to RS in glia.  
Figure 4.43 NRF2 
knockdown effects 
neural morphology 
following treatment 
with AAPH or 
rotenone. SH-SY5Y 
neuronal (A) and U-
87MG glial (B) cells 
were incubated with 
lipofectamine with 
NRF2, scramble or 
GAPDH siRNA for the 3 
days or 1 day, 
respectively. Following 
NRF2 knockdown cells 
were treated with 1 
mM AAPH or 0.5 μM 
rotenone for 48 hours. 
48-hour images were 
taken using the 
incucyte S3 live-cell 
analysis system. Scale 
bar = 200 μm.  
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Figure 4.44 NRF2 knockdown exacerbates decreased neural cell viability in response to reactive species. SH-
SY5Y neuronal and U-87MG glial cells were incubated with lipofectamine with NRF2, scramble or GAPDH siRNA 
for the 3 days or 1 day, respectively. Following NRF2 knockdown cells were treated with 1 mM AAPH or 0.5 μM 
rotenone for 48 hours. MTT reduction assay of (A) SH-SY5Y and (B) U-87MG cells treated with AAPH and rotenone 
for 48 hours following transfection. LDH release of (C) SH-SY5Y and (D) U-87MG treated with AAPH or rotenone 
for 48 hours following transfection. Endpoint images of neurons (E) and glia (F) were quantified using the incucyte 
S3 live-cell analysis system where results were normalised prior to addition of treatments ± SEM. MTT and LDH 
viability assays are presented as mean % against control ± SEM. Statistical analysis was performed using one-
way ANOVA with Dunnett’s post-hoc test where n=3 for all experiments. Statistical significance was recorded as 
*p<0.05, **p<0.01 and ***p<0.001. 
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4.2.7 Post-translational modifications induced by reactive species in 
differentiated neural cells 
As previous studies with antioxidants and gene expression suggested differences in AAPH and 
rotenone mediated RS, we investigated downstream post-translational modifications in neural cells 
to define variation in OS. As AAPH is known to mainly generate peroxyl radicals, lipid peroxidation was 
investigated using a Click-iT lipid peroxidation kit. Click-iT allows detection of lipid peroxidation by 
cellular incorporation of linoleamide alkyne into membranes, which decompose to reactive aldehydes 
that can modify proteins. Alkyne modified proteins can subsequently be detected. Furthermore, as 
lipid peroxides are unstable compounds that can decompose to reactive carbonyl molecules such as 
malondialdehyde (MDA), we measured MDA levels using a colourimetric assay.   
 SH-SY5Y cells were differentiated over 5 days prior to 48-hour treatment with 1 mM AAPH or 
0.5 μM rotenone to induce OS. Fluorescence quantification showed both AAPH and rotenone induced 
lipid peroxidation (figure 4.45A), where AAPH had a more significant effect on lipid peroxidation 
(figure 4.45B). Concurrent treatment with α-tocopherol or ascorbic acid attenuated fluorescence 
suggesting OS generated by these stressors resulted in lipid peroxidation. Preliminary investigations 
suggest AAPH significantly affected differentiated SH-SY5Y MDA levels, but rotenone did not, which 
was attenuated by both antioxidants (figure 4.45C).  
 U-87MG glial cells also showed significantly greater fluorescence levels when exposed to 
AAPH or rotenone for 48-hours following 5-day differentiation (figure 4.46A). Fluorescence 
quantification showed AAPH significantly increased lipid peroxidation more than rotenone, and this 
was attenuated by both α-tocopherol or ascorbic acid (Figure 4.46B). However, preliminary MDA 
quantification showed neither AAPH nor rotenone significantly affected MDA levels.   
Therefore, these results show Click-iT immunofluorescence studies suggest AAPH significantly 
increased lipid peroxidation more than rotenone for both differentiated SH-SY5Y neuronal and U-
87MG glial cells. This suggests AAPH generated RS that cause greater levels of lipid peroxidation than 
rotenone. Whereas MDA level quantification was controversial to these findings possibly due to 
limited replicates and kit sensitivity.   
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Figure 4.45 AAPH and 
rotenone increases lipid 
peroxidation in SH-SY5Y 
neuronal cells. (A) Lipid 
peroxidation fluorescent levels 
(green) for neuronal cells 
treated with AAPH and 
rotenone, with and without 
200 μM α-tocopherol or 1 mM 
ascorbic acid using Click-IT 
assay kit. Images taken using 
incucyte S3 live-cell analysis 
system. Scale bar = 200 μm. (B) 
Endpoint measurement of 
fluorescence was quantified 
using the incucyte S3 live-cell 
analysis system (Fluorescent 
intensity/cell area ± SEM). (C) 
Malondialdehyde levels (MDA), 
a by-product of lipid 
peroxidation were measured 
using a thiobarbituric acid 
reactive substances (TBARS) 
assay kit. Statistical analysis 
was performed using two-way 
ANOVA with Dunnett’s post-
hoc test relative to the control 
of each condition where n=3 
for Click-iT but n=2 for TBARS 
experiments. Statistical 
significance was recorded as 
*p<0.05, **p<0.01, 
***p<0.001 and 
****p<0.0001. 
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Figure 4.46 AAPH and rotenone 
increases lipid peroxidation in 
U-87MG glial cells. (A) Lipid 
peroxidation fluorescent levels 
(green) for glial cells treated with 
AAPH and rotenone with and 
without 200 μM α-tocopherol or 
1 mM ascorbic acid using Click-IT 
assay kit. Images taken using 
incucyte S3 live-cell analysis 
system. Scale bar = 200 μm. (B) 
Endpoint measurement of 
fluorescence was quantified 
using the incucyte S3 live-cell 
analysis system (Fluorescent 
intensity/cell area ± SEM). (C) 
Malondialdehyde levels (MDA), a 
by-product of lipid peroxidation 
were measured using a 
thiobarbituric acid reactive 
substances (TBARS) assay kit. 
Statistical analysis was 
performed using two-way 
ANOVA with Dunnett’s post-hoc 
test relative to the control of 
each condition where n=3 for 
Click-iT but n=2 for TBARS 
experiments. Statistical 
significance was recorded as 
*p<0.05, **p<0.01 and 
***p<0.001.  
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Nitrosylation and carbonylation are other common markers of OS, which are propagated by 
different RS. Therefore, the biotin switch method of Jaffrey et al. was used to visualise S-nitrosylated 
proteins by fluorescent microscopy (Jaffrey et al., 2001). This method initially blocks free SH groups, 
then any S-NO bonds present are cleaved and substituted for a biotin group. The previously 
nitrosylated groups are then detected by tagging the biotin using and anti-biotin antibody that is 
fluorescently labelled for visualisation. Carbonylation levels were quantified by a colourimetric assay.  
Differentiated SH-SY5Y neuronal cells showed higher levels of fluorescence when treated with 
AAPH or rotenone for 48-hours (figure 4.47A), suggesting greater levels of nitrosylation. This 
fluorescence was attenuated when SH-SY5Y neuronal cells were concurrently treated with 
antioxidants α-tocopherol or ascorbic acid (figure 4.47B). In addition, differentiated SH-SY5Y carbonyl 
content was significantly greater for 48-hour exposure to AAPH or rotenone (figure 4.47C). Carbonyl 
levels were attenuated by α-tocopherol, but ascorbic acid was only successful in attenuating rotenone 
induced carbonylation.  
U-87MG glial cells showed 48-hour AAPH or rotenone exposure significantly increased 
fluorescence levels (figure 4.48A), suggesting increased nitrosylation that was attenuated by both 
antioxidants α-tocopherol and ascorbic acid (figure 4.49B). Whilst rotenone significantly increased 
carbonyl levels in U-87MG cells, AAPH showed no significant change (figure 4.48C). Both antioxidants 
successfully attenuated rotenone induced carbonyl levels.   
Together, these results suggest AAPH and rotenone result in different PTM’s dependent on 
the neural cell type. For example, rotenone resulted in more significant changes in nitrosylation levels 
in neuronal cells relative to glial cells. Whereas while AAPH and rotenone increase carbonyl levels in 
neuronal cells AAPH did not affect glial carbonyl levels. This highlights how specific RS affect 
downstream processes in cells and due to different cell characteristics responses between cells vary.   
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Figure 4.47 AAPH and rotenone 
increases post-translational 
modifications in neuronal cells.  
(A) Nitrosylation fluorescent 
levels (green) for neuronal cells 
treated with AAPH and rotenone, 
with and without 200 μM α-
tocopherol or 1 mM ascorbic 
acid using S-nitrosylation protein 
detection kit. Images taken using 
incucyte S3 live-cell analysis 
system. Scale bar = 200 μm. (B) 
Endpoint measurement of 
fluorescence was quantified 
using the incucyte S3 live-cell 
analysis system (Fluorescent 
intensity/cell area ± SEM). (C) 
Carbonylation levels were 
measured using a protein 
carbonyl colourimetric kit. 
Statistical analysis was 
performed using two-way 
ANOVA with Dunnett’s post-hoc 
test relative to the control of 
each condition where n=3 for 
nitrosylation but n=2 for 
carbonylation experiments. 
Statistical significance was 
recorded as *p<0.05 and 
**p<0.01. 
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Figure 4.48 AAPH and rotenone 
increases post-translational 
modifications in glial cells.  (A) 
Nitrosylation fluorescent levels 
(green) for glial cells treated with 
AAPH and rotenone with and 
without 200 μM α-tocopherol or 
1 mM ascorbic acid using S-
nitrosylation protein detection 
kit. Images taken using incucyte 
S3 live-cell analysis system. Scale 
bar = 200 μm. (B) Endpoint 
measurement of fluorescence 
was quantified using the 
incucyte S3 live-cell analysis 
system (Fluorescent intensity/ 
cell area ± SEM). (C) 
Carbonylation levels were 
measured using a protein 
carbonyl colourimetric kit. 
Statistical analysis was 
performed using two-way 
ANOVA with Dunnett’s post-hoc 
test relative to the control of 
each condition when n=3 for 
nitrosylation but n=2 for 
carbonylation experiments. 
Statistical significance was 
recorded as *p<0.05 and 
**p<0.01. 
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4.3 DISCUSSION  
To assess the response of neural cells in more in vivo like conditions we initially investigation 
differentiation methods. Morphological features of SH-SY5Y and U-87MG neural cell lines were 
assessed following reduced FBS and RA differentiation. Phase contrast images of FBS/RA 
differentiated SH-SY5Y cells showed neuronal soma were elongated, while neurite outgrowth 
increased creating an interconnected network consistent previous studies (Mario Encinas et al., 
2002; Xicoy et al., 2017). However, our findings contravene some features described by Encinas et 
al., as like Teppola et al. we found RA alone showed limited attenuation of SH-SY5Y cell proliferation 
(figure 4.2; Teppola et al., 2016). This is possibly due to the different cell types in the SH-SY5Y 
neuroblastoma cell line, which includes both S- and N-type cells (Xicoy et al., 2017). While N-type 
cells undergo morphological changes when differentiated with RA S-type cells remain unaffected 
and continue to proliferate (Mario Encinas et al., 2002). Encinas et al. also report how longer culture 
periods in the presence of BDNF enhance the N-type population. This is supported by findings 
herein that show upon RA removal and addition of BDNF cell proliferation was reduced (figure 4.5). 
RA initially induced NTrkB enabling N-type cells to become receptive to BDNF, which arrested them 
into G1 phase so they no longer proliferated (Mario Encinas et al., 2002). In addition to the arrest 
of cell proliferation, BDNF further improved neurite outgrowth like others who also demonstrated 
an improved neuronal phenotype and morphology (Constantinescu et al., 2007; de Medeiros et al., 
2019; Mario Encinas et al., 2002).    
 While RA and subsequent BDNF is a universally accepted protocol for neuronal 
differentiation it is commonly known that astrocytes can aid neuronal survival, proliferation and 
differentiation (Kıray et al., 2016; Lin et al., 2016; Luo et al., 2017). In this study, we found U-87MG 
conditioned media improved neuronal survival and supported neurite outgrowth (figure 4.5). These 
results support others findings, where conditioned media from different glial cell lines enhanced 
neuronal survival and differntiation (Engele et al., 1991; Lo Furno et al., 2018). This may be due to 
U-87MG glial cells secreting neurotrophic factors such as BDNF (Fornaro et al., 2020; Liu et al., 
2012), as upon addition of BDNF to SH-SY5Y cells with and without U-87MG conditioned media 
similar levels of proliferation and neurite outgrowth were observed. However, further work is 
needed to determine the factors secreted by U-87MG cells and how these influence SH-SY5Y 
neuronal differentiation.    
 While FBS/RA differentiation enhanced SH-SY5Y neuronal morphology and altered U-87MG 
proliferation, we also found that markers of differentiation were expressed. Differentiated SH-SY5Y 
neuronal cells expressed βIII tubulin, which is almost exclusively expressed by neurons and is 
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commonly used as a marker for differentiation (Katsetos et al., 2003). Synaptophysin expression 
was also evident suggesting mature neurite development (Cheung et al., 2009; Kumar et al., 2018). 
While differentiated U-87MG glial cells expressed GFAP and S100, common astrocytic markers (Das 
et al., 2009; Grundmann et al., 2019; Karmakar et al., 2008). Therefore, FBS/RA enhanced SH-SY5Y 
and U-87MG differentiation and thus, was used for subsequent experiments while select 
investigations were conducted with BDNF and U-87MG conditioned media due to cost and difficulty 
in obtaining large quantities of conditioned media.  
In addition to morphological changes, we also investigated changes to bioenergetics as 
these would play a role in the response to OS. Herein, we found that RA induced differentiation 
altered the source of ATP in both SH-SY5Y neuronal and U-87MG glial cells. Differentiation of these 
neural cells resulted in ATP production shifting from glycolysis to OXPHOS, highlighting how 
undifferentiated cells rely more on glycolysis for cell division supporting the Warburg hypothesis 
(Kaczanowski et al., 2018; Warburg, 1956, 2010). From qRT-PCR studies, no increase in total 
mitochondrial number was seen between mitotic and differentiated cells (figure 4.7). This suggests 
the increase in ATP production from OXPHOS is not due to a greater quantity of mitochondria but 
due to a change in activity, consistent with other studies as Schneider et al. report RA induced 
differentiation altered SH-SY5Y mitochondrial function (Schneider et al., 2011). Additionally, 
mitochondrial membrane potential, cytochrome C oxidase and mitochondrial reserve capacity 
increased as a result of differentiation (Schneider et al., 2011; Xun et al., 2012). Primary neurons 
also demonstrate higher mitochondrial reserve capacity than mitotic neurons (Gerencser et al., 
2009). This change may be as a result of differentiated cells no longer proliferating, and as such are 
more vulnerable to mitochondrial dysfunction as cells cannot divide, remove or dissipate damaged 
components. This would be especially detrimental for neurons as they possess lower levels of 
antioxidants than other neural cells such as glia. As a result, mitochondria may change their capacity 
upon differentiation to ensure they are not as susceptible to damage and therefore reduce cell 
vulnerability.  
These changes in mitochondria may explain the susceptibility of differentiated SH-SY5Y 
neuronal cells to AAPH and rotenone. In this study, differentiated SH-SY5Y cells showed a dose-
dependent decrease in cell viability when exposed to AAPH or rotenone, but AAPH had a more 
significant effect. In contrast, differentiated cells appeared to have a greater resistance to rotenone 
than their mitotic counterparts (figure 3.22-3.23 and 3.26-3.27). This is possibly due to 
differentiation increasing OXPHOS capacity and as a result differentiated SH-SY5Y cells have greater 
resistance to rotenone induced RS (Schneider et al., 2011; Xun et al., 2012). However, 
differentiation appeared to increase susceptibility to AAPH, possibly due to previous Seahorse 
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investigations suggesting AAPH resulted in greater glycolysis (figure 3.29) and thus, because 
differentiated cells rely more on OXPHOS for ATP, they fail to cope with the changes induced by 
AAPH. This is supported by Dodson et al. who show that inhibition of glycolysis increases apoptosis 
induced by 4-hydroxynonenal, a well-known lipid peroxidation product produced during OS 
(Dodson et al., 2013). Interestingly, differentiated U-87MG glial cells treated with 1 mM AAPH 
exhibited proliferation whilst 5 mM resulted in decreased cell viability contrary to previous mitotic 
findings. This suggests certain levels of AAPH are beneficial for astrocytes, possibly causing an acute 
anti-inflammatory response while high levels of RS result in cell death similar to chronic 
inflammation (Amor et al., 2014; Koudriavtseva and Mainero, 2016).  
Further differentiation with BDNF appeared to have to opposite effect, where 
differentiated SH-SY5Y cells were more susceptible to rotenone but less to AAPH. This raises 
questions as to what changes differentiation induces. This is also highlighted when concurrent 
differentiation with U-87MG conditioned media improved resistance to these OS inducers. This 
suggests different differentiation methods may result in different biochemical changes and 
susceptibilities to specific RS. This may explain the controversies in the literature as to whether 
differentiation results in SH-SY5Y cells becoming more or less susceptible to different RS inducing 
toxins. More investigations into what changes each differentiation protocol generates are needed 
to understand why the observed changes are seen. Furthermore, these models need to be 
compared to more in vivo like conditions to generate a better in vitro model for high-throughput 
experiments with lower costs.  
 To compare clonal cell responses with primary cell responses, rat embryonic primary 
cortical neurons were exposed to AAPH and rotenone. One of the major neuronal morphological 
features of differentiation is the formation of axons. Axonal pathology has been implicated to 
precede cell body loss in neurodegenerative diseases such as Parkinson’s, Alzheimer’s and 
Huntington’s disease (Coleman, 2013; De Vos et al., 2008; Tagliaferro and Burke, 2016). Multiple 
methods of axonal degeneration have been described (Salvadores et al., 2017; Wang et al., 2012). 
Herein, we observed a greater sensitivity with primary neurons to AAPH and rotenone alongside a 
decrease in neurite length for both stressors (Nesti et al., 2011; Virga et al., 2018). In addition, we 
observed two distinct methods of axonal degeneration induced by different RS inducers: 
fragmentation and retraction.  
AAPH, a peroxyl radical generator resulted in fragmentation where processes appear to 
collapse compacting around areas of cytoplasm, which results in axons exhibiting a ‘beads on a 
string appearance’ (figure 4.19-4.20). This process was rapid, where fragmentation occurred within 
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4-6 hours of treatment progressing towards the cell soma in a retrograde manner. Whereas 
rotenone treatment appeared to result in process retraction, highlighted by Sholl analysis that 
occurred over a longer time period. Furthermore, fragmentation was quickly followed by cell death, 
whereas higher viability was observed with cells that exhibited retraction. These different 
timeframes and associated cell death with these unique degeneration methods suggests different 
molecular mechanisms underlie these changes.  
 The observed fragmentation with AAPH is similar to local axon and Wallerian degeneration, 
which is characterised by restricted granular disintegration of axons. Wallerian degeneration 
usually follows transection of axons resulting in axon fragmentation distal to the injury site 
(Coleman and Höke, 2020; Thomas, 1964). Similar fragmentation has been observed in both 
Parkinson’s and Huntington’s disease (Adalbert and Coleman, 2013). As our model did not involve 
axonal transection it is more likely these observations are due to local axon degeneration. Axons 
initially swelled before fragmenting, which has been observed in mammals where axons degrade 
in a synchronous manner in vivo, followed by glial cells removing this debris (Kneynsberg et al., 
2016; Saxena and Caroni, 2007). This method of degeneration is thought to help remove longer 
axons while retraction is preferential for shorter axons as this is a more efficient use of energy 
(Blanquie and Bradke, 2018; Portera-Cailliau et al., 2005).  
It is suggested that in order to survive neurons attempt to conserve energy and thus retract 
excessive or injured neurites (Blanquie and Bradke, 2018; Raff, 2002). This is consistent with 
previous studies alongside ours that show rotenone results in decreased ATP levels, and as a result 
neurons may retract neurites to conserve energy (Berbusse et al., 2016; Denton et al., 2018; 
Persson et al., 2013; Press and Milbrandt, 2008). However, others contravene this as treatment 
with Nicotinamide nucleotide adenylyltransferase 1 (Nmnat1) prevents neurite retraction and 
changes in ATP levels (Virga et al., 2018). Alternatively, RS produced by rotenone may play a role in 
neurite length as nitric oxide has been implicated in axonal retraction (He et al., 2002; Stroissnigg 
et al., 2007) and Nmnat1 is suggested to decrease OS induced by rotenone (Press and Milbrandt, 
2008), which is also supported by antioxidants attenuating motor nerve degeneration (Hall, 1987). 
Furthermore, retraction may also allow recovery of subcellular components of neurites to aid cell 
survival. This is supported by Öztürk et al. who demonstrate retracted neurites allowed 
regeneration of other neurites (Öztürk et al., 2013).   
Synaptophysin, a marker of presynaptic membrane protein is associated with recycling 
vesicles essential for neurotransmission and co-localises with axon terminals (Daly et al., 2000; 
Nithianantharajah, 2004; Riemann et al., 2018). In neurodegenerative conditions such as AD and 
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PD loss of synapses is observed (Henstridge et al., 2019; Schulz-Schaeffer, 2010). AAPH resulted in 
decreased synaptophysin expression whilst rotenone increased expression. The increased 
synaptophysin puncta along processes and in the cell soma of rotenone treated neurons may 
possibly be due to retraction. Retraction possibly results in vesicles transporting the cellular 
contents of the neurites back to the soma to be used elsewhere, as others have demonstrated 
transport between sister branches  potentially aiding neurite regrowth (Nakata et al., 1998). This is 
supported by others who have observed increased localisation of synaptophysin within the cell 
soma following rotenone treatment, suggesting vesicle accumulation (Jiang et al., 2006; Ren and 
Feng, 2007).  Furthermore, due to retraction axon terminals are closer together and thus, appear 
to be more abundant in neuronal processes as rotenone concentration increases. Together these 
results suggest AAPH and rotenone result in different axonal morphological changes. To determine 
if these effects are due to RS different concentrations of antioxidants in primary neurons need to 
be investigated to see if these changes can be attenuated.  
Unfortunately, our differentiation models for SH-SY5Y cells with BDNF, or in combination 
with U-87MG conditioned media did not display significant neurite branching. Whilst it showed a 
decrease in neurite length, it did not display the morphological changes that were observed with 
primary neurons. This is possibly due to the models not developing fully formed axons and 
therefore shows the limitations of the differentiated models.  
Neuroinflammation is another key feature of neurodegeneration that can effect neuronal 
viability (Segura-Aguilar et al., 2014). The results herein propose specific RS play a role in astrogliosis 
as AAPH increased process length while rotenone induced RS did not, both of which were 
attenuated by the antioxidant α-tocopherol. Others propose RS play a role in astrogliosis a common 
feature of neuroinflammation (Ferrer, 2017; Hirsch and Hunot, 2009; Teismann and Schulz, 2004). 
Together, these results suggest RS effect morphological feature of both neurons and astrocytes, 
where specific RS elicit different responses.  
With morphological and viability changes induced by AAPH and rotenone it was not 
surprising to see changes in the OS gene profile. As expected, basal profiles of differentiated SH-
SY5Y neuronal and U-87MG glial cells showed differences. Controversial to the literature we found 
that glutathione gene expression was lower in U-87MG relative to SH-SY5Y neuronal cells (Dringen 
and Hamprecht, 1997). However, while this study (figure 3.7) and many others suggest astrocytes 
possess greater levels of glutathione than neurons, none have investigated the effect of RA 
differentiation on U-87MG. There is increasing evidence that redox homeostasis and thus levels of 
antioxidants such as glutathione are important during this processes (Esposito et al., 2004; Paul D. 
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Ray et al., 2012; Sciarretta et al., 2019). In other cell lines such as HL-60 glutathione levels vary 
during differentiation where inhibition of glutathione increased differentiation (Krance et al., 2010). 
Furthermore, Xia et al. show RA differentiation in human carcinoma cells resulted in decreased 
glutathione S-transferase (Xia et al., 1993), which was also lower in our differentiated U-87MG glial 
cells relative to SH-SY5Y neuronal cells. Therefore, the lower glutathione gene expression in 
differentiated U-87MG glial cells may be due to RA induced differentiation. 
Upon further examination some of the genes downregulated in differentiated U-87MG glial 
cells relative to differentiated SH-SY5Y neuronal cells appear to be localised to the mitochondria 
such as PRDX3 (De Armas et al., 2019; Drechsel and Patel, 2010), BNIP3 (Bellot et al., 2009; Glick et 
al., 2012), GPX3 (Kritsiligkou et al., 2017) and GSTP1 (Goto et al., 2009). Although some 
mitochondrial genes are upregulated relative to SH-SY5Y neuronal cells such as SOD2 (Gomez and 
Germain, 2019; Zelko et al., 2002) and GSTZ1 (Li et al., 2011), the majority are cytosolic. The lower 
expression of mitochondrial localised genes in U-87MG glial cells relative to SH-SY5Y neuronal cells 
may be due to glia having lower levels of mitochondria than neurons, which we have shown with 
qRT-PCR and others support, reporting a greater rate of glycolysis in astrocytes (Hertz et al., 2007). 
Whereas neurons rely almost exclusively on OXPHOS for their energy (Franco-Iborra et al., 2016). 
Therefore, as neurons have more mitochondria and rely on them more to meet their energy 
demand, they may have higher antioxidant gene expression to counteract susceptibility to RS that 
would diminish cellular function. In contrast, as glia rely more on glycolysis for their energy they 
prioritise antioxidants in the cytosol where glycolysis could be affected by RS.    
RS generated by AAPH in differentiated SH-SY5Y neuronal cells resulted in upregulation of 
a variety of genes including those involved in glutathione synthesis, superoxide dismutation, and 
reducing oxidised enzymes (Dasuri et al., 2013; Gandhi and Abramov, 2012; Poole et al., 2011b; 
Turner-Ivey et al., 2013). Therefore, AAPH treated neurons exhibited upregulation of some 
antioxidant response genes to detoxify RS by increasing the amount of relative antioxidant enzymes 
(Korovila et al., 2017; Kwak et al., 2003). In contrast, many OS related genes were downregulated 
in rotenone treated neurons. This difference in response induced by these stressors may be due to 
the treatment timeframe, as viability assays showed at 48-hours rotenone treated SH-SY5Y cell 
death had plateaued while AAPH treated cell viability was still declining (figure 4.9). As rotenone 
viability had plateaued antioxidant systems may have already been switched off whereas AAPH 
treated cells are still dying and as a result, the OS response is still actively combatting this.  
Whereas AAPH and rotenone treatment resulted in similar gene expression profiles in 
differentiated U-87MG glial cells. Antioxidant genes such as glutathione related genes (Dringen et 
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al., 2000), GPX’s (Dasuri et al., 2013; Gandhi and Abramov, 2012), and PRDX’s (Fisher, 2011) were 
upregulated to combat RS. Interestingly different isoforms of SOD appeared to be affected by AAPH 
or rotenone treatment as SOD1 was upregulated for both treatments, but SOD2 was only 
upregulated by rotenone. This is possibly due to difference in localisation of  SOD1 (cytosolic) and 
SOD2 (mitochondrial; Dasuri et al., 2013,(Y. Wang et al., 2018). As rotenone inhibits mitochondria 
and thus generates RS in its vicinity it is possible glia upregulate the mitochondrial isoform to 
combat superoxide generated (L. Wang et al., 2015). In contrast, AAPH degrades in the cytosol and 
therefore the cytosolic isoform of SOD would be a more appropriate antioxidant (Bassett et al., 
1999; Sanz, 2016; Werber et al., 2011). These investigations highlight the possibility of RS 
localisation affecting the antioxidant response.  
Several neurodegenerative diseases are characterised by increased OS and activation of 
antioxidant related genes. This OS is observed in various neural cultures exposed to different toxins 
including rotenone (Fitzgerald et al., 2014; Sherer et al., 2003) and less so AAPH (Niki, 1990; Werber 
et al., 2011). To restore redox homeostasis neural cultures upregulate pathways involved in 
cytoprotective, antioxidant and anti-inflammation via signalling pathways such as NRF2-ARE 
(Schmidlin et al., 2019; Shih et al., 2005; Tufekci et al., 2011). Upon OS the NRF2-KEAP1 interaction 
is interrupted alleviating degradation and facilitating nuclear translocation (Dhakshinamoorthy and 
Jaiswal, 2001; Itoh et al., 1999; Suzuki and Yamamoto, 2015). In the nucleus, NRF2 binds the ARE 
upregulating antioxidant gene expression (Korovila et al., 2017; Kwak et al., 2003).  
Here we show for the first time that AAPH like rotenone results in activation of the NRF2 
pathway in both neurons and astrocytes, as shown by the change in viability upon NRF2 knockdown. 
Additionally, our results suggest rotenone also effects KEAP1 gene expression in glia possibly 
enhancing activation of the NRF2 pathway as Zagoura et al. have also recently reported (Zagoura 
et al., 2017). This is further supported by RT2 profiler array results that showed AAPH resulted in a 
variety of genes downstream of NRF2 (Korovila et al., 2017) being upregulated upon treatment in 
both differentiated SH-SY5Y neuronal and U-87MG glial cells. Presumably, AAPH generates RS, 
which results in NRF2 activation followed by upregulation of antioxidant genes to protect cells 
against possible oxidative damage to DNA, lipids and proteins. While activation and upregulation 
of other genes such as TXN (Poole et al., 2011b; Turner-Ivey et al., 2013) and sulfiredoxin (Biteau et 
al., 2003; Jönsson et al., 2008; Rhee et al., 2007) allows these downstream proteins to be reduced 
and thus, recycled continuously to combat OS. Although the list of NRF2 genes appears to vary 
between neural cell types as well as different toxins, NRF2 appears to be critical for cellular defence 
in the brain (Schmidlin et al., 2019).  
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Other than changes to gene expression, AAPH and rotenone also induced changes in PTM’s 
such as lipid peroxidation, carbonylation and S-nitrosylation. We propose herein that AAPH induces 
RS that result in greater lipid peroxidation than rotenone in both SH-SY5Y neuronal and U-87MG 
glial cells. Lipid peroxidation is frequently associated with decreased membrane fluidity and 
increased permeability supported by the greater LDH release exhibited with AAPH than rotenone 
(figure 4.11). Primary neuronal cultures treated with AAPH also demonstrated greater LDH release 
(figure 4.20), supporting AAPH increases membrane permeability more as compared to rotenone. 
In addition to lipid peroxidation, we show AAPH and rotenone also increased nitrosylation and 
carbonylation levels in differentiated SH-SY5Y neuronal cells. Interestingly, while AAPH and 
rotenone increased nitrosylation levels in U-87MG glial cells, only rotenone resulted in 
carbonylation levels increasing. This suggests AAPH and rotenone induce RS that result in different 
PTM’s where carbonylation possibly contributes to rotenone induced glial cell death. However, 
more research is needed to confirm if carbonylation is a detrimental PTM, as the other PTM’s are 
also present in AAPH treated glia that exhibited increased proliferation.  
In conclusion, understanding what changes unique differentiation protocols induce not 
only morphologically but also biochemically is important for understanding changes in RS 
susceptibility. The differentiation models we used herein are limited in terms of neurite branching, 
making comparisons to primary neurons more difficult. While primary neurons are more sensitive 
to RS inducers AAPH and rotenone, they affect neuronal axon morphology differently suggesting 
alternate mechanisms of action. In addition to altering neural viability RS induce antioxidant gene 
expression dependent on both the stressor and neural cell type. Indeed, this is also true for PTM’s 
where each toxin effects PTM levels uniquely, but the responses also depend on the neural cell 
type. Further investigations into the changes in gene expression and PTM’s specific RS induced 
within neural cells is needed to aid in understanding neurodegeneration and develop novel 
therapies.  
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5.1 INTRODUCTION  
5.1.1 In vitro co-culture methods  
Understanding both intracellular and intercellular mechanisms are crucial for understanding the 
formation, maintenance and repair of biological tissues as well as the disease pathogenesis and 
how drugs impact these. Initial studies to investigate these problems involve studying 
monocultures (de Oliveira et al., 2017; Park et al., 2011). Monocultures attempt to simplify and 
understand complex interactions in vitro by reducing cellular interactions while altering the 
environment to predict specific cell type behaviour in vivo. However, they also have their 
disadvantages, including if the observed phenotype has physiological relevance as various cell-cell 
connections are not present (Renaud and Martinoli, 2016). Additionally, because there is only a 
single cell type contributing to the environment intercellular signals are limited affecting some 
cellular functions (Volterra and Meldolesi, 2005). Therefore, to get a more representative model of 
what interactions occur in vitro co-cultures are needed to mimic more complex pathway 
interactions.  
Co-cultures consist of more than one cell type grown with some degree of 
interaction/contact, either physical or via secreted factors. There are two main in vitro methods for 
co-cultures summarised in figure 5.1 including: contact and non-contact co-cultures (Bogdanowicz 
and Lu, 2013).  
The simplest contact co-culture comprises of a monolayer of multiple cell types (figure 
5.1A; Wang et al., 2007; Proffen et al., 2013). These are produced by combining cell suspensions 
after determining a desired ratio prior to seeding (Jiang et al., 2005). This system allows heterotypic 
and homotypic communication that can be altered with the seeding density ratios. However, mixed 
co-cultures result in dilution effects while growth and metabolic rates differ between cell types 
making it difficult to discern the contribution of each cell type (Herrero-Mendez et al., 2009; Lovatt 
et al., 2007; Vilchez et al., 2007). Furthermore, as growth rates of cells differ there is no guarantee 
the starting ratio is maintained. Attempts to understand the contribution of each cell type requires 
separation techniques, which can adversely affect the results.   
Alternatively, physical barriers can be used to regulate cell contact to prevent the need for 
separation. Dividers can be removed at any time allowing migration and controlled cell contact 
(figure 5.1B; Wang et al., 2007). Physical barriers provide the advantage of control over heterotypic 
and homotypic interactions via control of physical contact and soluble factor interactions. However, 
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creating a seal between cellular compartments is challenging and soluble factor interactions 
depend critically on the barrier material (Delsing et al., 2018; Leddy et al., 2004).   
 
While maintaining bidirectional signalling inserts allow individual cell lines to be grown 
separately and then co-cultured later in the same environment (figure 5.1C). The separation of 
specific types of cells allows investigations into the response of each subpopulation. However, 
physical contact between individual cell lines cannot be permanently prevented, and multistage 
seeding can provide its own difficulties. One such difficulty includes preventing cell-cell contact 
while being close enough to allow short- and long-lived factors to reach the other culture. Cell 
membrane inserts have presented a way to provide more reproducible models (Grobstein, 1953). 
Studies into inflammation in the CNS between glia and neurons has greatly benefited from inserts 
allowing bi-directional signalling in the absence of cell-cell contact and studying soluble factors 
(Bournival et al., 2012; Zhu et al., 2014). Furthermore, soluble factors have also been implicated in 
differentiation (Abouelfetouh et al., 2004; Pyka et al., 2011; Yu et al., 2016). Additionally, inserts 
have supported investigations into the protective effects of secreted factors from glia on neurons 
(Du et al., 2018; Roqué et al., 2016; ZHU et al., 2014).   
Figure 5.1 Schematic representation of different methods of co-cultures to investigate cell-cell interactions. 
(A) Simplest co-culture consists of a full contact mixed co-culture. (B) Cell contact, and secreted factor affects 
can be controlled by a temporary barrier. (C) Insert co-culture system where the upper compartment consists 
of one cell type grown on an insert while the lower compartment consists of a well with the second cell type. 
The insert is designed to lie above the lower compartment so there is no cell-cell contact but the porous 
membrane allows bidirectional diffusion of secreted factors. (D) Unidirectional signalling of secreted factors 
can be investigated using conditioned media from one cell type on the other. Adapted from Bogdanowicz and 
Lu, 2013. 
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Inserts can be made of various materials including polyester (PET), polycarbonate or 
collagen coated polytetrafluoroethylene with differing pore sizes. Over the last decade the 
importance of cellular mechanosensitivity has arisen as materials have been found to affect cellular 
functions including differentiation, growth, survival, motility, adhesion and contractility (Spencer et 
al., 2017; Wells, 2008). Cells usually require adhesion for survival through focal adhesion points, 
primarily using integrins that vary from cell-to-cell (Discher, 2005; Moeton et al., 2016). Young’s 
modulus usually measured in pascals (Pa), is a common term used to determine resistance to 
deformation and thus, can be used to describe how hard a material is. Brains exhibit modulus in 
the magnitude of several hundred pascals whereas muscles demonstrate moduli of 12 kPa (Engler 
et al., 2004; Georges et al., 2006; Levental et al., 2007; Wellman et al., 2018). In contrast, plastics 
such as polystyrene and polyethylene terephthalate (PET), commonly used for tissue culture plastic 
and inserts exhibit a Young’s modulus of 3.2 (Sultanova et al., 2009) and 1.7 (Li et al., 2001) GPa, 
respectively demonstrating the non-physiological mechanical environment employed in tissue 
culture.   
The importance of the environment is further highlighted with different cell types within 
tissues showing a morphological dependence on substrate stiffness (Aregueta-Robles et al., 2019; 
Georges et al., 2006; Yeung et al., 2005). Even neuronal cells demonstrate a preference where 
dorsal root ganglion and motor neurons from the spine show increased neurite length and 
branching on soft materials (Balgude et al., 2001; Flanagan et al., 2002; Lantoine et al., 2016). Using 
hydrogels Georges et al. demonstrate astrocytes on soft surfaces show small rounded morphology 
while on harder surfaces they have a reactive morphology with highly extended processes; 
supported by greater F-actin staining and stress fibre expression on harder surfaces, which is absent 
on soft surfaces (Georges et al., 2006). In contrast, neurons showed branching and neurite growth 
on both soft and hard surfaces which was significantly greater on soft hydrogels consistent with 
previous findings that soft substrates enhance neurite branching (Balgude et al., 2001; Flanagan et 
al., 2002). As such, different materials can result in another variable being added to the system 
when using inserts and thus, needs to be considered when culturing different cell types together 
(Li et al., 2017).  
Alternatively, conditioned media can be used to mimic parameters of a co-culture system. 
For example, conditioned media can be used to explore intercellular communication where 
cultured media from one cell type is introduced to the other without the direct culture of both cells 
together, preventing the need for a seal between different cell compartments (figure 5.1D; Saeed 
et al., 2015). This provides a simpler strategy for identifying secreted factors and their effects. 
However, this produces its own challenges including nutrient deficiency and difficulty reproducing 
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optimal concentrations as well as temporal distribution of secreted factors (Lamarche et al., 2004). 
Furthermore, short-lived molecules are degraded over time limiting their identification and 
characterisation of their effects. Finally, only unidirectional signalling can take place as the other 
cell is not present, preventing feedback loops observed in vivo demonstrating the limitations of this 
method.  
5.1.2 Glia in neuroprotection and neurotoxicity 
While neurons have been the focus of neurodegenerative research due to their loss in various 
neurodegenerative diseases, glia are becoming key in solving possible underlying mechanisms. Glia, 
the most abundant cells within the brain can be separated into 3 types; oligodendrocytes, microglia 
and astrocytes, which are the most populous (Herculano-Houzel, 2009; Rasband, 2016; Verkhratsky 
et al., 2012). Microglia and astrocytes seem to play a role in neurodegeneration for example, 
microglia are primarily associated with neuroinflammation (Barcia et al., 2004; Piirainen et al., 
2017). Whereas astrocytes undergo astrogliosis following neuronal death and inflammation 
(Colombo and Farina, 2016; Hirsch and Hunot, 2009; Teismann and Schulz, 2004). Astrocytes have 
also been found to provide neuroprotection, particularly against OS, by producing detoxifying 
enzymes including ascorbic acid, glutathione and its precursors (Allaman et al., 2011; Thorne et al., 
2016; Vargas and Johnson, 2009), in addition to neurotrophic factors such as GNDF and BDNF 
(Skaper and Facci, 2018). 
 To determine the effect of astrocytes on neuron viability, investigations have utilised 
astrocyte rich and poor conditions (Desagher et al., 1996; Gritsenko et al., 2017; Lucius and Sievers, 
1996). Several studies have highlighted the importance of astrocytic glutathione content in 
neuronal protection (Chen et al., 2001; Drukarch et al., 1998; McBean, 2017). The importance of 
astrocytic glutathione is further supported by their incubation with the gamma-glutamylcysteine 
synthetase inhibitor, buthionine sulfoximine. This reduces their ability to  prevent neuronal death 
(Griffith and Meister, 1979). Indeed, astrocytes are reported to have greater levels of glutathione 
than neuronal cells (Makar et al., 2008; McBean, 2017) and thus, thought to be a key enzyme in 
reducing OS in neurons, in particular nitric oxide (Clancy et al., 1994; Hogg et al., 1996; Moriyama 
et al., 2016). Nitric oxide can damage cells by reacting with protein thiol groups and protein iron 
complexes leading to neuronal death and contributing to neurodegeneration (Dawson and Dawson, 
2018; Moncada and Bolanos, 2006; Shukla, 2007). However, high levels of nitric oxide result in 
cellular glutathione being quickly oxidised resulting in cells losing this defence (Clancy et al., 1994; 
Padgett and Whorton, 1998).  
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 In addition, to removing nitric oxide directly astrocytes may aid in reducing OS via oxidised 
vitamin C (also referred to as dehydroascorbic acid), which can be taken up by astrocytes, reduced 
back to ascorbate at the expense of glutathione and ascorbate is then released back into the 
extracellular fluid for neurons to utilise (Moretti et al., 2017; Wilson, 1997). While neurons cannot 
take up glutathione directly, astrocytes can secrete glutathione leading to its subsequent 
breakdown into γ-glutamyl and cysteinyl glycine via γ-glutamyl transferase. This is further broken 
down by ectopeptidases leading to cystine and glycine that can be taken up by neurons providing 
them with precursors for glutathione synthesis (Baxter and Hardingham, 2016; Dringen et al., 1999; 
Kranich et al., 1998). Additionally, glutathione synthesising enzyme glutamate cysteine ligase is 
controlled by NRF2, which is shown to have greater levels in astrocytes than neurons (Dowell and 
Johnson, 2013; Jimenez-Blasco et al., 2015; Lee et al., 2003a). Therefore, glutathione appears to 
play a critical role in neuroprotection.   
5.1.3 Glial secretome  
Astrocytes are no longer viewed to only have passive involvement in neuronal support but also play 
essential roles in neuronal development, extracellular maintenance and inflammatory responses 
and thus, it is important to investigate neuron-glial crosstalk. Furthermore, emerging evidence 
suggests astrocytes are secretory cells within the CNS (Verkhratsky et al., 2016). Currently, mass 
spectrometry-based proteomics has been employed to investigate both intracellular and secreted 
proteins within astrocytes (Delcourt et al., 2005; Samy et al., 2018; Yang et al., 2005). Astrocytes 
can secrete protective or neurotoxic proteins following injury or during diseased states. These can 
be detrimental via neuroinflammatory mediators or beneficial, where secreted neurotrophic 
factors can initiate repair processes, axon regeneration, angiogenesis and neural circuitry rewiring. 
Some secreted factors are believed to participate in neurodegenerative pathology (reviewed in Jha 
et al., 2018).  
Over the last decade secretome analysis has become more in-depth with mass 
spectrometry and bioinformatic tools allowing insights into astrocyte status, function and possible 
diagnostic/prognostic agent identification for CNS diseases (Jha et al., 2013; Kim et al., 2020). The 
first secretome analysis involved primary astrocytes under proinflammatory conditions. This 
showed only a few protein identities (<40) to generate a network (Lafon-Cazal et al., 2003). Later, 
mass spectrometry with astrocytes of CD-1 mice with labelled amino acid isotopes allowed the 
identification of 516 secreted proteins, where some possessed the N-terminal signal for secretion 
such as apoE, SPARC and cathepsins while others did not, including vimentin: ferritins and histones 
(Greco et al., 2010). Han et al. identified over 6000 proteins from conditioned media from murine 
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astrocyte cultures using a combination of two-step digestion, filter-aided sample preparation, 
StageTip-based high pH fractionation, and high-resolution mass spectrometry (Han et al., 2014). 
Most secretome studies have used rodent models (Greco et al., 2010; Keene et al., 2009; Moore et 
al., 2009; Yin et al., 2012) but RNA sequencing analysis revealed human astrocytes differ from 
murine astrocytes (Kim et al., 2020; Y. Zhang et al., 2016). While samples from both healthy and 
neurodegenerative patients would be ideal to characterise secreted factors and possible 
biomarkers, this is challenging and thus the use of human clonal cell lines may provide a 
reproducible profile.  
A recent systematic review by Jha et al. proposed the major functions of secreted factors 
including: regulation of the extracellular matrix (ECM), neuron regulation and homeostasis (Jha et 
al., 2018). Where regulation of the ECM involves cell adhesion, migration, metalloprotease activity, 
cell growth, synaptogenesis, neuronal differentiation and axonal guidance. Neuronal regulation and 
homeostasis include ion homeostasis, morphogenesis, redox homeostasis as well as cell growth, 
cell death and neuroinflammation.  
Within the CNS oxidants are implicated in axonal damage, including degeneration, swelling 
and incomplete regeneration, where cytoskeletal alterations are believed to be an early event in 
cell death (Bellomo and Mirabelli, 1992; Compagnucci et al., 2016). Cytoskeleton filaments are 
important for cell shape, determining polarity, facilitating movement and membrane organization 
where the cytoskeletons is composed of 3 majors filaments including microfilaments such as actin, 
microtubules including tubulin and intermediate filaments for example vimentin (Allani et al., 
2004). While not fully understood in neuronal cells, OS plays a role in cytoskeletal protein changes 
such as vimentin, tubulin and filamin A (Fratelli et al., 2002; Neely et al., 2002; Pierozan et al., 2017; 
Zhang et al., 2014). Additionally, lipid peroxidation product 4-HNE disrupted microtubules and 
modified tubulin inhibiting neurite outgrowth in N2a neuroblastoma cells (Neely et al., 2002). In 
PC12 cells tubulin depolymerization was observed under oxidative insult followed by cell death 
(Hinshaw et al., 1993). Furthermore, hippocampal neuronal cells showed OS altered vimentin (Choi 
et al., 2003). Thus, while not fully understood, together these studies suggest cytoskeletal proteins 
within the ECM appear to be altered in diseases. 
Fibronectin alongside glycosaminoglycans and proteoglycans are secreted and accumulate 
in the ECM, regulating matrix organization (Hynes, 2009; Oláh et al., 2009). Fibronectin is produced 
and secreted by astrocytes and endothelial cells, which is subsequently assembled in the ECM 
(Rieske et al., 2009). While fibronectin interacts with integrins playing a critical role in adhesion, it 
is also important in extrasynaptic transmission (Andrews et al., 2018; Wang et al., 2013). This 
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process involves bidirectional communication where molecules diffuse through the ECM 
modulating neuronal activity (Araque, 2008). Whilst dopamine is transported through channels, it 
can also be delivered via diffusion through the ECM (Rice et al., 2011). Thus levels of fibronectin 
can affect the ECM and the diffusion of dopamine thereby disrupting intercellular signalling during 
aging (Allani et al., 2004; Brodski et al., 2019). This is supported by downregulated expression of 
fibronectin in the elderly effecting dopamine transmission (Fuxe et al., 2006; Syková, 2001). 
Furthermore, extrinsic administration of fibronectin protects against PD development (Fuxe et al., 
2006; Hall et al., 2016; Nowak et al., 2006), suggesting its neuroprotective ability. This is supported 
by its anti-inflammatory properties highlighting the importance of the ECM (Lin et al., 2012; Tsuda 
et al., 2008).  
Metalloproteinases are involved in the degradation of the ECM (Levin et al., 2017), where 
disruption of the ECM occurs during disease (Chaturvedi and Kaczmarek, 2014; Lau et al., 2013). 
Additionally, metalloproteinases also stimulate proinflammatory mediators such as chemokines 
(Gómez-Piña et al., 2012; Rosenberg, 2002). OS, thrombin and TNF-α can induce astrocytic 
metalloproteinases (Gottschall and Deb, 1996; Gottschall and Yu, 2002). Under normal conditions 
metalloproteinases are suppressed by metalloproteinase inhibitors preventing neuronal 
degeneration (Brkic et al., 2015; Cunningham et al., 2005; Sadeghian et al., 2012).  
While the ECM can affect neuronal morphology and degeneration secreted proteins can 
also influence neurons. Wingless-type mouse mammary tumour proto-oncogene integration 
protein (WNT), is secreted by astrocytes and is involved in various signalling pathways including 
neurogenesis, neuronal survival, axonal extension, synapse formation and dopaminergic neuronal 
plasticity (Ciani and Salinas, 2005; F. L’Episcopo et al., 2011; Maiese et al., 2008; Marchetti et al., 
2013). WNT ligands bind to the transmembrane receptor of the frizzled family leading to 
stabilisation of β-catenin, which binds to transcription activators leading to upregulation of genes 
involved in growth, development, adhesion and synapse dynamics (Gordon and Nusse, 2006; Taylor 
et al., 2013; Valenta et al., 2012). If WNT is absent, β-catenin is phosphorylated by glycogen 
synthase kinase-3β (GSK-3β) targeting β-catenin for ubiquitination and degradation by the 
proteasome (Aberle et al., 1997; Gordon and Nusse, 2006). Leucine rich repeat 2 (LRRK) encoded 
by PARK8 is proposed to have a role in canonical WNT signalling, as LRRK2 mutations are shown to 
reduce WNT signalling, suggesting WNT may be involved in PD pathogenesis (Berwick and Harvey, 
2012). Frizzled receptor localisation reinforces WNT’s role in neuronal morphology as receptors are 
localised to growth cones of regenerating neurons, playing a role in pre-synaptic differentiation and 
hippocampal neurons function (Chacón et al., 2008; Toledo et al., 2008). The importance in PD is 
also highlighted as 6-OHDA, rotenone and MPTP/MPP+ induced neuronal apoptosis via GSK-3β in 
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SH-SY5Y, PC12 cell and primary mesencephalic neurons suggesting the importance of upstream 
WNT (Chen et al., 2004; Petit-Paitel et al., 2009; W. Wang et al., 2007). This is supported by siRNA 
studies of WNT in astrocytes, which resulted in decreased tyrosine hydroxylase positive neuron 
survival following 6-OHDA and MPP+ treatment in co-cultures (L’Episcopo et al., 2011). Together, 
these studies suggest secreted factors from astrocytes also affect the ECM contributing to 
neurodegenerative process.  
While astrocyte secretomes regulate the ECM and neuronal morphology they also 
coordinate neuronal homeostasis through heat shock proteins such as HSP70 and HSP90 (Lackie et 
al., 2017; Verkhratsky et al., 2016). HSP70 is an exosomal protein (Kowal et al., 2016) that regulates 
protein folding and is upregulated in various neurodegenerative diseases (reviewed in Turturici et 
al., 2011). Cells can secrete HSP70 into the extracellular space via exosomes. Extracellular HSP70 is 
reported to play a role in neuroprotection during aging (Houenou et al., 1996; Posimo et al., 2015). 
Recently, treatment of N2A neuronal cells with HSP70 attenuated amyloid-β peptide 
oligomerization, suggesting extracellular HSP70 may help prevent protein aggregation providing 
neuroprotection (Rivera et al., 2018).  
Stressed glia can also secrete antioxidants as an initial neuroprotective strategy. These 
include  peroxiredoxins, thioredoxins and extracellular SOD (Cásedas et al., 2019; Cruz-Garcia et al., 
2019; Sandhu et al., 2009). Under chronic stress, glia become enlarged and overactive leading to 
cytokine and chemokine secretion resulting in neuroinflammation; characteristics observed in 
neurodegenerative diseases (Jung et al., 2020; Mena and García de Yébenes, 2008; Tambuyzer et 
al., 2009). Animal models treated with MPTP, 6-OHDA and rotenone exhibit glial activation prior to 
neuronal death (Bjarkam et al., 2008; Grünblatt et al., 2000; Meredith et al., 2008; Schneider and 
Denaro, 1988). This activation is characterised by the release of cytokines and chemokines that 
affect neighbouring cells. However, due to glia heterogeneity within different CNS regions it is 
difficult to determine the target cell response. Therefore, a simplified cell model is needed to probe 
the functional role of astrocytes during astrogliosis and inflammation (Imura et al., 2006; Yeh et al., 
2009).  
During neuroinflammation dendritic cells can present major histocompatibility complexes 
(MHC) I and II, where I is proinflammatory and II is anti-inflammatory (Arbore et al., 2017), 
facilitating communication with other cells such as macrophages. MHC-I presentation has been 
observed in both rodent and human dopaminergic neurons (Cebrián et al., 2014; Song et al., 2016). 
If not controlled, neuroinflammation can lead to neuronal degeneration highlighting the 
importance of understanding glia factor secretion and their downstream consequences.   
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5.1.4 Aims of the chapter 
Previous chapters have established that AAPH and rotenone generate RS that lead to 
neurodegeneration in isolated mitotic and differentiated neural cell models. This chapter will 
investigate RS in a more in vivo like environment and will attempt to create a co-culture model 
using SH-SY5Y and U-87MG cells to represent neurons and astrocytes within the CNS.  
 To create a co-culture, we will investigate different methodologies to introduce these two 
cell lines together prior to investigating the effect of OS. This includes contact co-cultures by 
seeding cells together prior to exposure to RS stressors. An alternate method will utilise transwell 
inserts to determine the effect of secreted factors while maintaining feedback loops between SH-
SY5Y neuronal and U-87MG glial cells. Transwell inserts will also allow the cells lines to be kept 
separate, preventing one cell type overgrowing the other.   
 Finally, the effect of the glial secretome on neuronal cell parameters will also be 
investigated. Proteomic analysis via mass spectrometry and subsequent enrichment will allow the 
identification of perturbed pathways in glial cells and link this to the secretome profile. This will 
help identify possibly biomarkers of OS and pathways associated with neuroprotection or 
neurotoxicity potentially aiding understanding of neurodegenerative pathologies. 
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5.2 RESULTS  
5.2.1 Contact co-cultures 
Initially the project attempted to create a contact co-culture, where cells were seeded at the same time 
at a 1:1 ratio, and then treated with AAPH or rotenone for up to 48 hours.  
Following 48-hour growth mono- and co-cultures were treated with AAPH or rotenone for 24 
hours (figure 5.2). Phase contrast microscopy showed similar intercellular distances and morphology for 
0.25 and 1 mM AAPH treated mono- and co-cultures relative to the control (figure 5.2A). Whilst 5 mM 
AAPH appeared to have no significant effect on U-87MG monocultures, SH-SY5Y monocultures and co-
cultures showed increased intercellular distances and less processes relative to the control. This was 
supported by viability assays (figure 5.2B) that showed significantly lower MTT reduction levels for SH-
SY5Y monocultures and co-cultures but not for U-87MG monocultures. Additionally, LDH assays (figure 
5.2C) showed the greatest LDH release for SH-SY5Y monocultures, while U-87MG monocultures and co-
cultures were significantly increased relative to the control, but significantly less than SH-SY5Y 
monocultures. This suggests 5 mM AAPH reduced viability of SH-SY5Y cells but not U-87MG cells and 
the presence of the SH-SY5Y cells was enough to affect co-culture viability.  
24-hour treatment with rotenone resulted in lower viability than AAPH as both SH-SY5Y and U-
87MG monocultures, as well as co-cultures showed cellular rounding and increased intercellular 
distances (figure 5.2D). MTT assays supported this as they showed lower levels of MTT reduction for 
≥0.5 μM rotenone (figure 5.2E). While MTT assays suggested no significant difference between mono- 
or co-cultures, LDH assays showed lower levels of LDH release for U-87MG monocultures and co-
cultures (figure 5.2F). This suggests SH-SY5Y cells are more sensitive to membrane permeability induced 
by rotenone.  
Following 48-hour treatment phase contrast microscopy of AAPH treated SH-SY5Y 
monocultures exhibited greater intercellular distances and cellular rounding in a dose-dependent 
manner (figure 5.3A). In contrast, U-87MG monocultures appeared to proliferate exhibiting more 
processes. In the co-culture, some cells displayed cellular rounding while others still showed processes. 
These observations were consistent with MTT results (figure 5.3B), which showed the lowest level of 
MTT reduction for SH-SY5Y monocultures. Whereas, MTT reduction levels for co-cultures were lower 
than U-87MG monocultures, yet not as low as SH-SY5Y monocultures. This was consistent with LDH 
assays that showed 5 mM AAPH resulted in the greatest LDH release for SH-SY5Y monocultures, while 
U-87MG monocultures exhibited the lowest, with co-cultures somewhere in between (figure 5.3C). This 
suggests that co-cultures display altered viability in response to AAPH treatment. 
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Figure 5.2 Neuronal SH-SY5Y 
and glial U-87MG contact co-
culture cell viability after 24-
hour AAPH or rotenone 
exposure. Phase contrast 
microscopy of (A) AAPH and (D) 
rotenone treated mono- and co-
cultures after 24-hour exposure. 
Scale bar = 100 μm. MTT 
reduction assay of (B) AAPH and 
(E) rotenone treated mono- and 
co-cultures following 24-hour 
exposure. LDH release of (C) 
AAPH and (F) rotenone treated 
mono- and co-cultures after 24-
hours. All viability assays are 
presented as mean % against 
control ± SEM. Statistical 
analysis was performed using 
one-way ANOVA with Dunnett’s 
post-hoc test where n=4 for all 
experiments. Statistical 
significance was recorded as 
*p<0.05, **p<0.01 and 
***p<0.001, relative to the 
control unless otherwise 
demonstrated. 
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In contrast, 48-hour rotenone treatment of both mono- and co-cultures of SH-SY5Y and U-
87MG neural cells resulted in similar morphological changes, where cells exhibited increased 
intercellular distances and cellular rounding in a dose-dependent manner (figure 5.3D). This was 
consistent with MTT assays, which showed a dose-dependent decrease in MTT reduction for all 
cultures (figure 5.3E). These observations were supported with LDH assays, which showed similar LDH 
release for SH-SY5Y monocultures and co-cultures (figure 5.3F). In contrast, U-87MG monocultures 
demonstrated the lowest levels of LDH release. This suggests co-cultures had similar susceptibility to 
rotenone induced death as SH-SY5Y monocultures. 
Changes in morphology and viability could be affected by the relative cell ratio. Maintenance 
of the seeding ratio of 1:1 could change as specific neural cells grow at different rates. Indeed, U-
87MG cells proliferate with AAPH, possibly altering the ratio of neurons to glia. Thus, we investigated 
whether immunofluorescent staining of SH-SY5Y neuronal and U-87MG glial cells could be used to 
verify the neural cell ratio.  
Initially, SH-SY5Y and U-87MG cells were seeded at increasing densities and then stained with 
βIII-tubulin and GFAP, respectively. Immunofluorescent microscopy showed an increase in 
fluorescence with increasing cell density for both SH-SY5Y and U-87MG cells (figure 5.4A and C, 
respectively). Fluorescent quantification using the incucyte S3 live-cell analysis system showed a linear 
increase in fluorescence with cell density (figure 5.4B and D). However, it is important to note that at 
higher densities of U-87MG cells clustering occurs increasing the standard error.  
With immunofluorescent staining as a possible option 1:1 co-cultures of SH-SY5Y and U-87MG 
cells were grown for 48 hours prior to fixing and staining with βIII-tubulin (red) and GFAP (green; figure 
5.5). However, a large majority of the βIII-tubulin and GFAP staining overlapped in the merge image 
suggesting the cells may express both markers. As such, monocultures were stained with both βIII-
tubulin and GFAP where immunofluorescent microscopy showed U-87MG monocultures stained for 
both markers. This suggests immunofluorescent staining with these markers is not suitable for 
determining the ratio of the cells in co-culture posing a limitation for contact co-cultures. 
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Figure 5.3 Neuronal SH-SY5Y 
and glial U-87MG contact co-
culture cell viability after 48-
hour AAPH or rotenone 
exposure. Phase contrast 
microscopy of (A) AAPH and (D) 
rotenone treated mono- and co-
cultures after 48-hour exposure. 
Scale bar = 100 μm. MTT 
reduction assay of (B) AAPH and 
(E) rotenone treated mono- and 
co-cultures following 48-hour 
exposure. LDH release of (C) 
AAPH and (F) rotenone treated 
mono- and co-cultures after 48-
hours. All viability assays are 
presented as mean % against 
control ± SEM. Statistical 
analysis was performed using 
one-way ANOVA with Dunnett’s 
post-hoc test where n=4 for all 
experiments. Statistical 
significance was recorded as 
*p<0.05, **p<0.01 and 
***p<0.001, relative to the 
control unless otherwise 
demonstrated. 
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Figure 5.4 
Immunofluorescence 
density of SH-SY5Y 
and U-87MG 
monocultures. To 
determine if 
immunofluorescent 
staining was suitable 
for quantifying cell 
number, SH-SY5Y 
neuronal cells were 
stained with βIII-
tubulin and U-87MG 
glial cells were stained 
with GFAP. Using the 
incucyte S3-live cell 
analysis system phase 
contrast and 
immunofluorescent 
images were taken of 
βIII-tubulin stained SH-
SY5Y neuronal cells (A) 
and GFAP stained U-
87MG glial cells (C). 
Scale bar = 200 μm. 
Using the incucyte S3-
live analysis system 
the fluorescence of 
increasing SH-SY5Y (B) 
and U-87MG (D) cell 
density was 
quantified.  
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Figure 5.5 Immunofluorescence of SH-SY5Y neuronal and U-87MG glial co-cultures and monocultures. Co-
cultures of SH-SY5Y neuronal and U-87MG glial cells were stained with βIII-tubulin (Red) and GFAP (Green) 
to try to determine the ratio of the cells within the co-culture. Scale bar = 200 μm. SH-SY5Y neuronal and U-
87MG glial monocultures were stained with with βIII-tubulin (Red) and GFAP (Green), which revealed U-
87MG glial cells also express with βIII-tubulin.  
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5.2.2 Non-contact cell cultures using transwell inserts 
Due to difficulties encountered with contact co-cultures we employed transwell inserts to maintain 
communication between SH-SY5Y neuronal and U-87MG glial cells, but to avoid the problems of cell 
ratios altering through growth.  
 Herein SH-SY5Y and U-87MG cells were differentiated together in co-culture over 5 days 
initially to determine how co-cultures effect differentiation viability. To do this, SH-SY5Y neuronal cells 
were cultivated in 24-well plates, while U-87MG glial cells were seeded in inserts at the same cellular 
density. As neurons and glia are reported to have different mechanosensitivities this was also 
reversed, where U-87MG glial were cultivated in 24-well plates and SH-SY5Y neuronal cells were 
seeded on inserts, as represented in figure 5.6A. Following overnight growth, media was changed to 
differentiation media (0.1, 0.5 or 1% (v/v) FBS with 10 μM retinoic acid). After 5 days of differentiation, 
viability was assessed. As expected, higher FBS resulted in a greater absorbance/cell number at 570 
nm for both neural cells (figure 5.6D and E), suggesting lower FBS resulted in attenuated cell 
proliferation. Phase contrast microscopy of SH-SY5Y neuronal cells showed similar confluence and 
morphology when seeded on either 24-well plates or inserts (figure 5.6B). These observations were 
supported by MTT reduction assays, which showed that 0.1 and 0.5% (v/v) FBS resulted in comparable 
levels of absorbance (figure 5.6D), while 1% (v/v) FBS inserts showed greater absorbance. In contrast, 
LDH reduction assays showed that all FBS percentages showed greater LDH release for SH-SY5Y 
differentiation in 24-well plates compared to inserts (figure 5.6F). Together, this suggests SH-SY5Y cells 
grow more efficiently with higher membrane integrity during differentiation on inserts than 24-well 
plates. 
 In contrast, U-87MG glial showed a more stellate morphology in 24-well plates in comparison 
to the rounded state observed on inserts (figure 5.6C). These observations were consistent with 
viability assays, where all FBS percentages showed greater absorbance for U-87MG glial cells 
differentiated in 24-well plates relative to inserts (figure 5.6E). This was consistent with LDH assays 
that demonstrated greater LDH release for U-87MG glial cells differentiated in inserts relative to 24-
well plates (figure 5.6G). This suggests U-87MG viability during differentiation is improved when 
cultivated on 24-well plates compared to inserts.  
 Together, these results suggest SH-SY5Y neuronal cells have greater viability during 
differentiation on inserts whereas U-87MG glial cells grow more efficiently on 24-well plates. This is 
possibly due to 24-well plates being composed of polystyrene, whereas inserts are made of 
polyethylene terephthalate, which suggests neural cell growth is affected by cultivation material.  
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Figure 5.6 Insert material effects neural cell viability. (A) Diagrammatic scheme of how co-cultures were 
constructed where SH-SY5Y and U-87MG cells were seeded to either wells or inserts and grown in full media 
overnight. On day 1 inserts were brought into contact with wells to create co-culture and media was 
changed to differentiation media (0.1, 0.5 or 1% (v/v) FBS with 10 μM retinoic acid). Media was refreshed 
on day 3 and then MTT and LDH assays were conducted on day 5 where solutions were transferred to a 96-
well plate for the plate reader. Phase contrast microscopy of day 5 (B) SH-SY5Y cells or (C) U-87MG cells in 
wells or inserts. Scale bar = 200 μm. MTT reduction assay of 5-day differentiated (D) SH-SY5Y or (E) U-87MG 
cells in wells or inserts. LDH release of 5-day differentiated (F) SH-SY5Y or (G) U-87MG cells in wells or inserts.  
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    As material appeared to affect these neural cells, we performed 5-day co-culture 
differentiation under both circumstances, where SH-SY5Y neuronal cells were cultivated in 24-well 
plates and U-87MG glia in inserts (figure 5.7). Alternatively, U-87MG cells were cultivated in 24-well 
plates and SH-SY5Y neurons seeded on inserts (figure 5.8) to compare to monoculture differentiation.  
 SH-SY5Y differentiation showed decreased intercellular distances for both co-cultures of SH-
SY5Y neuronal cells cultivated on 24-well plates or inserts relative to monocultured SH-SY5Y cells. 
Furthermore, all conditions appeared to show pyramidal morphology upon differentiation (figure 
5.7A). MTT reduction assays showed significantly greater levels of absorbance for both conditions of 
co-cultures relative to monocultures at the same FBS concentration (figure 5.7B). For 0.1% (v/v) FBS, 
co-cultures showed significantly lower LDH release relative to monocultures (figure 5.7C). No 
significant differences were observed for 0.5% (v/v) FBS, while 1% (v/v) FBS in 24-well and insert co-
cultures showed greater LDH release than monocultures, possibly because this concentration 
alongside glia increased proliferation resulting in culture overgrowth (figure 5.7C). 
 U-87MG monoculture differentiation showed greater cell clustering with higher FBS 
concentrations, while co-cultures in 24-well plates exhibited a flat, fibroblast-like morphology (figure 
5.8A). Additionally, insert co-cultures with 0.1% (v/v) FBS showed greater intercellular distances and 
cellular rounding indicative of reduced viability, while 0.5 and 1% (v/v) FBS showed more stellate 
morphology but did not display the network like clusters observed in both the co-culture and 
monoculture in the 24-well plates (figure 5.8A). This suggests U-87MG differentiation on inserts was 
detrimental to cell viability even in co-culture, which was consistent with MTT reduction assays. All 
FBS concentrations showed lower levels of viability for U-87MG co-cultures cultivated on inserts 
(figure 5.8B). This supported by LDH release assays where 0.5 and 1% (v/v) FBS showed greater LDH 
release for U-87MG co-cultured on inserts (figure 5.8C). Furthermore, MTT reduction and LDH assays 
showed U-87MG co-cultured on 24-well plates showed greater cell proliferation, indicated by the 
higher MTT absorbance levels and lower LDH release levels. 
 Together, this suggests SH-SY5Y cells co-cultured on either plates or inserts showed increased 
viability relative to monocultures. Whereas U-87MG glial cells only showed increased viability for co-
cultures on 24-well plates, supporting previous observations that insert material is detrimental to U-
87MG viability. This suggests co-cultures improve neural cell viability during differentiation. 
Furthermore, to prevent overgrowth of the co-culture but not significantly increase cell death 0.5% 
(v/v) FBS was the most optimal differentiation condition. 
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Figure 5.7 The effect of non-
contact co-culture with U-
87MG on SH-SY5Y 
differentiation viability. 
Transwell inserts were used to 
culture SH-SY5Y neuronal cells 
and U-87MG glial cells together 
without contact. (A) Phase 
contrast microscopy of day 1, 3 
and 5 of differentiated SH-SY5Y 
monoculture, co-cultured SH-
SY5Y in wells and inserts. Scale 
bar = 200 μm. (B) MTT reduction 
assay of 5-day SH-SY5Y 
monoculture and SH-SY5Y well 
and insert co-cultures. (C) LDH 
release of 5-day SH-SY5Y 
monoculture and SH-SY5Y well 
and insert co-cultures. Statistical 
analysis was performed using 
two-way ANOVA with Tukey’s 
post-hoc test where n=4 for all 
experiments. Statistical 
significance was recorded 
*p<0.05, **p<0.01, ***p<0.001 
and ****p<0.0001. 
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Figure 5.8 The effect of non-
contact co-culture with SH-SY5Y 
on U-87MG differentiation 
viability. Transwell inserts were 
used to culture SH-SY5Y 
neuronal cells and U-87MG glial 
cells together without contact. 
(A) Phase contrast microscopy of 
day 1, 3 and 5 of differentiated 
U-87MG monoculture and U-
87MG well and insert co-
cultures. Scale bar = 200μm. (B) 
MTT reduction assay of 5-day U-
87MG monoculture and U-
87MG well and insert co-
cultures. (C) LDH release of 5-
day U-87MG monoculture and 
U-87MG well and insert co-
cultures. Statistical analysis was 
performed using two-way 
ANOVA with Tukey’s post-hoc 
test where n=4 for all 
experiments. Statistical 
significance was recorded 
*p<0.05, **p<0.01, ***p<0.001 
and ****p<0.0001. 
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To investigate the effect of RS on co-cultures, SH-SY5Y and U-87MG cells were differentiated 
over 5 days (0.5% (v/v) FBS, 10 µM retinoic acid) in co-culture, prior to treatment with AAPH or 
rotenone. As shown before, SH-SY5Y co-cultures in both 24-well plates and inserts showed lower 
intercellular distances in control cells relative to monocultures (figure 5.9A), suggesting co-cultures 
with U-87MG glial cells improve SH-SY5Y viability. Both AAPH and rotenone resulted in increased 
intercellular distances, where rotenone also resulted in cell rounding. While AAPH resulted in similar 
observations with phase contrast microscopy for both mono- and co-cultures of SH-SY5Y cells, 
rotenone treated SH-SY5Y co-cultures appeared to have lower intercellular distances and more 
processes relative to SH-SY5Y monocultures (figure 5.9A). MTT assays were consistent with this as 
both SH-SY5Y well and insert co-cultures treated with rotenone had greater absorbance levels relative 
to monocultures (figure 5.9B). This was supported by LDH assays, which showed lower levels of LDH 
release for SH-SY5Y co-cultures relative to monocultures following rotenone exposure (figure 5.9C). 
This suggests co-cultures with U-87MG glial cells improved SH-SY5Y viability in response to rotenone, 
but not AAPH, suggesting specific RS result in different responses in neural cells.  
 As shown before U-87MG glial cells co-cultured with SH-SY5Y cells when cultivated on inserts 
showed a more rounded morphology (figure 5.10A), while showing lower absorbance levels for MTT 
reduction assays (figure 5.9B), suggesting insert material significantly effects viability. As observed 
previously, AAPH treated monocultures show increased proliferation as observed with phase 
microscopy (figure 5.10A) and MTT assays (figure 5.10B). In contrast, AAPH treated co-cultures 
exhibited lower cell number in phase microscopy images (figure 5.10A) and decreased absorbance 
levels for MTT assays (figure 5.10B), suggesting co-cultures prevented the usual proliferation. This 
suggests the presence of SH-SY5Y cells affects the normal response of glia to this RS inducer. 
Furthermore, while U-87MG cells in co-culture still showed cellular rounding with rotenone treatment 
as seen with monocultures, co-cultures showed greater cell numbers and clusters (figure 5.10A). 
These observations were consistent with MTT reduction assays that showed greater absorbance for 
U-87MG glial cells co-cultured with SH-SY5Y cells (figure 5.10B), while LDH release levels were lower 
for co-cultures relative to monocultures (figure 5.10C). This suggests that like with SH-SY5Y co-
cultures, rotenone induced U-87MG glial death was attenuated relative to monocultures whereas 
AAPH treated co-cultures did not exhibit the previously observed proliferation. 
 Together this suggests co-cultures aid differentiated neural cell viability when treated with 
rotenone but not with AAPH. This strengthens that different RS species effect co-cultures in 
contrasting ways with feedback loops influencing viability in both a positive and negative ways.  
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Figure 5.9 The effect of non-
contact co-culture with U-
87MG on SH-SY5Y viability 
following AAPH or rotenone 
treatment. Transwell inserts 
were used to culture SH-SY5Y 
neuronal cells and U-87MG 
glial cells together without 
contact. (A) Phase contrast 
microscopy of 24 and 48-
hour AAPH or rotenone 
exposure to SH-SY5Y 
monocultures and SH-SY5Y 
well and insert co-cultures. 
Scale bar = 200 μm. (B) MTT 
reduction assay of 48-hour 1 
mM AAPH or 0.5 μM 
rotenone treatment of SH-
SY5Y monoculture and SH-
SY5Y well and insert co-
cultures. (C) LDH release of 
48-hour 1 mM AAPH or 0.5 
μM rotenone treatment of 
SH-SY5Y monoculture and 
SH-SY5Y well and insert co-
cultures. Statistical analysis 
was performed using two-
way ANOVA with Tukey’s 
post-hoc test where n=4 for 
all experiments. Statistical 
significance was recorded 
*p<0.05, **p<0.01, 
***p<0.001 and 
****p<0.0001.  
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Figure 5.10 The effect of 
non-contact co-culture with 
SH-SY5Y on U-87MG 
viability following AAPH or 
rotenone treatment. 
Transwell inserts were used 
to culture SH-SY5Y neuronal 
cells and U-87MG glial cells 
together without contact. (A) 
Phase contrast microscopy of 
24 and 48-hour AAPH or 
rotenone exposure to U-
87MG monocultures and U-
87MG well and insert co-
cultures. Scale bar = 200 μm. 
(B) MTT reduction assay of 
48-hour 1 mM AAPH or 0.5 
μM rotenone treatment of U-
87MG monoculture and U-
87MG well and insert co-
cultures. (C) LDH release of 
48-hour 1 mM AAPH or 0.5 
μM rotenone treatment of U-
87MG monoculture and U-
87MG well and insert co-
cultures. Statistical analysis 
was performed using two-
way ANOVA with Tukey’s 
post-hoc test where n=4 for 
all experiments. Statistical 
significance was recorded 
*p<0.05, **p<0.01, 
***p<0.001 and 
****p<0.0001. 
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5.2.3 Different reactive species induce divergent effects on the U-87MG glial 
secretome 
While inserts are one method, we utilised to create a co-culture of SH-SY5Y neuronal and U-87MG 
glial cells, they are difficult for high-throughput experiments. Thus, to determine if the effects are 
a consequence of secreted factors, conditioned media experiments were conducted.  
 As demonstrated in figure 5.11A, SH-SY5Y neuronal cells were plated in complete media for 
24 hours prior to changing to differentiation media (0.5% (v/v) FBS, 10 μM retinoic acid). Cells were 
differentiated over 5 days, where media was refreshed on day 3. In parallel, U-87MG glial cells were 
differentiated over 5 days and then treated with 1 mM AAPH or 0.5 μM rotenone for 48 hours. On 
day 5, SH-SY5Y cells were subjected to 4 conditions: media only, U-87MG conditioned media, 1 mM 
AAPH U-87MG conditioned media or 0.5 μM rotenone U-87MG conditioned media. Each condition 
was also treated with 1 mM AAPH or 0.5 μM rotenone to determine if stressed U-87MG glial secrete 
factors that affect SH-SY5Y viability in response to OS. Cell growth and cytotoxicity was monitored 
over 48-hours using the incucyte S3 live-cell analysis system and viability was subsequently 
assessed using in-house viability assays.  
 Phase contrast microscopy at 24 hours showed AAPH and rotenone in all conditions 
resulted in greater intercellular distances and cell rounding, which was greater with rotenone as 
AAPH treated SH-SY5Y cells still showed processes (figure 5.11B). Furthermore, U-87MG and AAPH 
U-87MG conditioned media appeared to result in more cell processes relative to media alone. 
Interestingly, SH-SY5Y cells cultured with rotenone U-87MG conditioned media showed similar 
morphology to AAPH and rotenone treatment of media alone, displaying a more cuboidal 
morphology and lack of processes. This suggests that while U-87MG and AAPH U-87MG conditioned 
media improved processes rotenone U-87MG conditioned media was detrimental to SH-SY5Y 
morphology. Additionally, all media conditions seemed to show similar changes to morphology 
upon AAPH or rotenone treatment.  
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Following 48-hour exposure to AAPH and rotenone, cells exhibited increased intercellular 
distance and greater cell rounding (figure 5.12A). However, control cells treated with U-87MG and 
AAPH U-87MG conditioned media showed improved parameters relative to SH-SY5Y media alone. 
SH-SY5Y cells cultured with rotenone U-87MG conditioned media demonstrated cuboidal shaped 
cells that lacked defined processes. Indeed, AAPH and rotenone treatment appeared to have a 
greater effect on SH-SY5Y morphology cultured with media alone, whilst U-87MG conditioned 
Figure 5.11 The effect of different U-87MG conditioned media on SH-SY5Y viability. (A) Schematic 
representation of conditioned media cultures where SH-SY5Y cells grown overnight in complete media. SH-
SY5Y cells were differentiated over 5 days with media replaced on day 3. In parallel, U-87MG glial cells were 
differentiated over 5 days and subsequently treated with 1 mM AAPH or 0.5 μM rotenone for 48 hours prior 
to addition in a 1:1 ratio with fresh media to differentiated SH-SY5Y neuronal cells. In addition, each 
condition was treated with 1 mM AAPH or 0.5 μM rotenone. Cells were monitored over 48 hours using the 
incucyte S3 live-cell analysis system. (B) 24-hour phase confluence microscopy of differentiated SH-SY5Y cells 
with different U-87MG conditioned media when treated with 1 mM AAPH or 0.5 μM rotenone. Scale bar 
200 μm. Inset scale bar = 100 μm.  
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media and AAPH U-87MG conditioned media improved neuronal viability. Cells still appeared 
elongated, with less rounding for U-87MG and AAPH U-87MG conditioned media cultivated cells 
treated with AAPH or rotenone, relative to media conditioned SH-SY5Y cells alone. As these two 
media conditions are where U-87MG cells are still growing, this suggests healthy U-87MG cells 
secrete factors that improve SH-SY5Y neuronal viability. In contrast, rotenone treated U-87MG glial 
cells show decreased viability, and this conditioned media resulted in SH-SY5Y cells showing 
morphological differences from other conditions, suggesting U-87MG cells undergoing cell death 
secrete different factors that are possibly neurotoxic. 
 MTT reduction assays showed that all U-87MG conditioned media increased absorbance 
levels relative to SH-SY5Y cultured with media alone (figure 5.12B). AAPH U-87MG conditioned 
media showed the greatest absorbance (viability), whereas rotenone U-87MG conditioned media 
showed the lowest viability levels supporting morphological observations. These observations were 
in contradiction to LDH assays as SH-SY5Y cells cultured with U-87MG conditioned media and 
treated with AAPH showed higher levels of LDH release relative to media alone (figure 5.12C). This 
may be due to AAPH specifically generating RS specific for lipid peroxidation, and thus increasing 
LDH release. Consistent with phase microscopy observations, LDH release levels were significantly 
higher for rotenone U-87MG conditioned media relative to media alone, suggesting reduced 
viability.  
 Live cell monitoring with the incucyte supported these findings in some parts where U-
87MG conditioned media improved the phase confluence of rotenone treated SH-SY5Y cells relative 
to media alone (figure 5.12D-G). In contrast, AAPH U-87MG conditioned media did not improve 
susceptibility to AAPH or rotenone treatment relative to media alone (figure 5.12F). However, 
interestingly, both treatments of SH-SY5Y cells with rotenone U-87MG conditioned media showed 
similar viability (figure 5.12G), which was also observed with viability assays, suggesting the 
secreted factors from rotenone treated U-87MG result in a senescence, of sort. While U-87MG and 
AAPH U-87MG conditioned media improved control SH-SY5Y growth (figure 5.12E and F, 
respectively) relative to media alone, rotenone U-87MG conditioned media resulted in reduced 
phase confluence (figure 5.12G). Therefore viability, phase microscopy and live-cell monitoring 
suggests media from growing/healthy U-87MG cells improves SH-SY5Y neuronal viability but does 
not significantly affect susceptibility to AAPH or rotenone treatment. In contrast, stressed U-87MG 
glial cells release factors detrimental to SH-SY5Y viability. However, the factors released are likely 
to be a mixture of positive and negative regulators of cell death as viability was improved with 
subsequent rotenone and AAPH treatment. 
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Figure 5.12 The effect of different U-87MG conditioned media on 48-hour SH-SY5Y viability in the presence of AAPH and rotenone. SH-SY5Y cells were 
differentiated over 5 days and subsequently treated with 1 mM AAPH or 0.5 μM Rotenone in the presence of U-87MG conditioned media, 1 mM AAPH U-
87MG conditioned media, and 0.5 μM rotenone U-87MG conditioned media. (A) 48-hour phase confluence microscopy of differentiated SH-SY5Y cells with 
different U-87MG conditioned media when treated with 1 mM AAPH or 0.5 μM rotenone. Scale bar = 200 μm. Inset scale bar = 100 μm. (B) 48-hour MTT 
reduction assay of 1 mM AAPH and 0.5 μM rotenone treated SH-SY5Y neuronal cells in the presence of different U-87MG conditioned media. (C) 48-hour 
LDH release assay of 1 mM AAPH and 0.5 μM rotenone treated SH-SY5Y neuronal cells in the presence of different U-87MG conditioned media. Incucyte S3 
live-cell monitoring of phase confluence of (D) media alone, (E) U-87 conditioned media, (F) 1 mM AAPH U-87 conditioned media and (G) 0.5 μM rotenone 
U-87 conditioned media.     
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 To get a better understanding of the possible factors secreted by U-87MG glia and their impact 
of SH-SY5Y neuronal cells, mass spectrometry of the secretomes of U-87MG glia treated with AAPH or 
rotenone were performed (figure 5.13). Lysates were digested with trypsin and prepared for SWATH 
MS (Sequential Windowed Acquisition of all Theoretical Fragment ion Mass Spectra) analysis as 
described in section 2.18.1-2.18.2 of chapter 2. Initially, a spectral library was generated using data 
dependent acquisition (DDA), followed by SWATH data gathering via data independent acquisition 
(DIA). Due to the extensive nature of proteins identified via mass spectrometry tables for AAPH and 
rotenone treated U-87MG lysates and secretomes are provided in the supplementary data (table 8.1 
and 8.2, respectively). Using differentially identified proteins with a 50% or greater confidence, 
pathway analysis was performed using MetaCore network enriched proteomic data analysis. 
 
 
Using Venny (Oliveros, 2007), an interactive tool we determined how many of these 
differentially identified proteins were up- or downregulated, but also unique and shared between 
AAPH and rotenone treated U-87MG lysates (figure 5.14A and C) and secretomes (figure 5.15A and 
C). In U-87MG lysates only 6 proteins were upregulated in both AAPH and rotenone treated cells, 
suggesting how specific RS effect different proteins relative to the control (figure 5.14A). Whereas a 
greater number of proteins (54) were downregulated in both AAPH and rotenone treated U-87MG 
cells (figure 5.14C). In both cases, rotenone resulted in a higher number of unique proteins identified, 
suggesting this treatment resulted in more proteins and possibly more pathways being affected. This 
is possibly due to rotenone effecting multiple cellular functions as it not only generates OS but also 
lowers ATP levels.  
 
 
Figure 5.13 Schematic representation of how U-87MG lysates and secretomes were obtained for mass 
spectrometry. U-87MG cells were differentiated over 5 days with media replaced on day 3. Cells were 
subsequently treated 1 mM AAPH or 0.5 μM for 48 hours where conditioned media and lysates were taken 
forward for mass spectrometry.  
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Figure 5.14 Mass spectrometry of differentially expressed proteins of AAPH and rotenone U-87MG treated cells and pathways identified using MetaCore. U-87MG glial cells were 
differentiated over 5 days (0.5% (v/v) FBS, 10 μM retinoic acid) and then treated with 1 mM AAPH or 0.5 μM rotenone for 48 hours. Venn diagrams were used to illustrate how many 
differentially identified proteins were upregulated (A) and downregulated (C), and how many were common and unique to AAPH and rotenone treatment. MetaCoreTM was used to determine 
upregulated (B) and downregulated (D) pathways and how many proteins in these were differentially expressed in AAPH and rotenone treated cells.  
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Figure 5.15 Mass spectrometry of differentially expressed proteins of AAPH and rotenone U-87MG treated secretomes and pathways identified using MetaCore. U-87MG glial cells were 
differentiated over 5 days (0.5% (v/v) FBS, 10 μM retinoic acid) and then treated with 1 mM AAPH or 0.5 μM rotenone for 48 hours where the mass spectrometry was performed on the conditioned 
media. Venn diagrams were used to illustrate how many differentially identified proteins were upregulated (A) and downregulated (C), and how many were common and unique to AAPH and 
rotenone treatment. MetaCoreTM was used to determine upregulated (B) and downregulated (D) pathways and how many proteins in these were differentially expressed in AAPH and rotenone 
treated cells. 
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While less proteins were identified in the U-87MG secretome (figure 5.15), rotenone treated 
glia still presented a greater number of differentially identified proteins both up- and downregulated 
(figure 5.15A and C). However, it is important to consider that rotenone results in glial death and thus, 
it is hard to determine if these proteins are actively secreted or just released due to cell lysis. This is 
less of a problem with AAPH treated cells as AAPH induced proliferation and therefore, we can be 
more confident the identified proteins are secreted factors.  
 Metacore enrichment highlighted multiple pathways in U-87MG lysates (figure 5.14B, table 
5.1), where some of the top 50 key upregulated pathways included activation of antioxidant defences 
including SOD and PRDX3, supporting previous findings in chapter 3. Other pathways included 
mitochondrial dysfunction, where more proteins were upregulated with rotenone including 
mitochondrial permeability transition pore complex and SOD2. In contrast, proteins associated with 
lipid trafficking and metabolism in age-related degeneration were upregulated more in AAPH treated 
U-87MG glial cells than rotenone. This suggests AAPH and rotenone both resulted in OS via different 
mechanisms as previously proposed. Rotenone primarily targeted mitochondria to a greater extent 
than AAPH; where the latter primarily affected lipids.  
As we have previously proposed that OS can also lead to changes in protein degradation as 
well as mitochondrial dysfunction via the “neurodegenerative Bermuda triangle”, it was interesting to 
note that HSP70 was significantly upregulated and its involvement in protein folding was highlighted 
as an important pathway.  Additionally, both the MHC I and MHC II class pathways were upregulated 
by both rotenone and AAPH, suggesting a neuroinflammatory response.  
AAPH and rotenone secretomes showed similar pathway upregulation associated with 
neuroinflammation including MHC class I and II presentation (table 5.3), suggesting 
neuroinflammatory pathways are extracellular as well as intracellular. Unlike lysates though, HSP70 
was downregulated in the secretome, possibly due HSP70 being retained to help cells cope with OS.   
Enrichment analysis highlighted a large majority of the downregulated pathways (table 5.2) 
were involved in cell adhesion including: cytoskeleton remodelling, integrin mediated cell adhesions, 
gap junctions, WNT signalling, remodelling of keratin filaments and neurofilaments. Some of the 
proteins highlighted in these pathways included fibronectin, filamin A, vimentin and tubulin. Filamin 
A and fibronectin were also downregulated in U-87MG secretomes alongside metalloproteinase 
inhibitors (MMP), suggesting oxidatively stressed glia secrete factors that influence cellular adhesion 
and the ECM (table 5.4) 
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Table 5.1 Upregulated pathway maps enriched in AAPH and rotenone treated U-87MG cells. U-87MG cells 
were treated with AAPH or rotenone for 48 hours and analysed using mass spectrometry. Using differentially 
identified proteins upregulated by AAPH or rotenone pathways were subsequently enriched using MetaCore.   
Lysate Pathway Map Enrichments Proteins upregulated by AAPH 
in pathway 
Proteins upregulated by 
rotenone in pathway 
Transcription-HIF-1 targets TGM2, Heme oxygenase 1 FGF2 
Chemotaxis-SDF-1/CXCR4-induced 
chemotaxis of immune cells 
RAP-1A, G-protein alpha-i 
family 
RAP-1A 
 
HSP70 and HSP40-dependent folding in 
Huntington’s disease 
Cathepsin D HSP90, HSP70 
 
Immune response – LTBR1 signalling RAP-1A, G-protein alpha-i 
family 
COX-2 (PTGS2), RAP-
1A 
Oxidative stress -Sirtuin1 and PGC1-α 
activation of antioxidant defence 
Heme oxygenase 1 
 
PBEF, SOD2, PRDX3 
 
Cell adhesion-integrin inside out 
signalling in T-cells 
RAP-1A, G-protein alpha-i 
family 
RAP-1A 
 
Aryl hydrocarbon receptor signalling CYP1B1, Cathepsin D 
 
COX-2 (PTGS2), IL-8, 
Epiregulin 
Cell adhesion – Ephrin signalling  RAP-1A, G-protein alpha-i 
family 
RAP-1A 
 
Chemotaxis-C5a-induced chemotaxis  RAP-1A, G-protein alpha-i 
family 
RAP-1A 
 
Apoptosis and survival-TNF-α-induced 
chemotaxis 
Acid sphingomyelinase, 
Cathepsin D 
HSP90 
 
Cell adhesion-IL-8 family dependent 
migration and adhesion 
RAP-1A, G-protein alpha-i 
family 
RAP-1A, IL-8 
 
Immune response-MHC class II MHC class II alpha chain, 
Rab-7, Itch 
HSP90, Endoplasmin, 
Cathepsin L 
Chemotaxis-CCR4-induced chemotaxis of 
immune cells 
RAP-1A, G-protein alpha-i 
family 
RAP-1A 
 
Cell adhesion-Integrin inside-out 
signalling in neutrophils 
RAP-1A, FPR, G-protein 
alpha-i family 
CD44, RAP-1A, IL-8 
 
Immune response-MHC class I Rab-7 
 
HSP90, Endoplasmin, 
Cathepsin L, HSP70, 
HSP60 
Riboflavin metabolism FLAD1, PPAL PPAL 
Aberrant lipid trafficking and metabolism 
in age-related degeneration  
CD36L2, SR-BI, Cathepsin D 
 
CD36L2 
 
Signal transduction Cyclic AMP signalling RAP-2A, RAP-1A, G-protein 
alpha-i family 
RAP-1A 
 
Mitochondrial dysfunction in 
neurodegeneration (ND) 
TGM2 
 
SDHA, MPTP complex, 
SOD2, VDAC 1, ANT 
Intracellular cholesterol transport  NPC2, MENTHO, CD36L2, 
Rab-7, SR-BI 
Rab-4, TIP47, PBR, 
CD36L2, Caveolin-1 
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Table 5.2 Downregulated pathway maps enriched in AAPH and rotenone treated U-87MG cells. U-87MG cells 
were treated with AAPH or rotenone for 48 hours and analysed using mass spectrometry. Using differentially 
identified proteins downregulated by AAPH or rotenone pathways were subsequently enriched using MetaCore.   
Lysate Pathway Map Enrichments Proteins Downregulated by 
AAPH in pathway 
Proteins downregulated by 
rotenone in pathway 
Development-neural stem cell lineage 
commitment (schema) 
Tubulin beta 3, Vimentin, 
MAP-1B 
Tubulin beta 3 
 
Possible regulation of HSF1/chaperone 
pathway in huntington’s disease 
HSP27 
 
HSP27, p23 co-
chaperone, E2I 
 
Cytoskeleton remodelling-reverse 
signalling by ephrin-b 
Tubulin alpha, Ephrin-B, 
Tubulin (in microtubules) 
Tubulin alpha, Tubulin (in 
microtubules) 
Oxidative stress-ROS-induced cellular 
signalling 
NF-kB, HSP27, RelA (p65 
NF-kB subunit), IL-1 beta 
HSP27, Cytochrome c, 
TfR1, SCD, FASN, DLC1 
(Dynein LC8a), E2I 
Cell adhesion-integrin-mediated cell 
adhesion and migration 
MLCP (cat), MyHC, Zyxin 
 
Alpha-actinin, MLCP 
(cat), Talin, MRLC, 
MyHC 
Signal transduction-calcium signalling CD44, IP3 receptor, IP3R1, 
PP1-cat 
PP1-cat 
 
Cell adhesion-histamine H1 receptor 
signalling 
MLCP (cat), IP3 receptor 
 
Alpha-actinin, MLCP 
(cat), Talin, MRLC, p120-
catenin 
Cytoskeleton remodelling-role of PKA in 
cytoskeleton reorganisation 
MLCP (cat), LASP1, Fodrin 
(spectrin), IP3 receptor 
 
MLCP (cat) 
 
WNT signalling in invasive type 
melanoma cells 
Filamin-A (CTF), CD44, 
Vimentin, Filamin A 
Filamin A, Filamin-A 
(CTF) 
Cell adhesion-gap junctions Tubulin beta, Tubulin alpha, 
Tubulin (in microtubules), 
Caveolin-1 
Tubulin beta, Tubulin 
alpha, Tubulin (in 
microtubules) 
Cytoskeleton remodelling-substance p 
mediated membrane blebbing 
MLCP (cat), Tubulin alpha, 
Tubulin (in microtubules) 
 
MLCP (cat), Tubulin 
alpha, MRLC, Tubulin (in 
microtubules) 
Apoptosis and survival-granzyme a 
signalling 
Histone H1, Lamin A/C 
 
Ku70/80, Ku80, Histone 
H2B, NDUFS3, Ku70 
Cytoskeleton remodelling-keratin 
filaments 
Plectin 1, Tubulin beta, 
Vimentin, Tubulin alpha, 
Tubulin (in microtubules) 
Plectin 1, Tubulin beta, 
Tubulin alpha, Tubulin (in 
microtubules) 
Translation-regulation of translation 
initiation 
eIF4G1/3, PABPC1, 
PABPC4, eIF3S8, RPS6 
eIF4A, eIF4G1/3, eIF4E, 
PABPC1, PABPC4 
Cytoskeleton remodelling-
neurofilaments 
Plectin 1, Tubulin beta, 
Vimentin, Tubulin alpha, 
Tubulin (in microtubules) 
Plectin 1, Tubulin beta, 
Tubulin alpha, Tubulin (in 
microtubules) 
Inhibition of remyelination in multiple 
sclerosis 
PCBP-1, hnRNP A2, MLCP 
(cat), Tubulin beta, Tubulin 
alpha, Tubulin (in 
microtubules) 
MLCP (cat), Tubulin beta, 
Tubulin alpha, PCBP-1, 
MRLC, Tubulin (in 
microtubules) 
Cytoskeleton remodelling -Rho GTPases Cortactin, MLCP (cat), 
MyHC, Filamin A, Spectrin 
Alpha-actinin, MLCP 
(cat), Talin, RhoC, RhoA-
related, Filamin A, 
MRLC, MyHC 
Signal transduction-angiotensin II 
signalling via β-arrestin 
Clathrin heavy chain, MLCP 
(cat), Clathrin 
Clathrin heavy chain, 
MLCP (cat), ARF6, 
p90Rsk, MRLC, eIF4E, 
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p23 co-chaperone, 14-3-
3 
Neurophysiological process-GABA-a 
receptor life cycle  
Clathrin heavy chain, Dynein 
1, cytoplasmic, heavy chain, 
Clathrin light chain, Clathrin, 
Tubulin (in microtubules), 
PP1-cat 
Clathrin heavy chain, 
Tubulin (in microtubules), 
PP1-cat 
 
Development-oligodendrocyte 
differentiation and myelination 
PCBP-1, hnRNP A2, 
Cortactin, MLCP (cat), 
MAP4, Tubulin beta, Tubulin 
alpha, Tubulin (in 
microtubules), MAP-1B 
MLCP (cat), Tubulin beta, 
Tubulin alpha, PCBP-1, 
MRLC, Tubulin (in 
microtubules) 
 
 
Table 5.3 Upregulated pathway maps enriched in AAPH and rotenone treated U-87MG secretomes. U-87MG 
cells were treated with AAPH or rotenone for 24 hours, media was then collected and analysed using mass 
spectrometry. Using differentially identified proteins upregulated by AAPH or rotenone pathways were 
subsequently enriched using MetaCore 
secretome Pathway Map 
Enrichments 
Proteins upregulated by 
AAPH in pathway 
Proteins upregulated by 
rotenone in pathway 
Immune response-MHC class II: 
presentation 
Tubulin (in microtubules), 
Rab-7, RhoA 
Cathepsin L, Tubulin (in 
microtubules) 
Immune response-MHC class I: cross-
presentation 
HSP70, Rab-7 
 
HSP70, HSP60, 
Cathepsin L, VCP 
Cell adhesion-integrin-mediated cell 
adhesion and migration 
MLCP (cat), RhoA 
 
MRLC, Alpha-actinin, 
MyHC 
Development-mag-dependent 
inhibition of neurite outgrowth 
MLCP (cat), RhoA 
 
MRLC, Reticulon 4, 
MyHC 
 
Inhibitory action of lipoxins on IL-8- 
and leukotriene B4-induced 
neutrophil migration 
MLCP (cat) 
 
MRLC, Alpha-actinin, 
Actin 
 
Immune response -CCR3 signalling in 
eosinophils 
MLCP (cat), RhoA 
 
MRLC, Profilin, Profilin I, 
MyHC 
Apoptosis and survival-NGF/TRKA 
PI3K-mediated signalling 
MLCP (cat), Tubulin (in 
microtubules), RhoA 
 
MRLC, Tubulin (in 
microtubules), MSN 
(moesin) 
Neurophysiological process-dynein-
dynactin motor complex in axonal 
transport in neurons 
Vimentin, Tubulin (in 
microtubules), Rab-7 
 
Tubulin (in microtubules) 
 
Immune response- MHC class I: 
classical pathway 
GANAB, Beta-2-
microglobulin, HSP70 
GANAB, PDIA3, HSP70 
 
Neurophysiological process-receptor 
mediated axon growth repulsion 
CRMP2, Tubulin (in 
microtubules), RhoA 
 
CRMP2, Tubulin (in 
microtubules) 
 
Neurophysiological process-gaba-a 
receptor life cycle  
Clathrin heavy chain, Tubulin 
(in microtubules), PP1-cat 
Clathrin heavy chain, 
Tubulin (in microtubules) 
Cell adhesion-interruption of cell 
barrier integrity 
MLCP (cat), RhoA 
 
MRLC, Alpha-actinin 
 
Apoptosis and survival-granzyme a 
signalling 
MLCP (cat), Tubulin (in 
microtubules), RhoA 
MRLC, Tubulin (in 
microtubules), MSN 
(moesin) 
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Cell adhesion-gap junctions Tubulin alpha, Tubulin beta, 
Tubulin (in microtubules) 
Tubulin alpha, Tubulin 
beta, Tubulin (in 
microtubules), Actin 
Regulation of actin cytoskeleton 
organization by kinase effectors of 
rho gtpases 
MLCP (cat), RhoA-related, 
Spectrin, RhoA 
 
MRLC, Alpha-actinin, 
ERM proteins, MyHC, 
MSN (moesin) 
Calcium signalling FKBP12, CD44, PP1-cat, 
RhoA 
FKBP12 
 
LRRK2 in neurons in parkinson’s 
disease 
Clathrin heavy chain, Tubulin 
(in microtubules) 
eEF1A, Clathrin heavy 
chain, Tubulin (in 
microtubules), 14-3-3, 
MSN (moesin) 
Regulation of cytoskeleton proteins 
in oligodendrocyte differentiation 
and myelination 
MLCP (cat), Tubulin alpha, 
Tubulin beta, Tubulin (in 
microtubules), RhoA 
 
MRLC, Tubulin alpha, 
Tubulin beta, Tubulin (in 
microtubules) 
 
Inhibition of remyelination in 
multiple sclerosis  
MLCP (cat), Tubulin alpha, 
Tubulin beta, Tubulin (in 
microtubules), RhoA 
MRLC, Tubulin alpha, 
Tubulin beta, Tubulin (in 
microtubules) 
Cytoskeleton remodelling-
neurofilaments 
Plectin 1, Tubulin alpha, 
Tubulin beta, Vimentin, 
Tubulin (in microtubules) 
Tubulin alpha, Tubulin 
beta, Tubulin (in 
microtubules) 
 
Table 5.4 Downregulated pathway maps enriched in AAPH and rotenone treated U-87MG secretomes. U-
87MG cells were treated with AAPH or rotenone for 24 hours, media was then collected and analysed using 
mass spectrometry. Using differentially identified proteins downregulated by AAPH or rotenone pathways were 
subsequently enriched using MetaCore 
Secretome Pathway Map 
Enrichments 
Proteins Downregulated by 
AAPH in pathway 
Proteins downregulated 
by rotenone in pathway 
Apoptosis and survival-TNF-α-
induced caspase-8 signalling 
Cathepsin D 
 
HSP90, Cathepsin B 
 
Immune reponse-MIF in innate 
immunity response 
MIF 
 
MIF, IL-8 
 
Immune response-IL-1 signalling 
pathway  
HSP27 
 
HSP27, CD44, IL-8 
 
Cytoskelelton remodelling-
neurofilaments 
Tubulin beta 
 
Plectin 1, Tubulin beta 
 
Immune response-MIF-mediated 
glucocorticoid regulation 
MIF 
 
MIF, CD44, IL-8 
 
Regulation of caspase activity in 
Huntington’s disease 
HSP27, HSP70 
 
HSP90, HSP27, HSP70 
 
Apoptosis and survival-FAS signalling 
cascades 
Lamin A/C, HSP27 
 
HSP27, Lamin A/C 
 
Cytoskeleton remodelling-integrin 
outside-in signalling 
Filamin A 
 
Fibronectin, Talin, 
Filamin A 
Immune response-MIF-induced cell 
adhesion, migration and angiogenesis  
MIF 
 
MIF, CD44, IL-8 
 
Cell adhesion-integrin-mediated cell 
adhesion and migration  
MyHC 
 
Fibronectin, MLCP (cat), 
Talin 
Cytoskelton remodelling-keratin 
filaments 
Tubulin beta, Keratin 14 
 
Plectin 1, Tubulin beta 
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WNT signalling in invasive-type 
melanoma cells 
Filamin A, Filamin-A (CTF) 
 
Filamin-A (CTF), CD44, 
MMP-2, Filamin A 
Transcription-HIF1 targets LDHA, ENO1, TGM2 LOXL2, PAI1, MMP-2 
HSP70 and HSP40-dependent folding 
in Huntington’s disease 
HSP27, Cathepsin D 
HSP70 
HSP90, HSP27 
HSP70 
Cell adhesion-α-4-integrins in cell 
migration and adhesion 
Filamin A 
 
Fibronectin, ITGB1, 
Filamin A 
Apoptosis and survival-granzyme A 
signalling 
Lamin A/C, Histone H1 
 
Ku80, Lamin A/C, HMG2 
 
Possible regulation of HSF1/ 
chaperone pathway in Huntington’s 
disease 
HSP27 
 
HSP90, HSP27, p23 co-
chaperone 
 
Cell adhesion-role of tetraspanins in 
integrin-mediated cell adhesion 
Filamin A 
 
Fibronectin, ITGB1, Talin, 
Filamin A 
 
CHDI-correlation from replication 
data-cytoskeleton and adhesion 
module 
MyHC 
 
Fibronectin, MLCP (cat), 
Plasminogen, Talin, 
Plasmin 
Immune reponse-alternative 
complement pathway  
Annexin II 
 
C3b, C3dg, C3a, C3, 
Factor I, C3c, Clusterin, 
iC3b 
 
A number of protein clusters were identified by STRING analysis from mass spectrometry data. 
Interestingly U-87MG lysates treated with both AAPH and rotenone resulted in downregulation of 
proteins associated with mRNA metabolic processing (figure 5.16 and 5.18). Furthermore, clusters 
identified cytoskeleton organisation was downregulated in both U-87MG lysates treated with AAPH 
or rotenone (figure 5.16 and 5.18), where different tubulins were affected. Of note, rotenone 
treatment resulted in mitochondrial gene associated proteins and those involved in mitochondrial 
organisation being downregulated (figure 5.18), which was not observed with AAP, suggesting specific 
RS have different effects. Further highlighting this AAPH resulted in proteins associated with lipid 
metabolism being upregulated potentially to combat lipid peroxidation induced by AAPH (figure 5.17). 
Both AAPH and rotenone treatment of U-87MG resulted in upregulated of secretion and vesicle 
mediated transport (figure 5.17 and 5.19), suggesting despite different RS there are some common 
processes affected. Furthermore, a greater number of proteins were downregulated by AAPH and 
rotenone than upregulated with more proteins identified from rotenone treatment (figure 5.16-5.19).       
STRING analysis of proteins identified by mass spectrometry in AAPH and rotenone treated U-
87MG secretomes demonstrates how less proteins were discovered. Of note from cluster analysis are 
that proteins associated with nitrogen processes were both downregulated and upregulated in U-
87MG secretomes treated with AAPH (figure 5.20), potentially to combat nitrogen induced stress from 
AAPH. In contrast, rotenone resulted in more proteins associated with nitrogen processes only being 
upregulated in the secretome (figure 5.23), suggesting they can spare these and thus secrete them. 
CHAPTER 5                                                                     REACTIVE SPECIES IN A DIFFERENTIATED MODEL 
 
262 
 
Additionally from looking at the protein clusters rotenone treatment appears to result in 
downregulation of proteins associated with cell adhesion and process development (figure 5.22), 
which was not observed with AAPH treat U-87MG secretomes, where process development even 
increased in AAPH secretomes (figure 5.20).    
Figure 5.16 STRING analysis of downregulated proteins identified from mass spectrometry of U-87MG lysates treated with 
AAPH. Proteins were clustered based on enrichment of GO biological processes. The nodes represent individual proteins, 
which are linked by coloured lines representing a category of interaction (purple: experiments, light blue: databases, dark 
blue: gene co-currence, black: co-expression). These interactions are based on the predicted and known protein information 
held within the database. Coloured nodes represent proteins associated with red: mRNA metabolic processing, blue: 
intercellular transport, and green: cytoskeleton organisation.     
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Figure 5.17 STRING analysis of upregulated proteins identified from mass spectrometry of U-87MG lysates treated with 
AAPH. Proteins were clustered based on enrichment of GO biological processes. The nodes represent individual proteins, 
which are linked by coloured lines representing a category of interaction (purple: experiments, light blue: databases, dark 
blue: gene co-currence, black: co-expression). These interactions are based on the predicted and known protein information 
held within the database. Coloured nodes represent proteins associated with red: vesicle mediated transport, blue: secretion, 
and green: lipid metabolic processes.     
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Figure 5.18 STRING analysis of downregulated proteins identified from mass spectrometry of U-87MG lysates treated with 
rotenone. Proteins were clustered based on enrichment of GO biological processes. The nodes represent individual proteins, 
which are linked by coloured lines representing a category of interaction (purple: experiments, light blue: databases, dark 
blue: gene co-currence, black: co-expression). These interactions are based on the predicted and known protein information 
held within the database. Coloured nodes represent proteins associated with red: proteins associated with mitochondrial 
genes, blue: mitochondrial organisation, green: cytoskeleton organisation and yellow: mRNA metabolic processing.     
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Figure 5.19 STRING analysis of upregulated proteins identified from mass spectrometry of U-87MG lysates treated with 
rotenone. Proteins were clustered based on enrichment of GO biological processes. The nodes represent individual proteins, 
which are linked by coloured lines representing a category of interaction (purple: experiments, light blue: databases, dark 
blue: gene co-currence, black: co-expression). These interactions are based on the predicted and known protein information 
held within the database. Coloured nodes represent proteins associated with red: vesicle mediated transport, blue: secretion, 
green: mitochondrial transport and yellow: protein targeting.     
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Figure 5.20 STRING analysis of downregulated proteins identified from mass spectrometry of U-87MG secretomes treated 
with AAPH. Proteins were clustered based on enrichment of GO biological processes. The nodes represent individual proteins, 
which are linked by coloured lines representing a category of interaction (purple: experiments, light blue: databases, dark 
blue: gene co-currence, black: co-expression). These interactions are based on the predicted and known protein information 
held within the database. Coloured nodes represent proteins associated with red: nitrogen processes, blue: negative 
regulation of processes, green: cytoskeleton organisation.     
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Figure 5.21 STRING analysis of upregulated proteins identified from mass spectrometry of U-87MG secretomes treated 
with AAPH. Proteins were clustered based on enrichment of GO biological processes. The nodes represent individual proteins, 
which are linked by coloured lines representing a category of interaction (purple: experiments, light blue: databases, dark 
blue: gene co-currence, black: co-expression). These interactions are based on the predicted and known protein information 
held within the database. Coloured nodes represent proteins associated with red: nitrogen processes, blue: translation, green: 
process development.     
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Figure 5.22 STRING analysis of downregulated proteins identified from mass spectrometry of U-87MG secretomes treated 
with rotenone. Proteins were clustered based on enrichment of GO biological processes. The nodes represent individual 
proteins, which are linked by coloured lines representing a category of interaction (purple: experiments, light blue: databases, 
dark blue: gene co-currence, black: co-expression). These interactions are based on the predicted and known protein 
information held within the database. Coloured nodes represent proteins associated with red: cell adhesion, blue: process 
development, green: negative regulation of biological processes.     
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Figure 5.23 STRING analysis of upregulated proteins identified from mass spectrometry of U-87MG secretomes treated 
with rotenone. Proteins were clustered based on enrichment of GO biological processes. The nodes represent individual 
proteins, which are linked by coloured lines representing a category of interaction (purple: experiments, light blue: databases, 
dark blue: gene co-currence, black: co-expression). These interactions are based on the predicted and known protein 
information held within the database. Coloured nodes represent proteins associated with red: nitrogen processes, blue: 
negative regulation of processes, green: translation.     
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Western blot analysis confirmed mass spectrometry observations where HSP70 increased as 
a result of AAPH and rotenone treatment while HSP27 (referred to as heat shock protein β1 in mass 
spectrometry data) decreased (figure 5.24) and was used to validate the mass spectrometry findings.     
 
Furthermore, post-translational modification identification following mass spectrometry 
using the statistical software PEAKS via peptide fragmentation, demonstrates that AAPH and rotenone 
induced a significant number of oxidative modifications on differentially identified proteins for both 
U-87MG lysates and secretomes (figure 5.25A and B, respectively). Interestingly, the average number 
of oxidative modifications in lysates was greater with rotenone treatment. However, in the secretome 
AAPH showed the highest oxidative modifications. PEAKS analysis also highlighted a greater number 
of malondialdehyde (MDA) adducts, a by-product of lipid peroxidation for AAPH treatment in both U-
87MG lysates and secretomes (figure 5.25C and D, respectively). Thus, supporting the idea that AAPH 
results in greater lipid peroxidation than rotenone. Together, these results suggest that while both 
AAPH and rotenone induce OS the RS they generate induce different pathways, which may explain the 
morphological differences observed when SH-SY5Y neuronal cells were treated with AAPH and 
rotenone conditioned U-87MG media.  
Figure 5.24 Western blot validation of mass spectrometry. Representative Western blot of differentiated 
glial U-87MG total cell extracts were probed with (A) HSP70 (1:1000) or (B) HSP27 (1:1000) after 
treatment with either 1 mM AAPH or 0.5 μM rotenone for 48 hours following 5 day differentiation (0.5% 
(v/v) FBS, 10 μM retinoic acid). Each Western blot is accompanied by a plot summarising densitometric 
analyses of Western blots using AIDA software. Results are presents as fold change against control ± SEM. 
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Figure 5.25 Post-translational modifications identified using the PEAKS software on both U-87MG lysates 
and secretomes that have been treated with AAPH or rotenone. U-87MG glial cells were differentiated 
over 5 days (0.5% (v/v) FBS, 10 μM retinoic acid) and then treated with 1 mM AAPH or 0.5 μM rotenone for 
48 hours where lysates and secretomes were analysed via mass spectrometry. Subsequently, the statistical 
search engine PEAKS was used to identify post-translational modifications. The average number of oxidative 
modifications was then calculated for both U-87MG lysates (A) and secretomes (B). The average number of 
malondialdehyde (MDA) adducts was also determined for U-87MG lysates (C) and secretomes (D).  
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5.3 DISCUSSION  
Over recent years intercellular communication has been receiving more attention to aid pathology 
understanding. However, the interactions between glia and neurons in neurodegenerative diseases 
still needs further investigation. Currently, generating co-cultures is difficult and involves cells brought 
together via contact or non-contact means. Initially, we attempted to create a 1:1 contact co-culture 
by combining cells suspensions prior to seeding (Jiang et al., 2005). While co-cultures of SH-SY5Y and 
U-87MG cells showed greater viability when treated with AAPH relative to SH-SY5Y monocultures, 
rotenone treatment resulted in similar viability. However, as previous viability studies show AAPH 
induced proliferation in U-87MG cells it is unknown whether the higher viability is because U-87MG 
cells within the co-culture proliferate, while SH-SY5Y cells underwent cell death. As such, we 
attempted to determine the ratio of neurons to glia using immunofluorescent staining. Unfortunately, 
this was unsuccessful due to the shared expression of βIII-tubulin by SH-SY5Y and U-87MG cells 
(Katsetos et al., 2007; Wang and Liu, 2019) and thus, co-staining was unsuccessful for determining cell 
ratios. As such, future experiments would require cells to be stably transfected with an 
immunofluorescent tag or other markers for immunofluorescence would be needed.    
With difficulties encountered with contact co-cultures, transwell inserts were used to 
investigate non-contact co-cultures. When using transwell inserts it is important to consider which 
insert to use. As we wanted to investigate secreted factors and feedback loops 0.4 μm pore sizes that 
allow soluble factor diffusion while preventing cell migration were utilised. However, due to the 
porous nature required for inserts companies tend to use PET due to their transparent properties, 
allowing phase microscopy visibility while not being collagen coated, which can be problematic with 
adherent cells making them optimal for morphological studies. However, as inserts are a different 
material from the polystyrene 24-well tissue culture plates this needed to be considered. Different 
cell types exhibit different cellular functions on different substrates including growth, proliferation, 
differentiation and adhesion that could affect results (Ventre and Netti, 2016; Wells, 2008).  
 Thus, initially co-cultures of SH-SY5Y neuronal and U-87MG glial cells were investigated, where 
each cell line was grown on either polystyrene 24-well plates or PET inserts. Of note, polystyrene has 
a Young’s modulus of 3.2 GPa (Sultanova et al., 2009) while PET is much lower with 1.7 GPa (Li et al., 
2001), suggesting polystyrene plates are a much harder surface than the PET membranes of inserts. 
As others have demonstrated, the results herein suggest SH-SY5Y neuronal and U-87MG glial cells 
have a morphological dependence on the culture material (Chemmarappally et al., 2020; Georges et 
al., 2006; Morçimen et al., 2019; Yeung et al., 2005). Indeed, SH-SY5Y neuronal cells appear to be able 
to grow on both polystyrene and PET surfaces, where improved membrane integrity was observed for 
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the softer PET insert surface consistent with previous findings (Balgude et al., 2001; Flanagan et al., 
2002; Georges et al., 2006). In contrast, U-87MG glial cells struggled to grow on PET inserts displaying 
a more rounded morphology compared to their stellate counterparts in the polystyrene plates, similar 
to results with astrocytes on softer hydrogels (Georges et al., 2006). Thus, when investigating a co-
culture between SH-SY5Y neuronal and U-87MG glial cells in the future the insert material needs to 
be considered as these cells show morphological dependence on cultivation material.   
Investigating neurodegeneration is not limited to neuronal cells, with research addressing 
other neural cells including oligodendrocytes, microglia and astrocytes (Cunningham et al., 2019; 
Hickman et al., 2018; Philips and Rothstein, 2017). Astrocytes in particular, are suggested to be 
involved in neuroprotection against OS (Allaman et al., 2011; Drukarch et al., 1998; Vargas and 
Johnson, 2009). One of the main astrocytic mechanisms proposed in neuroprotection involves 
glutathione, which is higher in astrocytes than neurons (Alsayyah et al., 2019; Li et al., 2019; Makar et 
al., 2008). The results herein propose U-87MG glial cells protect neurons against specific RS as co-
cultures show greater viability than their respective monocultures when treated with rotenone but 
not with AAPH. Looking at previous data we observed that rotenone upregulated glutathione in both 
SH-SY5Y neuronal and U-87MG glial cells but AAPH only upregulated glutathione levels in SH-SY5Y 
neuronal cells (figure 3.7). Glutathione is the primary cellular antioxidant against the RS nitric oxide, 
which can cause S-nitrosylation (Deng et al., 2018; Hogg et al., 1996). The results in chapter 4 support 
this as AAPH generated significantly more S-nitrosylation in AAPH treated U-87MG glia than rotenone 
(figure 4.48). This suggests greater levels of nitric oxide that can result in glutathione oxidation, leading 
to reduced antioxidant defence (Deng et al., 2018; Padgett and Whorton, 1998). Therefore, AAPH 
treatment of U-87MG cells may result in glutathione levels not being sufficient to support neurons 
against OS. In contrast, rotenone treated U-87MG exhibit greater levels of glutathione, which can be 
secreted into the extracellular space, where ectopeptidases can break glutathione down into its 
precursors; glycine and cysteine to be taken up by neurons thus, improving glutathione synthesis in 
neurons to combat RS (McBean, 2017; Sedlak et al., 2019). 
Alternatively, glutathione may be reducing oxidised vitamin C from neurons releasing 
ascorbate back into the extracellular fluid for neurons to utilise (García-Krauss et al., 2016; Wilson, 
1997). This may explain why co-cultures are effective against rotenone as we have previously shown 
that ascorbic acid was not effective at improving the viability of AAPH treated SH-SY5Y neuronal cells 
but was with rotenone treated cells, highlighting how different antioxidants are more effective against 
specific RS.   
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Therefore, while the results herein suggest U-87MG co-cultures are able to protect SH-SY5Y 
neurons against specific RS, the underlying mechanism is still not understood. To determine if U-87MG 
cells improve SH-SY5Y neuronal viability in response to rotenone via glutathione future studies could 
involve incubating U-87MG glial cells with buthionine sulfoximine, prior to treatment with rotenone. 
However, as glia struggle to grow on the soft insert material SH-SY5Y neuronal cells may have to be 
cultivated on inserts in future investigations.    
 With difficulties in creating co-cultures, a lot of research over the past decade has involved 
investigations into the secretome, further enhanced due to possible identification of biomarkers as 
diagnostic tools to identify neurodegenerative diseases before clinical symptoms arise, symbolising 
irreversible damage. Astrocytes are believed to be secretory cells able to release factors that mediate 
either neurotoxic or neuroprotective effects (Jha et al., 2018; Verkhratsky et al., 2016). Currently, most 
secretome analyses have used rodent models (Greco et al., 2010; Keene et al., 2009; Moore et al., 
2009; Yin et al., 2012), however, murine astrocytes differ from human astrocytes (Y. Zhang et al., 
2016). As such, immortalised and cancer cell lines are now being investigated to generate a catalogue 
of potential secreted proteins. The mass spectrometry results of the U-87MG glial secretome herein 
hope to add to the catalogue of proteins identified previously, in the hope of generating a more 
detailed proteome to infer the potential functions and pathways of secreted proteins.  
 Consistent with previous studies, we observed differential expression of common astrocytic 
secreted proteins including, vimentin, thrombospondin, fibronectin, cystatin, apolipoprotein E, 
extracellular SOD, SPARC, and metalloproteinase inhibitors (supplementary table 8.2; Greco et al., 
2010; Keene et al., 2009; Lafon-Cazal et al., 2003; Moore et al., 2009; Yin et al., 2012). This highlights 
that while the results herein are from a human glioblastoma cell line some secreted proteins are the 
same as those secreted by murine astrocytes, supporting the use of immortalised cell lines for 
secretome analysis.  
 Proteins secreted by astrocytes under OS could be grouped into proteins effecting the ECM 
and those effecting neuronal homeostasis including neuroinflammation (as also seen in Jha et al, 
2018). From pathway enrichment analysis using MetaCore, the majority of the downregulated 
pathways in AAPH and rotenone treated U-87MG glial lysates and secretomes were involved in cell 
adhesion (figure 5.14 and 5.15). Fibronectin and metalloproteinase inhibitors were some of the 
proteins downregulated possibly contributing to decreased cell adhesion pathways being enriched. 
Fibronectin, an ECM protein is involved in adhesion but also in regulating intercellular diffusion 
signalling by modulating the ECM (Wang et al., 2013), alongside having anti-inflammatory properties 
(Lin et al., 2012; Tsuda et al., 2008). As others have demonstrated the results included here suggest 
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OS downregulates fibronectin as rotenone treated U-87MG conditioned media exhibited lower levels 
of fibronectin (Allani et al., 2004), but increased in AAPH treated U-87MG conditioned media relative 
to the control. This possibly leads to reduced cell adhesion that could explain the glial clustering, cell 
rounding, and apoptosis observed in rotenone treatment. Additionally, rotenone U-87MG conditioned 
media also resulted in reduced SH-SY5Y viability, possibly due to decreased fibronectin levels leading 
to the ECM preventing signalling between neurons, or the presence of less anti-inflammatory 
mediators. These results suggest specific RS effect U-87MG glial secretome protein levels altering the 
ECM. 
Under normal conditions within the ECM metalloproteinases are inhibited however astrocytic 
metalloproteinases can be activated by OS (Gottschall and Deb, 1996; Gottschall and Yu, 2002; 
Latronico et al., 2018). Our results suggest RS from both AAPH and rotenone result in 
metalloproteinase inhibitors being downregulated in both the secretomes and lysates relative to 
controls. As metalloproteinases are involved in ECM degradation (Levin et al., 2017) downregulation 
of the inhibitors would lead to their activation and subsequent disruption of the ECM, possibly 
explaining the neuronal degeneration observed as others have reported (Brkic et al., 2015; 
Cunningham et al., 2005; Sadeghian et al., 2012).  
The results within suggest not only do different RS induce secretome changes that affect 
neuronal viability but also morphology, as rotenone U-87MG conditioned media culture conditions 
exhibited cuboidal morphology and lack of processes. Filamin A is an actin cross-linker involved in 
dendrites, where stable filamin A regulates dendritic morphogenesis (Zhang et al., 2014), axonal 
growth cones (Zheng et al., 2011) and neuronal migration (Sarkisian et al., 2006). Thus, the 
downregulation of filamin A in rotenone treated U-87MG cells and secretomes may explain the lack 
of processes. Furthermore, enrichment analysis highlighted the WNT-signalling pathway was 
downregulated in both rotenone treated U-87MG lysates and secretomes. This supports previous 
studies who suggest the WNT-signalling pathway plays a role in neuronal survival, axonal extension 
and synapse formation; where astrocytes may be involved in this through the secretome (Ciani and 
Salinas, 2005; F. L’Episcopo et al., 2011; Maiese et al., 2008; Marchetti et al., 2013; Patapoutian and 
Reichardt, 2000). Lower levels of WNT-signalling may explain the decreased neuronal viability as 
neuronal apoptosis may be triggered by GSK-3β as has been shown with other neurotoxins such as 6-
OHDA, rotenone and MPTP/MPP+ in SH-SY5Y and PC12 in vitro studies (Petit-Paitel et al., 2009; W. 
Wang et al., 2007). Further reinforcing the astrocyte secretome may play a role in this behaviour is 
highlighted by L’Episcopo et al., who show WNT knockdown in astrocytes resulted in decreased 
tyrosine hydroxylase positive neuronal viability relative to control astrocyte co-cultures (L’Episcopo et 
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al., 2011). Together, this suggests OS affects adhesion directly via the ECM and secreted factors that 
can also determine neuronal morphology.  
The results herein also suggest homestasis was affected as AAPH and rotenone resulted in 
downregulation of HSP70 and HSP90 in the U-87MG secretome, which are primary chaperones 
involved in protein folding (supplementary table 8.2; Lackie et al., 2017; Verkhratsky et al., 2016). 
Recently, HSP70 has been reported to be secreted in glial media via exosomes (Kowal et al., 2016). 
However, as the glia within this study were subjected to OS they may have retained HSP70 and HSP90 
in an attempt to combat OS. This suggests glia under OS do not provide as many supportive factors to 
neurons and thus, are not neuroprotective against stress and therefore may have a neurotoxic effect 
instead.  
 Further suggesting rotenone conditioned U-87MG media induced greater stress than AAPH 
conditioned U-87MG media relative to the control, neuroinflammation appeared to be induced. This 
was suggested by the enrichment analysis highlighting MHC-I and II pathways being in the top 50 
(figure 5.14 and 5.15). This supports previous observations of MHC-1 presentation observed in 
astrocytes of neurodegenerative diseases (Hinkle et al., 2019; Höftberger et al., 2004; Sorrentino et 
al., 2019). This suggests pro-inflammatory and anti-inflammatory factors (Arbore et al., 2017) have 
been stimulated in the U-87MG cells and secretomes as a result of OS.  
 Mass spectrometry while highlighting new pathways such as inflammation, the ECM and 
chaperones as potential mechanisms that play a role in the secretome affecting neurons, also 
confirmed previous observations and hypotheses. As mentioned previously, we hypothesise the 
hallmarks of neurodegeneration: mitochondrial dysfunction, protein degradation and OS are not 
independent but are linked in what we refer to as the “neurodegenerative Bermuda triangle”. 
Pathways enrichment highlighted mitochondrial dysfunction and changes to chaperone proteins such 
as HSP70 and HSP90 accompanied by increased oxidative modifications, this supports our hypothesis. 
Furthermore, AAPH is recognised as a peroxyl generator (Bassett et al., 1999; Terao and Niki, 1986; 
Werber et al., 2011) and thus, we proposed it could be used as a more specific RS generator to 
investigate lipid peroxidation. PTM analysis using PEAKs further supported results in chapter 4, where 
AAPH generated a larger average of MDA adducts, a by-product of lipid peroxidation (Esterbauer et 
al., 1991; Gaschler and Stockwell, 2017), suggesting the RS generated by AAPH resulted in greater lipid 
peroxidation than rotenone.  
 In conclusion, co-cultures remain difficult to investigate with multiple methods being utilised 
herein. Contact co-cultures are one procedure that can be exploited but for future investigations, 
immunofluorescent tagging would aid in determining cell ratios as it is difficult to determine each 
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cell types contribution, and if the observations are due to cell ratio or feedback between the cells. 
Transwell inserts allow these problems to be countered but have their own problems. With the need 
for inserts to be transparent but also possess pores companies have employed the use of PET, which 
has a different hardness to the 24-well plates these inserts are suspended over. As such, the use of 
these needs to be considered as specific cell types can grow and react differently depending on the 
material they are grown on. This is particularly important to note when creating co-cultures between 
glia and neurons as they prefer hard and soft materials, respectively (Balgude et al., 2001; Engler et 
al., 2004; Georges et al., 2006; Yeung et al., 2005). Furthermore, with the inserts only having a small 
surface area which limits the well size that can be used it is difficult to obtain enough protein from 
cells to conduct experiments without using multiple plates, which can be costly. As such, transwell 
inserts while avoiding the problems encountered with contact co-cultures still host a series of 
problems and should be used for select experiments. Finally, conditioned media is posing an 
alternative way for investigating cellular interactions if only in one direction but could allow the 
identification of potential biomarkers that may aid in diagnosing neurodegenerative diseases before 
clinical symptoms arise. However, for this to occur a large amount of research is needed, exploiting 
the recent advances in mass spectrometry and bioinformatic analysis to help create a catalogue of 
secreted proteins in diseased and physiological conditions. Through collaborating and combining 
these findings pathways and potentially novels therapies can be generated to help treat or combat 
neurodegenerative diseases.       
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6.1 CONCLUSIONS  
A worldwide increase in the aging population highlights neurodegeneration as a key disease that 
significantly impacts both lifestyle and the economy. Epidemiological predictions suggest the 
population affected by neurodegenerative disease will increase by 50% by 2030 (Dorsey et al., 
2013). Alzheimer’s and Parkinson’s disease are the most common neurodegenerative diseases and 
while they affect different brain regions, they share progressive and irreversible loss of neuronal 
structure and function (Feitosa et al., 2018). Thus, understanding the individual underlying 
mechanisms and commonalities that contribute to these neurodegenerative processes will help 
pinpoint the molecular targets. Indeed, there are several common molecular features that 
characterise the diseases including: changes in protein degradation leading to protein aggregates, 
mitochondrial defects, neuroinflammation and OS (Chaturvedi and Flint Beal, 2013; Feitosa et al., 
2018; Heneka et al., 2014; Jucker and Walker, 2013).  
 Currently, most if not all therapies treat the symptoms of neurodegenerative diseases and 
not the underlying cause. Multiple mechanisms have been implicated in neurodegenerative 
diseases, which highlights the need to develop novel therapies that target these pathways to 
prevent neuronal loss and prevent the manifestation of clinical symptoms (Nieoullon, 2011). OS is 
one of the primary hallmarks of neurodegeneration but is one of the least understood mechanisms 
as various RS can be generated. RS include reactive oxygen and nitrogen species. ROS include 
superoxide, hydrogen peroxide, peroxyl radicals, hydroxyl radicals and lipid hydroperoxides. While 
nitric oxide, nitrite, nitrogen dioxide and peroxynitrites are examples of RNS (Koskenkorva-Frank et 
al., 2013).  
 The ROS, superoxide is the main precursor that leads to a cascade of other RS, where 
superoxide is generated due to electrons leaking from the electron transport chain during the 
reduction of molecular oxygen in mitochondria but also nicotinamide adenine dinucleotide 
phosphate (NADPH) oxidase, within membranes and the non-membrane bound enzyme xanthine 
oxidase (Nita and Grzybowski, 2016; Winterbourn, 2015). As such, mitochondrial dysfunction is 
proposed to increase OS within cells. RNS instead, are generated from L-arginine, where the 
reaction is catalysed by nitric oxide synthase (NOS) enzymes within the cytosol including neuronal, 
endothelial and inducible NOS (Ghasemi and Fatemi, 2014). Furthermore the combination of nitric 
oxide with superoxide also forms the RNS peroxynitrite which can result in various cellular damage 
if not controlled (Steinert et al., 2010).  
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Under physiological conditions, various antioxidant systems function to counteract the 
damaged induced by RS. For example, SOD dismutates superoxide to hydrogen peroxide (Dasuri et 
al., 2013; Donnelly et al., 1989), which can be degraded to water via catalase (CAT), peroxiredoxins 
(PRDX) and glutathione peroxidase (GPX; Gandhi and Abramov, 2012; Sue et al., 2005) . However, 
if not degraded hydrogen peroxide can be converted to the highly reactive hydroxyl radical. 
Alternatively low molecular weight antioxidants such as vitamin C and E in addition to glutathione 
(GLUT) help scavenge RS within the CNS (Birben et al., 2012; Feitosa et al., 2018; Rice, 2000). Within 
the CNS, the antioxidant levels differ depending on the neural cell types, possibly explaining varying 
susceptibilities to OS (Hertz et al., 2007; Schönfeld and Reiser, 2013). If RS levels become 
uncontrolled both ROS and RNS can result in DNA damage, lipid peroxidation and protein 
modifications leading to aggregates that can impair protein degradation further promoting OS 
(summarised in figure 6.1). Thus, OS also appears to contribute and exacerbate other mechanisms 
involved in neurodegeneration including mitochondrial dysfunction and protein degradation; 
collectively referred to as the “Neurodegenerative Bermuda triangle”.  
 
Figure 6.1 Diagrammatic representation of reactive species sources, antioxidants and changes induced by 
oxidative stress in neurodegeneration. Under physiological conditions reactive species and controlled by 
antioxidants: glutathione peroxidase (GPX), peroxiredoxin (PRDX), catalase (CAT), superoxide dismutase (SOD), 
vitamin C and E (VIT C/E) and glutathione (GLUT). Common by-products of lipid peroxidation include 4-
hydroxynonenal (4-HNE) and malondialdehyde (MDA). Other common post-translational modifications (PTM’s) 
observed include carbonylation and S-nitrosylation. Adapted from Feitosa et al., 2018      
CHAPTER 6                                                   CONCLUSIONS AND FUTURE WORK 
 
281 
 
 The aim of this thesis was to investigate the role of RS in neural cell models and initiate the 
development of an in vitro co-culture to investigate OS. By using clonal SH-SY5Y and U-87MG cell 
lines we were able to mimic neurons and astrocytes within the CNS, respectively. OS was induced 
in SH-SY5Y and U-87MG monocultures, specifically peroxy radicals and superoxide radicals using 
2,2′-Azobis(2-methylpropionamidine) dihydrochloride (AAPH; a ROS generating lipid peroxidation 
agent) and rotenone (a mitochondrial disruptor that inhibits complex I), respectively.  
The initial treatment of monocultures showed that rotenone and AAPH could generate RS 
that could be fluorescently measured using DCFDA. These RS could be attenuated using 
antioxidants (Patra et al., 2001; Wenzel, 2003). The different responses of each cell line were first 
highlighted here, as the rate of fluorescence in response to AAPH was greater in SH-SY5Y cells than 
U-87MG cells. This suggested U-87MG glial cells could mitigate changes in RS levels more effectively 
than SH-SY5Y neuronal cells, suggesting glia possess greater antioxidant capacity (Dringen and 
Hamprecht, 1997). This was supported by higher levels of glutathione and NRF2 being observed in 
U-87MG cells relative to SH-SY5Y cells, where glutathione can directly reduce RS levels (Dringen et 
al., 2005; Dringen and Hamprecht, 1997) and NRF2 can upregulate antioxidant gene transcription 
via the ARE pathway (Lee et al., 2003b; Shih et al., 2005; Tufekci et al., 2011). Additionally, between 
glia and neurons the sources of cellular energy appeared to differ as U-87MG glial cells appeared 
to depend more on glycolysis for energy, while neurons relied more on mitochondria consistent 
with previous literature (Jády et al., 2016; Juaristi et al., 2019). The results herein propose this 
difference is in part due to U-87MG glial cells exhibiting lower mitochondrial gene expression, 
implying glia possess less mitochondria than SH-SY5Y neuronal cells, explaining their greater 
susceptibility to rotenone induced cellular death. Furthermore, despite both SH-SY5Y and U-87MG 
cells being treated with AAPH or rotenone they displayed different levels of carbonylation and S-
nitrosylation, demonstrating different PTM’s result from the same treatment in different cells. 
Together these results highlight how neuronal SH-SY5Y and glial U-87MG cells respond differently 
to OS, mimicking the differences reported in the CNS.  
RS treatments also elicited different responses within the neural cells suggesting AAPH and 
rotenone affected specific pathways in glia and neurons. Viability assays showed rotenone resulted 
in a dose-dependent decrease in viability for both SH-SY5Y neuronal and U-87MG glial cells. In 
contrast, AAPH only decreased SH-SY5Y neuronal viability but appeared to increase U-87MG glial 
up to a threshold concentration. Furthermore, the antioxidant ascorbic acid (reported primarily to 
scavenge superoxide, Kondo et al., 2008; Wenzel et al., 2004) was not effective at attenuating RS 
levels or cell death in AAPH treated SH-SY5Y cells but was effective against rotenone. Additionally, 
PTM assays demonstrated that both SH-SY5Y neuronal and U-87MG glial cells treated with AAPH 
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exhibited higher levels of lipid peroxidation than rotenone treatment. These greater levels of lipid 
peroxidation are possibly due to AAPH mainly generating peroxyl radicals (Bassett et al., 1999; 
Terao and Niki, 1986; Werber et al., 2011), supporting other studies that demonstrate AAPH 
enhanced lipid peroxidation (Ben Othman et al., 2016; Sun et al., 2001). Indeed, AAPH altered cell 
membranes more so than rotenone. LDH assays showed greater LDH release for both SH-SY5Y and 
U-87MG cells treated with AAPH relative to control cells. Limited experiments with rat primary 
cortical neurons also suggest different pathways were induced by AAPH and rotenone as 
contrasting morphological changes in axon degradation was observed. Alongside OS induced 
changes in viability and PTM’s, AAPH and rotenone also affected mitochondrial function as 
demonstrated by changes in the source of respiration, mitochondrial membrane potential and 
mitochondrial fission/fusion protein levels. Additionally, treatments also altered ubiquitination, 
proteasomal activity and chaperone levels, calling attention to changes in protein degradation. 
Together, the results herein suggest that while AAPH and rotenone appear to generate different 
RS, mitochondrial function and protein degradation pathways were also affected by OS, 
emphasising the “Neurodegenerative Bermuda triangle”.     
With OS being generated by both AAPH and rotenone we investigated changes in 
antioxidant gene expression using a specialised OS PCR array. This resulted in the upregulation of 
several target genes in glial cells following both AAPH and rotenone treatment. In contrast, 
neuronal exposure to rotenone resulted in the suppression of target gene expression. However, we 
believe the down regulation of gene expression in rotenone treated SH-SY5Y cells was due to the 
time of treatments. Upstream of these genes we identified NRF2 as a possible transcription factor. 
NRF2 has been recently proposed as a possible therapeutic target for neurodegeneration due to its 
major role as a regulator of antioxidant enzymes within neurons (Dinkova-Kostova et al., 2018). The 
results herein support NRF2’s role in counteracting OS as both AAPH and rotenone increased 
nuclear NRF2 localisation, leading to target gene expression (Liddell et al., 2016; Rizzi et al., 2018). 
Additionally, antioxidants possibly help to regulate NRF2 expression and hence antioxidant enzyme 
levels to protect neurons (Kim et al., 2015; Mostafavi-Pour et al., 2017; Vineetha et al., 2018). NRF2 
knockdown experiments with siRNA suggested for the first time that AAPH activated the NRF2 
pathway, as knockdown exacerbated neuronal death and attenuated glial proliferation; parameters 
that the initial consequence of AAPH treatment. Therefore, while AAPH and rotenone generated 
different RS, both appeared to alter NRF2 localisation and downstream gene expression. Changes 
to NRF2 were significant in AAPH treated neural cells suggesting the NRF2-ARE pathway plays a 
protective role against lipid peroxidation.   
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The results herein also suggest different differentiation methods of mitotic SH-SY5Y 
neuronal cells effects susceptibility to OS, as some conditions made SH-SY5Y cells more susceptible 
to AAPH or rotenone treatment. This possibly explains why current literature shows conflicting 
evidence as to whether differentiation results in SH-SY5Y neuronal cells becoming more or less 
vulnerable to OS (Beck et al., 2006; Cheung et al., 2009; Ferreira et al., 2013; Lopes et al., 2010). 
Furthermore, differentiated SH-SY5Y cells still lack the lengthy neurites observed with primary 
neuronal cultures and thus, limits investigations into morphological and functional changes with 
synapses. Therefore, while SH-SY5Y neuroblastoma cells allow high-throughput investigations into 
OS in a cost-effective manner the results herein propose the limitations of these cells as a neural 
model, which needs further improvement.  
One of the other limitations of in vitro cell models is that investigations are carried out using 
monocultures, which is not how cells function in vivo. With multiple cells present in the CNS 
including neurons, microglia, oligodendrocytes and astrocytes (Herculano-Houzel, 2009; 
Verkhratsky et al., 2012) the interaction between these cells may help identify possible therapeutic 
targets. Therefore, co-cultures have become more relevant over the last decade, where culture 
complexity has been increased in the hope of understanding cell-cell interactions and how these 
influence neurodegeneration (Renaud and Martinoli, 2016). With astrocytes being proposed to 
have neurotoxic and neuroprotective effects (Jha et al., 2018) we attempted to create a co-culture 
between SH-SY5Y neuronal and U-87MG glial cells. The results herein are the first to utilise 
transwell inserts with these mitotic cell lines, stressing the importance of culture material for future 
investigations. U-87MG glial cells exhibited reduced viability on PET inserts relative to polystyrene 
24-well plates and thus, should be considered in future co-culture investigations. However, 
currently the maximum size of transwell inserts only allows 24-well plates to be used and 
investigations with inserts are still constrained due to difficulty in obtaining enough cell protein 
from lysates and creating sufficient replicates are economically demanding.  
Due to the difficulties posed with transwell inserts we like others reverted to investigating 
the astrocytic secretome under conditions of OS using mass spectrometry. We demonstrated the 
U-87MG glioblastoma line expresses several proteins identified in previous research (Greco et al., 
2010; Keene et al., 2009; Moore et al., 2009; Yin et al., 2012), which has primarily focused on rodent 
models. Our approach adds to the growing catalogue of secreted proteins in a human model and 
provides the first insights into the secretome mediated by OS (AAPH and rotenone). To probe the 
effects of these secreted factors differentiated SH-SY5Y neuronal cells were exposed to U-87MG 
conditioned media, with morphological alterations being noted. Through enrichment analysis using 
MetaCore, potential pathways involved in neurodegeneration have been identified. The results 
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herein highlight the importance of the ECM, neuroinflammation and protein degradation during 
OS.  
In conclusion, this thesis identified the differences between SH-SY5Y neuronal and U-87MG 
glial cell lines, which could attribute to their differential responses to OS. While rotenone is 
commonly used to mimic Parkinson’s disease in neuronal models (Blesa et al., 2015; Franco-Iborra 
et al., 2016; Schapira, 2008), we propose that specific RS effect different pathways in neural cells 
and suggest AAPH as a lipid peroxidising agent for future studies. Furthermore, we suggest like 
others, that NRF2 plays an important role in OS and may be a therapeutic target in the future 
(Dinkova-Kostova et al., 2018). Additionally, we provide the first insights into how rat primary 
cortical neurons respond to AAPH, where there appears to be a significant change in morphology 
that is dissimilar to rotenone, supporting the hypothesis that specific RS stimulate different 
pathways, which requires further investigations to understand their role in neurodegeneration. We 
have also taken the first steps to creating a co-culture between SH-SY5Y neuronal and U-87MG glial 
cells using transwell inserts, with the materials being an important consideration for the future. 
Finally, initial investigations into the U-87MG secretome under OS have yielded a catalogue of 
differentially identified proteins and pathways effected by conditioned media highlighting potential 
factors involved in neurodegeneration that require further investigations.  
6.2 FUTURE WORK  
With current treatment of neurodegenerative diseases confined to limiting the symptoms and not 
treating the underlying pathological conditions the diseases still progress, where neurons 
continue to degrade. Thus, there is a greater need to understand the pathological hallmarks 
including mitochondrial dysfunction, protein degradation and OS to generate novel therapies.  
The current work herein suggests specific RS affect neural cells differently; however, 
current research into OS has not looked in depth at how these RS induce specific pathways or 
changes. AAPH provides a novel way to generate lipid peroxidation that is more specific than the 
currently used rotenone, which can have other effects due to complex I inhibition, including lower 
ATP levels (Caneda-Ferrón et al., 2008; Sherer et al., 2003). To confirm that AAPH primarily results 
in lipid peroxidation, the TBARS assays need to be repeated to obtain a representative set of data 
as not enough replicates were obtained. Additionally, detection of 4-hydroxynonenal via 
dinitrophenylhydrazine would allow the detection of another lipid peroxidation product to further 
confirm if AAPH results in greater lipid peroxidation than rotenone.  
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 With NRF2 being a possible upstream transcription factor involved in the antioxidant 
response to AAPH and rotenone, future experiments should utilise siRNA to knockdown NRF2 and 
determine which proteins are affected (Lee et al., 2003b; Shih et al., 2005; Tufekci et al., 2011). 
Following this, specific knockdown of these proteins will help identify which ones have the 
greatest neuroprotective role and hence provide a therapeutic target. As mentioned in chapter 3 
the hallmarks of neurodegeneration that make up the “Neurodegenerative Bermuda triangle” 
appear to be linked and more research needs to be done into how these factors are linked. 
Therefore, when conducting these investigations, one should also look at proteins that also effect 
mitochondrial dysfunction and protein degradation. This will allow a therapeutic target that 
effects all three mechanisms to be targeted, hopefully preventing neuronal degeneration as if 
only one hallmark is targeted others may overcompensate leading to their eventual failure as 
well. Furthermore, this may explain why current treatments only effect the symptoms of 
neurodegeneration but do not prevent its progression. 
 Future treatments also need investigating in a co-culture model as monocultures do not 
provide adequate in vivo like conditions. Therefore, the results herein regarding the effect of 
materials needs to be considered when using inserts with glia and neurons. Additionally, 
differentially identified proteins and the pathways enriched by MetaCore need further 
investigations to determine if secreted factors could provide an alternative therapeutic target. 
This will provide an advantage over intracellular proteins targets as these may be taken up more 
easily by cells making the treatment more effective. The initial results herein suggest OS alters the 
secretome highlighting the ECM, neuroinflammation and chaperones are possible targets to 
investigate. Recent studies demonstrate chaperones such as HSP70 are secreted by astrocytes 
possibly via exosomes, but this has yet to be confirmed (Lackie et al., 2017; Rivera et al., 2018; 
Verkhratsky et al., 2016). Therefore, further studies should aim to investigate exosomes from U-
87MG glial cells to determine if they possess chaperones or other antioxidants that may be 
neuroprotective providing the basis for novel therapies.  
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Table 8.2 Differentially identified proteins in AAPH or rotenone treated U-87MG lysates using mass spectrometry. U-
87MG cells were differentiated over 5 days and then treated with 1 mM AAPH or 0.5 μM rotenone for 48 hours and 
lysate was subjected to mass spectrometry.  
Secondary Name Accession 
Number 
AAPH 
fold 
change 
Secondary Name Accession 
Number 
Rotenone 
fold change  
Adipocyte plasma 
membrane-associated 
protein 
Q9HDC9 7.8 Deoxyribonuclease-2-
alpha 
O00115 17.9 
Ras-related protein Rab-43 Q86YS6 6.2 Peroxisomal carnitine O-
octanoyltransferase 
Q9UKG9 5.0 
Interleukin-1 beta P01584 3.4 Prostaglandin G/H 
synthase 2 
P35354 4.1 
Cytochrome P450 1B1 Q16678 3.1 Interleukin-8 P10145 3.9 
E3 ubiquitin-protein ligase 
Itchy homolog 
Q96J02 2.5 Hemoglobin subunit alpha P69905 3.1 
Heme oxygenase 1 P09601 2.2 ADP-ribosylation factor-
like protein 6-interacting 
protein 1 
Q15041 3.0 
Sphingomyelin 
phosphodiesterase 
P17405 2.1 Growth/differentiation 
factor 15 
Q99988 2.9 
45 kDa calcium-binding 
protein 
Q9BRK5 2.0 Pentraxin-related protein 
PTX3 
P26022 2.8 
Proline synthase co-
transcribed bacterial 
homolog protein 
O94903 2.0 Annexin A7 P20073 2.6 
T-cell differentiation 
antigen CD6 
P30203 2.0 Proepiregulin O14944 2.5 
Multiple inositol 
polyphosphate 
phosphatase 1 
Q9UNW1 2.0 Histone H2A.Z P0C0S5 2.4 
Cathepsin D P07339 1.9 Podocalyxin O00592 2.3 
Insulin-like growth factor-
binding protein 7 
Q16270 1.9 General transcription 
factor IIF subunit 1 
P35269 2.1 
Palmitoyl-protein 
thioesterase 1 
P50897 1.8 Annexin A6 P08133 2.1 
Integral membrane protein 
2C 
Q9NQX7 1.7 Thrombomodulin P07204 2.1 
Anthrax toxin receptor 2 P58335 1.7 Uncharacterized protein 
C11orf98 
E9PRG8 2.0 
Cytochrome c oxidase 
subunit 5A, mitochondrial 
P20674 1.7 Large neutral amino acids 
transporter small subunit 
1 
Q01650 2.0 
Raftlin Q14699 1.7 D-tyrosyl-tRNA(Tyr) 
deacylase 1 
Q8TEA8 2.0 
fMet-Leu-Phe receptor P21462 1.6 Zinc transporter SLC39A7 Q92504 1.9 
Golgi apparatus protein 1 Q92896 1.6 WD repeat-containing 
protein 43 
Q15061 1.9 
Aldehyde dehydrogenase 
family 3 member B1 
P43353 1.6 Tissue factor pathway 
inhibitor 2 
P48307 1.9 
Tissue alpha-L-fucosidase P04066 1.6 Solute carrier family 43 
member 3 
Q8NBI5 1.8 
Acid ceramidase Q13510 1.5 Fibroblast growth factor 2 P09038 1.7 
Reticulon-3 O95197 1.5 DNA-(apurinic or 
apyrimidinic site) lyase 
P27695 1.7 
ORM1-like protein 2 Q53FV1 1.5 Transmembrane protein 
41B 
Q5BJD5 1.7 
Keratin, type I cuticular 
Ha1 
Q15323 1.5 ADP/ATP translocase 3 P12236 1.7 
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Acyl-CoA desaturase O00767 1.5 CD44 antigen P16070 1.7 
Keratin, type I cytoskeletal 
14 
P02533 1.5 MICOS complex subunit 
MIC10 
Q5TGZ0 1.7 
HLA class II 
histocompatibility antigen, 
DP alpha 1 chain 
P20036 1.4 40S ribosomal protein S25 P62851 1.6 
Guanine nucleotide-
binding protein G(i) subunit 
alpha-1 
P63096 1.4 26S proteasome non-
ATPase regulatory subunit 
8 
P48556 1.6 
5'-nucleotidase domain-
containing protein 2 
Q9H857 1.4 Alpha-2-HS-glycoprotein P02765 1.6 
Osteoclast-stimulating 
factor 1 
Q92882 1.4 Secretory carrier-
associated membrane 
protein 3 
O14828 1.6 
KDEL motif-containing 
protein 2 
Q7Z4H8 1.4 Secretory carrier-
associated membrane 
protein 2 
O15127 1.6 
Glycogenin-1 P46976 1.4 Phospholipid phosphatase 
3 
O14495 1.6 
Neuropilin-2 O60462 1.4 4F2 cell-surface antigen 
heavy chain 
P08195 1.6 
Sulfatase-modifying factor 
2 
Q8NBJ7 1.4 Glucose-6-phosphate 
exchanger SLC37A4 
O43826 1.6 
GDP-fucose protein O-
fucosyltransferase 2 
Q9Y2G5 1.4 ADP/ATP translocase 2 P05141 1.6 
Transmembrane 9 
superfamily member 2 
Q99805 1.4 40S ribosomal protein S17 P08708 1.6 
Protein-glutamine gamma-
glutamyltransferase 2 
P21980 1.4 Translocon-associated 
protein subunit alpha 
P43307 1.6 
Ras-related protein Rap-2a P10114 1.4 Transmembrane emp24 
domain-containing 
protein 10 
P49755 1.6 
Glucosamine-6-phosphate 
isomerase 1 
P46926 1.4 Histone H2B type 1-L Q99880 1.5 
Protein FAM210B Q96KR6 1.3 Transmembrane emp24 
domain-containing 
protein 7 
Q9Y3B3 1.5 
Sorting nexin-2 O60749 1.3 78 kDa glucose-regulated 
protein 
P11021 1.5 
N-acetylglucosamine-6-
sulfatase 
P15586 1.3 Calcium-binding 
mitochondrial carrier 
protein SCaMC-1 
Q6NUK1 1.5 
Ras-related protein Rap-1A P62834 1.3 Prohibitin-2 Q99623 1.5 
Long-chain-fatty-acid--CoA 
ligase 4 
O60488 1.3 Acid ceramidase Q13510 1.5 
Myeloid-derived growth 
factor 
Q969H8 1.3 Phosphate carrier protein, 
mitochondrial 
Q00325 1.5 
Gamma-secretase subunit 
APH-1B 
Q8WW43 1.3 ADP/ATP translocase 1 P12235 1.5 
Scavenger receptor class B 
member 1 
Q8WTV0 1.3 Prohibitin P35232 1.5 
Epididymal secretory 
protein E1 
P61916 1.3 Transmembrane emp24 
domain-containing 
protein 2 
Q15363 1.5 
Protein FAM3C Q92520 1.3 60S ribosomal protein L9 P32969 1.5 
Lysosome membrane 
protein 2 
Q14108 1.3 Cathepsin L1 P07711 1.5 
MLN64 N-terminal domain 
homolog 
O95772 1.3 Translocating chain-
associated membrane 
protein 1 
Q15629 1.5 
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NADH dehydrogenase 
[ubiquinone] 1 alpha 
subcomplex subunit 6 
P56556 1.3 Very-long-chain (3R)-3-
hydroxyacyl-CoA 
dehydratase 3 
Q9P035 1.5 
Lysosomal acid 
phosphatase 
P11117 1.2 Prenylated Rab acceptor 
protein 1 
Q9UI14 1.5 
Ras-related protein Rab-7a P51149 1.2 Transmembrane emp24 
domain-containing 
protein 5 
Q9Y3A6 1.5 
Ras-related protein Rab-
27B 
O00194 1.2 Transmembrane emp24 
domain-containing 
protein 4 
Q7Z7H5 1.5 
FAD synthase Q8NFF5 1.2 CAAX prenyl protease 1 
homolog 
O75844 1.5 
Serine/threonine-protein 
phosphatase PP1-beta 
catalytic subunit 
P62140 -1.2 Protein NDRG1 Q92597 1.5 
40S ribosomal protein S9 P46781 -1.3 40S ribosomal protein S15 P62841 1.5 
40S ribosomal protein S24 P62847 -1.3 Transmembrane emp24 
domain-containing 
protein 9 
Q9BVK6 1.5 
BET1 homolog O15155 -1.3 Ethanolaminephosphotra
nsferase 1 
Q9C0D9 1.5 
60S ribosomal protein L4 P36578 -1.3 Ribosomal L1 domain-
containing protein 1 
O76021 1.5 
Transcription factor BTF3 
homolog 4 
Q96K17 -1.3 40S ribosomal protein S10 P46783 1.5 
CD44 antigen P16070 -1.3 Mitochondrial 2-
oxoglutarate/malate 
carrier protein 
Q02978 1.5 
60S ribosomal protein L23 P62829 -1.3 Stromal interaction 
molecule 2 
Q9P246 1.5 
60S ribosomal protein L18 Q07020 -1.3 Transmembrane protein 
41A 
Q96HV5 1.5 
Endothelial differentiation-
related factor 1 
O60869 -1.3 Transmembrane 9 
superfamily member 3 
Q9HD45 1.5 
Perilipin-3 O60664 -1.3 Sideroflexin-1 Q9H9B4 1.5 
Cytoplasmic dynein 1 
heavy chain 1 
Q14204 -1.3 Reticulon-4 Q9NQC3 1.5 
60S ribosomal protein L28 P46779 -1.3 Thioredoxin-dependent 
peroxide reductase, 
mitochondrial 
P30048 1.5 
Calfacilitin Q96CP7 -1.3 Translocation protein 
SEC62 
Q99442 1.5 
Poly(rC)-binding protein 1 Q15365 -1.3 3-ketodihydrosphingosine 
reductase 
Q06136 1.5 
Signal recognition particle 
9 kDa protein 
P49458 -1.3 Protein jagunal homolog 1 Q8N5M9 1.4 
Spectrin beta chain, non-
erythrocytic 1 
Q01082 -1.3 Minor histocompatibility 
antigen H13 
Q8TCT9 1.4 
WASH complex subunit 5 Q12768 -1.3 Transmembrane protein 
70, mitochondrial 
Q9BUB7 1.4 
Caveolin-1 Q03135 -1.3 Calcium-binding 
mitochondrial carrier 
protein Aralar1 
O75746 1.4 
ATP synthase subunit O, 
mitochondrial 
P48047 -1.3 Cytochrome b P00156 1.4 
Eukaryotic translation 
initiation factor 4E type 2 
O60573 -1.3 LETM1 and EF-hand 
domain-containing 
protein 1, mitochondrial 
O95202 1.4 
Spectrin alpha chain, non-
erythrocytic 1 
Q13813 -1.3 Gamma-glutamyl 
hydrolase 
Q92820 1.4 
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LIM and SH3 domain 
protein 1 
Q14847 -1.3 Transmembrane emp24 
domain-containing 
protein 1 
Q13445 1.4 
Basigin P35613 -1.3 Translocon-associated 
protein subunit gamma 
Q9UNL2 1.4 
60S ribosomal protein L34 P49207 -1.3 Zinc transporter 7 Q8NEW0 1.4 
Eukaryotic translation 
initiation factor 3 subunit E 
P60228 -1.3 Epoxide hydrolase 1 P07099 1.4 
40S ribosomal protein S8 P62241 -1.3 Type-1 angiotensin II 
receptor-associated 
protein 
Q6RW13 1.4 
Transmembrane protein 
109 
Q9BVC6 -1.3 Endoplasmic reticulum 
resident protein 29 
P30040 1.4 
Migration and invasion 
enhancer 1 
Q9BRT3 -1.4 Sideroflexin-3 Q9BWM7 1.4 
40S ribosomal protein S6 P62753 -1.4 Sigma non-opioid 
intracellular receptor 1 
Q99720 1.4 
39S ribosomal protein L41, 
mitochondrial 
Q8IXM3 -1.4 Caveolin-1 Q03135 1.4 
RNA-binding protein PNO1 Q9NRX1 -1.4 CMP-N-
acetylneuraminate-beta-
galactosamide-alpha-2,3-
sialyltransferase 1 
Q11201 1.4 
60S ribosomal protein L23a P62750 -1.4 Nicotinamide 
phosphoribosyltransferas
e 
P43490 1.4 
Caprin-1 Q14444 -1.4 Transmembrane protein 
65 
Q6PI78 1.4 
Serine/arginine-rich 
splicing factor 3 
P84103 -1.4 Dolichol kinase Q9UPQ8 1.4 
Heat shock protein beta-1 P04792 -1.4 ER membrane protein 
complex subunit 4 
Q5J8M3 1.4 
Sorcin P30626 -1.4 High affinity cationic 
amino acid transporter 1 
P30825 1.4 
Protein kish-A Q8TBQ9 -1.4 2,4-dienoyl-CoA 
reductase, mitochondrial 
Q16698 1.4 
Serine/arginine-rich 
splicing factor 2 
Q01130 -1.4 Transmembrane 9 
superfamily member 4 
Q92544 1.4 
Keratin, type I cytoskeletal 
9 
P35527 -1.4 Perilipin-3 O60664 1.4 
Nuclear pore complex 
protein Nup205 
Q92621 -1.4 Alpha-mannosidase 2 Q16706 1.4 
Ephrin-B2 P52799 -1.4 B-cell receptor-associated 
protein 31 
P51572 1.4 
Insulin-like growth factor 2 
mRNA-binding protein 2 
Q9Y6M1 -1.4 ER membrane protein 
complex subunit 2 
Q15006 1.4 
Eukaryotic translation 
initiation factor 3 subunit A 
Q14152 -1.4 Acetyl-coenzyme A 
transporter 1 
O00400 1.4 
Eukaryotic translation 
initiation factor 3 subunit C 
Q99613 -1.4 Neutral cholesterol ester 
hydrolase 1 
Q6PIU2 1.4 
Soluble calcium-activated 
nucleotidase 1 
Q8WVQ1 -1.4 Translocator protein P30536 1.4 
Cytoplasmic FMR1-
interacting protein 1 
Q7L576 -1.4 ATP synthase subunit 
gamma, mitochondrial 
P36542 1.4 
60S ribosomal protein L6 Q02878 -1.4 Cytochrome P450 20A1 Q6UW02 1.4 
40S ribosomal protein S30 P62861 -1.4 Tissue alpha-L-fucosidase P04066 1.4 
Interleukin enhancer-
binding factor 2 
Q12905 -1.4 Mitochondrial fission 
process protein 1 
Q9UDX5 1.4 
40S ribosomal protein S19 P39019 -1.4 Thioredoxin-related 
transmembrane protein 2 
Q9Y320 1.4 
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Myosin-9 P35579 -1.4 Ras-related protein Rab-
4B 
P61018 1.4 
Interleukin enhancer-
binding factor 3 
Q12906 -1.4 Neutral amino acid 
transporter B(0) 
Q15758 1.4 
Heterogeneous nuclear 
ribonucleoprotein L 
P14866 -1.4 Major prion protein P04156 1.4 
Eukaryotic translation 
initiation factor 4 gamma 2 
P78344 -1.4 39S ribosomal protein 
L48, mitochondrial 
Q96GC5 1.4 
Probable global 
transcription activator 
SNF2L1 
P28370 -1.5 Glutamate 
dehydrogenase 1, 
mitochondrial 
P00367 1.4 
Filamin-A P21333 -1.5 Secretory carrier-
associated membrane 
protein 4 
Q969E2 1.4 
Neuroblast differentiation-
associated protein AHNAK 
Q09666 -1.5 Calcium-binding 
mitochondrial carrier 
protein SCaMC-2 
Q6KCM7 1.4 
Eukaryotic translation 
initiation factor 4 gamma 1 
Q04637 -1.5 UDP-glucuronic acid 
decarboxylase 1 
Q8NBZ7 1.4 
Charged multivesicular 
body protein 4b 
Q9H444 -1.5 Calcium-binding 
mitochondrial carrier 
protein Aralar2 
Q9UJS0 1.4 
Actin-related protein 2/3 
complex subunit 5 
O15511 -1.5 Fumarate hydratase, 
mitochondrial 
P07954 1.4 
ATP-dependent RNA 
helicase DDX3X 
O00571 -1.5 Transmembrane protein 
33 
P57088 1.4 
Abl interactor 1 Q8IZP0 -1.5 ATP-dependent Clp 
protease proteolytic 
subunit, mitochondrial 
Q16740 1.4 
Splicing factor 3B subunit 6 Q9Y3B4 -1.5 Protein SET Q01105 1.4 
Serine/threonine-protein 
phosphatase PGAM5, 
mitochondrial 
Q96HS1 -1.5 Heat shock 70 kDa protein 
1-like 
P34931 1.4 
Heterogeneous nuclear 
ribonucleoprotein K 
P61978 -1.5 Sodium/myo-inositol 
cotransporter 
P53794 1.4 
rRNA 2'-O-
methyltransferase 
fibrillarin 
P22087 -1.5 Annexin A1 P04083 1.4 
Dihydropyrimidinase-
related protein 2 
Q16555 -1.5 ATP synthase F(0) 
complex subunit B1, 
mitochondrial 
P24539 1.4 
ATP-dependent RNA 
helicase DDX18 
Q9NVP1 -1.5 Peroxisomal membrane 
protein PEX16 
Q9Y5Y5 1.4 
Small nuclear 
ribonucleoprotein F 
P62306 -1.5 Translocon-associated 
protein subunit delta 
P51571 1.4 
Ribosomal L1 domain-
containing protein 1 
O76021 -1.5 Protein RFT1 homolog Q96AA3 1.4 
Protein quaking Q96PU8 -1.5 UPF0160 protein MYG1, 
mitochondrial 
Q9HB07 1.4 
Macrophage migration 
inhibitory factor 
P14174 -1.5 Glycerol-3-phosphate 
dehydrogenase, 
mitochondrial 
P43304 1.4 
Microtubule-associated 
protein 1B 
P46821 -1.5 Adipocyte plasma 
membrane-associated 
protein 
Q9HDC9 1.4 
Activated RNA polymerase 
II transcriptional 
coactivator p15 
P53999 -1.5 Dehydrogenase/reductas
e SDR family member 7 
Q9Y394 1.4 
Microtubule-associated 
protein 4 
P27816 -1.5 Lysosomal acid 
phosphatase 
P11117 1.4 
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Mitochondrial fission factor Q9GZY8 -1.5 Peroxisomal membrane 
protein PMP34 
O43808 1.4 
Selenoprotein S Q9BQE4 -1.5 Lanosterol synthase P48449 1.4 
Nucleoporin SEH1 Q96EE3 -1.5 Superoxide dismutase 
[Mn], mitochondrial 
P04179 1.4 
Tumor susceptibility gene 
101 protein 
Q99816 -1.5 ATP synthase subunit 
beta, mitochondrial 
P06576 1.4 
Microtubule-associated 
proteins 1A/1B light chain 
3B 
Q9GZQ8 -1.6 Mitochondrial 
dicarboxylate carrier 
Q9UBX3 1.4 
Inositol 1,4,5-trisphosphate 
receptor type 1 
Q14643 -1.6 60 kDa heat shock 
protein, mitochondrial 
P10809 1.4 
Symplekin Q92797 -1.6 Leucine-rich repeat-
containing protein 59 
Q96AG4 1.4 
Mitochondrial import 
receptor subunit TOM22 
homolog 
Q9NS69 -1.6 Succinate dehydrogenase 
[ubiquinone] flavoprotein 
subunit, mitochondrial 
P31040 1.4 
Probable ATP-dependent 
RNA helicase DDX6 
P26196 -1.6 Signal peptidase complex 
catalytic subunit SEC11A 
P67812 1.4 
Protein transport protein 
Sec31A 
O94979 -1.6 Dol-P-
Man:Man(5)GlcNAc(2)-PP-
Dol alpha-1,3-
mannosyltransferase 
Q92685 1.3 
TBC1 domain family 
member 20 
Q96BZ9 -1.6 Ras-related protein Rab-
14 
P61106 1.3 
Heterogeneous nuclear 
ribonucleoproteins A2/B1 
P22626 -1.6 ATP synthase subunit 
alpha, mitochondrial 
P25705 1.3 
Major vault protein Q14764 -1.6 Aspartate 
aminotransferase, 
mitochondrial 
P00505 1.3 
Vimentin P08670 -1.6 ER membrane protein 
complex subunit 3 
Q9P0I2 1.3 
U2 small nuclear 
ribonucleoprotein A' 
P09661 -1.6 Vesicle transport protein 
GOT1B 
Q9Y3E0 1.3 
Dihydropyrimidinase-
related protein 3 
Q14195 -1.6 Lysosome membrane 
protein 2 
Q14108 1.3 
Dolichyl-
diphosphooligosaccharide--
protein glycosyltransferase 
subunit DAD1 
P61803 -1.7 Carnitine O-
palmitoyltransferase 1, 
liver isoform 
P50416 1.3 
Annexin A4 P09525 -1.7 Mannose-P-dolichol 
utilization defect 1 
protein 
O75352 1.3 
Probable rRNA-processing 
protein EBP2 
Q99848 -1.7 Activated RNA 
polymerase II 
transcriptional coactivator 
p15 
P53999 1.3 
40S ribosomal protein S26 P62854 -1.7 Surfeit locus protein 4 O15260 1.3 
Heterogeneous nuclear 
ribonucleoprotein H3 
P31942 -1.7 Growth hormone-
inducible transmembrane 
protein 
Q9H3K2 1.3 
Probable ATP-dependent 
RNA helicase DDX17 
Q92841 -1.7 Vacuole membrane 
protein 1 
Q96GC9 1.3 
Cell cycle and apoptosis 
regulator protein 2 
Q8N163 -1.7 Protein transport protein 
Sec61 subunit alpha 
isoform 1 
P61619 1.3 
Protein LSM12 homolog Q3MHD2 -1.7 Thioredoxin-related 
transmembrane protein 1 
Q9H3N1 1.3 
Protein TFG Q92734 -1.7 NIF3-like protein 1 Q9GZT8 1.3 
40S ribosomal protein S21 P63220 -1.7 Reticulon-1 Q16799 1.3 
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Heterogeneous nuclear 
ribonucleoprotein R 
O43390 -1.7 ER membrane protein 
complex subunit 6 
Q9BV81 1.3 
Far upstream element-
binding protein 2 
Q92945 -1.7 Stomatin-like protein 2, 
mitochondrial 
Q9UJZ1 1.3 
Septin-7 Q16181 -1.7 Sphingosine-1-phosphate 
phosphatase 1 
Q9BX95 1.3 
Zyxin Q15942 -1.7 Quinone oxidoreductase Q08257 1.3 
Serine/arginine-rich 
splicing factor 1 
Q07955 -1.7 Prenylcysteine oxidase 1 Q9UHG3 1.3 
Immunoglobulin 
superfamily member 8 
Q969P0 -1.7 Signal peptidase complex 
subunit 3 
P61009 1.3 
CAD protein P27708 -1.7 Protein disulfide-
isomerase A6 
Q15084 1.3 
Septin-2 Q15019 -1.7 Microsomal glutathione S-
transferase 1 
P10620 1.3 
Annexin A2 P07355 -1.7 Ubiquinol-cytochrome-c 
reductase complex 
assembly factor 1 
Q9NVA1 1.3 
Src substrate cortactin Q14247 -1.7 Hydroxyacyl-coenzyme A 
dehydrogenase, 
mitochondrial 
Q16836 1.3 
Clathrin light chain A P09496 -1.7 Ras-related protein Ral-A P11233 1.3 
Polyadenylate-binding 
protein 1 
P11940 -1.8 60S ribosomal protein L22 P35268 1.3 
Septin-9 Q9UHD8 -1.8 CDGSH iron-sulfur 
domain-containing 
protein 2 
Q8N5K1 1.3 
Far upstream element-
binding protein 3 
Q96I24 -1.8 Eukaryotic translation 
initiation factor 2 subunit 
3 
P41091 1.3 
Golgin subfamily A 
member 2 
Q08379 -1.8 Sodium/potassium-
transporting ATPase 
subunit alpha-1 
P05023 1.3 
Serine/arginine-rich 
splicing factor 7 
Q16629 -1.8 Malate dehydrogenase, 
mitochondrial 
P40926 1.3 
Large proline-rich protein 
BAG6 
P46379 -1.8 Ras-related protein Rab-
2A 
P61019 1.3 
Heterogeneous nuclear 
ribonucleoprotein A3 
P51991 -1.8 Putative 60S ribosomal 
protein L39-like 5 
Q59GN2 1.2 
Nuclear pore complex 
protein Nup160 
Q12769 -1.9 PRA1 family protein 3 O75915 1.2 
Polymerase I and transcript 
release factor 
Q6NZI2 -1.9 40S ribosomal protein S3a P61247 1.2 
Polyadenylate-binding 
protein 4 
Q13310 -1.9 40S ribosomal protein S3 P23396 1.2 
Clathrin heavy chain 1 Q00610 -1.9 GH3 domain-containing 
protein 
Q8N2G8 1.2 
ATP-dependent RNA 
helicase DDX24 
Q9GZR7 -1.9 Endoplasmin P14625 1.2 
Histone H1x Q92522 -1.9 NADH-cytochrome b5 
reductase 3 
P00387 1.2 
Serine/arginine-rich 
splicing factor 10 
O75494 -1.9 40S ribosomal protein S19 P39019 1.2 
Plectin Q15149 -1.9 V-type proton ATPase 
subunit d 1 
P61421 1.2 
Nuclear pore complex 
protein Nup88 
Q99567 -1.9 Transferrin receptor 
protein 1 
P02786 -1.2 
40S ribosomal protein S28 P62857 -1.9 Protein Mpv17 P39210 -1.2 
BAG family molecular 
chaperone regulator 2 
O95816 -1.9 Cytoskeleton-associated 
protein 4 
Q07065 -1.2 
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Exosome complex 
component RRP43 
Q96B26 -1.9 Peptidyl-prolyl cis-trans 
isomerase FKBP9 
O95302 -1.2 
AMP deaminase 2 Q01433 -2.0 Zinc finger RNA-binding 
protein 
Q96KR1 -1.3 
Tubulin beta-3 chain Q13509 -2.0 Delta-1-pyrroline-5-
carboxylate synthase 
P54886 -1.3 
CCR4-NOT transcription 
complex subunit 7 
Q9UIV1 -2.0 60S acidic ribosomal 
protein P0 
P05388 -1.3 
Tubulin alpha-1C chain Q9BQE3 -2.0 Ras-related protein Rap-
1A 
P62834 -1.3 
Transformer-2 protein 
homolog beta 
P62995 -2.0 Ragulator complex 
protein LAMTOR3 
Q9UHA4 -1.3 
Protein S100-A10 P60903 -2.0 SUMO-conjugating 
enzyme UBC9 
P63279 -1.3 
Scaffold attachment factor 
B1 
Q15424 -2.0 40S ribosomal protein S8 P62241 -1.3 
Tubulin beta-2A chain Q13885 -2.0 Long-chain-fatty-acid--
CoA ligase 3 
O95573 -1.3 
Tubulin alpha-1A chain Q71U36 -2.1 E3 ubiquitin-protein ligase 
NEDD4 
P46934 -1.3 
Tubulin beta chain P07437 -2.1 60S ribosomal protein L3 P39023 -1.3 
Zinc finger protein 285 Q96NJ3 -2.1 GTP-binding protein 
SAR1a 
Q9NR31 -1.3 
Protein S100-A6 P06703 -2.1 Dolichyl-
diphosphooligosaccharide
--protein 
glycosyltransferase 
subunit DAD1 
P61803 -1.3 
Tubulin beta-6 chain Q9BUF5 -2.3 60S ribosomal protein 
L18a 
Q02543 -1.3 
Four and a half LIM 
domains protein 2 
Q14192 -2.3 ADP-ribosylation factor 5 P84085 -1.3 
Small nuclear 
ribonucleoprotein Sm D3 
P62318 -2.3 Endothelial 
differentiation-related 
factor 1 
O60869 -1.3 
Prelamin-A/C P02545 -2.4 Rho-related GTP-binding 
protein RhoC 
P08134 -1.3 
Serine/arginine-rich 
splicing factor 9 
Q13242 -2.4 Peptidyl-prolyl cis-trans 
isomerase A 
P62937 -1.3 
Small nuclear 
ribonucleoprotein-
associated proteins B and 
B' 
P14678 -2.4 Protein SGT1 homolog Q9Y2Z0 -1.3 
Tubulin beta-4B chain P68371 -2.5 Dihydropyrimidinase-
related protein 2 
Q16555 -1.3 
MICAL-like protein 1 Q8N3F8 -2.9 Signal recognition particle 
9 kDa protein 
P49458 -1.3 
Transcription factor p65 Q04206 -3.6 Stromal interaction 
molecule 1 
Q13586 -1.3 
FK506-binding protein 15 Q5T1M5 -4.0 39S ribosomal protein 
L38, mitochondrial 
Q96DV4 -1.3 
Suppressor of SWI4 1 
homolog 
Q9NQ55 -4.2 Peptidyl-prolyl cis-trans 
isomerase FKBP10 
Q96AY3 -1.4 
Protein S100-A13 Q99584 -4.8 Mitofusin-1 Q8IWA4 -1.4 
Pleckstrin homology-like 
domain family A member 3 
Q9Y5J5 -5.1 Spectrin alpha chain, non-
erythrocytic 1 
Q13813 -1.4 
Protein 4.1 P11171 -5.9 Bifunctional 
glutamate/proline--tRNA 
ligase 
P07814 -1.4 
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Zinc finger RNA-binding 
protein 
Q96KR1 -6.5 Serine/threonine-protein 
phosphatase PP1-alpha 
catalytic subunit 
P62136 -1.4 
Phosphatidate 
cytidylyltransferase, 
mitochondrial 
Q96BW9 -7.5 Heterogeneous nuclear 
ribonucleoprotein K 
P61978 -1.4 
   
Eukaryotic translation 
initiation factor 4E 
P06730 -1.4 
   
Osteoclast-stimulating 
factor 1 
Q92882 -1.4 
   
Filamin-B O75369 -1.4 
   
39S ribosomal protein 
S18a, mitochondrial 
Q9NVS2 -1.4 
   
40S ribosomal protein S24 P62847 -1.4 
   
Aspartate--tRNA ligase, 
cytoplasmic 
P14868 -1.4 
   
Ubiquitin-conjugating 
enzyme E2 variant 2 
Q15819 -1.4 
   
Alpha-2-macroglobulin 
receptor-associated 
protein 
P30533 -1.4 
   
Beta-galactosidase P16278 -1.4 
   
Dihydrolipoyl 
dehydrogenase, 
mitochondrial 
P09622 -1.4 
   
Low-density lipoprotein 
receptor 
P01130 -1.4 
   
Regulation of nuclear pre-
mRNA domain-containing 
protein 1B 
Q9NQG5 -1.4 
   
NADH dehydrogenase 
[ubiquinone] iron-sulfur 
protein 3, mitochondrial 
O75489 -1.4 
   
RNA-binding protein 
PNO1 
Q9NRX1 -1.4 
   
Alpha-actinin-1 P12814 -1.4 
   
Isoleucine--tRNA ligase, 
cytoplasmic 
P41252 -1.4 
   
Serine 
palmitoyltransferase 1 
O15269 -1.4 
   
Peripheral plasma 
membrane protein CASK 
O14936 -1.4 
   
Unconventional myosin-Ic O00159 -1.4 
   
Poly(rC)-binding protein 1 Q15365 -1.4 
   
Dihydropyrimidinase-
related protein 3 
Q14195 -1.4 
   
28S ribosomal protein 
S29, mitochondrial 
P51398 -1.4 
   
WD repeat and FYVE 
domain-containing 
protein 1 
Q8IWB7 -1.4 
   
Protein-glutamine 
gamma-
glutamyltransferase 2 
P21980 -1.4 
   
Leucine--tRNA ligase, 
cytoplasmic 
Q9P2J5 -1.4 
   
28S ribosomal protein 
S23, mitochondrial 
Q9Y3D9 -1.4 
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HLA class II 
histocompatibility antigen 
gamma chain 
P04233 -1.4 
   
Procollagen-lysine,2-
oxoglutarate 5-
dioxygenase 2 
O00469 -1.5 
   
Methylcrotonoyl-CoA 
carboxylase subunit 
alpha, mitochondrial 
Q96RQ3 -1.5 
   
Double-stranded RNA-
binding protein Staufen 
homolog 1 
O95793 -1.5 
   
39S ribosomal protein 
L23, mitochondrial 
Q16540 -1.5 
   
Epsin-1 Q9Y6I3 -1.5 
   
40S ribosomal protein S26 P62854 -1.5 
   
ADP-ribosylation factor 6 P62330 -1.5 
   
Filamin-A P21333 -1.5 
   
Ras-related protein Rab-
32 
Q13637 -1.5 
   
Ras-related protein Rab-
13 
P51153 -1.5 
   
60S ribosomal protein L23 P62829 -1.5 
   
ATP-dependent 6-
phosphofructokinase, 
platelet type 
Q01813 -1.5 
   
Mannosyl-oligosaccharide 
glucosidase 
Q13724 -1.5 
   
Serine/threonine-protein 
phosphatase PP1-beta 
catalytic subunit 
P62140 -1.5 
   
Leucine-rich PPR motif-
containing protein, 
mitochondrial 
P42704 -1.5 
   
Protein mago nashi 
homolog 2 
Q96A72 -1.5 
   
Procollagen-lysine,2-
oxoglutarate 5-
dioxygenase 1 
Q02809 -1.5 
   
Filamin-C Q14315 -1.5 
   
14-3-3 protein zeta/delta P63104 -1.5 
   
Lipase maturation factor 2 Q9BU23 -1.5 
   
Interferon-induced, 
double-stranded RNA-
activated protein kinase 
P19525 -1.5 
   
Staphylococcal nuclease 
domain-containing 
protein 1 
Q7KZF4 -1.5 
   
14-3-3 protein theta P27348 -1.5 
   
Poly(rC)-binding protein 2 Q15366 -1.5 
   
Poliovirus receptor P15151 -1.5 
   
Talin-1 Q9Y490 -1.5 
   
Plectin Q15149 -1.5 
   
[3-methyl-2-
oxobutanoate 
dehydrogenase 
[lipoamide]] kinase, 
mitochondrial 
O14874 -1.5 
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Interferon-inducible 
double-stranded RNA-
dependent protein kinase 
activator A 
O75569 -1.5 
   
Adenosylhomocysteinase 
2 
O43865 -1.5 
   
Alpha-actinin-4 O43707 -1.5 
   
ADP-ribosylation factor 4 P18085 -1.5 
   
60S ribosomal protein L34 P49207 -1.5 
   
NADH dehydrogenase 
[ubiquinone] 1 alpha 
subcomplex subunit 13 
Q9P0J0 -1.5 
   
Nucleolin P19338 -1.5 
   
Actin-related protein 2/3 
complex subunit 3 
O15145 -1.5 
   
Gamma-adducin Q9UEY8 -1.5 
   
Spliceosome RNA helicase 
DDX39B 
Q13838 -1.5 
   
Protein transport protein 
Sec31A 
O94979 -1.5 
   
Microtubule-associated 
proteins 1A/1B light chain 
3B 
Q9GZQ8 -1.5 
   
Adenylate kinase 2, 
mitochondrial 
P54819 -1.6 
   
CCR4-NOT transcription 
complex subunit 1 
A5YKK6 -1.6 
   
Metalloreductase STEAP3 Q658P3 -1.6 
   
Tubulin beta chain P07437 -1.6 
   
ATP-dependent 6-
phosphofructokinase, 
muscle type 
P08237 -1.6 
   
Protein S100-A10 P60903 -1.6 
   
Fatty acid synthase P49327 -1.6 
   
Mitochondrial fission 
factor 
Q9GZY8 -1.6 
   
Hexokinase-1 P19367 -1.6 
   
Procollagen 
galactosyltransferase 1 
Q8NBJ5 -1.6 
   
Prolyl 3-hydroxylase 3 Q8IVL6 -1.6 
   
Protein S100-A11 P31949 -1.6 
   
39S ribosomal protein 
L49, mitochondrial 
Q13405 -1.6 
   
Coronin-1B Q9BR76 -1.6 
   
Armadillo repeat-
containing X-linked 
protein 3 
Q9UH62 -1.6 
   
EH domain-containing 
protein 2 
Q9NZN4 -1.6 
   
C-1-tetrahydrofolate 
synthase, cytoplasmic 
P11586 -1.6 
   
Lysyl oxidase homolog 1 Q08397 -1.6 
   
Thioredoxin-related 
transmembrane protein 4 
Q9H1E5 -1.6 
   
Glutathione S-transferase 
kappa 1 
Q9Y2Q3 -1.6 
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Voltage-dependent anion-
selective channel protein 
1 
P21796 -1.6 
   
40S ribosomal protein S21 P63220 -1.6 
   
Cellular nucleic acid-
binding protein 
P62633 -1.6 
   
Eukaryotic translation 
initiation factor 4 gamma 
1 
Q04637 -1.6 
   
Protein quaking Q96PU8 -1.6 
   
Clathrin heavy chain 1 Q00610 -1.6 
   
Tubulin beta-3 chain Q13509 -1.6 
   
General vesicular 
transport factor p115 
O60763 -1.7 
   
Isocitrate dehydrogenase 
[NADP], mitochondrial 
P48735 -1.7 
   
ATP-dependent RNA 
helicase DDX3X 
O00571 -1.7 
   
Tubulin alpha-1C chain Q9BQE3 -1.7 
   
Beta-2-microglobulin P61769 -1.7 
   
Ubiquitin carboxyl-
terminal hydrolase 10 
Q14694 -1.7 
   
SRA stem-loop-interacting 
RNA-binding protein, 
mitochondrial 
Q9GZT3 -1.7 
   
ORM1-like protein 2 Q53FV1 -1.7 
   
Polyadenylate-binding 
protein 1 
P11940 -1.7 
   
Fragile X mental 
retardation syndrome-
related protein 1 
P51114 -1.7 
   
39S ribosomal protein L3, 
mitochondrial 
P09001 -1.7 
   
NADH dehydrogenase 
[ubiquinone] iron-sulfur 
protein 7, mitochondrial 
O75251 -1.7 
   
Dimethyladenosine 
transferase 2, 
mitochondrial 
Q9H5Q4 -1.7 
   
Protein SEC13 homolog P55735 -1.7 
   
Cytochrome c oxidase 
assembly protein COX11, 
mitochondrial 
Q9Y6N1 -1.7 
   
Prostaglandin E synthase 
3 
Q15185 -1.7 
   
Nucleophosmin P06748 -1.7 
   
Coronin-1C Q9ULV4 -1.7 
   
Eukaryotic initiation 
factor 4A-III 
P38919 -1.7 
   
Scaffold attachment 
factor B1 
Q15424 -1.7 
   
Elongin-B Q15370 -1.7 
   
Prolow-density 
lipoprotein receptor-
related protein 1 
Q07954 -1.7 
   
Ras-related protein R-
Ras2 
P62070 -1.7 
   
Protein S100-A6 P06703 -1.7 
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tRNA pseudouridine 
synthase A, mitochondrial 
Q9Y606 -1.8 
   
40S ribosomal protein S28 P62857 -1.8 
   
ER membrane protein 
complex subunit 7 
Q9NPA0 -1.8 
   
Bax inhibitor 1 P55061 -1.8 
   
DnaJ homolog subfamily C 
member 13 
O75165 -1.8 
   
Myosin regulatory light 
chain 12A 
P19105 -1.8 
   
Actin-related protein 2/3 
complex subunit 5 
O15511 -1.8 
   
E3 ubiquitin-protein ligase 
TRIP12 
Q14669 -1.8 
   
Glycosyltransferase 8 
domain-containing 
protein 1 
Q68CQ7 -1.8 
   
X-ray repair cross-
complementing protein 5 
P13010 -1.8 
   
Kinesin-like protein KIF3B O15066 -1.8 
   
Coiled-coil domain-
containing protein 58 
Q4VC31 -1.8 
   
X-ray repair cross-
complementing protein 6 
P12956 -1.8 
   
Ribosomal protein S6 
kinase alpha-3 
P51812 -1.8 
   
Polymerase delta-
interacting protein 2 
Q9Y2S7 -1.8 
   
Carboxypeptidase D O75976 -1.8 
   
Cytochrome b5 P00167 -1.8 
   
Ubiquitin-associated 
protein 2-like 
Q14157 -1.8 
   
Dynein light chain 1, 
cytoplasmic 
P63167 -1.8 
   
Polyadenylate-binding 
protein 4 
Q13310 -1.8 
   
Tyrosine-protein kinase 
Yes 
P07947 -1.8 
   
Lysyl oxidase homolog 2 Q9Y4K0 -1.8 
   
Myosin-9 P35579 -1.8 
   
Elongation factor Tu, 
mitochondrial 
P49411 -1.8 
   
60S ribosomal protein L38 P63173 -1.8 
   
Macrophage migration 
inhibitory factor 
P14174 -1.8 
   
Adenylate kinase 4, 
mitochondrial 
P27144 -1.9 
   
OCIA domain-containing 
protein 2 
Q56VL3 -1.9 
   
Chitobiosyldiphosphodoli
chol beta-
mannosyltransferase 
Q9BT22 -1.9 
   
Nuclear pore complex 
protein Nup88 
Q99567 -1.9 
   
Sorcin P30626 -1.9 
   
Short-chain 
dehydrogenase/reductase 
3 
O75911 -1.9 
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Very long-chain specific 
acyl-CoA dehydrogenase, 
mitochondrial 
P49748 -1.9 
   
PDZ and LIM domain 
protein 5 
Q96HC4 -1.9 
   
Insulin-like growth factor 
2 mRNA-binding protein 2 
Q9Y6M1 -1.9 
   
Solute carrier family 35 
member E1 
Q96K37 -1.9 
   
HLA class I 
histocompatibility 
antigen, B-44 alpha chain 
P30481 -1.9 
   
Probable ATP-dependent 
RNA helicase DDX47 
Q9H0S4 -1.9 
   
Tumor susceptibility gene 
101 protein 
Q99816 -1.9 
   
Catenin delta-1 O60716 -1.9 
   
General transcription 
factor IIE subunit 1 
P29083 -1.9 
   
Symplekin Q92797 -1.9 
   
Retinol dehydrogenase 11 Q8TC12 -2.0 
   
ADP-ribosylation factor-
like protein 1 
P40616 -2.0 
   
GTP-binding protein RAD P55042 -2.0 
   
Acyl-CoA synthetase 
family member 2, 
mitochondrial 
Q96CM8 -2.0 
   
Ubiquitin carboxyl-
terminal hydrolase 5 
P45974 -2.0 
   
Exocyst complex 
component 5 
O00471 -2.0 
   
Cytochrome P450 1B1 Q16678 -2.0 
   
Serpin H1 P50454 -2.0 
   
Synaptonemal complex 
protein SC65 
Q92791 -2.0 
   
Heterogeneous nuclear 
ribonucleoprotein H2 
P55795 -2.0 
   
Rho GTPase-activating 
protein 1 
Q07960 -2.0 
   
Eukaryotic initiation 
factor 4A-I 
P60842 -2.0 
   
GTP-binding protein Rheb Q15382 -2.0 
   
Tubulin beta-4B chain P68371 -2.1 
   
Heterogeneous nuclear 
ribonucleoprotein H3 
P31942 -2.1 
   
eIF-2-alpha kinase 
activator GCN1 
Q92616 -2.1 
   
Golgi resident protein 
GCP60 
Q9H3P7 -2.1 
   
Acyl-CoA dehydrogenase 
family member 9, 
mitochondrial 
Q9H845 -2.1 
   
Vigilin Q00341 -2.1 
   
HLA class I 
histocompatibility 
antigen, A-2 alpha chain 
P01892 -2.1 
   
ATP-dependent Clp 
protease ATP-binding 
O76031 -2.2 
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subunit clpX-like, 
mitochondrial    
Protein ABHD11 Q8NFV4 -2.2 
   
Peptidyl-prolyl cis-trans 
isomerase FKBP8 
Q14318 -2.2 
   
Eukaryotic translation 
initiation factor 4 gamma 
2 
P78344 -2.2 
   
Transcription 
intermediary factor 1-
beta 
Q13263 -2.2 
   
ATP-dependent RNA 
helicase DDX39A 
O00148 -2.2 
   
Mothers against 
decapentaplegic homolog 
3 
P84022 -2.2 
   
Clusterin P10909 -2.2 
   
RNA-binding protein 3 P98179 -2.2 
   
SPARC P09486 -2.3 
   
Serine/arginine-rich 
splicing factor 9 
Q13242 -2.3 
   
Tubulin beta-2A chain Q13885 -2.4 
   
Pyruvate carboxylase, 
mitochondrial 
P11498 -2.4 
   
Heterogeneous nuclear 
ribonucleoproteins C1/C2 
P07910 -2.4 
   
Phospholipase D3 Q8IV08 -2.5 
   
Heat shock protein beta-1 P04792 -2.6 
   
Transducin beta-like 
protein 2 
Q9Y4P3 -2.6 
   
Cytochrome c P99999 -2.6 
   
Tubulin alpha-1A chain Q71U36 -2.6 
   
Tubulin beta-6 chain Q9BUF5 -2.7 
   
E3 ubiquitin/ISG15 ligase 
TRIM25 
Q14258 -2.7 
   
Follistatin-related protein 
1 
Q12841 -2.8 
   
NADH dehydrogenase 
[ubiquinone] 1 alpha 
subcomplex subunit 9, 
mitochondrial 
Q16795 -2.9 
   
NADH-ubiquinone 
oxidoreductase 75 kDa 
subunit, mitochondrial 
P28331 -2.9 
   
Fibronectin type III 
domain-containing 
protein 3B 
Q53EP0 -3.0 
   
DNA topoisomerase 2-
alpha 
P11388 -3.2 
   
28S ribosomal protein 
S18b, mitochondrial 
Q9Y676 -3.2 
   
Large proline-rich protein 
BAG6 
P46379 -3.2 
   
Protein TBRG4 Q969Z0 -3.3 
   
Copine-1 Q99829 -3.4 
   
5'-nucleotidase domain-
containing protein 2 
Q9H857 -3.4 
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Corticosteroid 11-beta-
dehydrogenase isozyme 1 
P28845 -3.5 
   
Growth arrest and DNA 
damage-inducible 
proteins-interacting 
protein 1 
Q8TAE8 -3.6 
   
NADH dehydrogenase 
[ubiquinone] flavoprotein 
2, mitochondrial 
P19404 -3.6 
   
Glutaminase kidney 
isoform, mitochondrial 
O94925 -3.7 
   
Conserved oligomeric 
Golgi complex subunit 7 
P83436 -3.8 
   
Pleckstrin homology-like 
domain family A member 
3 
Q9Y5J5 -4.1 
   
Thymidine kinase, 
cytosolic 
P04183 -4.1 
   
Cell differentiation 
protein RCD1 homolog 
Q92600 -4.3 
   
Phosphatidate 
cytidylyltransferase, 
mitochondrial 
Q96BW9 -4.5 
   
Vesicle transport protein 
SEC20 
Q12981 -4.7 
   
Grancalcin P28676 -4.8 
   
Translation factor GUF1, 
mitochondrial 
Q8N442 -4.9 
   
Integral membrane 
protein 2C 
Q9NQX7 -5.2 
   
Cytochrome P450 26B1 Q9NR63 -5.4 
   
NADH dehydrogenase 
[ubiquinone] 1 alpha 
subcomplex subunit 6 
P56556 -5.5 
   
NADH dehydrogenase 
[ubiquinone] flavoprotein 
1, mitochondrial 
P49821 -5.5 
   
E3 ubiquitin-protein ligase 
ZFP91 
Q96JP5 -5.7 
   
Ubiquitin-associated 
domain-containing 
protein 2 
Q8NBM4 -6.0 
   
Chondroitin sulfate 
synthase 1 
Q86X52 -6.8 
   
Ankyrin repeat and LEM 
domain-containing 
protein 2 
Q86XL3 -8.1 
   
Acyl-CoA desaturase O00767 -9.5 
   
Protein-lysine 6-oxidase P28300 -12.1 
   
Selenoprotein N Q9NZV5 -12.2 
   
28S ribosomal protein 
S24, mitochondrial 
Q96EL2 -17.7 
   
Cat eye syndrome critical 
region protein 5 
Q9BXW7 -23.2 
   
PDZ domain-containing 
protein GIPC1 
O14908 -46.8 
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Table 8.2 Differentially identified proteins in AAPH or rotenone treated U-87MG secretomes using mass spectrometry. 
U-87MG cells were differentiated over 5 days and then treated with 1 mM AAPH or 0.5 μM rotenone for 48 hours and 
secretome was collected and subjected to mass spectrometry.  
Secondary Name Accession 
Number 
AAPH 
fold 
change 
Secondary name Accession 
Number 
Rotenone 
fold change 
Protein S100-A11 P31949 77.7 Actin-related protein 2 P61160 27.5 
Histone H2A type 1-J Q99878 33.3 BolA-like protein 2 Q9H3K6 20.2 
Eukaryotic translation 
initiation factor 2 subunit 1 
P05198 28.3 COP9 signalosome 
complex subunit 4 
Q9BT78 12.3 
Histone H2A type 2-A Q6FI13 18.0 Glucose-6-phosphate 1-
dehydrogenase 
P11413 11.1 
F-actin-capping protein 
subunit beta 
P47756 16.7 Alanine--tRNA ligase, 
cytoplasmic 
P49588 10.5 
Neuroblast differentiation-
associated protein AHNAK 
Q09666 16.6 Nucleoside diphosphate 
kinase A 
P15531 9.9 
Syndecan-4 P31431 15.0 Elongation factor 1-beta P24534 8.9 
Heat shock protein 105 kDa Q92598 14.4 Serotransferrin P02787 8.4 
Guanine nucleotide-binding 
protein G(s) subunit alpha 
isoforms XLas 
Q5JWF2 12.4 Lysine--tRNA ligase Q15046 8.4 
Elongation factor 1-beta P24534 12.1 SKI family transcriptional 
corepressor 2 
Q2VWA4 7.6 
Protein DJ-1 Q99497 12.0 40S ribosomal protein S16 P62249 7.4 
Activated RNA polymerase 
II transcriptional 
coactivator p15 
P53999 11.6 Stanniocalcin-2 O76061 7.0 
6-phosphogluconate 
dehydrogenase, 
decarboxylating 
P52209 10.9 40S ribosomal protein S20 P60866 6.9 
Ras-related protein Rab-2A P61019 10.7 Nucleophosmin P06748 6.3 
Gamma-enolase P09104 10.7 Peptidyl-prolyl cis-trans 
isomerase FKBP1A 
P62942 6.2 
Reticulocalbin-1 Q15293 10.2 Histone H2A type 1-C Q93077 6.1 
Alpha-2-antiplasmin P08697 10.2 Eukaryotic translation 
initiation factor 3 subunit 
B 
P55884 5.9 
Calpain small subunit 1 P04632 9.8 Superoxide dismutase [Cu-
Zn] 
P00441 5.8 
Barrier-to-autointegration 
factor 
O75531 9.6 Kynureninase Q16719 5.5 
Ras-related protein Rab-1B Q9H0U4 8.9 Heterogeneous nuclear 
ribonucleoprotein Q 
O60506 5.5 
Histidine--tRNA ligase, 
cytoplasmic 
P12081 8.4 Major vault protein Q14764 5.4 
Superoxide dismutase [Cu-
Zn] 
P00441 8.0 Galectin-3 P17931 5.4 
Integrator complex subunit 
4 
Q96HW7 8.0 Proliferation-associated 
protein 2G4 
Q9UQ80 5.2 
40S ribosomal protein S14 P62263 7.8 40S ribosomal protein S14 P62263 5.2 
Keratin, type I cytoskeletal 
9 
P35527 7.5 Malate dehydrogenase, 
mitochondrial 
P40926 5.0 
Cysteine--tRNA ligase, 
cytoplasmic 
P49589 7.5 Caldesmon Q05682 5.0 
D-3-phosphoglycerate 
dehydrogenase 
O43175 7.3 Heat shock protein 105 
kDa 
Q92598 4.9 
Fatty acid synthase P49327 6.8 Apolipoprotein B-100 P04114 4.7 
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Filamin-B O75369 6.7 28 kDa heat- and acid-
stable phosphoprotein 
Q13442 4.5 
ADP/ATP translocase 2 P05141 6.7 Nucleosome assembly 
protein 1-like 1 
P55209 4.4 
Transaldolase P37837 6.5 Tryptophan--tRNA ligase, 
cytoplasmic 
P23381 4.4 
Reticulocalbin-3 Q96D15 6.2 Desmoplakin P15924 4.4 
Collagen alpha-1(II) chain P02458 6.1 40S ribosomal protein S25 P62851 4.3 
Purine nucleoside 
phosphorylase 
P00491 5.9 Activated RNA polymerase 
II transcriptional 
coactivator p15 
P53999 4.2 
Lactoylglutathione lyase Q04760 5.6 Guanine nucleotide-
binding protein G(s) 
subunit alpha isoforms 
XLas 
Q5JWF2 4.2 
Ezrin P15311 5.4 Glycine--tRNA ligase P41250 4.1 
Clathrin heavy chain 1 Q00610 5.3 Eukaryotic translation 
initiation factor 4H 
Q15056 4.0 
Serine/arginine-rich splicing 
factor 1 
Q07955 5.0 Glucose-6-phosphate 
isomerase 
P06744 4.0 
Biliverdin reductase A P53004 5.0 Fatty acid synthase P49327 4.0 
Desmoplakin P15924 4.7 Uroporphyrinogen 
decarboxylase 
P06132 3.9 
60S ribosomal protein L19 P84098 4.6 Adenylyl cyclase-
associated protein 1 
Q01518 3.9 
Nucleophosmin P06748 4.5 Ubiquitin-conjugating 
enzyme E2 variant 2 
Q15819 3.8 
Aldehyde dehydrogenase 
family 1 member A3 
P47895 4.5 Tenascin P24821 3.8 
C-type lectin domain family 
11 member A 
Q9Y240 4.3 Filamin-B O75369 3.8 
40S ribosomal protein S21 P63220 4.3 60S ribosomal protein L4 P36578 3.8 
Tropomyosin alpha-1 chain P09493 4.3 60S ribosomal protein L5 P46777 3.7 
Eukaryotic translation 
initiation factor 3 subunit B 
P55884 4.2 Ezrin P15311 3.7 
Actin-related protein 2 P61160 4.2 Rab GDP dissociation 
inhibitor beta 
P50395 3.7 
Osteopontin P10451 4.2 Glucosidase 2 subunit 
beta 
P14314 3.7 
Importin subunit beta-1 Q14974 4.2 Tubulin alpha-1C chain Q9BQE3 3.6 
Hexokinase-1 P19367 4.1 Cysteine--tRNA ligase, 
cytoplasmic 
P49589 3.6 
40S ribosomal protein S28 P62857 4.0 LIM and SH3 domain 
protein 1 
Q14847 3.6 
Stanniocalcin-2 O76061 3.9 Barrier-to-autointegration 
factor 
O75531 3.6 
Eukaryotic translation 
initiation factor 3 subunit A 
Q14152 3.9 60S ribosomal protein L19 P84098 3.5 
Basigin P35613 3.9 Calpain-2 catalytic subunit P17655 3.4 
Protein SET Q01105 3.9 Eukaryotic translation 
initiation factor 3 subunit 
A 
Q14152 3.3 
LIM and SH3 domain 
protein 1 
Q14847 3.8 Ras-related protein Rab-
10 
P61026 3.3 
SKI family transcriptional 
corepressor 2 
Q2VWA4 3.8 Hexokinase-1 P19367 3.3 
Eukaryotic translation 
initiation factor 4 gamma 1 
Q04637 3.7 Acidic leucine-rich nuclear 
phosphoprotein 32 family 
member B 
Q92688 3.3 
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Ectonucleotide 
pyrophosphatase/phospho
diesterase family member 2 
Q13822 3.6 ATP-dependent 6-
phosphofructokinase, 
platelet type 
Q01813 3.3 
40S ribosomal protein S5 P46782 3.6 Heterogeneous nuclear 
ribonucleoprotein D0 
Q14103 3.3 
Lysine--tRNA ligase Q15046 3.6 40S ribosomal protein S3 P23396 3.3 
40S ribosomal protein S18 P62269 3.6 Rab GDP dissociation 
inhibitor alpha 
P31150 3.2 
Neutral alpha-glucosidase 
AB 
Q14697 3.5 Lactoylglutathione lyase Q04760 3.2 
ADP-ribosylation factor 4 P18085 3.5 60S ribosomal protein L18 Q07020 3.1 
Ubiquitin thioesterase 
OTUB1 
Q96FW1 3.5 Spermine synthase P52788 3.1 
Histone H2A type 1-C Q93077 3.4 Aldose reductase P15121 3.1 
Ras-related protein Rab-7a P51149 3.3 Stress-induced-
phosphoprotein 1 
P31948 3.0 
60S ribosomal protein L12 P30050 3.3 Ubiquitin-conjugating 
enzyme E2 L3 
P68036 3.0 
Metalloproteinase inhibitor 
1 
P01033 3.2 C-type lectin domain 
family 11 member A 
Q9Y240 3.0 
Tryptophan--tRNA ligase, 
cytoplasmic 
P23381 3.1 Phosphoserine 
aminotransferase 
Q9Y617 3.0 
Caldesmon Q05682 3.1 Alpha-enolase P06733 3.0 
Alanine--tRNA ligase, 
cytoplasmic 
P49588 3.1 Protein S100-A6 P06703 2.9 
Calpain-2 catalytic subunit P17655 3.1 40S ribosomal protein S18 P62269 2.9 
Uroporphyrinogen 
decarboxylase 
P06132 3.0 Reticulocalbin-1 Q15293 2.9 
Coactosin-like protein Q14019 3.0 Thymosin beta-10 P63313 2.9 
CD82 antigen P27701 2.9 Gamma-enolase P09104 2.9 
Ras-related protein Rab-10 P61026 2.9 Filamin-C Q14315 2.8 
60S acidic ribosomal 
protein P2 
P05387 2.8 40S ribosomal protein S2 P15880 2.8 
Hippocalcin-like protein 1 P37235 2.6 Protein S100-A11 P31949 2.8 
Complement C1s 
subcomponent 
P09871 2.6 Thioredoxin P10599 2.7 
Plasminogen activator 
inhibitor 1 RNA-binding 
protein 
Q8NC51 2.6 Tubulin-specific 
chaperone A 
O75347 2.7 
Heterogeneous nuclear 
ribonucleoprotein Q 
O60506 2.5 14-3-3 protein beta/alpha P31946 2.6 
Heterogeneous nuclear 
ribonucleoprotein K 
P61978 2.5 Elongation factor 1-delta P29692 2.6 
Coatomer subunit delta P48444 2.4 Vimentin P08670 2.6 
Guanine nucleotide-binding 
protein G(I)/G(S)/G(O) 
subunit gamma-12 
Q9UBI6 2.4 Myosin-9 P35579 2.6 
Procollagen C-
endopeptidase enhancer 2 
Q9UKZ9 2.4 Myosin regulatory light 
chain 12A 
P19105 2.6 
GPALPP motifs-containing 
protein 1 
Q8IXQ4 2.3 Stathmin P16949 2.5 
Rho GDP-dissociation 
inhibitor 1 
P52565 2.3 Tropomyosin alpha-1 
chain 
P09493 2.5 
L-lactate dehydrogenase B 
chain 
P07195 2.3 78 kDa glucose-regulated 
protein 
P11021 2.5 
Tenascin P24821 2.3 Actin-related protein 2/3 
complex subunit 1B 
O15143 2.5 
Tumor protein D54 O43399 2.2 Galectin-1 P09382 2.5 
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Stress-70 protein, 
mitochondrial 
P38646 2.2 Neuroblast 
differentiation-associated 
protein AHNAK 
Q09666 2.4 
Heterogeneous nuclear 
ribonucleoprotein R 
O43390 2.2 Proteasome activator 
complex subunit 1 
Q06323 2.4 
Laminin subunit gamma-1 P11047 2.2 Fructose-bisphosphate 
aldolase A 
P04075 2.4 
Coronin-1C Q9ULV4 2.2 ADP-ribosylation factor 1 P84077 2.4 
Collagen alpha-2(VI) chain P12110 2.1 F-actin-capping protein 
subunit beta 
P47756 2.4 
Adenylate kinase 2, 
mitochondrial 
P54819 2.1 Stress-70 protein, 
mitochondrial 
P38646 2.4 
Apolipoprotein B-100 P04114 2.1 Elongation factor 1-
gamma 
P26641 2.4 
Hemoglobin subunit alpha P69905 2.1 Guanine nucleotide-
binding protein 
G(I)/G(S)/G(O) subunit 
gamma-12 
Q9UBI6 2.4 
Flavin reductase (NADPH) P30043 2.0 Actin, alpha skeletal 
muscle 
P68133 2.3 
Phosphoserine 
aminotransferase 
Q9Y617 2.0 Glyceraldehyde-3-
phosphate dehydrogenase 
P04406 2.3 
Reticulon-4 Q9NQC3 2.0 Acylamino-acid-releasing 
enzyme 
P13798 2.3 
Complement C1r 
subcomponent 
P00736 1.9 Synaptic vesicle 
membrane protein VAT-1 
homolog 
Q99536 2.3 
Peroxiredoxin-1 Q06830 1.9 Glutathione S-transferase 
omega-1 
P78417 2.3 
Retinoic acid receptor 
responder protein 1 
P49788 1.9 Coactosin-like protein Q14019 2.3 
Tubulin alpha-4A chain P68366 1.9 Actin, cytoplasmic 2 P63261 2.3 
Translationally-controlled 
tumor protein 
P13693 1.9 ADP/ATP translocase 2 P05141 2.3 
Extracellular matrix protein 
1 
Q16610 1.9 Eukaryotic translation 
initiation factor 3 subunit 
E 
P60228 2.2 
Versican core protein P13611 1.8 Protein DJ-1 Q99497 2.2 
Calsyntenin-1 O94985 1.8 Basigin P35613 2.2 
Filamin-A P21333 1.8 Adenylate kinase 2, 
mitochondrial 
P54819 2.2 
Sulfhydryl oxidase 1 O00391 1.8 14-3-3 protein theta P27348 2.2 
Spermine synthase P52788 1.8 Calpain small subunit 1 P04632 2.2 
Actin-related protein 3B Q9P1U1 1.7 Serine/arginine-rich 
splicing factor 1 
Q07955 2.2 
Histone H2B type 1-L Q99880 1.7 Prothymosin alpha P06454 2.1 
ICOS ligand O75144 1.7 Putative trypsin-6 Q8NHM4 2.1 
Transitional endoplasmic 
reticulum ATPase 
P55072 1.6 Trypsin-2 P07478 2.1 
Heterogeneous nuclear 
ribonucleoprotein A3 
P51991 1.6 Aldehyde dehydrogenase 
family 1 member A3 
P47895 2.1 
Nucleoside diphosphate 
kinase A 
P15531 1.6 StAR-related lipid transfer 
protein 9 
Q9P2P6 2.1 
Multifunctional protein 
ADE2 
P22234 1.6 60 kDa heat shock protein, 
mitochondrial 
P10809 2.1 
Transgelin-2 P37802 1.6 6-phosphogluconate 
dehydrogenase, 
decarboxylating 
P52209 2.1 
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Peptidyl-prolyl cis-trans 
isomerase B 
P23284 1.5 Triosephosphate 
isomerase 
P60174 2.0 
Latent-transforming growth 
factor beta-binding protein 
1 
Q14766 1.5 Microtubule-associated 
protein 4 
P27816 2.0 
Cation-independent 
mannose-6-phosphate 
receptor 
P11717 1.5 Transaldolase P37837 2.0 
Periostin Q15063 1.5 NAD(P)H dehydrogenase 
[quinone] 1 
P15559 2.0 
Apolipoprotein E P02649 1.5 Malate dehydrogenase, 
cytoplasmic 
P40925 2.0 
Acylamino-acid-releasing 
enzyme 
P13798 1.5 Fructose-bisphosphate 
aldolase C 
P09972 2.0 
Insulin-like growth factor-
binding protein 2 
P18065 1.5 Multifunctional protein 
ADE2 
P22234 2.0 
Myosin light polypeptide 6 P60660 1.5 Clathrin heavy chain 1 Q00610 2.0 
Sushi repeat-containing 
protein SRPX 
P78539 1.5 Brain acid soluble protein 
1 
P80723 2.0 
Brain acid soluble protein 1 P80723 1.5 Peptidyl-prolyl cis-trans 
isomerase A 
P62937 2.0 
Collagen alpha-1(V) chain P20908 1.5 Eukaryotic translation 
initiation factor 4 gamma 
1 
Q04637 2.0 
Eukaryotic translation 
initiation factor 4H 
Q15056 1.4 Reticulon-4 Q9NQC3 2.0 
Galectin-3-binding protein Q08380 1.4 Profilin-1 P07737 2.0 
Eukaryotic translation 
initiation factor 3 subunit D 
O15371 1.4 Annexin A5 P08758 2.0 
40S ribosomal protein S16 P62249 1.4 Heterogeneous nuclear 
ribonucleoprotein A1 
P09651 1.9 
Small ubiquitin-related 
modifier 2 
P61956 1.4 Phosphoglycerate kinase 1 P00558 1.9 
Coagulation factor IX P00740 1.4 Transgelin-2 P37802 1.9 
72 kDa type IV collagenase P08253 1.4 Receptor of activated 
protein C kinase 1 
P63244 1.9 
Leukemia inhibitory factor P15018 1.4 Tumor protein D54 O43399 1.9 
Collagen alpha-2(I) chain P08123 1.4 Ubiquitin-like modifier-
activating enzyme 1 
P22314 1.9 
Pregnancy zone protein P20742 1.4 14-3-3 protein epsilon P62258 1.9 
Vinculin P18206 1.4 Pyruvate kinase PKM P14618 1.9 
Prothymosin alpha P06454 1.4 Ras-related protein Rab-
7a 
P51149 1.9 
Serine protease HTRA1 Q92743 1.4 Protein-glutamine 
gamma-
glutamyltransferase 2 
P21980 1.9 
Beta-2-microglobulin P61769 1.4 Tubulin beta-4B chain P68371 1.8 
Phospholipid transfer 
protein 
P55058 1.4 Annexin A1 P04083 1.8 
Insulin-like growth factor II P01344 1.4 Plasminogen activator 
inhibitor 1 RNA-binding 
protein 
Q8NC51 1.8 
Hepatocyte growth factor 
activator 
Q04756 1.4 Inter-alpha-trypsin 
inhibitor heavy chain H3 
Q06033 1.8 
Amyloid beta A4 protein P05067 1.4 Peroxiredoxin-5, 
mitochondrial 
P30044 1.8 
SPARC P09486 1.4 Tubulin beta-6 chain Q9BUF5 1.8 
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EGF-containing fibulin-like 
extracellular matrix protein 
1 
Q12805 1.3 40S ribosomal protein S10 P46783 1.8 
Molybdopterin synthase 
catalytic subunit 
O96007 1.3 T-complex protein 1 
subunit theta 
P50990 1.8 
Cartilage oligomeric matrix 
protein 
P49747 1.3 Vinculin P18206 1.8 
Thrombospondin-1 P07996 1.3 Peroxiredoxin-1 Q06830 1.8 
Elongation factor 1-gamma P26641 1.3 Cystatin-B P04080 1.8 
Afamin P43652 1.3 10 kDa heat shock protein, 
mitochondrial 
P61604 1.8 
Protein FAM47E Q6ZV65 1.3 Moesin P26038 1.8 
Tropomyosin alpha-3 chain P06753 1.3 Serine/threonine-protein 
phosphatase 5 
P53041 1.8 
Coagulation factor V P12259 1.3 Heat shock protein HSP 
90-alpha 
P07900 1.8 
Cystatin-C P01034 1.3 Guanine nucleotide-
binding protein 
G(I)/G(S)/G(T) subunit 
beta-1 
P62873 1.8 
Transforming growth 
factor-beta-induced protein 
ig-h3 
Q15582 1.3 Cofilin-1 P23528 1.8 
WD repeat-containing 
protein 1 
O75083 1.3 Biliverdin reductase A P53004 1.8 
Complement factor I P05156 1.3 GTP-binding nuclear 
protein Ran 
P62826 1.8 
Collagen alpha-1(VI) chain P12109 1.3 Ubiquitin-60S ribosomal 
protein L40 
P62987 1.8 
Lysyl oxidase homolog 2 Q9Y4K0 1.3 Actin-related protein 3B Q9P1U1 1.7 
Fibrinogen gamma chain P02679 1.3 Protein SET Q01105 1.7 
Retinol-binding protein 4 P02753 1.3 L-lactate dehydrogenase A 
chain 
P00338 1.7 
Heparin cofactor 2 P05546 1.3 Peroxiredoxin-6 P30041 1.7 
Lactotransferrin P02788 1.3 Myosin light polypeptide 6 P60660 1.7 
Lumican P51884 1.3 Transitional endoplasmic 
reticulum ATPase 
P55072 1.7 
Clusterin P10909 1.3 Ras-related protein Rab-
2A 
P61019 1.7 
Collagen alpha-1(I) chain P02452 1.3 Transketolase P29401 1.7 
Plasminogen activator 
inhibitor 1 
P05121 1.3 WD repeat-containing 
protein 1 
O75083 1.6 
Collagen alpha-3(VI) chain P12111 1.3 Adenosylhomocysteinase P23526 1.6 
Sacsin Q9NZJ4 1.3 Small ubiquitin-related 
modifier 2 
P61956 1.6 
Tetranectin P05452 1.3 Alpha-actinin-4 O43707 1.6 
CD44 antigen P16070 1.3 D-3-phosphoglycerate 
dehydrogenase 
O43175 1.6 
Prothrombin P00734 1.3 Importin subunit beta-1 Q14974 1.6 
Thrombospondin-2 P35442 1.3 Tropomyosin alpha-4 
chain 
P67936 1.6 
Vitronectin P04004 1.3 Ubiquitin carboxyl-
terminal hydrolase 
isozyme L1 
P09936 1.6 
ATP-binding cassette sub-
family A member 10 
Q8WWZ4 1.3 Putative elongation factor 
1-alpha-like 3 
Q5VTE0 1.6 
Sex hormone-binding 
globulin 
P04278 1.2 Ras-related protein Rab-
1B 
Q9H0U4 1.6 
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Fibronectin P02751 1.2 Flavin reductase (NADPH) P30043 1.6 
Apolipoprotein M O95445 1.2 Elongation factor 1-alpha 
1 
P68104 1.6 
Beta-2-syntrophin Q13425 1.2 Peroxiredoxin-2 P32119 1.5 
E3 ubiquitin-protein ligase 
MARCH4 
Q9P2E8 1.2 Filamin-A P21333 1.5 
Plasminogen P00747 1.2 Nicotinamide 
phosphoribosyltransferase 
P43490 1.5 
Collagen alpha-1(III) chain P02461 1.2 14-3-3 protein zeta/delta P63104 1.5 
Insulin-like growth factor-
binding protein 7 
Q16270 1.2 Rho GDP-dissociation 
inhibitor 1 
P52565 1.5 
Alpha-1B-glycoprotein P04217 1.2 Phosphatidylethanolamin
e-binding protein 1 
P30086 1.5 
Complement C3 P01024 1.2 L-lactate dehydrogenase B 
chain 
P07195 1.5 
Apolipoprotein C-III P02656 1.2 Talin-1 Q9Y490 1.5 
Fibulin-1 P23142 1.2 Heat shock protein HSP 
90-beta 
P08238 1.5 
Complement C5 P01031 1.2 Phosphoglycerate mutase 
1 
P18669 1.5 
Alpha-2-macroglobulin P01023 1.2 Puromycin-sensitive 
aminopeptidase 
P55786 1.5 
ADP-ribosylation factor 1 P84077 1.2 Tubulin alpha-1B chain P68363 1.5 
Antithrombin-III P01008 1.2 Heat shock cognate 71 
kDa protein 
P11142 1.5 
Talin-1 Q9Y490 1.2 14-3-3 protein gamma P61981 1.5 
Serotransferrin P02787 1.2 Ribonuclease inhibitor P13489 1.5 
Trafficking protein particle 
complex subunit 6A 
O75865 1.2 Eukaryotic translation 
initiation factor 2 subunit 
1 
P05198 1.4 
Inter-alpha-trypsin inhibitor 
heavy chain H3 
Q06033 1.2 Nucleoside diphosphate 
kinase B 
P22392 1.4 
Single-pass membrane and 
coiled-coil domain-
containing protein 2 
A6NFE2 1.2 Beta-2-syntrophin Q13425 1.4 
Pigment epithelium-
derived factor 
P36955 1.2 Sterol 26-hydroxylase, 
mitochondrial 
Q02318 1.4 
Inter-alpha-trypsin inhibitor 
heavy chain H4 
Q14624 1.2 T-complex protein 1 
subunit gamma 
P49368 1.4 
Complement component C7 P10643 1.2 Apolipoprotein A-I P02647 1.4 
PiggyBac transposable 
element-derived protein 5 
Q8N414 1.2 Annexin A2 P07355 1.4 
Vimentin P08670 1.1 60S ribosomal protein 
L27a 
P46776 1.4 
Vitamin D-binding protein P02774 1.1 HLA class I 
histocompatibility 
antigen, B-44 alpha chain 
P30481 1.4 
Putative trypsin-6 Q8NHM4 1.1 Collagen alpha-1(III) chain P02461 1.4 
60 kDa heat shock protein, 
mitochondrial 
P10809 1.1 Endoplasmin P14625 1.4 
Trypsin-2 P07478 1.1 40S ribosomal protein S12 P25398 1.4 
Heat shock 70 kDa protein 
1B 
P0DMV9 -1.1 CD82 antigen P27701 1.4 
E3 ubiquitin-protein ligase 
BRE1B 
O75150 -1.2 E3 ubiquitin-protein ligase 
MARCH4 
Q9P2E8 1.4 
Beta-2-glycoprotein 1 P02749 -1.2 Elongation factor 2 P13639 1.4 
Tubulin-specific chaperone 
A 
O75347 -1.2 Calmodulin-3 P0DP25 1.4 
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Gelsolin P06396 -1.2 Glutaredoxin-1 P35754 1.4 
Nicotinamide 
phosphoribosyltransferase 
P43490 -1.2 Fascin Q16658 1.3 
Alpha-fetoprotein P02771 -1.2 40S ribosomal protein S28 P62857 1.3 
Complement component C9 P02748 -1.2 Protein disulfide-
isomerase 
P07237 1.3 
45 kDa calcium-binding 
protein 
Q9BRK5 -1.2 Parathymosin P20962 1.3 
Inorganic pyrophosphatase 
2, mitochondrial 
Q9H2U2 -1.2 Tubulin alpha-4A chain P68366 1.3 
Histone H4 P62805 -1.2 14-3-3 protein eta Q04917 1.3 
Hemopexin P02790 -1.2 Tropomyosin alpha-3 
chain 
P06753 1.2 
Apolipoprotein A-I P02647 -1.2 CD44 antigen P16070 1.2 
Peroxiredoxin-2 P32119 -1.2 Trafficking protein particle 
complex subunit 6A 
O75865 1.2 
Myotrophin P58546 -1.2 Sacsin Q9NZJ4 1.2 
Ubiquitin carboxyl-terminal 
hydrolase isozyme L1 
P09936 -1.3 Aldo-keto reductase 
family 1 member C1 
Q04828 1.2 
Proteasome subunit alpha 
type-6 
P60900 -1.3 Eukaryotic initiation factor 
4A-I 
P60842 1.2 
Tropomyosin alpha-4 chain P67936 -1.3 Copper-transporting 
ATPase 2 
P35670 -1.1 
Nucleosome assembly 
protein 1-like 1 
P55209 -1.3 Metallothionein-1E P04732 -1.2 
Annexin A5 P08758 -1.3 Tetranectin P05452 -1.2 
Basement membrane-
specific heparan sulfate 
proteoglycan core protein 
P98160 -1.3 SH3 domain-binding 
glutamic acid-rich-like 
protein 3 
Q9H299 -1.2 
Heat shock cognate 71 kDa 
protein 
P11142 -1.3 Fibrinogen beta chain P02675 -1.2 
Alpha-amylase 2B P19961 -1.3 PiggyBac transposable 
element-derived protein 5 
Q8N414 -1.2 
Inter-alpha-trypsin inhibitor 
heavy chain H2 
P19823 -1.3 Molybdopterin synthase 
catalytic subunit 
O96007 -1.3 
Hemoglobin subunit beta P68871 -1.3 Afamin P43652 -1.3 
Endoplasmin P14625 -1.3 Calumenin O43852 -1.3 
Chloride intracellular 
channel protein 1 
O00299 -1.3 E3 ubiquitin-protein ligase 
BRE1B 
O75150 -1.3 
Alpha-2-HS-glycoprotein P02765 -1.3 Apolipoprotein C-III P02656 -1.3 
Pantetheinase O95497 -1.3 Insulin-like growth factor-
binding protein 3 
P17936 -1.3 
Carboxypeptidase A4 Q9UI42 -1.3 Inter-alpha-trypsin 
inhibitor heavy chain H4 
Q14624 -1.4 
Protein S100-A6 P06703 -1.3 Complement component 
C7 
P10643 -1.4 
Phosphoglycerate kinase 1 P00558 -1.3 Collagen alpha-1(I) chain P02452 -1.4 
Nucleoside diphosphate 
kinase B 
P22392 -1.3 ICOS ligand O75144 -1.4 
Cystatin-B P04080 -1.3 Procollagen C-
endopeptidase enhancer 2 
Q9UKZ9 -1.4 
Myosin regulatory light 
chain 12A 
P19105 -1.3 Leukemia inhibitory factor P15018 -1.4 
Metallothionein-1E P04732 -1.3 Complement C5 P01031 -1.4 
Insulin-like growth factor-
binding protein 3 
P17936 -1.3 Insulin-like growth factor 
II 
P01344 -1.4 
14-3-3 protein zeta/delta P63104 -1.4 Fibulin-1 P23142 -1.5 
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MOB kinase activator 1A Q9H8S9 -1.4 Alpha-2-antiplasmin P08697 -1.5 
Moesin P26038 -1.4 Heat shock 70 kDa protein 
1B 
P0DMV9 -1.5 
Alpha-enolase P06733 -1.4 TLR4 interactor with 
leucine rich repeats 
Q7L0X0 -1.5 
Cofilin-1 P23528 -1.4 Lumican P51884 -1.5 
Annexin A2 P07355 -1.4 Alpha-2-macroglobulin P01023 -1.5 
Parathymosin P20962 -1.4 Collagen alpha-1(XI) chain P12107 -1.5 
14-3-3 protein theta P27348 -1.4 Protein Z-dependent 
protease inhibitor 
Q9UK55 -1.5 
Eukaryotic initiation factor 
4A-I 
P60842 -1.4 Serine/threonine-protein 
phosphatase 2A catalytic 
subunit alpha isoform 
P67775 -1.5 
Glutaredoxin-1 P35754 -1.4 60S acidic ribosomal 
protein P2 
P05387 -1.5 
Fibrinogen beta chain P02675 -1.4 ATP-binding cassette sub-
family A member 10 
Q8WWZ4 -1.5 
Phosphatidylethanolamine-
binding protein 1 
P30086 -1.4 Fibrinogen gamma chain P02679 -1.5 
Elongation factor 1-alpha 1 P68104 -1.4 Cathepsin B P07858 -1.5 
Fructose-bisphosphate 
aldolase C 
P09972 -1.4 Coronin-1C Q9ULV4 -1.5 
Glutathione S-transferase 
omega-1 
P78417 -1.4 Apolipoprotein E P02649 -1.6 
Alpha-actinin-4 O43707 -1.4 Inter-alpha-trypsin 
inhibitor heavy chain H1 
P19827 -1.6 
Glutathione S-transferase P P09211 -1.4 Hemopexin P02790 -1.6 
SH3 domain-binding 
glutamic acid-rich-like 
protein 3 
Q9H299 -1.4 Hemoglobin subunit alpha P69905 -1.6 
Cathepsin B P07858 -1.4 Pigment epithelium-
derived factor 
P36955 -1.6 
Putative elongation factor 
1-alpha-like 3 
Q5VTE0 -1.4 Complement component 
C9 
P02748 -1.6 
Heat shock protein HSP 90-
alpha 
P07900 -1.4 Hepatocyte growth factor 
activator 
Q04756 -1.6 
Eukaryotic translation 
initiation factor 5A-1 
P63241 -1.4 Gelsolin P06396 -1.6 
Transketolase P29401 -1.4 Pentraxin-related protein 
PTX3 
P26022 -1.6 
Inter-alpha-trypsin inhibitor 
heavy chain H1 
P19827 -1.4 Vitamin K-dependent 
protein S 
P07225 -1.6 
60S ribosomal protein L22 P35268 -1.4 Protein disulfide-
isomerase A3 
P30101 -1.6 
Fructose-bisphosphate 
aldolase A 
P04075 -1.4 Coagulation factor V P12259 -1.6 
Elongation factor 2 P13639 -1.4 HLA class I 
histocompatibility 
antigen, B-59 alpha chain 
Q29940 -1.6 
Histone H3.1 P68431 -1.4 Vitamin D-binding protein P02774 -1.6 
Glyceraldehyde-3-
phosphate dehydrogenase 
P04406 -1.5 Nucleolin P19338 -1.6 
Pyruvate kinase PKM P14618 -1.5 Prothrombin P00734 -1.6 
GTP-binding nuclear 
protein Ran 
P62826 -1.5 Cartilage oligomeric 
matrix protein 
P49747 -1.6 
Aldo-keto reductase family 
1 member C1 
Q04828 -1.5 Hemoglobin subunit beta P68871 -1.7 
Prosaposin P07602 -1.5 Complement factor I P05156 -1.7 
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14-3-3 protein eta Q04917 -1.5 Heat shock protein beta-1 P04792 -1.7 
L-lactate dehydrogenase A 
chain 
P00338 -1.5 Heparin cofactor 2 P05546 -1.7 
Complement factor B P00751 -1.5 Complement C4-A P0C0L4 -1.7 
Profilin-1 P07737 -1.5 Basement membrane-
specific heparan sulfate 
proteoglycan core protein 
P98160 -1.7 
Galectin-1 P09382 -1.5 Apolipoprotein M O95445 -1.7 
Calumenin O43852 -1.5 Alpha-fetoprotein P02771 -1.7 
Heat shock protein beta-1 P04792 -1.5 Thrombospondin-1 P07996 -1.7 
Aldose reductase P15121 -1.5 Reticulocalbin-3 Q96D15 -1.7 
Triosephosphate isomerase P60174 -1.5 Histone H2B type 1-L Q99880 -1.7 
HLA class I 
histocompatibility antigen, 
B-59 alpha chain 
Q29940 -1.5 Complement factor B P00751 -1.7 
Stanniocalcin-1 P52823 -1.5 EGF-containing fibulin-like 
extracellular matrix 
protein 1 
Q12805 -1.7 
Tubulin alpha-1B chain P68363 -1.5 Protein FAM47E Q6ZV65 -1.7 
Peroxiredoxin-6 P30041 -1.5 Periostin Q15063 -1.7 
Peptidyl-prolyl cis-trans 
isomerase A 
P62937 -1.5 Aspartate 
aminotransferase, 
cytoplasmic 
P17174 -1.7 
Myosin-9 P35579 -1.6 Collagen alpha-1(II) chain P02458 -1.8 
Pentraxin-related protein 
PTX3 
P26022 -1.6 Peptidyl-prolyl cis-trans 
isomerase FKBP4 
Q02790 -1.8 
Annexin A1 P04083 -1.6 Hemoglobin subunit 
gamma-2 
P69892 -1.8 
Protein disulfide-isomerase P07237 -1.6 Hippocalcin-like protein 1 P37235 -1.8 
14-3-3 protein gamma P61981 -1.6 Syndecan-4 P31431 -1.8 
Interleukin-8 P10145 -1.6 Vitronectin P04004 -1.8 
Laminin subunit beta-1 P07942 -1.6 Histone H4 P62805 -1.8 
Protein disulfide-isomerase 
A3 
P30101 -1.6 Antithrombin-III P01008 -1.8 
40S ribosomal protein S12 P25398 -1.6 Insulin-like growth factor-
binding protein 2 
P18065 -1.8 
Thioredoxin P10599 -1.6 Coagulation factor IX P00740 -1.8 
Nuclear ubiquitous casein 
and cyclin-dependent 
kinase substrate 1 
Q9H1E3 -1.6 Complement C3 P01024 -1.8 
Actin, cytoplasmic 2 P63261 -1.7 Cation-independent 
mannose-6-phosphate 
receptor 
P11717 -1.8 
StAR-related lipid transfer 
protein 9 
Q9P2P6 -1.7 Inter-alpha-trypsin 
inhibitor heavy chain H2 
P19823 -1.9 
78 kDa glucose-regulated 
protein 
P11021 -1.7 Plasminogen activator 
inhibitor 1 
P05121 -1.9 
Insulin-like growth factor-
binding protein 6 
P24592 -1.8 Proteasome subunit alpha 
type-6 
P60900 -1.9 
Macrophage migration 
inhibitory factor 
P14174 -1.8 Pantetheinase O95497 -1.9 
Cathepsin L1 P07711 -1.8 Coagulation factor XIII A 
chain 
P00488 -1.9 
10 kDa heat shock protein, 
mitochondrial 
P61604 -1.8 Plasminogen P00747 -1.9 
Heat shock protein HSP 90-
beta 
P08238 -1.9 Ubiquitin thioesterase 
OTUB1 
Q96FW1 -1.9 
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14-3-3 protein beta/alpha P31946 -1.9 Serine protease HTRA1 Q92743 -2.0 
Thymosin beta-10 P63313 -1.9 Glia-derived nexin P07093 -2.0 
Serine/threonine-protein 
phosphatase 2A catalytic 
subunit alpha isoform 
P67775 -1.9 Histone H1.5 P16401 -2.0 
Tubulin beta-4B chain P68371 -2.0 60S ribosomal protein L22 P35268 -2.0 
Nucleolin P19338 -2.0 Collagen alpha-2(VI) chain P12110 -2.0 
28 kDa heat- and acid-
stable phosphoprotein 
Q13442 -2.0 Beta-2-glycoprotein 1 P02749 -2.0 
Copper-transporting 
ATPase 2 
P35670 -2.0 Delta(3,5)-Delta(2,4)-
dienoyl-CoA isomerase, 
mitochondrial 
Q13011 -2.1 
Interleukin enhancer-
binding factor 2 
Q12905 -2.0 Collagen alpha-3(VI) chain P12111 -2.1 
14-3-3 protein epsilon P62258 -2.0 Collagen alpha-2(I) chain P08123 -2.1 
Metallothionein-2 P02795 -2.0 Protein DENND6A Q8IWF6 -2.1 
60S ribosomal protein L27a P46776 -2.1 UPF0160 protein MYG1, 
mitochondrial 
Q9HB07 -2.1 
Synaptic vesicle membrane 
protein VAT-1 homolog 
Q99536 -2.1 60S ribosomal protein L12 P30050 -2.1 
Actin, cytoplasmic 1 P60709 -2.1 Peptidyl-prolyl cis-trans 
isomerase B 
P23284 -2.2 
Histone H1.5 P16401 -2.1 Amyloid beta A4 protein P05067 -2.2 
Pachytene checkpoint 
protein 2 homolog 
Q15645 -2.1 Versican core protein P13611 -2.2 
T-complex protein 1 
subunit gamma 
P49368 -2.2 Retinol-binding protein 4 P02753 -2.2 
Protein DENND6A Q8IWF6 -2.2 Beta-2-microglobulin P61769 -2.2 
Serum albumin P02768 -2.2 Heterogeneous nuclear 
ribonucleoprotein R 
O43390 -2.2 
Integrin beta-1 P05556 -2.3 Eukaryotic translation 
initiation factor 5A-1 
P63241 -2.2 
Cathepsin D P07339 -2.3 Transforming growth 
factor-beta-induced 
protein ig-h3 
Q15582 -2.3 
Stress-induced-
phosphoprotein 1 
P31948 -2.3 Cathepsin L1 P07711 -2.3 
40S ribosomal protein S2 P15880 -2.4 Thrombospondin-4 P35443 -2.4 
Hepatocyte growth factor-
like protein 
P26927 -2.4 Collagen alpha-1(VI) chain P12109 -2.5 
Actin-related protein 2/3 
complex subunit 3 
O15145 -2.4 Single-pass membrane 
and coiled-coil domain-
containing protein 2 
A6NFE2 -2.5 
Stathmin P16949 -2.5 Collagen alpha-1(V) chain P20908 -2.5 
Proteasome subunit alpha 
type-2 
P25787 -2.5 Lactotransferrin P02788 -2.5 
Glucose-6-phosphate 
isomerase 
P06744 -2.5 Cathepsin D P07339 -2.5 
Metalloproteinase inhibitor 
2 
P16035 -2.6 Serine/threonine-protein 
phosphatase 2A 55 kDa 
regulatory subunit B alpha 
isoform 
P63151 -2.5 
Malate dehydrogenase, 
mitochondrial 
P40926 -2.6 Alpha-2-HS-glycoprotein P02765 -2.5 
Adenylyl cyclase-associated 
protein 1 
Q01518 -2.6 Clusterin P10909 -2.5 
Elongation factor 1-delta P29692 -2.7 40S ribosomal protein S4, 
X isoform 
P62701 -2.5 
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Ubiquitin-conjugating 
enzyme E2 variant 2 
Q15819 -2.7 Nuclear ubiquitous casein 
and cyclin-dependent 
kinase substrate 1 
Q9H1E3 -2.6 
Filamin-C Q14315 -2.8 Ras-related C3 botulinum 
toxin substrate 1 
P63000 -2.6 
Adenosylhomocysteinase P23526 -2.9 Lysyl oxidase homolog 2 Q9Y4K0 -2.6 
Aspartate 
aminotransferase, 
cytoplasmic 
P17174 -3.0 GPALPP motifs-containing 
protein 1 
Q8IXQ4 -2.7 
Prelamin-A/C P02545 -3.0 SPARC P09486 -2.7 
Rab GDP dissociation 
inhibitor beta 
P50395 -3.0 Interleukin-8 P10145 -2.8 
Ubiquitin-60S ribosomal 
protein L40 
P62987 -3.1 Fibronectin P02751 -2.8 
40S ribosomal protein S20 P60866 -3.1 Sulfhydryl oxidase 1 O00391 -2.8 
Peptidyl-prolyl cis-trans 
isomerase FKBP4 
Q02790 -3.1 Prosaposin P07602 -2.9 
Acidic leucine-rich nuclear 
phosphoprotein 32 family 
member B 
Q92688 -3.2 Histone H3.1 P68431 -2.9 
Actin-related protein 2/3 
complex subunit 1B 
O15143 -3.2 Ectonucleotide 
pyrophosphatase/phosph
odiesterase family 
member 2 
Q13822 -2.9 
Proteasome subunit alpha 
type-3 
P25788 -3.3 Sex hormone-binding 
globulin 
P04278 -2.9 
Heterogeneous nuclear 
ribonucleoprotein D0 
Q14103 -3.4 Phospholipid transfer 
protein 
P55058 -2.9 
Proteasome activator 
complex subunit 1 
Q06323 -3.4 Calsyntenin-1 O94985 -3.0 
Protein-glutamine gamma-
glutamyltransferase 2 
P21980 -3.4 Insulin-like growth factor-
binding protein 7 
Q16270 -3.0 
Mitochondrial import 
receptor subunit TOM70 
O94826 -3.4 Hepatocyte growth factor-
like protein 
P26927 -3.0 
Actin, alpha skeletal muscle P68133 -3.4 Cystatin-C P01034 -3.1 
Galectin-3 P17931 -3.4 Pregnancy zone protein P20742 -3.1 
Latexin Q9BS40 -3.5 Procollagen-lysine,2-
oxoglutarate 5-
dioxygenase 2 
O00469 -3.1 
Granulocyte colony-
stimulating factor 
P09919 -3.5 Galectin-3-binding protein Q08380 -3.2 
Protein Z-dependent 
protease inhibitor 
Q9UK55 -3.5 72 kDa type IV collagenase P08253 -3.2 
Coagulation factor XIII A 
chain 
P00488 -3.5 60S ribosomal protein L7 P18124 -3.2 
Guanine nucleotide-binding 
protein G(I)/G(S)/G(T) 
subunit beta-1 
P62873 -3.5 Growth/differentiation 
factor 15 
Q99988 -3.3 
Peptidyl-prolyl cis-trans 
isomerase FKBP1A 
P62942 -3.5 Latexin Q9BS40 -3.4 
Glia-derived nexin P07093 -3.5 Insulin-like growth factor-
binding protein 6 
P24592 -3.5 
Ribonuclease inhibitor P13489 -3.5 Xaa-Pro aminopeptidase 1 Q9NQW7 -3.5 
UPF0160 protein MYG1, 
mitochondrial 
Q9HB07 -3.6 Metalloproteinase 
inhibitor 2 
P16035 -3.5 
Procollagen-lysine,2-
oxoglutarate 5-dioxygenase 
1 
Q02809 -3.6 60S acidic ribosomal 
protein P1 
P05386 -3.5 
Calmodulin-3 P0DP25 -3.9 Complement C1s 
subcomponent 
P09871 -3.5 
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40S ribosomal protein S10 P46783 -3.9 45 kDa calcium-binding 
protein 
Q9BRK5 -3.6 
Sterol 26-hydroxylase, 
mitochondrial 
Q02318 -3.9 Actin-related protein 2/3 
complex subunit 3 
O15145 -3.6 
Serine/threonine-protein 
phosphatase 2A 55 kDa 
regulatory subunit B alpha 
isoform 
P63151 -3.9 Purine nucleoside 
phosphorylase 
P00491 -3.7 
Xaa-Pro aminopeptidase 1 Q9NQW7 -4.0 Complement C1r 
subcomponent 
P00736 -3.7 
Puromycin-sensitive 
aminopeptidase 
P55786 -4.0 Macrophage migration 
inhibitory factor 
P14174 -3.8 
Kynureninase Q16719 -4.0 Metalloproteinase 
inhibitor 1 
P01033 -3.9 
Rab GDP dissociation 
inhibitor alpha 
P31150 -4.1 Heterogeneous nuclear 
ribonucleoprotein K 
P61978 -3.9 
40S ribosomal protein S25 P62851 -4.1 Alpha-1B-glycoprotein P04217 -4.0 
60S ribosomal protein L4 P36578 -4.2 Integrator complex 
subunit 4 
Q96HW7 -4.3 
Eukaryotic translation 
initiation factor 3 subunit E 
P60228 -4.2 Retinoic acid receptor 
responder protein 1 
P49788 -4.5 
Growth/differentiation 
factor 15 
Q99988 -4.2 Macrophage colony-
stimulating factor 1 
P09603 -4.6 
Microtubule-associated 
protein 4 
P27816 -4.2 Laminin subunit gamma-1 P11047 -4.8 
Peroxiredoxin-5, 
mitochondrial 
P30044 -4.3 Histidine--tRNA ligase, 
cytoplasmic 
P12081 -4.8 
Thrombospondin-4 P35443 -4.3 Inorganic 
pyrophosphatase 
Q15181 -5.1 
40S ribosomal protein S3 P23396 -4.4 Histone H2A type 2-A Q6FI13 -5.3 
Malate dehydrogenase, 
cytoplasmic 
P40925 -4.4 Extracellular matrix 
protein 1 
Q16610 -5.5 
Receptor of activated 
protein C kinase 1 
P63244 -4.5 Heterogeneous nuclear 
ribonucleoprotein A3 
P51991 -5.5 
T-complex protein 1 
subunit theta 
P50990 -4.6 Neutral alpha-glucosidase 
AB 
Q14697 -5.5 
Ras-related C3 botulinum 
toxin substrate 1 
P63000 -4.6 Sushi repeat-containing 
protein SRPX 
P78539 -5.7 
Ubiquitin-like modifier-
activating enzyme 1 
P22314 -4.8 Serum albumin P02768 -5.7 
Programmed cell death 6-
interacting protein 
Q8WUM4 -4.8 Proteasome subunit alpha 
type-3 
P25788 -5.8 
Glutathione synthetase P48637 -4.8 Serine/threonine-protein 
phosphatase 2A 65 kDa 
regulatory subunit A alpha 
isoform 
P30153 -5.9 
60S acidic ribosomal 
protein P1 
P05386 -4.9 Myotrophin P58546 -5.9 
Ras-related protein Rab-
11B 
Q15907 -5.0 Mitochondrial import 
receptor subunit TOM70 
O94826 -6.0 
TLR4 interactor with 
leucine rich repeats 
Q7L0X0 -5.1 Ras-related protein Rab-
11B 
Q15907 -6.1 
T-complex protein 1 
subunit eta 
Q99832 -5.3 Procollagen-lysine,2-
oxoglutarate 5-
dioxygenase 1 
Q02809 -6.2 
Glycine--tRNA ligase P41250 -5.4 40S ribosomal protein S5 P46782 -6.2 
Heterogeneous nuclear 
ribonucleoprotein A1 
P09651 -5.4 Interleukin enhancer-
binding factor 2 
Q12905 -6.7 
Phosphoglycerate mutase 1 P18669 -5.7 Integrin beta-1 P05556 -6.8 
Collagen alpha-1(XI) chain P12107 -5.8 Prelamin-A/C P02545 -6.9 
CHAPTER 8                                                  SUPPLEMENTARY DATA 
 
473 
 
Macrophage colony-
stimulating factor 1 
P09603 -5.9 Metallothionein-2 P02795 -6.9 
Serine/threonine-protein 
phosphatase 5 
P53041 -5.9 Alpha-amylase 2B P19961 -7.1 
Major vault protein Q14764 -6.0 Coatomer subunit delta P48444 -7.4 
ATP-dependent 6-
phosphofructokinase, 
platelet type 
Q01813 -6.1 Laminin subunit beta-1 P07942 -7.4 
Ubiquitin-conjugating 
enzyme E2 L3 
P68036 -6.4 Stanniocalcin-1 P52823 -7.5 
COP9 signalosome complex 
subunit 4 
Q9BT78 -6.5 Thrombospondin-2 P35442 -7.5 
Thioredoxin reductase 1, 
cytoplasmic 
Q16881 -6.5 Serine/arginine-rich 
splicing factor 3 
P84103 -7.9 
Hemoglobin subunit 
gamma-2 
P69892 -6.6 T-complex protein 1 
subunit eta 
Q99832 -7.9 
60S ribosomal protein L7 P18124 -6.6 Thioredoxin reductase 1, 
cytoplasmic 
Q16881 -8.1 
Glucose-6-phosphate 1-
dehydrogenase 
P11413 -6.8 Actin, cytoplasmic 1 P60709 -8.6 
Serine/threonine-protein 
phosphatase 2A 65 kDa 
regulatory subunit A alpha 
isoform 
P30153 -7.0 Fibrillin-1 P35555 -8.7 
HLA class I 
histocompatibility antigen, 
B-44 alpha chain 
P30481 -7.6 Granulocyte colony-
stimulating factor 
P09919 -8.7 
60S ribosomal protein L5 P46777 -7.7 Keratin, type I cytoskeletal 
9 
P35527 -9.6 
Fibrillin-1 P35555 -7.9 Suprabasin Q6UWP8 -11.2 
Vitamin K-dependent 
protein S 
P07225 -8.0 Inorganic 
pyrophosphatase 2, 
mitochondrial 
Q9H2U2 -11.4 
Proliferation-associated 
protein 2G4 
Q9UQ80 -8.1 40S ribosomal protein S21 P63220 -12.3 
Tubulin beta-6 chain Q9BUF5 -8.3 Programmed cell death 6-
interacting protein 
Q8WUM4 -12.5 
40S ribosomal protein S4, X 
isoform 
P62701 -8.5 ADP-ribosylation factor 4 P18085 -12.7 
Delta(3,5)-Delta(2,4)-
dienoyl-CoA isomerase, 
mitochondrial 
Q13011 -9.5 Translationally-controlled 
tumor protein 
P13693 -14.1 
Procollagen-lysine,2-
oxoglutarate 5-dioxygenase 
2 
O00469 -10.6 Osteopontin P10451 -15.1 
Suprabasin Q6UWP8 -11.2 MOB kinase activator 1A Q9H8S9 -16.3 
Glucosidase 2 subunit beta P14314 -11.8 Glutathione synthetase P48637 -19.3 
60S ribosomal protein L18 Q07020 -13.6 Glutathione S-transferase 
P 
P09211 -19.6 
Serine/arginine-rich splicing 
factor 3 
P84103 -14.9 Latent-transforming 
growth factor beta-
binding protein 1 
Q14766 -20.2 
BolA-like protein 2 Q9H3K6 -16.7 Proteasome subunit alpha 
type-2 
P25787 -25.6 
Fascin Q16658 -17.2 Eukaryotic translation 
initiation factor 3 subunit 
D 
O15371 -31.5 
Tubulin alpha-1C chain Q9BQE3 -17.4 Chloride intracellular 
channel protein 1 
O00299 -37.4 
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NAD(P)H dehydrogenase 
[quinone] 1 
P15559 -26.2 Pachytene checkpoint 
protein 2 homolog 
Q15645 -44.6 
Inorganic pyrophosphatase Q15181 -26.9 Carboxypeptidase A4 Q9UI42 -78.5 
Complement C4-A P0C0L4 -36.4 Histone H2A type 1-J Q99878 -87.8 
 
 
 
 
